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Summary
SUMMARY
Human cytomegalovirus (HCMV) is of considerable medical importance, with infection 
in utero being a major health risk for the developing foetus, causing a variety of neonatal 
abnormalities including deafness, physical abnormality and mental retardation. HCMV 
also poses a life-threatening risk to immunosuppressed individuals such as allograft 
recipients and HIV-infected people. HCMV is responsible for the blindness due to 
retinitis that can affect some AIDS patients.
The gene content of HCMV is less well understood than that of any other human 
herpesvirus. This reflects the large size and complexity of the genome, and also the lack 
of a laboratory strain with the full genetic complement of wild type virus. The complete 
DNA sequence (229,354 bp) of HCMV strain AD 169 was published in 1990, and the 
genome was predicted to contain 208 protein-coding open reading frames (ORFs). This 
is not likely to be an accurate estimate of the actual number of genes, as the criteria 
employed to identify coding regions were necessarily arbitrary and applied without the 
benefit of comparisons with other betaherpesviruses. Moreover, HCMV strain Toledo 
and other low passage isolates were later found to possess a 15 kbp genome segment 
absent from AD 169. Recently, the gene content of HCMV has been revised by 
comparison to the chimpanzee cytomegalovirus (CCMV) sequence (241,087 bp), and 
the number of protein-coding genes in AD 169 is now estimated at 145, several of which 
are novel. It is anticipated that this picture of the gene content of HCMV will be 
improved further.
The HCMV genome contains a set of 41 conserved herpesvirus-common ‘core’ genes, 
which are arranged in blocks that maintain relative position and orientation in different 
herpesviruses and reflect evolution from a common ancestor. The majority of genes are 
not spliced and overall the genome has relatively few polyadenylation signals. At the 
outset of this project, 12 HCMV genes had been shown experimentally to be spliced, 
and more spliced genes probably remained to be identified. Ten different families of 
related genes (RL11, US6, US22, GCR, UL25, UL82, UL146, US1, US12 and US22) 
have been recognised in HCMV that appear to have been generated by gene duplication 
events.
Summary
The US22 gene family contains 13 distantly related members (UL23, UL24, UL26, 
UL36, UL43, US22, US23, US24, US26, TRS1 and IRS1) sharing one or more of four 
conserved amino acid sequence motifs. Three members of this family (UL36, TRS1 and 
IRS1) have been reported as exhibiting transcriptional trans-activating properties in 
transient transfection assays, indicating that US22 genes are likely to be regulatory 
proteins. Moreover, since each of the sequenced betaherpesviruses contains a similar 
number of US22 genes, it is anticipated that these genes provide important functions 
during virus replication.
Although the AD 169 genome was sequenced over ten years ago, the products of a large 
number of HCMV genes have not been identified, and the assignment of gene function 
is largely based on sequence similarity to homologous genes in herpes simplex virus 
type 1 (HSV-1). Transcript mapping data are also fragmentary. The purpose of this study 
was to evaluate transcription of a selection of AD 169 genes, including several that are 
conserved in CCMV and some that appear unlikely to encode functional proteins 
because the HCMV ORFs are not conserved in CCMV. Primary use was made of 
northern blotting, RT-PCR and RACE techniques, employing RNA isolated from 
infected human fibroblasts. Three groups of genes were analysed: the 13 members of the 
US22 gene family; the 14 ORFs in TRl and 30 adjacent ORFs at the left end of Ul; and 
the novel spliced genes UL128 and UL131A.
Transcripts were detected by northern blotting for nine members of the US22 family, 
and 5’- and 3’-ends were identified for eight. Failure to obtain data for the other 
members analysed was probably due to transcription at low levels. RNAs were identified 
for most ORFs in TRl and the adjacent part of Ul. Most of the 5’-ends are located 20-30 
bp downstream from TATA elements, and all the 3’-ends are located 20-24 bp 
downstream from polyadenylation signals. The 5’-ends of two genes (UL18 and US24) 
appeared to be located downstream from the first ATG codon in the relevant ORF. 
Transcripts were detected for five ORFs in T R l and one in U l that appear unlikely to 
encode proteins. Certain ORFs in T R l and U l have more than one 5’-end, suggesting 
that they are transcribed in a complex manner.
Summary
PCR and the RACE analysis confirmed expression of three novel genes predicted from 
comparisons of HCMV with CCMV (UL21A, UL128 and UL131A). RT-PCR analysis 
confirmed that UL128 and UL131A are spliced genes, the former consisting of three 
exons and the latter of two. The 5’- and 3’-ends of UL21A and UL128 was mapped, but 
attempts to detect the 5’-end of UL131A were unsuccessful.
PCR and sequence analysis led to the identification of errors in the original sequences of 
ORFs UL15, UL102, UL145 and US22, as predicted from comparisons between HCMV 
and CCMV. In addition, two other ORFs in AD169 (UL131A and TRL13/14) were 
shown to be naturally frameshifted.
This work consolidates our understanding of the genetic content of HCMV and 
transcription of HCMV genes. It also provides a foundation for further experimental 
studies of gene expression in HCMV.
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Introduction
Introduction
Introduction t
This chapter is divided into three sections. Sections 1.1 and 1.2 give an overview of the 
Herpesviridae and human herpesviruses, respectively. Section 1.3 provides a brief 
description of human cytomegalovirus (HCMV), including discovery and classification, 
general characteristics, clinical relevance, virion structure, genome content, gene 
expression and gene functions. The chapter concludes with short description of the 
justification and objectives of the study.
1.1 The Herpesviridae: overview
1.1.1 General properties
The general characteristics of the Herpesviridae have been reviewed in the recent report of 
the International Committee on the Taxonomy of Viruses (ICTV) (Minson et al., 2000). 
The family Herpesviridae comprises over 120 large DNA viruses that infect vertebrates, 
including humans (Minson et al., 2000), and at least one invertebrate, the oyster (Comps 
and Cochennec, 1993). Herpesviruses are well adapted to their hosts. Most display a high 
degree of host specificity, and a single host may be infected by several different 
herpesviruses; for example, eight human herpesviruses have been identified.
1.1.2 Virion structure
Virions of herpesviruses have complex and characteristic structures consisting of both 
symmetric and nonsymmetric components (Homa and Brown, 1997; Steven and Spear, 
1997). The spherical virion of herpes simplex virus type 1 (HSV-1) comprises core, capsid, 
tegument and envelope (Fig 1.1). The core consists of the viral genome packed in a liquid 
crystalline array that fills the entire volume of the preformed icosahedral capsid. The 
mature capsid is 125 nm in diameter and is composed of 162 capsomers: 12 pentavalent 
capsomers (pentons) at the vertices, 60 hexavalent capsomers (hexons) at the 20 faces and 
90 hexavalent capsomers along the 30 edges (Wildy et al., 1960).
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Introduction
The tegument is an amorphous proteinaceous layer which lies between the nucleocapsid 
and envelope (Roizman and Furlong, 1974; Zhou et al., 1999). It consists of at least 18 
proteins, the functions of many of which have not been fully elucidated. Certain functions 
related to morphogenesis, uncoating and regulation of gene expression have been assigned 
to its component proteins.
The virion is enclosed by a host-derived lipid bilayer, the envelope (Roizman and Furlong, 
1974; Wildy et al., 1960). The envelope contains protruding glycoprotein spikes (Stannard 
et al., 1987) which vary in size from 8-24 nm. Thus far, 11 glycoproteins have been 
identified (reviewed by Spear, 1993; Haarr and Skulstad, 1994): gB, gC, gD, gE, gG, gH, 
gl, gJ, gK, gL and gM. Virions range in diameter between 160 nm and 230 nm, averaging 
180 nm (Szilagyi and Berriman, 1994).
1.1.3 Herpesvirus classification
A formal system of classification for the herpesviruses has been developed by the ICTV 
(Roizman et al., 1981, 1992, 1995; Minson et al., 2000), in which the family Herpesviridae 
is divided into three subfamilies, the Alphaherpesvirinae (informally known as the a- 
herpesviruses), the Betaherpesvirinae (p-herpesviruses) and Gammaherpesvirinae (y- 
herpesviruses). The Alphaherpesvirinae exhibit rapid cytolytic growth in vitro and establish 
latency in the nervous system. The Betaherpesvirinae have a restricted host range in vitro 
and have a long productive cycle, and are usually associated with the formation of enlarged 
(cytomegalic) cells. The Gammaherpesvirinae establish latent infection in lymphocytes and 
are often associated with lymphoproliferative disease. The subfamilies are further divided 
into genera. For example, the Alphaherpesvirinae subfamily consists of four genera: 
Simplexvirus (informally ai), Varicellovirus (ot2), ‘Marek’s disease-like virus’ (0C3) and 
‘Infectious laryngotracheitis-like virus’ ((X4). Table 1.1 gives an outline of the current 
herpesvirus classification and accession numbers for the sequenced genomes.
Limited sequence data from herpesviruses isolated from turtles (Quackenbush et al., 1998) 
suggest that these viruses belong to the a-herpesviruses. However, herpesviruses of fish 
(Davison, 1992, 1998), amphibians (Davison et al., 1999) and one invertebrate (the oyster)
3
Introduction
Com m on nam e/abbreviationa ICTV designation/abbreviation Gen Bank accession no.
ALPHA HERPESVIRINA E 
Sintplexvirus (a,)
Herpes sim plex  virus type 1 /(H S V -1) 
Herpes sim plex  virus type 2 / (H SV -2) 
Bovine m am m ilitis virus/ B H V-2
Human herpesvirus //H H V -1  
Human herpesvirus 2/H H V-2  
Bovine herpesvirus 21 BoH V -2
X I4112
Z 86099
N A b
Varicellovirus (a^
V aricella-zoster virus/ (VZV)
Sim ian varicella v ir u s /(S W )
Infectious bovine rhinotracheitis virus/ BHV-1
Pseudorabies virus/PRV
Feline rhinotracheitis virus/FH V-l
Equine abortion virus/EHV-1
Equine rhinopneumonitis virus/EHV-4
Human herpesvirus 3/H H V-3  
C eropithecine herpesvirus 9 /C ell V9 
Bovine herpesvirus 1/ BoHV-1  
Suid herpesvirus  //SuH V -1  
F eh d herpesvirus  //F eH V -l 
E quid herpesvirus  //E H V -1 
E quid herpesvirus  4/EH V-4
X 04370
A F275348
AJ004801
N A b
N A b
M 86664
A F030027
“ M arek 's d isease-lik e  v iru s” (ct3)
M arek’s disease virus 1/(M D V -1) 
M arek’s disease virus 2 /(M D V -2) 
Herpesvirus o f  turkeys/HVT
G a llid  herpesvirus  2 /GaHV-2 
G a ll id  herpesvirus  J/GaHV-3  
M eleagrid  herpesvirus  //M eH V -1
A F243438
A B 049735
A F291866
“ Infectious laryngotracheitis-lik e v iru s” ( a 4)
Infectious laryngotracheitis virus/(ILTV) G a llid  herpesvirus  //G aH V-1
N A b
BETA HERPESVIRUS A E  
Cytomegalovirus ((5,)
Human cytom egalovirus/(H C M V ) 
Chim panzee cytom egalovirus/C C M V  
Rhesus cytom egalovirus/R H C M
Human herpesvirus  5/H H V-5  
None fN one
Cercopithecine herpesvirus  S /C ellV -8
X I 7403 
Unpublished
N A b
Mu romegalo virus (f t,)
Murine cytom egalovirus/(M C M  V) 
Rat cytom egalovirus/R C M V
M ur id  herpesvirus  //M uH V-1  
M urid herpesvirus  2/M uH V-2
U 68299
A F232689
Roseolovirus {faj 
Human herpesvirus 6/(H H V -6) 
Human herpesvirus 7/(H H V-7) Human herpesvirus  6/H H V-6  
Human herpesvirus  7/HHV-7
X 83413, A B 02I506 , A F 157706  
U 43400, A F037218
Unassigned member
Tupaia herpesvirus/TuHV
Tupaiid herpesvirus / /T u H V -1 A F 2818I7
GAMMA H ERPESVIRID AE  
Lymphocryptovirus (/,)
Epstein-Barr virus/(EBV)
Rhadinovirus (y^
Herpesvirus saim iri/(H VS)
Herpesvirus ateles/H V A
Kapsi’s sarcom a-associated herpesvirus/KSHV
Rhesus rhadinovirus/RRV
M ouse herpesvirus 68/M H V 68
Equine herpesvirus 2/EH V-2
Malignant catarrhal fever virus/ AHV-1
Bovine herpesvirus 4/BH V -4
Human herpesvirus  4/H H V-4
Saim irine herpesvirus  2/SaH V-2  
Ateline herpesvirus  2/AtH V-2  
Human herpesvirus  3/H H V-8  
C ercopithecine herpesvirus 17/C eH V -l 7 
M ur id  herpesvirus  4/M uH V-4 
Equid herpesvirus  2/EH V-2  
Alcelaphine herpesvirus  //A IH V -1  
Bovine herpesvirus  9 /B oIIV -4
M 35547, V 0I555 , M 80517
X 64346  
A F083424  
U 75698, U 93872  
A F 083501, A F210726  
U 97553, AF 105037  
U20824  
A F 005370  
A F 3 18573
UNDEFINED SUBFAM ILY  
“ Ictalurid herpes-like virus”
Channel catfish virus/(CCV) Ictalurid herpesvirus  //IcH V -l M 75136
Table 1.1: Herpesvirus classification and accession numbers for sequenced 
genomes.
“Generic names and their alternative synonyms (lowercase bold) are given for each subfamily 
(uppercase bold). Abbreviations for the names of virus species are given. bComplete sequence not 
available. Adapted from Davison (2001).
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(A J . Davison, unpublished data) are very remotely related to the mammalian/avian group. 
Fig. 1.2 shows an illustrative phylogenic tree of the Herpesviridae, indicating evolution of 
three major groups from a putative ancestor (McGeoch and Davison, 1999a).
Although herpesviruses of mammals and birds are highly divergent, conservation of a 
subset of about 40 core genes across the three subfamilies suggests a common evolutionary 
origin. Herpesvirus evolution is thought to have proceeded through mutational and 
recombinational processes, including large scale genomic rearrangements, gene capture and 
gene duplications (McGeoch, 1989; McGeoch and Cook, 1994). An in-depth phylogenetic 
analysis of mammalian and avian herpesviruses based on a set of eight conserved genes has 
recently been accomplished by McGeoch et al. (2000), confirming the overall high level of 
congruence between the virus hosts’ lineages and the herpesvirus phylogenetic tree. This 
supports the inference made previously that herpesviruses have evolved with their hosts. 
Based on this hypothesis and using the divergence times of the host lineages (Benton, 
1990; Kumar and Hedges, 1998), it is estimated that the a-, p- and y-herpesviruses arose 
approximately 180-220 million years ago and that the genera diverged 60-80 million years 
ago.
1.1.4 Genetic content
Herpesviruses have large, linear, double-stranded DNA genomes which range in size from 
124 kbp (e.g. simian varicella virus (SVV)) to 240 kbp (e.g. HCMV) (McGeoch and 
Davison, 1999a). The viruses also exhibit an impressively wide range of base compositions 
ranging from 32-75% in G+C content (Honess, 1984; Minson et al., 2000). A characteristic 
of herpesvirus genome structure is the presence of terminal or internal repeated sequences, 
in direct or inverse orientation. The layouts of these repeat elements in relation to unique 
sequences define at least six genome types (Fig 1.3).
Herpesviruses reportedly contain between about 70 and 200 genes. For example, the HSV- 
1 genome contains 74 unique protein-coding genes, and the HCMV genome contains 
approximately 165. The genes are densely packed and arranged in about equal numbers on 
each DNA strand. Most are expressed as single exons from their own promoters, although
5
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ocl — cx4 
p i ,  p 2  
y l ,  y 2
c c v
SalHVs
RaHV
Oyster HV
Figure 1.2: Phylogeny of herpesviruses.
A schematic view is given of the organisation of the three major lineages of herpesviruses 
and their possible relationships. Subfamily groupings of the mammalian/avian viruses, the 
counterparts of these for fish and amphibian viruses, and the invertebrate (oyster) virus, are 
shown as grey triangles. Evolution of such groupings from common ancesters is indicated by 
solid lines and a hypothetical overall common origin by dashed, incompletely joined lines. 
SalHV; salmonid herpesvirus, RaHV; ranid (frog) herpesvirus. Adapted from McGeoch and 
Davison (1999).
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Figure 1.3: Types of herpesvirus genome structure.
Unique sequences and repeat elements are represented by black lines and coloured 
rectangles, respectively. The number of terminal repeats in types B and C and the number of 
internal repeats in type C are variable. Arrows indicate locations and orientations of repeated 
regions. The genomes are not to scale.
A. A long unique sequence flanked by large direct terminal repeats (CCV, EHV-2, HHV-6 and 
HHV-7) (Chousterman et al., 1979; Davison, 1992; Browning and Studdert, 1989; Telford et 
al., 1995; Martin et al., 1991; Gompels et al., 1995; Nicholas, 1996).
B. A long unique sequence flanked by multiple smaller tandem direct repeats at the genome 
termini (HVS and HHV-8) (Bornkamm etal., 1976; Albrecht etal., 1992; Russo etal., 1996).
C. Multiple smaller direct tandem repeats at the genome termini plus a different sequence 
repeated a variable number of times at an internal location (EBV) (Given and Kieff, 1979; 
Baer et al., 1984).
D. A short unique sequence flanked by large inverted repeats, and a long unique sequence 
flanked by very small or no terminal repeats (EHV-1 and VZV) (Whalley et al., 1981; Telford 
etal., 1991; Dumas etal., 1981; Davison and Scott, 1986).
E. Short and long unique sequences each flanked by a pair of large inverted repeats. A 
terminal direct repeat, the a sequence, is found at the genomic termini and in inverted 
orientation at the junction between the internal repeats (IRL and IRS) (HSV-1 and HCMV) 
(McGeoch et al., 1988; Weststrate et al., 1983; Chee et al., 1990).
F. A single unique region with very small or no terminal repeats (TuHV-1) (Roizman et al., 
1995).
Adapted from McGeoch and Davison (1999).
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families of genes arranged tandemly on the same strand commonly share a single 
polyadenylation site (Wagner, 1985). Overlaps between genes in different reading frames 
on the same strand or on opposing strands are infrequent and usually not extensive. Few 
genes are spliced in the a-herpesviruses, but splicing is more common in the p- and y- 
herpesviruses (Davison and Clements, 1996).
The genes that have counterparts in a-, p- and y-herpesviruses (core genes; McGeoch and 
Davison, 1999b) are arranged in seven gene blocks (Fig. 1.4). The great majority of core 
genes are involved in vital aspects of the viral life cycle, such as entry into the cell, viral 
DNA replication, packaging of the genome and virion assembly. Nine genes (of which all 
but one are involved in DNA metabolism and replication) are clearly related by similarities 
in encoded amino acid sequences to cellular genes (McGeoch and Davison, 1999b) and are 
probably originated from the cellular genome. Viral structural genes, on the other hand, do 
not appear to have any obvious cellular homologues. Non-core genes are involved in 
control of the life cycle, latency, pathogenicity and modification of the immune response.
1.1.5 Life cycle
The life cycle of herpesviruses replication consists of lytic and latent phases. It can best be 
illustrated by briefly considering the life cycle of the best-studied herpesvirus, HSV-1 (Fig. 
1.5); its general aspects apply to other herpesviruses.
1.1.5.1 The lytic cycle
Initial association of HSV-1 with the host cell is mediated by viral envelope glycoproteins, 
which have important roles in adsorption and penetration of virus into the cell (Campadelli- 
Fiume, 1994). After the virus envelope fuses with the plasma membrane, the nucleocapsid 
is released into the cytoplasm and migrate to the nucleus where the DNA enters via nuclear 
pores. At least some of the tegument proteins also enter the nucleus, although the process 
by which this occurs is not clear. Transcription and replication of viral DNA and capsid 
assembly take place in the nucleus.
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HSV-1 (a-herpesviruses)
gL gM pol
t r , ™
h/p MCP gH SSBF
i = - H  vii F VI v h IV II
LTeg
RR h/p IR, I Re TRCL " ' S
n -
1-2 5-15b 18-19 22-26 27-30 31-42 49a-54
HCMV ((3-herpesviruses)
TR,
_ III IV VI
iRJRs
f v T H — ^
44-53 54-57 69-72 75-80 85-87 89-105 114-115
EBV (y-herpesviruses)
TRC
TR IR
□—n i i 11111111 rm~m ■III ■____ VII
BFLF2-BMRF1 BMLF1- BKRF2- BBLF4- BDLF1- BXLF2- BALF5- 
BLRF1 BKRF3 BDRF1 BcRF1 BVRF5 BALF2
Figure 1.4: Organisation of conserved gene blocks in m em bers of different 
herpesvirus subfam ilies.
Prototype genome arrangements (not to scale) are shown of HSV-1, HCMV and EBV. Seven 
conserved gene blocks are shown. Yellow blocks in HSV-1 and EBV genomes denote the 
inverted orientation of the blocks relative to HCMV. The numbers below the sequence blocks for 
HCMV and HSV-1 denote the UL ORFs that bracket each conserved block in these viruses. The 
names listed below the blocks for EBV denote the ORFs bracketing each conserved block in that 
virus. Examples of genes in each block are indicated for HSV-1. UDG; uracil-DNA glycosylase, 
gL, gM, gH; glycoproteins L, M, H, h/p; subunit of the helicase-primase complex; pol; catalytic 
subunit of DNA polymerase, SSBP; single-stranded DNA binding protein, RR; ribonucleotide 
reductase, MCP; major capsid protein, Lteg; large tegument protein. Adapted from Minson et al. 
(2000).
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Gene expression occurs from the viral genome in a co-ordinated, regulated and sequentially 
ordered cascade, with three main phases: immediate early (IE or a), early (E or P) and late 
(L or y) (Honess and Roizman, 1975; Roizman and Sears, 1990). Some IE proteins are 
trans-acting regulators of virus genes, and initiate cascade expression. E genes encode 
several enzymes involved in DNA replication and nucleotide metabolism, as well as a 
subset of glycoproteins and some uncharacterised proteins. L genes encode many virion 
structural proteins (Honess and Roizman, 1975). The tegument protein (VP 16) encoded by 
the UL48 gene transactivates IE promoters upon infection (O’Hare, 1993; Amosti et al., 
1993).
Replication starts in the nucleus, with circularisation of viral genomic DNA by direct 
ligation of the termini. Viral DNA synthesis is initiated from the viral origins of replication 
(oriS and oriL) to produce DNA in an endless conformation, probably as head-to-tail 
concatemers, by a rolling circle mechanism (Roizman, 1979; Jacob et al, 1979). Replicated 
DNA is cleaved specifically into unit-length molecules and packaged into preformed 
capsids.
The processes by which the capsid acquires tegument and envelope are not fully 
understood. The envelope is derived from altered host membranes and contains viral 
glycoproteins, which are processed into their mature forms in the Golgi apparatus. New 
viral progeny are released from the cell by exocytosis (Rixon, 1993).
1.1.5.2 The latent cycle
Latent infections are produced by all of the human herpesviruses, but are established at 
sites that are specific to the virus. For example, HSV-1 and VZV become latent in sensory 
ganglia, whereas EBV latently infects circulating B lymphocytes (Rock, 1993; Kieff and 
Liebowitz, 1990; Bastian et al., 1972). The monocyte is the probable site of HCMV latency 
(Kondo et al., 1994).
In its latent form, HSV-1 DNA is present either as a circular molecule or as a concatemer 
(Rock and Fraser, 1983, 1985; Efstathiou et al., 1986) and is not thought to integrate into
10
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Introduction
the host DNA (Mellerick and Fraser, 1987). EBV latent DNA is maintained as covalently 
closed circular episom^s (Lindhal et a l, 1976), and EBV infection can result in cell 
transformation and proliferation that may lead to carcinomas or lymphomas (Zur Hausen 
and Schultz-Hausen, 1970).
The products of viral genes expressed during the latent state appear to function in 
maintenance of and reactivation from latency (Steiner et a l , 1989; Dambaugh and 
Hennessy, 1986; Speck and Strominger, 1989), but differ between HSV-1 (latency- 
associated transcripts or LATs: Spivack and Fraser, 1987; Deatly et a l , 1988) and EBV 
(Epstein-Barr virus nuclear antigen or EBNA proteins: Lindahl et a l, 1974).
1.2 Human herpesviruses
Eight herpesviruses (Table 1.2) of humans have been isolated to date, including members 
of all three subfamilies (Table 1.1). Most are widespread in both the developed and the 
developing world (Whitely and Schlitt, 1991), and humans remain the sole known reservoir 
for transmission, which occurs via person to person contact. These viruses cause a wide 
variety of diseases and possess varied molecular properties. The infections range from 
inapparent to severe, with disabling or fatal infections in the foetus, the very young or the 
immunosuppressed. Symptoms, which are summarised in Table 1.3, cover a broad 
spectrum of clinical manifestations, from minor lesions to severe and life-threatening 
encephalopathies. Most of these viruses occur at high prevalence levels in human 
populations with few exceptions, such as, HHV-8 occurs at high prevalence only in some 
populations, such as those in central and southern Africa (>50%). The viruses establish a 
life long infection in their host, utilizing varied mechanisms of latency; HSV-1, HSV-2 and 
VZV are neurotropic, HHV-6, HHV-7 and EBV are lymphotropic, while HCMV 
establishes latency in the monocytic lineage. The situation with HCMV will be discussed in 
detail below. EBV and HHV-8 are implicated in human cancers.
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Virus ICTV
designation
Subfam ily Genus G enom e
size
G enom e
type
R eview
HSV-1 HHV-1 a-herpesvirus a. 152 E Subak-Sharpe and 
Dargan (1998)
HSV-2 HHV-2 a-herpesvirus a . 155 E Levine (1992)
VZV HHV-3 a-herpesvirus a 2 124 D Gelb (1990)
EBV HHV-4 y-herpesvirus Yi 184 C Miller (1990)
HCMV HHV-5 P-herpesvirus P. 230 E Britt (1996)
HHV-6 HHV-6 P-herpesvirus P2 159 A Levy (1997)
HHV-7 HHV-7 P-herpesvirus P2 153 A Levy (1997)
KSHV HHV-8 Y-herpesvirus Y 2 141 B Levy (1997)
Table 1.2: The eight herpesviruses known to infect humans and their 
corresponding designations by the ICTV.
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Virus , Associated illness
HSV-1 80-95% o f  oral lesions, or “ cold sores,” and 30-50% o f genital lesions are caused by HSV-1. 
Primary infection and reactivation give similar symptoms. In rare cases it causes conjunctivitis, 
herpetic whitlow, keratitis and encephalitis. Neonatal infections are often life threatening.
HSV-2 5-20% o f  oral lesions and 50-70% o f genital lesions are caused by HSV-2. Primary infection 
and reactivation give similar symptoms. In rare cases it causes conjunctivitis, herpetic whitlow, 
keratitis and encephalitis. Neonatal infections are often life threatening.
VZV Primary infection: chicken pox, a rash which appears 14-15 days post-infection, accompanied 
by a fever. Reactivated infection, “ shingles” , appears at the relevant dermatome often 
accompanied by pain and is sometimes followed by post-herpetic neuralgia.
HCMV Primary infection: enlargement and fusion o f  macrophages often occurs. Usually asymptomatic 
but can be fatal. Reactivation can occur. Infection is problematic in immunocompromised 
individuals. Symptoms can include gastro-enteritis and retinitis.
HHV-6 Febrile illness and infant rash exanthem subitum. May act as an opportunistic agent in 
immunosuppressed patients suffering from AIDS or undergoing organ or bone marrow 
transplants. Symptoms can include pneumonia and encephalitis.
HHV-7 Febrile illness. May act as an opportunistic agent in immunosuppressed patients.
EBV Primary infection is often asymptomatic in young children, but occurs as infectious 
mononucleosis in older children and adults. Associated with Burkitt’s lymphoma and 
nasopharyngeal carcinoma.
KSHV Associated with Kaposi’s sarcoma, a vasculated skin lesion. Associated with Castlemans 
disease.
Table 1.3: Summary of the clinical manifestations of the eight human 
herpesviruses.
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1.3.1 General characteristics
The isolation of HCMV was independently accomplished by Smith (1956), Rowe et al. 
(1956) and Weller et al. (1957). The phrase “ cytomegalovirus”  was coined by Weller 
(1971), who observed salivary gland tropism and cytomegalic inclusions in the nuclei of 
infected cells. Human cytomegalovirus (HCMV) is a member of the Betaherpesvirinae 
subfamily of the Herpesviridae (Roizman, 1996), and is formally designated human 
herpesvirus 5 (HHV-5) (see Table 1.1).
HCMV shares a number of features with other herpesviruses including a similar virion 
structure, a shared gene subset and the ability to establish a latent infection within the host. 
HCMV also has some distinguishing features such as salivary gland tropism (Roizman et 
al., 1981), slow growth in cell culture and a highly species-specific host range.
DNA sequence-based analysis indicates that a large number of different HCMV strains are 
in circulation worldwide. The AD 169 strain was isolated almost half a century ago (Rowe 
et al., 1956) and became a widely used strain because of its efficient replication in cultured 
cells. However, little care was taken to ensure that a single, uniform stock was distributed 
to laboratories. At least two forms of AD 169 are currently available, AD169varUK and 
AD 169 va r  ATCC. The Towne strain (passage 125), a vaccine candidate that has also 
become a common laboratory strain (Plotkin et al., 1975), induces seroconversion without 
producing disease. However, other forms of Towne at different passage numbers are also 
available. In contrast a low passage HCMV strain, Toledo, produced clinically apparent 
disease when administrated to healthy volunteers (Quinnan et al., 1984). HCMV strains 
that are widely used in laboratory research are listed in Table 1.4. In each case, passage was 
carried out on human fibroblasts.
15
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HCMV ATCC* Isolation Comments
strain number
AD 169 VR-538 T onsillectomy-adenoidectomy, 
7-year-old girl.
Attenuated high passage strain.
Towne VR-977 Urine from patient with congenital 
cytomegalic inclusion.
Attenuated high passage strain.
Toledo Not known. Low passage strain.
Davis VR-807 Liver biopsy from 3 month old girl 
with microencephaly and other 
symptoms resembling congenital 
toxoplasmosis.
High passage strain.
Table 1.4: HCMV strains in research use.
“American Type Culture Collection.
1.3.2 Clinical relevance
The importance of HCMV as a pathogen has increased over the past two decades as 
immunosuppressive post-transplant therapies, as well as acquired immunodeficiency 
syndrome (AIDS) and other immunodeficiency states, have become prominent medical 
concerns. These conditions predispose individuals to primary HCMV infection or 
reactivation of latent infection resulting in fulminant, life-threatening, acute disease.
1.3.2.1 Epidemiology
HCMV is ubiquitous in the human population and the prevalence of antibodies in normal 
adults ranges from 40 to 100% (Krech, 1973). Transmission of HCMV occurs by person to 
person contact and infection can occur at any age. Transmission during birth and from 
breast milk is very common in developing countries. Infants and young children excrete 
HCMV in their urine and respiratory tract and may be the source of infection for adults and 
other children (Stango and Cloud, 1994). The most important mode of transmission post 
puberty is probably sexual (Handsfield et al., 1985) especially among sexually active male 
homosexuals (Drew et al., 1981; Collier et al., 1987), and reinfection is common in
16
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sexually active populations (Drew et al., 1984; Spector et al., 1984). HCMV can also be 
transmitted via blood products and transplanted organs (Van der Meer et al., 1996).
Primary HCMV infection is endemic and is present throughout the year rather than being 
seasonal (Gold et al., 1990). Ill-defined socioeconomic factors predispose certain 
populations to higher infection rates, both by vertical and horizontal transmission.
HCMV is the most common congenital viral infection in humans, owing to the high 
prevalence of the virus in the general population. 60% of the UK population has 
experienced infection by the age of 40. In North America, HCMV infects about 50% of the 
population outside urban centres and up to 90% of the population within cities (Mocarski, 
1996). HCMV is the major cause of viral congenital infection and an estimated 40000 
infected infants are bom each year in the United States, with 4000 to 6000 exhibiting long 
term neurological sequelae (Britt and Alford, 1996). Acute infection and reactivation of 
latent infection presents a life-threatening risk to allograft recipients, HIV-infected 
individuals and immunosuppressed persons. Prior to recent advances in diagnosis and 
treatment, HCMV was the major infectious cause of death in bone marrow allograft 
recipients, with mortality rates from untreated HCMV pneumonia of approximately 90% 
(Meyers et al., 1982)
1.3.2.2 Disease and therapy
Primary infection with HCMV in normal adults is often asymptomatic, but may be 
manifested by a self-limiting mononucleosis-like syndrome in less than 1:1000 cases 
(Horwitz et al., 1986). In contrast, infections in immunocompromised hosts range from 
similar asymptomatic infection to fulminant life-threatening disease. HCMV is associated 
with different diseases depending on the type and level of immunosuppression.
In AIDS patients, HCMV infection is commonly manifested as retinitis and gastrointestinal 
dysfunction (Jacobson and Mills, 1988; Jabs et al., 1989; Dietrich and Rehmin, 1991; 
Gallant et al., 1992; Spector et al., 1993; Boppana et al., 1992). The risk of developing 
HCMV disease and death in persons with advanced AIDS is directly related to the quantity
17
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of HCMV DNA in plasma (Spector et al., 1998). In allograft transplantations the majority 
of morbidity for HCMV disease occurs when the recipient is seronegative but the donor is 
seropositive (Ho et al., 1975; Smiley et al., 1985; Meyers et al., 1986; Appereley and 
Goldman, 1988; Winston et al., 1990). The risk for, and the manifestations of, HCMV 
disease are associated with the organ of transplant. For example, pneumonia is a major 
problem in bone marrow or lung transplant recipients, whereas hepatitis is quite common 
after liver transplantation.
The risk of foetal infection with HCMV correlates with the lack of pre-existing 
seroimmunity in women infected with the virus during pregnancy. Infants with congenital 
infection exhibit many of the findings of both AIDS patients and allograft recipients 
infected with HCMV (Becroft, 1981; Boppana et al., 1992). Post-natally, HCMV infections 
are self-limiting, but frequent central nervous system (CNS) sequelae result from damage 
secondary to foetal infection (Stango et al., 1983; Boppana et al., 1992; Williamson et al., 
1992).
Resources generated to control HCMV infection include HCMV vaccines and anti-HCMV 
drugs (Harper and Kinchington, 1998). The live HCMV vaccine developed for the Towne 
laboratory strain, however, appears to induce only limited protection (reviewed in Britt and 
Alford, 1996). Attention has now focused on subunit vaccines, particularly those directed 
against the viral glycoprotein gB, which is the major antigen elucidating viral neutralising 
antibodies (Speckner et al., 1999). The anti-HCMV drug ganciclovir, a nucleoside 
analogue and a derivative of acyclovir, is licensed to treat HCMV-induced retinitis in 
immunocompromised patients but has been associated with myelotoxicity (Flint et al., 
2000). Foscamet, a pyrophosphate analogue, has also been used to treat HCMV infections 
but is nephrotoxic and is used only in life-threatening cases or when other anti-viral drugs 
are no longer effective (Chan et al., 2001). Clearly, there is a continued need to develop 
more effective and less toxic anti-HCMV therapies. The molecular genetic investigation of 
HCMV, in so much as it identifies new potential antiviral targets, will play an important 
role in facilitating new intervention strategies for HCMV. One characteristic of 
herpesviruses that makes anti-herpesvirus intervention strategies difficult to develop is their 
ability to establish life-long persistent infections. HCMV latency is associated with bone 
marrow CD34+ myeloid progenitor cells. However it has not been conclusively
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established whether HCMV establishes a true non-replicating latent infection in a specific 
cell type or persists by low-level replication (Mocarski, 1996).
Murine cytomegalovirus (MCMV) has been extensively used as a surrogate animal model 
to represent HCMV infection with respect to viral transmission, pathogenesis, acute 
infection and/or reactivation after immunosuppression, transfusion or transplantation (Xiao 
et a l , 2000). However, as MCMV does not cross the placenta, its utility as a model for 
congenital HCMV infection is questionable. More recently, however, guinea pig 
cytomegalovirus (GPCMV), which does cross the placenta and shares many biological 
similarities with HCMV, has been proposed as a better model for HCMV foetal infection 
(McGregor and Schliess, 2001).
1.3.3 Cell tropism
HCMV can infect almost all organ systems, but can normally be propagated in vitro only in 
human fibroblast cells such as HFL1 (human foetal lung) and HFFF2 (human foetal 
foreskin fibroblast). HCMV has also been reported to infect a wide range of other cell types 
in vitro, although the infection tends to be abortive (reviewed by Sinzger and Jahn, 1996). 
Various strains also vary in competencies in tropism for endothelial cells (Brown et al., 
1995). Towne or AD 169 have lost certain host range capabilities of low passaged strain 
Toledo.
It has been shown that the growth restrictions in cell culture may be partly due to passaging 
laboratory stocks in fibroblasts (Waldman et al., 1989; Brown et al., 1995; Sinzger et al.,
2000). Passaging HCMV in cell culture may be associated with gross changes, especially 
large-scale deletions, within the virus genome (Cha et al., 1996), and loss of certain genes 
may, as seen for MCMV (Cavanaugh et al., 1996), result in altered tropism.
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Figure 1.6: HCMV particles.
Surface of a cell onto which virions (V) and dense bodies (DB) of HCMV (Towne strain) 
have attached. This illustrates the sizes and approximate ratio of these two types of 
particles in a virus preparation. Adapted from Mocarski and Stinski (1979).
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1.3.4 HCMV particles
Three types of virus-related particles are released into the extracellular medium from 
HCMV-infected cells in culture. These are the mature infectious virion and two non- 
infectious particles: non-infectious enveloped particles (NIEPs) and dense bodies (Fig. 1.6) 
(Mocarski and Stinski, 1979; Irmiere and Gibson, 1983). Dense bodies and NIEPs can be 
distinguished from virions and each other by morphology and by biochemical analysis. 
Dense bodies, which are present only in the cytoplasm of infected cells, lack nucleocapsids 
and DNA and are predominantly composed of a single tegument protein, pp65 (pUL83). 
Whether dense bodies are produced in natural HCMV infections or whether they represent 
an artifact of in vitro culture systems is controversial. In support of the latter view it has 
been noted that dense bodies are not produced in tissue culture cells infected with MCMV. 
It has been suggested that dense bodies may consist of surplus cellular and viral products 
accumulated in a storage vacuole that is subsequently voided into the extra-cellular medium 
(Severi et al., 1992). NIEPs are morphologically indistinguishable from virions but lack the 
virus genome and retain one of the scaffolding proteins (pUL80.5). As has been reported 
for HSV-1 (Roizman, 1996), several forms of HCMV capsid structures (A, B and C 
capsids) can be identified in infected cells. Type A capsids lack the DNA and accumulate 
because of a failure to stably package the viral genome, whereas, B capsids lack DNA but 
contain the viral scaffolding/assembly protein, and are found in the nucleus as a precursor 
of mature capsids. Type C capsids are fully mature nucleocapsids and are present in the 
cytoplasm of infected cells (Gibson, 1996).
HCMV has a virion structure typical of herpesviruses, consisting of a double-stranded 
DNA genome packaged inside the icosahedral capsid, which is embedded in the tegument, 
and the whole then enclosed within a lipid envelope decorated with surface viral 
glycoprotein spikes (Roizman, 1996). To date, approximately 30 HCMV genes are reported 
to encode products that are present in the virion particle.
1.3.4.1 The capsid
The three dimensional structure of the HCMV strain AD 169 capsid has been determined by 
electron cryomicroscopy and image reconstruction (Fig. 1.7). Comparisons indicate that
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certain features of the HCMV capsid differ from those of HSV-1: the HCMV capsid shell 
is larger (diameter of 130 nm) and has to accommodate a genome that is some 37% larger. 
Differences between HCMV and HSV-1 in capsid shell architecture have been reported, 
including hexamer spacing, relative tilt, morphology of the tips of the hexons, and the 
average diameter of the scaffold (Butcher et al., 1998). The internal volume of the HCMV 
capsid is 17% larger than that of HSV-1, but this is insufficient by itself to account for 
packaging of the larger HCMV genome. It has been shown that the HCMV genome is more 
densely packed than that of HSV-1 (Bhella et al., 2000).
The HCMV capsid shell contains at least four proteins: the major capsid protein (MCP) 
(pUL86), the minor capsid protein (mCP) (pUL85), the mCP binding protein (mC-BP) 
(pUL46) and the small capsid protein (SCP) (pUL48A) (Gibson, 1996). The HCMV MCP 
is the largest of the four capsid proteins. It constitutes approximately 90% of the capsid 
protein mass and comprises the pentamers and hexamers. The mC-BP and mCP are present 
in a 1:2 ratio and constitute the inter-capsomeric triplex that links adjacent capsomeres. The 
HSV-1 SCP is not essential for the production of a stable capsid shell structure, and its 
location at the tips of the hexon is thought to direct tegument attachment (Zhou et al.,
1995), but the HCMV SCP has been shown to be essential for generation of infectious 
progeny in tissue culture cells (Borst et al., 2001). The role of capsid shell proteins in 
interaction with tegument proteins is relatively little studied. However, it has been 
demonstrated that HCMV tegument proteins are attached to the pentons, hexons and 
triplexes (Chen et al., 1999; Trus et a l, 1999). HSV-1 tegument proteins have also been 
shown to be attached to the pentons (Thomsen et al., 1994).
The HCMV ‘assemblin’ or ‘assembly protein’ (pUL80.5), is a 36 kDa scaffolding protein 
and, corresponding to the C-terminal half of the 85 kDa UL80 gene product. Like its HSV- 
1 counterpart pUL26.5, pUL80.5 forms a scaffold by self-interaction, via N-terminal 
sequences, and also interacts with the MCP via C-terminal sequences (Oien et al., 1997). 
Once nucleocapsids are assembled, the scaffolding proteins vacate the capsid following 
protease cleavage of a short C-terminal region, leaving space within the capsid to package 
the genome.
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Tegument
Figure 1.7: HCMV m orphology.
A. A reconstruction of an HCMV capsid generated from cryo-electron micrograph 
(EM) images. B. A cryo-EM image of HCMV virions. (Courtesy of D. Bhella, MRC 
Virology Unit, Glasgow.)
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1.3.4.2 The tegument
The tegument of HCMV particles lies between the capsid and the envelope and contains 
approximately 40% of the virion protein mass (Gibson, 1996). At least 25 proteins are 
located in the tegument layer. The products of 11 ORFs (UL25, UL26, UL32, UL47, UL48, 
UL48A, UL82, UL83, UL85, UL88 and UL99) appear to be both phosphorylated and 
highly immunogenic (Gibson, 1983; Gibson, 1996). Certain HCMV tegument proteins 
have counterparts in other betaherpesviruses and in the alphaherpesviruses, indicating 
important conserved functions. Many genes, for example, UL32, UL36, UL82, UL88, 
appear to have no counterparts in HSV-1, but have homologues in the other 
betaherpesviruses, and this indicates an important function for the gene products in this 
subfamily.
Two tegument proteins, pp65 (pUL83 or Tower matrix protein’) and ppl50 (pUL32 or 
‘basic phosphoprotein’), are the major HCMV tegument components and are highly 
immunogenic (Gibson, 1996; Mocarski, 1996). pp65 is an abundant virion protein 
(approximately 18% of total virion protein mass) and is the main protein constituent of 
dense bodies (approximately 95% of particle mass) (Irmiere and Gibson, 1983). There is 
evidence, however, that the amount of this protein is reduced in virions of low passage, 
clinical isolates (Klages et al., 1989). pp65 appears to be dispensable for growth in cell 
culture (Schmolke et a l , 1995). pp65 localises to the nucleus immediately after infection 
with virus or dense bodies, prior to IE protein synthesis (i.e. in cells treated with 
cycloheximide (Hensel et al., 1995)), and is therefore believed to have a role in initiating 
lytic infection. pp65 is strongly associated with the nuclear matrix of infected cells, and 
accumulating along the nuclear periphery and possibly associating with nuclear lamins 
(Sanchez et a l, 1998).
ppl50 is an essential gene product, constituting approximately 20% of total virion mass. It 
is one of the most immunogenic proteins of virion (Gibson and Irmiere, 1984; Jahn et al., 
1987; Pereira et al., 1993). HCMV seropositive individuals have high titres of anti-ppl50 
antibodies at up to 48 h post-infection. Hensel et al. (1995) reported that ppl50 is present in 
the nuclei of infected cells, where it associates with viral assembly compartments or with 
the nuclear membrane, but at 72 h post-infection it is also cytoplasmic. However, more
24
Introduction
recent investigation has failed to detect ppl50 in the nucleus but shown it to be present in 
the cytoplasm throughout infection, accumulating in a stable juxtanuclear structure 
(Sanchez et a l , 2000). The function of ppl50 is unknown, but its simian CMV (SCMV) 
homologue (Trus et al., 1999) is tightly bound to the capsid by an interaction involving a 
conserved sequence near the N terminus of the ppl50 protein and the MCP (Baxter and 
Gibson, 2001). It is possible that ppl50 provides an anchor for attachment of additional 
tegument proteins that are built subsequently around the particle.
The roles performed by protein constituents of the tegument layer may be multifunctional 
and complex. Certain tegument proteins are thought to perform key architectural roles or 
function to facilitate virus egress. Some, delivered to cells at the time of infection, may 
operate prior to IE protein synthesis to induce a favourable intracellular environment for 
lytic replication in the infected cell. These tegument proteins may be determinants of tissue 
tropism or be involved in abrogating host defences. Certain HCMV tegument proteins (e.g. 
pp71 (pUL82), pUL69 and pTRSl/pIRSl), can trans-activate the major IE promoter and/or 
other viral or cellular promoters.
The tegument of HCMV particles contains an antibody Fc receptor that can bind all 
subtypes of human IgG, and is likely to be involved in preventing antibody-mediated 
clearance of HCMV (Stannard and Hardie, 1991; Antonsson and Johansson, 2001). 
Recently, HCMV TRL11/IRL11 has been shown to encode a glycoprotein which is thought 
to encode the Fc receptor (Lilley et a l , 2001).
Unexpectedly, the tegument has also been reported to contain a specific subset of viral 
transcripts, termed ‘virion RNAs’, originating from ORFs UL21.5 (termed UL22A in this 
thesis), UL109, IRL4 and IRL7 (Bresnahan andShenk, 2000; Greijer et al., 2000). These 
genes are of unknown function, although UL22A is known to encode a protein that 
localizes to the Golgi network. TRL4/IRL4 is a major early transcript, but no protein 
product has been identified, and it is therefore possible that it operates as a functional RNA 
molecule. It is assumed that delivery of virion RNAs to the host cell allows for their 
expression immediately after virus entry in the absence of new transcription. Several host 
cell proteins, including P2-microglobulin, annexin II, an actin-like protein, and enzymes, 
such as capsid-associated protein phosphatase PP2A and DNA polymerase, have also been
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reported to be associated with particles (Baldick and Shenk, 1996; Gallina et al., 1999; 
Michelson et al., 1996)/
1.3.4.3 The envelope
The HCMV envelope is composed of viral proteins embedded in host-derived cytoplasmic 
membranes (Mocarski, 1996). HCMV encodes an abundance of putative glycoprotein (gp) 
genes (approximately 60), many of which appear to lack homologues in other herpesviruses 
(Chee et al., 1990). Most of these glycoproteins have not been studied, and it is not yet 
clear which are expressed on the surface of the infected cell or in the virion envelope. Early 
studies revealed approximately eight major HCMV glycoproteins (Stinski, 1976; Gibson,
1983) with homologues in other herpesviruses which are known to be involved in forming 
glycoprotein complexes (gel, gcll and gcIII) in the virion envelope (Gibson, 1983; Pachl et 
al., 1989; Britt and Mach, 1996).
HCMV gB (gpUL55) is the major envelope glycoprotein. Homodimeric molecules of gB 
are linked by disulphide bonds to form glycoprotein complex gel. gB binds to heparin 
sulphate on the cell surface and is essential for virus entry, cell to cell transmission of 
infection and fusion of infected cells (Boyle and Compton, 1998; Mocarski, 1996). gB is 
the principal target of neutralising antibodies against HCMV and is an important candidate 
of subunit vaccines initiatives. Four major genotypes of gB are known, along with several 
rare variants (reviewed in Pignatelli et al., 2001). Most of the HCMV-infected individuals 
develop anti-gB antibodies, targeted primarily to a region called AD-1 (amino acids 552- 
635), although neutralization is complement-dependent (Speckner et al. 1999). 
Neutralization reaches 50% efficiency at best, indicating that during natural infection the 
virus may escape the immune system by inducing production of non-neutralizing 
antibodies, or by producing viruses with variant gBs (Speckner et al. 1999).
Glycoprotein complex gcll, which consists of gM (gpULlOO) and gN (gpUL73), is another 
important and abundant constituent of the HCMV envelope (Mach et al., 2000). Hobom et 
al. (2000) reported that the gcll complex probably contains more than a single gM/gN 
dimer. The gcll complex binds heparin and is thought to play a role in virus entry and 
membrane fusion. Conuterparts of gM and gN in HSV-1 also form a complex. The gM/gN
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complex is essential for replication of HCMV (Kari et al., 1994), whereas HSV-1 mutants 
lacking this complex replicated to lower titres and exhibited reduced virulence (MacLean et 
al., 1993).
Glycoproteins gH (gpUL75), gL (gpUL115) and gO (gpUL74) form complex gcIII, which 
is involved in membrane fusion and virus penetration. Homologues of gH and gL are also 
present in HSV-1, where they are essential genes with a role in virus release and entry. gH 
is also a target for complement-independent anti-HCMV neutralising antibodies (Mocarski,
1996) and anti-gH antibody can prevent cell to cell transmission of virus (Ramussen et al,
1984). Antibodies that mimic the gH/gL complex also block virus penetration (Keay and 
Baldwin, 1992). Thus all three components of the HCMV gH/gL/gO are likely to be 
essential for viral entry.
The HCMV envelope also contains gene products that exhibit amino acid sequence 
similarity to seven-transmembrane-spanning (7TM) receptors (UL33, UL78, US27 and 
US28) (Gompels et al., 1995; Margulies et al., 1996). Three of these are related to G 
protein-coupled receptors (GCRs) (UL33, US27, and the CC/CX3C chemokine receptor 
US28) (Margulies et al., 1996; Beisser et al, 2001). GCRs transduce extracellular signals to 
alter intracellular processes, and the HCMV GCRs may function similarly during the initial 
virus binding stage of infection. The HCMV envelope-associated chemokine receptor 
(US28) is expressed on the surface of latently-infected THP-1 monocytes (Beisser et al.,
2001), and it has been suggested that circulating infected monocytes expressing US28 in 
vivo might promote dissemination of HCMV by adhering to CX3 C-expressing endothelial 
cells.
1.3.5 HCMV genome
The double-stranded linear DNA genome of HCMV (around 230 kbp for AD 169) is larger 
than that of any other known herpesvirus. It exhibits a class E structure (see Fig. 1.3) and is 
capable of genome inversion, forming four genome isomers (Mocarski, 1996).
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The complete DNA sequence of HCMV strain AD 169 has been determined (Chee et al., 
1990) by chain termination sequencing of M13 clones generated from Hindlll fragments 
cloned in plasmids (Oram et al., 1982). Double-stranded sequencing on appropriate 
overlapping plasmid clones (Fleckenstein et al., 1982) confirmed that the sequence was 
contiguous except for an extra 393 bp Hindlll fragment that was absent from the clone 
library (Chee et al., 1990). The sequence of AD 169 as determined by Chee et al. (1990) 
consists of 229354 bp. U l is 166972 bp, the flanking repeats (IR l and T R l)  are 11247 bp 
each. Us is 35418 bp and is flanked by 2524 bp repeats (IRs and TRs). A directly repeated 
a sequence is present at the genome termini and also in inverted orientation at the IR l-IR s 
junction (Mocarski et al., 1987). The sizes given above, IR l and IRs are conserved as 
overlapping by one copy of the a sequence. The a sequence contains cw-signals, called 
pac-1 and pac-2, for cleavage and packaging of the viral genome (Mocarski et al., 1987; 
McVoy et al., 1997). The average nucleotide composition is 57.2% G+C.
Open reading frames (ORFs) was identified in the sequence on the basis of three criteria 
(Chee et al., 1990): length of the ORF (300 bp or larger), overlap between ORFs (not more 
than 60%) and codon usage. Chee et al. (1990) found 778 ORFs that are over 300 bp, but 
581 of these are extensively overlapped by larger ORFs. Consequently 197 candidate 
protein-coding ORFs were initially proposed. The sequence was then examined for ORFs 
of less than 300 bp in the gaps, and these were assessed using additional criteria, for 
example, the presence of potential transcriptional signals, and initiation codons, homology 
to other ORFs or known genes, presence of protein structural or functional motifs in the 
amino acid sequence, and patterns of codon usage. From this analysis, Chee et al (1990) 
proposed a map of 208 ORFs (Fig. 1.8) that are predicted to encode proteins. This amounts 
to 189 ORFs if diploid genes are counted once only. The ORFs are arranged about equally 
on both strands of the genome with little overlap. ORFs were numbered sequentially and 
named with a prefix related to their location in the genome: TRL (TRL 1-TRL 14), UL 
(UL1-UL132), IRL (IRL14-IRL1), IRS (IRS1), US (US1-US36), TRS (TRS1) and J (the 
junction between TRl and TRs) (Fig. 1.8).
HCMV is noted for its extensive gene families (Chee et al., 1990). Fifty-two of the ORFs 
shown in Fig. 1.8 can be grouped into nine families of related genes (RL11, US6, US22,
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GCR, UL25, UL82, US1, US 12 and US2) that appear to have been generated by gene 
duplication events. There are three pairs (UL25, UL82 and US2) and six larger groups 
containing 3-14 genes in each family. The gene families (represented by colour coding in 
Fig. 1.9.) are clustered in Us and at one end of U l , regions of the genome that appear to be 
unique to the p-herpesviruses. The US22 gene family is discussed in section 1.3.9. An 
additional gene family (UL146) was identified in Toledo and Towne (Penfold et al., 1999; 
Davison et al, unpublished data), but is absent from AD 169.
The analysis of Chee et al. (1990) indicates that the majority of HCMV genes appear not to 
be spliced, and overall the genome has relatively few polyadenylation signals. 
Consequently, many genes have a polycistronic 3’-coterminal structure (Chee et a l , 1990). 
This pattern can also be seen in other herpesviruses.
A number of studies since 1990 have produced data that have required amendments to be 
made to the AD 169 sequence or to its interpretation. Major changes are described in the 
following sections.
1.3.5.1 Smith and Pari (1995)
UL102, together with an upstream region of 735 bp, was found to be absolutely necessary 
for origin-dependent HCMV DNA replication (Pari and Anders, 1993). Subsequently, this 
upstream region was shown to contain a small ORF (UL101X; overlaps UL101 in a 
different reading frame) comprising 208 bp immediately upstream from the first ATG 
codon in UL102. Smith and Pari (1995) mapped a single mRNA species extending through 
UL102 with its 5’-end located 20 bp upstream from the first ATG codon in UL101X. 
Sequencing of this region from the Towne and AD 169 genomes showed that the UL101X 
stop codon (TAG) was actually a TAC codon. Moreover, the subsequent codon GGT was a 
GCT codon. Smith and Pari (1995) found that a cDNA clone started upstream from the first 
ATG codon in UL101X, continued through the first ATG codon in UL102, and ended 
downstream from the UL102 stop codon. Therefore, UL101 and UL102 as originally 
defined were replaced by a larger single ORF, also called UL102.
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1.3.5.2 Cha ef a/. (1996)
*
Cha et al. (1996) looked at genome variation in different strains of HCMV and found that a 
large DNA sequence of Toledo was absent from high passage laboratory strains. AD 169 
lacks about 15 kbp and Towne about 13 kbp of DNA. Southern blotting indicated that this 
additional sequence is at the right end of Ul. Sequence analysis of this extra region, using 
the criteria of Chee et al. (1990), identified 19 additional ORFs in Toledo and 4 in Towne 
compared to AD 169. Most of the ORFs contained in the novel 15 kbp Toledo sequence 
appear to code for membrane proteins, and are obviously not required for replication in cell 
culture, giving rise to the speculation that they may have roles in cell tropism, pathogenesis 
or latency (Cha et al., 1996). Lurain et al. (1999) reported that the extra 19 ORFs found in 
Toledo by Cha et al. (1996) are also present in clinical isolates. The extra sequence in 
Toledo and other low passage isolates is therefore likely to be present in wild-type 
unpassaged HCMV.
Despite having a novel 15 kbp of DNA sequence not present in AD 169, the Toledo genome 
is likely to have a size of about 235 kbp (5 kbp larger than AD 169) since IR l is much 
shorter than in AD 169 or Towne (Cha et al., 1996). Consequently the diploid genes in 
AD 169 T R l/IR l are haploid in Towne and Toledo and presumably also in clinical isolates. 
None of the extra ORFs in Toledo show homology to ORFs in other p-herpesviruses.
Cha et al. (1996) speculated that part of the additional sequence present in Toledo but 
missing from AD 169 is in inverted orientation compared with other low passage isolates. 
Davison et al. (unpublished data) confirmed this by sequencing this region from three low 
passage and two clinical isolates. Moreover, the gene order in CCMV supports the presence 
of an inverted region in Toledo (Davison et al., unpublished data). It is now clear, 
therefore, that Toledo is a mutant, even though it is a low passage strain.
1.3.5.3 Dargan etal. (1997) and Mocarski etal. (1997)
These workers reported a 929 bp segment of AD 169 DNA that is absent from the published 
sequence. This segment was found to be present in most stocks of AD 169 at a location 
within the left part of Ul.
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Several AD 169 stocks (including AD169var\JK and AD169vaMTCC) were obtained from 
different laboratories and digested with EcoRl, revealing a novel fragment of 2.8 kbp in 
place of a 1.9 kbp fragment present in the sequenced strain (Chee et al., 1990). Some stocks 
consisted of a mixed population of both genomes. The 2.8 kbp fragment was exactly the 
same as the published sequence of the 1.9 kbp fragment except for an extra 929 bp inserted 
after nucleotide 54612. The deletion point lies within coding region for UL43 (Chee et al., 
1990). Since this extra sequence was present in the majority of AD 169 stocks, it is probable 
that the stock sequenced by Chee et al. (1990) had been passaged further than others. 
Therefore, an amendment to the published sequence was made by Dargan et al. (1997) and 
Mocarski et al. (1997). The insertion lengthens UL42 and UL43 and alters the total 
sequence length to 230283 bp. Dargan et al. (1997) also provided a reinterpretation of this 
region of the genome that replaced UL41 by an alternative ORF (UL41 A). UL43 is now a 
complete member of the US22 gene family.
1.3.5.4 Davison etal. (unpublished data)
Comparison of published HCMV sequences with those of other betaherpesviruses is a 
powerful tool for evaluating the likelihood of ORFs encoding protein (Davison, 1993). 
Recently, the gene content of HCMV has been re-evaluated by comparison to the CCMV 
sequence (241,087 bp). On the basis of the conservation of ORFs and other sequence 
features, some previously identified ORFs were excluded, some were modified, and ten 
novel genes were proposed (five in AD 169 and five in Toledo). Davison, A., Dolan, A., 
Akter, P., Wright, K., Addison, C., Alcendor, D., McGeoch, D. and Hayward, G. 
(unpublished data) recognised 145 unique genes in AD 169, compared with the 189 listed 
by Chee et al. (1990). The number of genes in wild type HCMV is estimated at 164. This 
analysis is considered a more accurate representation of the genetic content of HCMV than 
was previously available. The deduced layout of these genes is given in Fig. 1.9.
1.3.6 Regions in the HCMV genome not encoding protein
Amino acid sequence comparisons carried out between AD 169 and CCMV revealed three 
substantial regions in AD 169 that are unlikely to encode proteins because the ORFs and
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Introduction
their amino acid sequences are not conserved (Davison et al., unpublished data). These 
regions contain ORFs TRL2-TRL9, UL58-UL68 and UL106-UL111 identified by Cheeef 
a l  (1990) (Fig. 1.9).
1.3.6.1 TRL2-TRL9
Chambers et a l (1999) determined the kinetics of expression of most of these ORFs using 
DNA microarray technology, and in some cases, northern blotting. Hutchinson et a l  (1986) 
identified TRL5 and TRL6 as expressing an E and E-L RNA by northern blotting. The 
most abundantly transcribed E gene of HCMV (termed p2.7) is located in the TRl/IRl and 
represents approximately 20-40% of the total viral RNA. This RNA appears not to encode 
any protein, although the RNA is polysome-associated (Greenway and Wilkinson, 1987; 
Staprans et al, 1988). There is some evidence that the P2.7 transcript might be a functional 
RNA, with a role in specific interactions with cell proteins. It is possible that one role of 
this RNA is to interact with the host translational machinery to regulate viral and host 
translation differentially during infection (Greenway and Wilkinson, 1987; Sinclair et al, 
2000). A recent study detected a 1.2 kb E RNA from TRL7 that is associated with the 
virion (Bresnahan and Shenk, 2000).
1.3.6.2 UL58-UL68
RNAs mapped in this region (except UL58 and UL63) fall into the L expression class 
(Chambers e ta l , 1999).
The HCMV origin of lytic DNA replication (on'Lyt) is located in the region UL58-UL68. 
This element covers 2.4 kbp of a structurally complex region which encodes several 
transcripts (Huang et a l,  1996). The minimal core region of oriLyX is located in a region 
approximately 1.5 kbp between nucleotides 91751 and 93299 in the AD 169 genome 
(Huang et a l, 1996), and contains two essential regions (I and II) of 364 and 166 bp 
separated by non-essential sequence of approximately 400 bp. The central non-essential 
segment and sequences upstream of essential region I contribute significantly to origin 
function.
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Essential region I (92209-92573) contains the Y-block, a polypyrimidine tract (92471- 
92501), which is immediately upstream of the region of termination of transcription of the 
smallest replicator transcript (SRT; see below) (Huang et al., 1996). Region I also contains 
numerous repeated sequences (Zhu et al., 1998).
Essential region II (92979-93145) has been less intensively studied. This region contains 
Spl binding sites and has been shown to contribute to SRT promoter activity (Huang et al., 
1996; Zhu et al., 1998). Region II also contains vRNA2 (Prichard et al., 1998). vRNAs are 
two small or/Lyt-derived RNAs reported to be covalently integrated into the replication 
origins of some packaged HCMV genomes (Prichard et al., 1998). The literature suggests 
that the 500 bp vRNAl lies between nucleotides 93700 and 94340 and the 300 bp long 
vRNA2 between nucleotides 92949 and 93290.
SRT refers to a series of non-polyadenylated early transcripts, with a common 5’-end and 
loosely defined 3’-ends, which are transcribed from or/Lyt (Huang et al., 1996). SRT 
transcription is cycloheximide-sensitive but phosphonoformic acid (PFA)-insensitive, and 
is probably directed by host-cell RNA polymerase (Zhu et al., 1998). A number of factors 
(e.g. location in the centre of the oriLyt core, E expression, similarity to replicator 
transcripts in other systems, etc.) suggest that SRT plays a role in initiating or regulating 
lytic phase HCMV DNA synthesis (Zhu et al., 1998)
1.3.6.3 UL106-UL111
A 5 kb IE RNA was described in this region of AD169 by Plachter et al. (1988) before the 
published sequence of AD 169 became available. Nuclease protection assay, primer 
extension and RNA ligase-mediated 3’-RACE showed that the transcript appeared in the 
polyA+ and poly A' RNA fractions. This is consistent with the previous findings by Jahn et 
al. (1984) that part of the this RNA is poly adenylated, but most is not. The 5 kb RNA was 
also found in other strains, such as Towne (Wathen et al., 1981), Davis (DeMarchi, 1983) 
and many other low passage isolates (Chandler and McDougall, 1986; Somogyi, et al., 
1987). Chambers et al. (1999) detected the kinetics of expression of all the ORFs in the 
UL106-UL111 region.
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Wilkinson et al. (1984) and Stinski et al. (1983) reported that the 5 kb transcript was likely 
to be originated by splicing from the MIEP. However, no indication of splicing at either the 
3’- or 5’-end of this 5 kb transcript was found by Plachter et al. (1988). No signals known 
to be important elements in eukaryotic RNA polymerase II promoters (such as TATA or 
CCAAT), are present near the 5’-end. Since sequence analysis did not reveal significant 
evidence for a protein encoded by this transcript, it is likely to represent a large non-coding 
IE transcript (Plachter et al., 1988). The 5 kb RNA copurified with virions (Bresnahan and 
Shenk, 2000).
1.3.7 Relationships to other herpesviruses
Chee et al. (1990) identified homologs of HCMV ORFs by screening predicted protein 
sequences against the PIR (George et al., 1986) and SWISSPROT (Barioch, 1988) libraries 
using the FastA program (Pearson and Lipman (1988). Searches were also performed 
against a herpesvirus protein library that contained HSV-1, VZV and EBV sequences. 
More recently, the DNA sequences of five p-herpesviruses have been available and have 
been compared to HCMV.
Analysis of the DNA sequence of the Smith strain of MCMV (230,278 bp; Rawlinson et 
al., 1996) shows significant genetic similarities to HCMV strain AD 169, particularly in the 
78 centrally located ORFs. Homologues of the HCMV UL25, UL82, US22 and GCR gene 
families exist in MCMV, but there appear to be no homologues of the HCMV RL11, US1, 
US2, US6 or US 12 gene families. The Maastricht strain of rat CMV (229,896 bp; Vink et 
al., 2000) contains counterparts to all but one of the ORFs that are conserved between 
MCMV and HCMV.
The DNA sequence of strain U1102 of HHV-6 (159,321 bp; Gompels et al., 1995) was 
predicted to contain 102 protein-coding ORFs, More recently, Megaw et al. (1998) revised 
the gene content to 85 genes. The HHV-6 genome lacks the RL11, US1, US2, US6 and 
US 12 families. The genome of HHV-7 (144,861 bp; Nicholas, 1996 or 153,080 bp; Megaw 
et al, 1998) is related to that of HHV-6. Megaw et al. (1998) predicted a total of 84 genes
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O R F H S V -1
h o m o l o g u e
K i n e t i c
c l a s s 3
F u n c t i o n  o r  c h a r a c t e r i s t i c s R e f e r e n c e s
TRL1 E NKC
TRL10 E-L Structural glycoprotein Spaderna et al. (2002)
TRL11 L Glycoprotein with IgG Fc-binding 
capabilities
Lilley et al. (2001)
TRL12 E-L Glycoprotein Chee et al. (1990)
TRL13 E-L Glycoprotein Chee et al. (1990)
UL1 E-L Glycoprotein
UL2 L NK
UL3 L NK
UL4 E Glycoprotein Alderete et al. (1999); 
Chang et al. (1989)
UL5 E Glycoprotein
UL6 Glycoprotein
UL7 L Glycoprotein
UL8 Glycoprotein
UL9 L Glycoprotein
UL10 Glycoprotein
UL11 Glycoprotein
UL13 E
UL14 L Glycoprotein
UL15A Hydrophobic domain
UL16 Glycoprotein Kaye et al. (1992a)
UL17 E NK
UL18 L Immune evasion; MHC-1 homologue Chapman etal. (1999); 
Browne et al. (1992)
UL19 NK
UL20 Glycoprotein, Similar to T cell 
receptor y chain
Beck and Barrell (1991)
UL21A NK
UL22A NK
UL23 NK
UL24 NK
UL25 Associated with virion, possibly 
involved in transcriptional activation 
or interaction with chromatin
Baldick and Shenk (1996)
UL26 E Virion protein Baldick and Shenk (1996)
UL27 E NK
UL28 NK
UL29 L NK
UL30 NK
UL31 L NK
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UL32 L Virion basic phosphoprotein (BPP), 
possibly binds to the capsid triplex 
structure
Greis et al. (1994)
UL33 E Glycoprotein, homology to GCR Margulies et al. (1996)
UL34 E-L Represses transcription of US3. LaPierre and Biegalke 
(2001)
UL35 E NK
UL36 E Transcriptional transactivator, anti- 
apoptotic protein
Patterson and Shenk 
(1999); Goldmacher et al. 
(1999); Colberg-Poley et 
al. (2001)
UL37 Anti-apoptotic glycoprotein Goldmacher etal. (1999); 
Colberg-Poley et al. 
(2001)
UL38 UL36-UL38 region acts as a 
transcriptional transactivator
UL39 NK
UL40 E-L Glycoprotein. Involved in immune 
evasion by protecting infected cells 
from NK lysis
Tomasec et al. (2000)
UL41A Hydrophobic domain
UL42 Hydrophobic domain
UL43 L NK
UL44 UL42 E-L DNA polymerase processivity factor Ripalti et al. (1995)
UL45 UL39 Homologue of large subunit of 
ribonucleotide reductase but 
probably not functional.
Lembo et al. (2000)
UL46 UL38 E-L Minor capsid binding protein (mC- 
BP), forms intercapsomeric triplex 
with pUL85
Gibson et al. (1996)
UL47 UL37 E-L Virion protein Baldick and Shenk (1996)
UL48 UL36 L Tegument protein/ required for 
release of viral DNA from capsid
Batterson et al. (1983)
UL48A UL35 Small capsid protein (SCP) bound to 
tips of hexons
Borst et al. (2001)
UL49 E-L NK
UL50 UL34 Inner nuclear membrane protein, 
interacts with UL31 protein
UL51 UL33 Processing and packaging of DNA
UL52 UL32 L Processing and packaging of DNA
UL53 UL31 E Nuclear matrix protein, interacts with 
UL34 protein
UL54 UL30 E Catalytic subunit of DNA polymerase Kouzaride et al. (1987)
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UL55 UL27 E Glycoprotein (gB), binding to ligand 
up regulates cellular transcription 
factors Sp-1 and NF-kB
Yurochko et al. (1997)
UL56 UL28 E Terminase subunit, interacts with 
pUL89
Buerger et al. (2001)
UL57 UL29 E Single-stranded DNA-binding protein Anders and McCue 
(1996); Penfold and 
Mocarski (1997)
UL69 UL54 E-L Transactivator, synergy with pp71 to 
activate MIEP. Induces cells to 
accumulate in Gi. One form is a 
tegument protein
Winkler et al. (2000)
UL70 UL52 Component of helicase/primase Anders and McCue 
(1996); Pari and Anders 
(1993)
UL71 UL51 Tegument protein
UL72 UL50 E-L Related to dUTPase, but lacks 
active site motifs.
McGeoch (1990)
UL73 UL49A E-L Glycoprotein (gN). Complexed with 
gM.
Mach et al. (2000)
UL74 Glycoprotein (gO), required for 
envelope structure.
Huber and Compton 
(1998)
UL75 UL22 E-L Glycoprotein (gH). Mediates fusion 
of the envelope for virus entry.
Yurochko et al. (1997)
UL76 UL24 NK
UL77 UL25 E Processing and packaging of DNA
UL78 E Glycoprotein, homology to GCR Milne et al. (2000)
UL79 NK
UL80 UL26 Assemblin precursor Gibson et al. (1996)
UL80.5 UL26.5 L Scaffolding protein Oien et al. (1997)
UL82 L pp71, phosphorylated upper matrix 
protein, transactivator of MIEP
Liu and Stinski (1992); 
Rawlinson et al. (1996); 
Bresnahan et al. (2000)
UL83 L pp65, phosphorylated lower matrix 
protein
Schmolke et al. (1995)
UL84 E-L IE2/UL84 complex enhances 
negative regulation of MIEP
Gebert etal. (1997)
UL85 UL18 E-L Minor capsid protein (mCP), forms 
intercapsomeric triplex with pUL46
Baldick and Shenk (1996)
UL86 UL19 E-L Major capsid protein (MCP), forms 
hexons and pentons
Rudolph et al. (1990)
UL87 NK
UL88 Virion component Baldick and Shenk (1996)
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UL89 UL15 E-L Terminase subunit Underwood et al. (1998)
UL91 L NK
UL92 L NK
UL93 UL17 L Tegument protein; role in DNA 
packaging
UL94 UL16 L Tegument protein
UL95 UL14 Tegument protein
UL96 E-L NK
UL97 UL13 E-L Serine/threonine protein kinase, 
phosphorylates ganciclovir
Prichard etal. (1999)
UL98 UL12 E-L Alkaline exonuclease. Sheafferetal. (1997)
UL99 UL11 Myristylated tegument protein, role 
in envelopment and transport of 
virions
UL100 UL10 E-L Glycoprotein (gM), integral 
membrane protein, complexes with 
gN
Mach et al. (2000)
UL102 UL8 L Component of helicase-primase Smith and Pari (1995)
UL103 UL7 L Tegument protein
UL104 UL6 E Capsid portal protein
UL105 UL5 E ATPase component of helicase- 
primase complex
Anders and McCue (1996)
UL111A E-L IL-10 homolog (cmvlL-10) Kotenko et al. (2000)
UL112 E Encodes 4 phosphoproteins, pp34, 
pp43, pp50, pp84. pp43 is 
responsible for IE2 dependent 
activation of UL54 promoter. 
Accumulates with IE2 in replication 
compartments that initiate from 
PODs
Ahn etal. (1999)
UL114 UL2 E Uracil-DNA glycosylase Prichard et al. (1996)
UL115 UL1 Glycoprotein (gL), complexes with 
gH, role in cell entry
Kaye et al. (1992b); 
Spaete et al. (1993)
UL116 E-L NK
UL117 NK
UL119 E Glycoprotein
UL120 L Glycoprotein
UL121 L Glycoprotein
UL122 IE, L Major IE gene, IE2. Transcriptional 
transactivator
Romanowski et al. (1997); 
Spector (1996); Stenberg 
(1996); Liu and Stinski 
(1992); Stenberg et al. 
(1989)
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UL123 IE Major IE gene, IE1. Transcriptional 
transactivator
Romanowski etal. (1997); 
Spector (1996); Stenberg 
(1996); Liu and Stinski 
(1992); Stenberg et al. 
(1989)
UL124 E Glycoprotein
UL128 E NK
UL130 E-L NK
UL131A L NK
UL132 E-L Glycoprotein
UL133b NK
UL135b NK
UL136b NK
UL138b NK
UL139b NK
UL140b NK
UL141b Hydrophobic domain
UL142b Hydrophobic domain
UL144b Homolog of TNFR Benedict et al. (1999)
UL145b NK
UL146b CXC chemokine Penfold etal. (1999)
UL147b E-L Putative CXC chemokine Penfold etal. (1999)
UL147Ab Hydrophobic domain
UL148b NK
UL148Ab Hydrophobic domain
UL148Bb Hydrophobic domain
UL148Cb Hydrophobic domain
UL148Db Hydrophobic domain
UL150° NK
IRS1 / Transcriptional transactivator Pari et al. (1993);
TRS1 Romanowski et al. (1997)
US1 NK
US2 Glycoprotein, immune evasion, US2 
and US11 induce rapid export of 
MHC-1 from ER to cytosol where it 
is degraded by proteasomes
Wiertz et al. (1996)
US3 IE Glycoprotein, immune evasion, 
involved in activating expression of 
cellular hsp70 and causing retention 
of MHC-1 chains in the ER
Jones et al. (1996); 
Biegalke (1999)
US6 E-L Glycoprotein, immune evasion, 
inhibits with TAP-mediated peptide 
translocation
Ahn et al. (1997)
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US7 E-L Glycoprotein
US8 E Glycoprotein
US9 E Glycoprotein, implicated in cell-to- 
cell spread in epithelial cells
Maidji et al. (1998)
US10 E Glycoprotein
US11 E Glycoprotein, US2 and US11 induce 
rapid export of MHC-1 from ER to 
cytosol where it is degraded by 
proteasomes
US12 E Multiply hydrophobic
US13 E Multiply hydrophobic
US14 E Multiply hydrophobic
US15 E-L Multiply hydrophobic
US16 E Multiply hydrophobic
US17 E Multiply hydrophobic
US18 E Multiply hydrophobic
US19 E Multiply hydrophobic
US20 E Multiply hydrophobic
US21 Multiply hydrophobic
US22 E Secreted protein Mocarski et al. (1988)
US23 E NK
US24 E NK
US26 E NK
US27 E Multiply hydrophobic, homology to G 
protein-coupled receptor (GCR)
Kledal etal. (1998); Chee 
et al. (1990)
US28 E Multiply hydrophobic, chemokine 
receptor
Gao and Murphy (1994); 
Bodaghi et al. (1998)
US29 E-L NK
US30 E NK
US31 NK
US32 L NK
US34 E NK
US34A NK
Table 1.5: Functions of HCMV genes.
HCMV gene function is provided with references where applicable. The function of the homologous 
gene in HSV-1 is provided (pink italic font) where the function of HCMV gene is unknown. The 
proposed gene content of HCMV is derived from Davison et al. (unpublished data). Essential and 
non-essential genes are shown in red and blue, respectively.a From Chambers et al. (1999).b Gene 
present only in Toledo strain (Cha etal., 1996, Davison etal., unpublished).c Function not known.
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arranged co-linearly with those of HCMV. The DNA sequence of tupaiid herpesvirus 
(195,857 bp; Bahr and Darai, 2001) has been published recently. The sequence is predicted 
to contain 158 protein-coding ORFs, of which 76 genes have significant homology to genes 
in HCMV. Homologues of most of the members of the HCMV US22 gene family exist, but 
there appear to be no counterparts of the TRS1, IRS1, UL24 or UL43.
The HCMV genome contains 41 of the core genes common to a-, p- and y-herpesviruses 
(Fig. 1.9). These are arranged in blocks (see section 1.1.4) in different herpesviruses and 
reflect evolution from a common ancestor (McGeoch and Davison, 1999; Davison, 1993).
Chambers et al. (1999) determined the kinetic class of approximately 75% of transcripts 
specified by the ORFs identified by Chee et al. (1990). However, much work is still 
required to characterise gene functions. The functions ascribed to many HCMV genes 
depend upon their homology with identified HSV-1 gene products. Many such genes are 
involved in DNA replication, nucleotide metabolism, capsid structure and virion 
morphogenesis. Little or nothing is known about the functions of more than half of the 
predicted HCMV genes. At least 54 genes have characteristics of glycoproteins (Chee et 
al., 1990). The products of at least 44 AD 169 ORFs (TRL4-TRL14, UL1-UL10, UL16, 
UL18, UL20, UL33, UL128, IRS1, US1-US13, US27; UL24; UL36; UL43; those coded by 
the additional region in Toledo) are dispensable for virus growth in cell culture (Mocarski, 
1996; Patterson and Shenk, 1999; Dargan et al., 1997; Cha et al., 1996). A list of HCMV 
genes and their functions is given in Table 1.5.
Novotny et al. (2001) showed possible matches between predicted HCMV proteins and a 
library of three-dimensional protein structures, using a threading program. However, the 
significance of this analysis in being able to discriminate meaningful findings is uncertain.
1.3.8 Spliced transcripts in HCMV
HCMV encodes a number of spliced mRNAs (Elliot et al, 1991), The donor and acceptor 
sequences of published splice sites are shown in Table 1.6.
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ORF Position8 Sequenceb (5’-3’) References
Donor Acceptor Donor Acceptor
UL22A 3 3 2 3 3 2 5 3 ACGGTGAAT ATCGTGTTTTTGCAGC l , 7
UL33 4 3 0 8 7 4 3 2 0 9 TCGGTGAGC TGCTGTTCCGCCCAGA 5
UL36 4 9 5 7 5 4 9 4 7 1 AAGGTAAGC TCTATTCTCTACCAGG 4
UL37 5 2 2 1 9 5 0 9 8 9 CCAGTAAGC TCATTTTCTTTCTAGT 3 , 4
5 0 9 4 7 5 0 8 4 2 CAGGTAAAA GTCGTCTCCACGTAGG
UL8 9 1 3 7 5 0 2 1 3 3 5 9 9 AACGTGAGT CTCCTCTCTACACAGA 2 , 7
U L 111A 1 5 9 8 5 7 1 5 9 9 3 4 TTGGTAGGT GTTTTCCTCTTGTAGC 6
1 6 0 1 3 4 1 6 0 2 1 8 TGTGTAAGT TTGTCGGGCTCCCAGC
U L 1 1 2 -U L 1 1 3 1 6 1 3 4 5 1 6 1 5 0 3 ACGGTGAGT TCGTCCCGTCTGTAGG 9
U L 1 1 9 -U L 1 1 8 1 6 7 5 6 3 1 6 7 4 7 4 AAGGTAAGT GAATTTTATCCACAGG 7
U L 122 1 7 2 3 9 6 1 7 2 2 2 5 TCGGTAAGT T C T TAT CAC CAT CAGG 9
U L 123 1 7 3 6 1 0 1 7 2 7 8 2 GACGTAAGT GGGTCTTTTCTGCAGT 8
1 7 2 6 9 5 1 7 2 5 8 0 ACGGTACGT TTCTCATGTGTTTAGG
1 7 2 3 9 6 1 7 2 2 2 5 TCGGTAAGT TATCCTCCTCTACAGT
Table 1.6: Published splice sites in AD169.
a Underlining indicates the last base of the upstream exon and the first base the next exon. 
b Donor and acceptor splice sequences as shown for mapped mRNAs.
References: 1; Bresnahan and Shenk (2000), 2; Costa et al. (1985), 3; Goldmacher et al. (1999), 4; 
Kouzarides et al. (1988), 5; Margulies et al. (1996), 6; Muralidhar et al. (1996), 7; Rawlinson and 
Barrell (1993), 8; Stenberg etal. (1989). 9; Wright etal. (1988).
Splicing has been reported for additional ORFs, e.g. UL116-UL115, UL118-UL117, US3 
and US6 (Leatham et al., 1991; Jones and Muzithras, 1991; Rawlinson and Barrell, 1993), 
but in these cases the functional significance is not clear. In some cases, locations of intron- 
exon boundaries are not known precisely (e.g. US6) or the putative acceptor and donor 
splices in HCMV are not conserved in CCMV.
Splicing patterns may differ between P-herpesviruses. For example, the homolog of UL112 
is spliced differently in HHV-6 and HHV-7 (U79). U79 contains three exons (Nicholas, 
1996; Megaw et al., 1998), whereas only two have been identified in HCMV. The MCMV 
counterpart of UL112 (Ml 12) also consists of three exons (Rawlinson et al., 1996).
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It is probable that more spliced genes remain to be identified in HCMV. For example, two 
novel spliced genes (UL128 and UL131A) were identified from comparisons between 
HCMV and CCMV (Davison et al., unpublished data).
1.3.9 The HCMV US22 gene family
The HCMV US22 gene family contains 13 members: US22, US23, US24, US26, TRS1, 
IRS1, UL23, UL24, UL26, UL28, UL29, UL36, and UL43. Among these, UL26 is a new 
member identified by Davison et al. (unpublished data). Most of the HCMV US22 genes 
have counterparts in other p-herpesviruses (HHV-6, Gompels et al., 1995; HHV-7, 
Nicholas, 1996; Megaw et al., 1998; MCMV, Rawlinson et al., 1996; Rat CMV, Vink et 
al., 2000; and Tupaiid herpesvirus, Bahr and Darai, 2001), although the precise 
correspondence is difficult to establish for some, particularly those in TRs/IRs and Us. 
Homologues have not been identified in other herpesviruses, but the presence of a similar 
number of US22 genes in the sequenced p-herpesviruses suggests that these genes provide 
important functions during replication.
Genes belonging to the US22 gene family contain one or more of four conserved amino 
acid sequence motifs (Chee et al., 1990; Nicholas, 1996). Among these, motifs I and II are 
well conserved in most US22 genes (Fig. 1.10). Motif I differs between UL and US 
members and is defined as GXXOXOXWP in UL members and OXOXXPXXW in the 
latter (where O is a hydrophobic residue and X any residue). Motif II, OOCCXXXLXXOG 
(Kouzarides et al., 1988; Chee et al., 1990) is present in all US22 genes except UL28, 
UL29, TRS1 and IRS1. Motif III, originally defined as OOOCXD/E(X)MOXXOG by 
Nicholas (1996) and recently revised by Davison et al. (unpublished data), is present in all 
US22 genes. Motif IV consists of a short run of charged residues in the C-terminal region 
(Efstathiou et a/., 1992). This motif is poorly defined and therefore not shown in Fig. 1.10.
The functions provided by the conserved motifs are unknown, but their existence argues for 
some similarity in biochemistry or biology of the US22 family proteins. Interestingly, the 
spacing of motifs I and II appears to be conserved (20-22 amino acids) and this is 
presumably reflected in protein folding and function. The direct repeat (DR) regions of
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HHV-6 and HHV-7 appear to be related to sequences located in the US region of HCMV 
and contain US22 gene homologues (Gompels et al., 1995; Nicholas, 1996; Megaw et al., 
1998). Homologues of HCMV UL36 (both exons) exist in HHV-6 and HHV-7, and the 
positions of the splice donor and acceptor sequences are well conserved (Nicholas, 1996). 
Splicing may also be important for expression of certain HHV-6 and HHV-7 US22 gene 
family members, since splicing of two pairs of ORFs would result in proteins containing 
the US22 motifs in their usual order (Megaw et al., 1998).
Approximately twelve MCMV ORFs belong to the US22 gene family (Rawlinson et al.,
1996), but as in HCMV, their functions largely unknown. However, MCMV M43 (UL43 
homologue) has been shown to be a determinant for viral growth in the salivary gland 
(Xiao et a l, 2000). M139, M140 and M141 (US22, US23 and US24 homologues, 
respectively) are early proteins that are distributed throughout the infected cell (Hanson et 
a l, 2001). Deletion of MHO or M141 results in impaired replication in macrophages and 
spleen tissue, whereas M l39 does not appear to be required for replication in macrophages. 
M l40 and M141 appear to act individually and together to regulate MCMV replication in a 
cell-type specific manner and are predicted to influence viral pathogenesis.
To date viral mutants in two HCMV US22 family genes, (IRS1 and UL36), have been 
generated (Jones and Muzithras, 1992; Patterson and Shenk, 1999). However a naturally 
occurring mutant with a partial deletion of gene UL43 has been identified (Dargan et a l,
1997) (see section 1.3.5.3). Few antibodies have been generated to identify US22 family 
proteins; those reported are against pTRSl/pIRSl (Romanowski et a l, 1997), pUS22 
(Mocarski et a l, 1988) and pUL36 (Patterson and Shenk, 1999).
HCMV gene US22, after which the gene family was named, specifies a protein of 
approximately 76 kDa in infected cells (Mocarski et al., 1988; Dal Monte et al., 1998). 
US22 is transcribed as an E gene, and pUS22 can be detected from 24 h post-infection 
(Mocarski et a l, 1988). Immune fluorescence showed that pUS22 is present in the nuclei of 
infected cells at E and L times in infection. However, cell fractionation studies showed that 
pUS22 is cytoplasmic with a proportion released from cells as a soluble protein at E (24 h) 
and L (72 to 120 h) times post-infection.
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The UL36-38 gene locus is a complex region that codes a number of gene products, only 
one of which (pUL36) is a member of the US22 family. Both UL36 and UL37 are spliced 
genes, and UL38 is contained within one of the UL37 introns. Proteins from the UL36-38 
locus have previously been shown to be essential for transient complementation of HMCV 
orzLyt-dependent DNA replication (Pari et al., 1993; Pari and Anders, 1993). One or more 
protein products from the UL36-38 locus have also been reported to co-operate with the 
major IE genes IE1 (72 kDa) and IE2 (86 kDa) in a synergistic manner to enhance 
transcriptional trans-activation from some cellular (heat shock protein 70 (hsp70) and brain 
creatine kinase) and HCMV gene (UL112) promoters (Colberg-Poley et al., 1992). The 
extent to which the transcriptional trans-activating activity of the UL36-38 locus resides in 
the UL36 gene product has yet to be determined. Recent investigations, however, have 
indicated that the acidic domain of pUL37xl and gpUL37 is probably responsible for the 
trans-activation properties of the UL36-38 locus and the synergism observed in the 
presence of HCMV IE1/IE2 proteins (Colberg-Poley et al., 1998). Zhang et al. (1996), 
have shown that the acidic domain of pUL37xl is dispensable for trans-activation of the 
hsp70 promoter but is required for IE1/IE2 synergism.
gpUL37 is a type I membrane-glycoprotein, modified by N-linked glycosylation (Al-Barazi 
and Colberg-Poley, 1996). After being processed through the secretory apparatus gpUL37 
is deposited in mitochondria in infected cells (Colberg-Poley et al., 2000). Recently, each 
of the spliced variants of UL37 (gpUL37, pUL37xl and gpUL37M) has been shown to 
function as a mitochondria-localised inhibitor of apoptosis (vMIA), inhibiting Fas-mediated 
apoptosis (Goldmacher et al., 1999). The Towne strain of CMV does not express gpUL37 
or gpUL37\i, indicating that pUL37xl alone is sufficient to block apoptosis during 
infection.
UL36 is a tegument component that is dispensable for viral replication in cell culture 
(Patterson and Shenk, 1999). pUL36 is expressed under IE conditions and is present 
throughout infection. On SDS-PAGE gels, pUL36 migrates as a doublet of bands, 
suggesting possible post-translational modification. The role of pUL36 immediately after 
delivery to the infected cell is almost certainly to inhibit the initiation of apoptosis. The
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Motif I
UL US
GXXOXOXWP O XO XXPXXW
UL23 GORVALVWP US22 VALRNPANW
UL24 GQVLPVVWP US23 LSLGIPHNW
UL28 GRWLPLCWP US24 LSLGPPKGW
UL2 9 GSCVSLGWP US26 LPISAPPGW
UL36 GTRLHVAWP
UL43 GTVLRLSWP
(X= any residue, O=hydrophobic residue)
Motif II
O O C C XXXLXXO G
UL23
UL24
UL36
UL43
US22
US23
US24
US26
YLCCPEPLRFVG
YLCCQTRLAFVG
YVCCQEYLHPFG
FLCCDKFLLPVG
YLCCDDTLEAVG
VICCPERLIVLG
LICCREPLTPLG
LICCEESLESLG
Motif III
00OO00 g OyOy oyrOA so eFor G1 y
UL23 SELYLGASGAMYLWTDHIYSDSLTFVAESITEFLNIGL RRCNF
UL24 AVCLISDEGYVFCY VRE DTAVYYLARNLME FARVGL RAVETLH
UL26 SVAGVAADGSVLCY EISRENFVVRAADSLPQLLERGL LHSY
UL28 PEIWVSGHGHAFAY LPGEDKVYVLGLSFGEFFENGL FAVY
UL2 9 RILCGDTGTVYAAL VGQDKLVRLARDLRGFVRVGL ALLIDDFRY
UL36 LIVLIGQRGGIYCY DDLRDCVYELAPTMKDFLRNGF RHRD FH
UL43 ISILVNECGLVRGV HPETNRAHFLARGLQTFFNVGF LRFNNNY
US22 GLVLLDKFGVVYLH KIEDSDLYRIADNFHMFLKCGL LKLRGLCRF
US23 VVIVKSHLDRSPPL QRLAGEIYRLADSLEELFRAGL MKVYVRRRY
US24 VLVLLDWFGAVYAIQMDDPNHYVRRVANTITEFFRMGL LKMVF
US2 6 LVLLLGRYETVWCL DRDRGVLYYLAHSLDDFARHGL LHCEAIY
TRS1/IRS1 LVVLLDELGAVFGY CPLDGHVYPLAAELSHFLRAGV LGALALG
Figure 1.10: Three conserved motifs present in HCMV US22 gene family 
members.
Adapted from Chee etal. (1990), Nicholas (1996) and Davison etal. (unpublished data).
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UL36 gene encodes an inhibitor of caspase-8 activated (vICA) apoptosis (Skaletskaya et 
al., 2001). pUL36 binds the pro-domain of caspase-8 and prevents activation of Fas- 
mediated apoptosis. vICA does not share sequence homology with FLICE-inhibitory 
proteins (FLIPs) or other known suppressors of apoptosis, and therefore UL36, like 
UL37xl, appears to encode a new class of cell-death suppressor.
Two additional members of the US22 gene family, pIRSl and pTRSl, are known to be 
tegument proteins (Romanowski et al., 1997). The TRS1 gene is transcribed as an 
unspliced 2.7 kb mRNA. pIRSl has been shown to be dispensable (Jones and Muzithras,
1992). pIRSl and pTRSl are present throughout infected cells at IE and E times post­
infection, but become more abundant and predominantly cytoplasmic at L times post­
infection (Romanowski and Shenk, 1997). Overall, pIRSl and pTRSl are 55% identical 
and, despite divergence after amino acid 549, the C terminus of each protein is charged, 
which may be important for protein-protein or protein-DNA interactions.
1.3.10 Gene Expression
Transcription of HCMV genes upon infection is temporally controlled and regulated in a 
cascade system. In common with other herpesviruses, gene expression falls into three major 
kinetic classes; immediate early ( IE or a), early ( E or P) and late (L or y).
IE genes are those transcribed by host cell RNA polymerase II in the presence of inhibitors 
of protein synthesis. They include UL123 (IE1), UL122 (IE2), UL36-38, TRS1/IRS1 and 
US3, whose products appear to be involved largely in subsequent gene regulation steps 
(Stenberg et al., 1985; Weston, 1988; Kieff and Liebowitz, 1990).
Transcription of E genes requires the presence of IE proteins and is not affected by 
inhibitors of viral DNA replication (Depto and Stenberg, 1989). E genes are distributed 
throughout the genome, although TRl /IRl is the most transcriptionally active region 
(DeMarchi, 1981; Staprans et al., 1988). The products of this class of genes have roles in 
DNA replication, nucleotide metabolism and immune evasion.
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L genes are expressed essentially after the onset of viral DNA replication, from around 24 h 
postinfection (Stamminger and Fleckenstein, 1990). L gene expression may be divided into 
two sub-classes; yi (leaky late or E-L) and 72 (true late or L). E-L transcription and 
translation start prior to viral DNA replication, but maximal expression occurs 
subsequently. L gene expression is strictly dependent on viral DNA replication (Stasiak and 
Mocarski, 1992). Expression at L times occurs from the entire genome and results in the 
production of transcripts encoding proteins that contribute to the assembly and 
morphogenesis of the virion, (e.g. virion proteins such as pUL86, phosphoproteins such as 
ppl50 (pUL32) and pp65 (pUL83) and glycoproteins such as gB (pUL55)).
The kinetic classes of HCMV genes can be determined using chemical inhibitors. For 
example, in the presence of cycloheximide (a protein synthesis inhibitor), only IE RNA 
will accumulate. In the presence of phosphonoacetic acid (PAA) or ganciclovir (GCV) 
(inhibitors of viral DNA replication), IE and E RNA will accumulate. Further classification 
of transcripts as E-L or L is done quantitatively (Chambers et al., 1999).
Although this simplistic scheme provides a convenient system by which individual HCMV 
genes can be grouped, it is based on highly artificial inhibitor studies. The reality is more 
complex, with overlap between transcriptional classes. Indeed some genes are expressed in 
two classes from different promoters (e.g. UL122). Moreover, with some genes there is a 
delay between transcript production and protein synthesis, indicating that translational 
control mechanisms contribute to the overall regulation of gene expression. For example, 
expression of gpUL4 is repressed at the translational level by the presence of a short 
upstream open reading frame (uORF2) within the UL4 transcript leader, and mutation of 
uORF2 eliminates ribosomal stalling and results in abundant early expression of gpUL4 
(Alderete et al., 2001).
Chambers et a l (1999) used DNA microarray technology to detect the expression of 151 
HCMV ORFs, 16% of which are IE, 26% of which are E, 26% of which are E-L and 32% 
of which are L. Some of the differences between microarray data and previously published 
results are probably due to the inability of the microarray technology to distinguish 
between overlapping transcripts. This is a serious drawback to the technique, and indicates
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the importance of using other techniques to determine the individual kinetic classes, sizes 
and 5’- and 3’-ends of transcripts.
1.3.11 Transcriptional trans-activators in HCMV
Several proteins encoded by HCMV function as transcriptional trans-activators and thereby 
create a complex regulatory network that controls gene expression and establishes a 
progressively changing environment inside the infected cell. Some of trans-activators are 
expressed at IE times post-infection (IE1 72, IE2 86), whereas others are virion 
components (pIRSl, pTRSl, pUL69, pp71 (pUL82)) (Romanowski et al., 1997; Winkler et 
al., 1995; Liu and Stinski, 1992). Certain trans-activators (pIRSl and pTRSl) are delivered 
to the infected cell as particle components and are also expressed at IE times.
1.3.11.1 Major immediate early (MIE) gene locus
The major HCMV trans-activators are the nuclear phosphoproteins IE l49iaa 72 kDa (IE1 72) 
and IE2579aa 86 kDa (IE2 86), which are expressed by differential splicing from the major 
immediate-early (MIE) gene locus. The MIE gene region of HCMV is located between 167 
and 175 kbp on the HCMV genome (Fig. 1.9). The first sequence data for this region were 
reported for HCMV Towne (Stenberg et al., 1984). This region is abundantly expressed 
from a strong and complex enhancer/promoter, and expression results in the generation of 
differentially spliced polyadenylated transcripts (exon 4 corresponds to UL123 and exon 5 
to UL122 in Fig. 1.11). These transcripts encode two major products, IE l49iaa which shares 
an 85 residue N-terminal domain with IE2579aa (Spector, 1996; Stenberg, 1996). IE ^iaa 
exhibits an apparent size of 68 to 72 kDa and is phosphorylated (Blanton and Tevethia, 
1981). IE2579aa also a nuclear phosphoprotein (Hermiston et al., 1987). In addition to 
IE2579aa, a less abundant protein (IE2425aa) is made from a transcript in which an additional 
intron is removed from exon 5. The most abundant IE2 gene product (yIE233gaa) is expressed 
exclusively late in infection from a non-spliced transcript originating within exon 5 
(Stenberg, 1996; Jenkins and Mocarski, 1994). IE233gaa is both a repressor of IE gene 
expression and a transactivator of E and L genes, although the mechanism of action is 
different from that of IE2579aa (Barracchini et al., 1992; Mocarski, 1996).
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Figure 1.11: Structural organisation of the AD169 MIE gene locus.
The AD169 genome is depicted on the top line with the region between 165 and 178 kbp 
expanded below (not to scale). EcoRI, Sail, C/al and H/ndlll restriction sites common to AD169 
and Towne are shown. The position of the enhancer is indicated by a red box. Three principal 
spliced IE transcripts are depicted by arrows with exons numbered and coding regions are 
indicated by the coloured boxes below. Adapted from Edward and Mocarski (1996).
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Figure 1.13: Regulation of HCMV gene expression.
The top line depicts the structure of the HCMV genome (not to scale) with the virion 
transactivator gene UL82, depicted above the line and IE genes (IE1 and IE2, UL36, UL37, 
UL69, TRS1, IRS1 and US3) along with both IE gene enhancers (red boxes) depicted below 
the line. Both enhancers contain a high concentration of binding sites for cellular transcription 
factors (described in text). The lower three parts of the diagram show the IE1/IE2 locus 
expanded and depict models of the role of regulatory functions in the activation and 
repression of HCMV gene expression as described in the text. A: Activation of the IE1/IE2 
enhancer. B: Repression of IE1/IE2 gene expression. C: Activation of E and L gene 
expression. Adapted from Edward and Mocarski (1996).
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The MIE locus is under the control of the MIE promoter-enhancer (MIEP), which is subject 
to both positive and negative regulation. The MIEP contains a large number of binding 
sites for cellular transcription factors and certain viral proteins (Mocarski, 1996). 
Analogous promoter-enhancers are found upstream of the predominant IE gene locus in 
MCMV and SCMV, and similar enhancer elements control expression of HCMV US3 
(Biegalke, 1999; Colberg-Poley, 1996). The MIEP can be divided into the enhancer region 
(-500 to + 1, relative to the IE1/IE2 transcription start site), the specific NF-1 binding 
region (-800 to -500) and the modulator region (-1,100 to -800). Several cellular factors 
(e.g. p53, YY1, NF-&B, ATF, CREB, API, Spl, C/EBP, SREB, NF1, TNF-ot) have been 
shown to bind within and upstream of the enhancer region and downstream of the 
transcriptional start site (Mocarski, 1996; Prosch et al., 1996; Zhang et al., 2001). The 
enhancer contains repeated sequence elements (16, 18, 19 and 21 bp repeats) interspersed 
with unique sequences. This complex array of binding sites allows the MIEP to respond to 
the intracellular environment in a broad range of different cell types. Deletion of the distal 
enhancer region has been shown to correspond to a deficiency in production of MIE and 
US3 RNAs, but only during low m.o.i. infections (Meier and Pruessner, 2000). The role of 
the modulator region is not fully understood, but binding of transcription factors, such as 
Yin Yang-1 (YY1), has been shown to repress transcription.
IE1 is known to activate its own promoter through the 18 bp repeats and NF-&B elements 
and to act via a TATA box-independent mechanism. The IE1 and IE2 gene products have 
been implicated in both positive and negative regulation of viral gene expression (Fig. 1.12). 
The critical player in switching from a  to p gene expression is IE2579aa. IE2579aa 
downregulates expression of gene products by binding to the czs-repression {crs) signal, a 15 
bp target sequence. The crs sequence is orientation-independent and can confer IE2- 
dependent repression on heterologous promoters (Cherrington et al., 1991). Repression 
occurs at the transcriptional level, possibly by IE2 altering RNA polymerase II before the 
initiation of complex formation. Only the C-terminal half of IE2579aa is required for this 
repression, whereas it appears that both N and C terminal regions of IE2579aa are important 
for trans-activation (Mocarski, 1996).
IE2338aa is both a repressor of a gene expression and a trans-activator of P and y genes. The 
target sequence for activation is different from the sequence for IE2579aa repression (Fig.
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1.12) (Baracchini et al., 1992). The mechanism of synergistic co-operation between IE l49iaa 
and IE2579aa is not fjally understood, although protein-protein interactions with host 
transcription factors may be more important for both than direct binding to DNA (Mocarski, 
1996). Experiments on activation of HIV-LTR and hsp 70 promoters reveal that trans- 
activation by IE2 is TATA box-dependent (Caswell et al., 1993, Hagemeier et al., 1992). 
IE2 can overcome Dr-1 mediated repression of the hsp-10 promoter via a novel derepression 
mechanism and can bind to DNA and counter histone-mediated repression (Klucher et al.,
1993). The ability to bind DNA and engage in protein-protein interactions may allow 
IE2579aa to serve as the active recruiter for the formation of multiprotein-DNA complexes on 
HCMV E promoters to ensure that the proteins needed for high level HCMV transcription 
are present.
1.3.11.2 Other trans-activators
The virion component, pp71 (pUL82) is encoded by a 1.9 kb mRNA that is 3' co-terminal 
with UL83 transcript (Nowak et al., 1984). pp71 is located at the inner part of the tegument 
layer attached to the major capsid protein and is translocated into the nucleus immediately 
after infection (Hensel et al., 1996; Trus et al., 1999). pp71 is critical for initiating lytic 
infection since it is a potent trans-activator of the MIEP and can also activate a number of 
viral promoters in conjunction with other viral proteins, including pUL69 (Homer et al., 
1999; Winkler et al., 1995). pp71 activates MIE promoters with upstream ATF or AP-1 
binding sites and, has been shown to enhance the infectivity of HCMV DNA up to 80-fold 
(Liu and Stinski, 1992; Baldick et al., 1997).
All mammalian herpesviruses encode a protein that is homologous to HCMV pUL69 
(Winkler et al., 2000). Winkler et a l (1994) reported that pUL69 is expressed at E-L 
conditions, but Mocarski (1996) showed that pUL69 is actually expressed with IE kinetics. 
Three isoforms of pUL69 are expressed: 105 kDa, 110 kDa, 116 kDa. However, only the 
110 kDa isoform is incorporated into the tegument (Winkler and Stamminger, 1996). pUL69 
stimulates activation of the MIEP in synergy with the tegument trans-activator pp71 
(Winkler et al., 1995). This suggests that pp71 and pUL69 may augment the initiation of 
lytic infection until sufficient IE1 and IE2 have accumulated for their own auto-stimulation. 
pUL69 exhibits broad trans-activating properties and has a stimulatory effect on several
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viral E and heterologous promoters. It can induce cells to arrest in Gi phase of the cell cycle 
(Lu and Shenk, 1999;, Hayashi et al., 2000). pUL69 localises to nuclear and DNA 
replication compartments and interacts with a cellular protein that is homologous to yeast 
factor SPT6, which is thought to regulate chromatin structure. Mutagenesis of the central 
domain of pUL69, disrupts the pUL69-SPT6 interaction and also results in loss of the trans­
activation potential of pUL69, thus implicating the interaction as being essential for trans­
activation by pUL69 (Winkler et al., 2000). pUL69 was shown to antagonise the interaction 
of the C terminus of SPT6 with histone H3, indicating that pUL69 exhibits broad trans- 
activating properties and affects lytic DNA replication by targeting a chromatin regulatory 
protein, SPT6, that acts as a repressor of gene expression.
pIRSl and pTRSl, have been reported to activate the MIEP modestly in transient 
transfection assays (Romanowski and Shenk, 1997). pIRSl/pTRSl, in combination with 
pUL69, can activate reporter expression driven by the IRS1/TRS1 promoter. Although 
pIRSl/pTRSl can synergise with IE1 and IE2 to activate a range of heterologous 
promoters, they do not appear to be a broad acting trans-activators. pTRSl is required for 
activation of the E UL44 (ICP36) promoter, in combination with IE1 and IE2 (Stasiak and 
Mocarski, 1992). pIRSl263 is a truncated version of pIRSl that is expressed from a 
promoter within the IRS1 ORF and encoded entirely within the C-terminal domain and 
same reading frame as pIRSl (Romanowski and Shenk, 1997). pIRSl263 is entirely nuclear 
and is part of a regulatory loop, since it antagonizes transcriptional trans-activation 
associated with pIRSl and pTRSl.
The interactions of the HCMV trans-activators are evidently complex and not fully 
understood. It is known that the tegument proteins pp71, pUL69, pIRSl and pTRSl are 
delivered to the cell immediately after infection and are probably immediately translocated 
to the nucleus. pp71 can activate the MIEP, in combination with pUL69, inducing 
expression of IE1 and IE2. pp71 and pUL69 only modestly activate expression of gene 
US3, although expression is up-regulated by the combination of IE1, IE2, pIRSl and 
pTRSl (Biegalke, 1999). This synergistic activation of US3 expression is inhibited by 
products from genes UL37xl, UL38 and UL84, the latter also inhibiting expression of IE2 
86, and this probably represents a critical step in the switch from IE to E gene expression.
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To date, trans-activation has been studied using transient transfection assays (Romanowski 
and Shenk, 1997). Such an artificial system cannot reveal all the complex interactions that 
occur in vivo, particularly since it is clear that viral gene products intimately interact with 
cellular products to create the appropriate cellular environment for viral growth. The recent 
introduction of gene micro-array technology (Bresnahan and Shenk, 1999) will enable the 
total cellular response to HCMV infection to be monitored and may provide more 
information on the complex pattern of transcript activation.
1.4 Justification of the study
HCMV is a subject of intense research effort, yet its gene content is less well understood 
than that of any other human herpesvirus. This reflects the large size and complexity of the 
genome, and also lack of a laboratory strain with the full genetic content of wild type virus. 
The genetic content of HCMV strain AD 169 as described by Chee et al. (1990) was the 
best available at the time. However, it is not likely to be complete as the criteria employed 
to identify protein-coding regions were necessarily arbitrary and applied without the benefit 
of comparisons with other P-herpesviruses.
Moreover, AD 169 is a vaccine strain derived by multiple passage in human fibroblasts. 
Many studies have shown a link between laboratory passaging and genetic loss. Substantial 
variability in Ul was reported even before the AD 169 sequence was available (Weststrate 
et a l, 1983; Takekoshi et al., 1987). Subsequently, Cha et al. (1996) found that a large 
region in the Toledo genome was absent from high passage strains; AD 169 lacks about 15 
kbp and Towne strain lacks about 13 kbp. This was confirmed by Lurain et al. (1999) who 
reported that the extra 19 ORFs in Toledo were also present in a set of clinical isolates. In 
1997, Mocarski et al (1997) and Dargan et a l (1997) reported the presence of an extra 929 
bp in most AD 169 stocks but not in the stock sequenced by Chee et al. (1990). Wild type 
HCMV has therefore been surmised to contain over 220 genes.
Recently, Davison et a l (unpublished data) re-evaluated the gene content of HCMV on the 
basis of amino acid sequence comparisons between HCMV and CCMV, and revised the
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gene content of wild type HCMV to 164 genes. It is anticipated that this picture of HCMV 
gene content will be improved further.
Although the AD 169 genome was sequenced over ten years ago, transcriptional and 
functional data are available for a minority of genes. Recently, Chambers et a l (1999) 
determined the kinetic class of the majority of predicted HCMV transcripts by DNA 
microarray. However, much work is still required to characterise these transcripts, as this 
technique does not lead to a full understanding of transcript structure. Therefore, an 
accurate transcript map for AD 169 is still required. The purpose of my study was to 
evaluate the transcription of a selection of HCMV ORFs, including several that are 
conserved in CCMV, some that appear unlikely to encode functional proteins because they 
are not conserved in CCMV, and two novel genes.
1.5 Specific objectives of the study
1. To check potential errors in the HCMV genome sequence indicated from sequence 
comparisons between HCMV and CCMV.
2. To determine the transcriptional expression patterns of genes in the HCMV US22 
family.
3. To assess transcription of other HCMV genes in TRl and at left end of Ul.
4. To investigate transcription of two novel spliced HCMV genes (UL128 and UL131A) 
that emerged from sequence comparisons between HCMV and CCMV.
CHAPTER 2:
Materials and methods
Materials and methods
2.1 Materials
2.1.1 Viruses
HCMV strain AD 169 (Chee et al., 1990) was used in all studies. HCMV strain Toledo 
(Cha et al., 1996) and DNA from virus isolated directly from the urine of an HCMV- 
infected child (strain GW; kindly provided by Dr. Gavin Wilkinson, University of 
Cardiff) were also used for comparative studies.
2.1.2 Cells
The HFFF-2 cell line (initially supplied by J. Mitchell, Institute of Virology) was used 
for growth of virus and studies of viral gene expression.
2.1.3 Cell culture media
HFFF-2 cells were grown in Dulbecco’s Modified Eagle’s Medium (DMEM) 
supplemented with 10% (v/v) foetal calf serum (FCS), 1% non-essential amino acids, 
1% L-glutamine (stock solution of 200 mM) and 1% penicillin-streptomycin (stock 
solution of 1000 IU/ml and 100 pg/ml, respectively).
Versene (0.6 mM EDTA in PBS, 0.002% (w/v) phenol red) and trypsin (0.25% (w/v) 
in Tris-saline) were used for washing and removal of cell monolayers during 
passaging or setting up confluent monolayers for infections.
2.1.4 Cosmids
Cosmid IB (contains the region in the AD 169 genome at nucleotides 197042-229354 
and 1-7854) was supplied by Dr. D. Dargan.
2.1.5 Chemicals
All general chemicals were obtained from BDH, Boehringer-Mannheim or Sigma.
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2.1.6 Solutions and buffers
Cell culture growth media
Eagles A
Eagles B 
Salts/plus
Amino acids/plus
Vitamins
0.23 g/1 CaCl2.2H20  
0.23 g/1 MgS04.7H20  
0.1 ml/1 HC1
50% (v/v) salts/plus 
40% (v/v) amino acids/plus 
3.2% (v/v) vitamins
10.24 g/1 NaCl
0.64 g/1 KC1
0.24 g/1 NaH2P 0 4.2H20
7.2 g/1 glucose
0.00016% (v/v) Fe2(N 03)3
0.468 g/1 L-glutamine
0.016% (v/v) penicillin
0.016 g/1 streptomycin
0.00032% (v/v) amphotericin B
0.84 g/1 arginine mono-HCl
0.48 g/1 cystine
0.384 g/1 histidine mono-HCl
1.048 g/1 isoleucine
1.048 g/1 leucine
1.462 g/1 lycine mono-HCl 
0.66 g/1 phenylalanine 
0.952 g/1 threonine 
0.16 g/1 tryptophan 
0.724 g/1 tyrosine 
0.936 g/1 valine 
0.3 g/1 methionine 
0.07% (v/v) inositol 
0.03% (v/v) phenol red 
55 g/1 NaHC03
0.05 g/1 choline chloride
0.05 g/1 folic acid
0.05 g/1 nicotinamide
0.05 g/1 pantothentic acid, Ca salt
0.05 g/1 pyridoxal-HCl
0.05 g/1 thiamine-HCl
0.005 g/1 riboflavine
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Methylcellulose overlay
Giemsa stain
Phosphate buffered saline (PBS)
Storage medium 
Tris-saline
RNA extraction
Stock buffer
Binding buffer
39% (v/v) carboxymethylcellulose 
1.56% (v/v) tryptose phosphate 
3.9% (v/v) FCS 
24.3% (v/v) NaHC03 (7.5%)
1.56% (v/v) penicillin/streptomycin 
(10000 IU/ml)
0.08% (v/v) amphotericin B
7% (v/v) 10 x Glasgow’s modified
medium
1.5% (w/v) suspension of Giemsa in 
glycerol heated at 65°C for 2 h, 
diluted with an equal volume of 
methanol
170 mM NaCl
3.4 mM KC1 
10 mM Na2HP04
1.8 mM KH2P 04
6.8 mM CaCl2
4.9 mM MgCl2
90% (v/v) foetal calf serum (FCS) 
10% (v/v) dimethylsulfoxide (DMSO)
140 mM NaCl 
30 mM KC1 
280 mM Na2HP04 
25 mM Tris-HCl 
1 mg/ml glucose 
0.1 mg/ml streptomycin 
10011/ml penicillin 
0.0015% (w/v) phenol red
0.2 M NaCl 
0.2 M Tris-HCl, pH 7.5 
1.5 mM MgCl2 
2% (v/v) SDS
0.5 M NaCl
10 mM Tris-HCl, pH 7.5
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Wash buffer 
TE
Elution buffer 
Northern blotting
10 x MOPS
Electrophoresis buffer 
Loading buffer
Nucleic acid transfer buffer (20 x SSC)
RACE PCR
5 x First strand buffer
Tricine-EDTA buffer
Agarose Gel electrophoresis
lOxTBE
DF dyes
0.25 M NaCl
10 mM Tris-HCl, pH 7.5
10 mM Tris-HCl, pH 8 
1 mM EDTA
10 mM Tris-HCl, pH 7.5
41.2 g/1 MOPS [3-(N-morpholino) 
propanesulfonic acid]
6.6 g/1 anhydrous sodium acetate
3.7 g/1 EDTA sodium salt, pH 7
1 x MOPS
4 mg/ml bromophenol blue 
4 mg/ml xylene cyanol 
0.25 g/ml Ficoll 400
88.2 g/1 tri-sodium citrate 
174 g/1 NaCl
250 mM Tris-HCl, pH 8.3 
375 mM KC1 
30 mM MgCh
10 mM Tricine-KOH, pH 8.5 
1.0 mM EDTA
109 g/1 Trizma 
55 g/1 boric acid
9.3 g/1 EDTA
37.2 g/1 EDTA 
100 g/1 Ficoll 400 
5X TB E
1% (w/v) bromophenol blue
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Plasmid preparation
X-gal
IPTG
GTE
NaOH/SDS
Potassium acetate solution
PEG/NaCl
Phenol TE 
Prim er extension
10 x T4 polynucleotide kinase (PNK) 
buffer
2 x AMY Primer extension buffer
Loading dyes
40 mg/ml 5-bromo-4-chloro-3-indoyl 
p-D-galactoside in N, N ’-dimethyl 
formamide
30 mg/ml isopropylthio-P-D- 
galactoside
50 mM D-glucose 
25 mM Tris-HCl, pH 8 
10 mM EDTA
200 mM NaOH 
1% (w/v) SDS
3 M potassium acetate 
2 M acetic acid
20% (w/v) PEG 6000 
2.5 M NaCl
Phenol equilibrated with TE
500 mM Tris-HCl, pH 7.5 
100 mM MgCl2 
50 mM dithiothreitol 
1 mM spermidine
100 mM Tris-HCl, pH 8.3 at 42°C
lOOmMKCl
20 mM MgCl2
20 mM dithiothreitol
2 mM each dNTP
1 mM spermidine
98% (v/v) formamide 
10 mM EDTA 
0.1% (w/v) xylene cyanol 
0.1% (w/v) bromophenol blue
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Acrylamide solution
Top gel mix (TGM)
2.1.7 RNA extraction
FastTrack 2.0 mRNA isolation kit:-
Stock buffer
Protein/Rnase degrader
Binding buffer
Low salt wash buffer
Elution buffer
2 M Sodium acetate
5 M NaCl
Glycogen carrier
Oligo (dT) cellulose
Spin columns
Microfuge tubes
TRIZOL Reagent
- Oligo (dT)-cellulose
if
Spin-X column
I
Cycloheximide [3 - {2-(3,5-dimethy 
oxocyclohexy l)-2-hy droxy ethyl} 
glutarimide]
Phosphonoacetic acid (PAA)
40% (w/v) Acrylogel 5 premix, 
deionized
6 ml 10 x TBE 
18 ml acrylamide solution
55.2 g urea 
Final volume 120 ml
Invitrogen
Gibco Life Technologies
Sigma
Costar
Sigma
Sigma
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2.1.8 Northern blotting
Nytran SuperCharge Membrane
3 MM Paper
Lign’Scribe kit:-
10 x Ligation buffer
10 x T4 DNA ligase
T7 Promoter Adapter
PCR Adapter primer 1(10 pM)
Control DNA template
(mouse cyclophilin; 1 ng/pl)
5’-Cyclophilin PCR primer (10 pM) 
3’-Cyclophilin PCR primer (10 pM)
MaxiScript T7 kit:- 
RNA polymerase (15 U/pl) 
Ribonuclease inhibitor (5 U/pl) 
10 x transcription buffer 
ATP (10 mM)
CTP(lOmM )
GTP (10 mM)
UTP (10 mM)
DNase I (Rnase-free; 2 U/pl) 
Loading buffer
PTRI-actin-mouse (0.5 mg/ml)
Rapid hyb buffer
Gene-specific primers (GSPs)
Schleicher & Schuell
Whatman
Ambion
Ambion
Amersham 
MWG Biotech AG
[a32P]CTP, [a32P]GTP and [a32P]UTP NEN Life Science Products 
(3000 Ci/mmol, 10 pCi/ml)
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2.1.9 PCR techniques: PCR, RT- PCR and SMART RACE PCR
Taq DNA polymerase, 10 x PCR buffer with MgCl2 Boehringer-Marmheim
Titan One Tube RT-PCR System:- Boehringer-Mannheim
Enzyme mix, AMV-Reverse transcriptase, Taq DNA
polymerase, Pwo DNA polymerase
RT-PCR buffer with 7.5 mM MgCl2 and DMSO
Dithiothreitol (100 mM)
SMART RACE cDNA Amplification kit:- Clontech
SMART II oligonucleotide (10 pM)
3’-CDS (10 pM)
5’-CDS (10 pM)
5 x first strand buffer 
20 mM dithiothreitol 
Deionized water
10 x Universal primer mix (UPM)
Human placental total RNA (1 pg/pl)
5’-RACE transferrin receptor (TFR) primer (10 pM)
3’-RACE TFR primer (10 pM) 
dNTP (each at 10 mM)
Tricine-EDTA buffer
50 x Advantage 2 Polymerase Mix Clontech
and 2 x Advan 2 PCR buffer
dNTPs (10 mM each) Amersham Life
Sciences
Primers MWG-Biotech AG
2.1.10 Agarose gel electrophoresis
Standard agarose and ethidium bromide (10 Sigma 
mg/ml aqueous solution)
Low melting point (SeaPlaque) agarose FMC Bioproducts
DNA markers (1 kbp and 100 bp ladders) New England BioLabs
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2.1.11 Recovery, cloning and sequencing of DNA fragments
p-agarase I and 10 x p-agarase buffer New England Biolabs
pGEM-T Vector System I Promega
One Shot TOP 10 competent E. coli cells Invitrogen
Restriction endonucleases and other New England Biolabs
enzymes and buffers
Internal gene primers for sequencing MWG-Biotech AG
M l3 universal sequencing primers Pharmacia Biotech
2.1.12 Primer extension
Primer Extension System-AMV Reverse Promega
Transcriptase :-
2 x AMV primer extension buffer 
Sodium pyrophosphate (40 mM)
1.2 kb kanamycin positive control RNA 
Primer extension control primer (5 pmol/pl)
AMV reverse transcriptase (AMV-RT)
Dephosphorylated <j>X174 DNA IHinf I markers 
T4 polynucleotide kinase (T4 PNK)
10 x T4 PNK buffer 
Loading dye 
Nuclease-free water
Sigmacote Sigma
N,N,N’,N ’ -tetramethy lethylenediamine Sigma
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2.1.13 Bacterial strains
One shot TOP 10 Escherichia coli strain K12 competent cells (genotype: F" mcrA 
A(mrr-hsdRMS-mcrBC) <|)80/acZAM15 AlacX14deoR recAX araD\2>9 A(ara- 
leu)1691 galU galK rpsL (StrR) end Al nupG) (Invitrogen) were used for 
maintenance and propagation of plasmids.
2.1.14 Bacterial growth media
2YT broth 85 mM NaCl
1% (w/v) bactopeptone 
1% (w/v) yeast extract 
autoclaved
L-broth 177 mM NaCl
1% (w/v) bactopeptone 
autoclaved
L-broth agar 1.5% (w/v) agar in L-broth
autoclaved
2.1.15 Autoclaving and glassware sterilisation
Equipment and solutions were sterilised at 15 psi for 20 min by staff in the wash room 
of the Institute of Virology. Glassware was sterilised by baking in an oven at 180°C 
for at least 2 h. Heat-labile solutions were sterilised by filtration through a Whatman 
syringe filter (0.2 pm) into a sterile tube.
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2.2 Methods
2.2.1 Cell culture
HFFF-2 cells were grown in Dulbecco’s Modified Eagle’s Medium (DMEM) 
supplemented with 10% (v/v) FCS in plastic roller bottles. Cells were grown at 37°C 
in a humidified atmosphere comprising 90% (v/v) air and 10% (v/v) CO2. The cells 
were harvested from the roller bottles by pouring off the medium and washing the 
monolayer with 20 ml versene. They were then washed with 20 ml trypsin/versene to 
remove the monolayer and resuspended in fresh medium at a concentration of
7 7approximately 10 cells/ml. Aliquots of 10 cells were seeded into roller bottles 
containing 100 ml of medium. For storage, cells were harvested, pelleted at 1000 x g 
in a Sorvall RC-5B superspeed centrifuge, and resuspended in storage medium.
Aliquoted cells were frozen slowly to -70°C overnight and then stored in liquid 
nitrogen. For recovery, cells were thawed quickly and resuspended in growth medium.
2.2.2 Preparation of virus stocks
HFFF-2 cells were grown in roller bottles containing 100 ml medium until 90% 
confluent. The medium was replaced with 50 ml fresh medium. The appropriate 
amount of HCMV (usually 0.01 p.f.u./cell) was added to the roller bottles, which were 
then returned to 37°C. The infected cells were incubated until maximal c.p.e. was 
observed (usually 10-15 days p.i.). The medium containing infected cells were 
decanted and the cells pelleted by centrifugation for 15 min at 1000 x g at 4°C in a 
Sorvall RC-5B superspeed centrifuge. The supernatant was collected and stored at - 
70°C. Virus stocks were titrated before use.
2.2.3 Titration of virus
Titres of HCMV stocks were determined by plaque assay on HFFF-2 cells. HCMV 
strain AD 169 stocks were serially diluted ten-fold, and 200 pi of each dilution was 
used to infect an HFFF-2 monolayer in a 35 mm diameter tissue culture dish. Each
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dilution was usually titrated in duplicate. After 1 h adsorption with rocking every 20 
min. to prevent drying of the monolayers, the inocula were removed and the cells were 
overlaid with 2 ml *per dish of DMEM. Monolayers were incubated at 37°C until 
plaques were easily visible under a low magnification light microscope. The medium 
was removed and approximately 1 ml Giemsa stain was added to each dish. After 
staining for 1 h at room temperature, the cells were washed with water and the plaques 
counted under a dissection microscope.
2.2.4 Preparation of immediate early (IE), early (E), late (L) and 
mock infected (Ml) RNA
2.2.4.1 Preparation of IE RNA
"7
HFFF-2 cells (10 per flask) were inoculated into large flasks and grown overnight. 
The medium was replaced by fresh medium containing 200 pg/ml cycloheximide, and 
the flasks incubated at 37°C for 1 h. The monolayers were then infected with HCMV 
at 5 p.f.u/cell and the flasks incubated at 37°C for 1 h with gentle shaking every 15 
min. The monolayers were washed three times with fresh medium containing 200 
pg/ml cycloheximide, supplemented with fresh medium containing 200 pg/ml 
cycloheximide, and incubated at 37°C for 24 h. The flasks were then washed three 
times with fresh medium containing 200 pg/ml cycloheximide, drained and stored at 
-70°C.
i
2.2.4.2 Preparation of E RNA
HFFF-2 cells (107 per flask) were inoculated into large flasks and grown overnight. 
\ The medium was replaced by fresh medium. The monolayers were then infected with
f
! HCMV at 5 p.f.u./cell and the flasks incubated at 37°C for 1 h with gentle shaking
i
every 15 min. The monolayers were washed three times with fresh medium, 
supplemented with fresh medium containing 300 pg/ml phosphonoacetic acid (PAA), 
and incubated at 37°C for 48 h. The flasks were then washed three times with fresh 
medium containing 300 pg/ml PAA, drained and stored at -70°C.
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2.2.43 Preparation of L RNA
7  ^HFFF-2 cells (10 per flask) were inoculated into large flasks and grown overnight. 
The medium was replaced by fresh medium. The monolayers were then infected with 
HCMV at 5 p.f.u./cell and the flasks were incubated at 37°C for 1 h with gentle 
shaking every 15 min. The monolayers were washed three times with fresh medium, 
supplemented with fresh medium, and incubated at 37°C for 72 h. The flasks were 
washed three times with fresh DMEM, drained and stored at -70°C.
2.2.4.4 Preparation of MI RNA
HFFF-2 cells (10 per flask) were inoculated into large flasks and grown overnight. 
The medium was replaced by fresh medium, and the flasks were incubated at 37°C for 
72 h. The flasks were washed three times with fresh medium, drained and stored at - 
70°C.
2.2.5 Preparation of total cellular RNA
Total cellular RNA was made from infected cells using TRIZOL extraction. Use of 
this reagent, a mono-phasic solution of phenol and guanidine isothiocyanate, offers an 
improvement to the single-step RNA isolation method developed by Chomczynski 
and Sacchi (1987).
Drained infected cells containing MI, IE, E or L RNA were lysed directly in the 
flasks by adding TRIZOL (2 ml/107 cells) and passing the cell lysate several times 
through a 1 ml pipette. The samples were transferred to 1.5 ml microfuge tubes, and 
incubated at room temperature for 5 min to permit complete dissociation of 
nucleoprotein complexes. Chloroform (200 pl/ml of TRIZOL) was then added to each 
tube. The tubes were capped securely, shaken vigorously by hand for 30 sec and 
incubated at room temperature for 3 min. Centrifugation was then carried out in a 
microfuge at 12000 x g for 15 min at 4°C. During centrifugation, the mixture 
separated into a lower phenol-chloroform phase, an interphase and a colourless upper 
aqueous phase. The aqueous phase (containing RNA) was transferred to a fresh tube.
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RNA was precipitated by mixing with a half volume of propan-2-ol and incubating at 
room temperature for 10 min. RNA was pelleted in a microfuge at 12000 x g for 10 
min at 4°C. The pellet was rinsed with 75% ethanol, air dried, resuspended in 20 pi 
sterile TE and incubated at 55°C for 10 min to dissolve RNA. Total cellular RNA was 
stored at -70°C.
2.2.6 Isolation of polyA* mRNA
PolyA+ mRNA was purified in two ways.
2.2.6.1 Isolation of polyA* mRNA from total cellular RNA
Total cellular RNA (200 pg) prepared from infected cells was added to 800 pi binding 
buffer and transferred to a 1.5 ml microfuge tube containing 15 mg oligo (dT) 
cellulose. The tube was rotated in a rotator at least for 30 min and centrifuged at 4000 
x g for 3 min. A microfuge was used throughout for centrifugation steps. The 
supernatant was discarded and the pellet was resuspended in 800 pi binding buffer. 
This step was repeated at least twice before transferring the pellet to a Spin-X column 
in binding buffer. Centrifugation was carried out at 4000 x g for 3 min, and the flow­
through was discarded. After repeating this step three times, the pellet was 
resuspended in wash buffer and centrifuged at 4000 rpm for 3 min. DNA, proteins and 
cell debris were eluted by treating the pellet in this way with wash buffer several 
times. The Spin-X column was then placed in a fresh tube and the pellet was twice 
resuspended in 100 pi 10 mM Tris-HCl (pH 7.5) and centrifuged at 4000 x g for 2 
min. 3 M sodium acetate (20 pi) and 500 pi ethanol (100%) were added to the flow­
through, and the tube was incubated at -20°C for 3 h. PolyA* mRNA was pelleted at 
12000 x g for 15 min at 4°C, washed with 70% ethanol, air-dried for 15 min and 
resuspended in sterile TE (at about 0.3 pg/pl) and stored at -70°C.
2.2.6.2 Isolation of polyA+ mRNA directly from cells
PolyA+ selected mRNA was isolated using the FastTrack 2.0 mRNA isolation kit 
(Invitrogen). This kit allows polyA+ mRNA to be isolated directly from cells (107 -  
108) or tissue (0.5 -  1.0 g) in 2-3 h. Cells were lysed in the flasks by adding lysis
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buffer, and the lysate was passed several times through a 18-21 gauge needle using a 2 
ml syringe. Lysis buffer was made by combining stock buffer with 20 pl/ml 
RNase/protein degrader. For complete digestion of ribonucleases and other proteins, 
the samples were incubated at 45°C for 30 min. Centrifugation was carried out at 3000 
x g for 5 min and the supernatant was transferred to a fresh tube. A microfuge was 
used throughout for centrifugation steps.
The NaCl concentration of the lysate was adjusted to 0.5 M by adding 5 M NaCl (63 
pl/ml). The lysate was then passed through a 18-21 gauge needle several times using a 
2 ml syringe to shear any remaining DNA. Oligo (dT) cellulose (25 mg) was added 
and allowed to swell for 2 min. To increase the efficiency of mRNA binding to oligo 
(dT) cellulose, the tube was rotated gently at room temperature for at least 30 min 
using a rotator. The oligo (dT) cellulose was then pelleted at 4000 x g for 5 min at 
room temperature, and the supernatant removed carefully. The oligo (dT) cellulose 
was resuspended in binding buffer and centrifuged at 4000 x g for 5 min. This step 
was repeated until the supernatant was no longer cloudy. The oligo (dT) cellulose was 
gently resuspended in binding buffer, transferred to a spin-column, and centrifuged at 
4000 x g for 10 sec.
The spin-column was removed from the tube, the liquid inside the tube was discarded, 
and the spin-column was placed back into the tube. Binding buffer was added to the 
spin-column, after centrifugation at 4000 x g for 10 sec, and the flow-through was 
discarded. This step was repeated several (at least three) times. The oligo (dT) 
cellulose was resuspended carefully in wash buffer using a sterile pipette tip, 
centrifuged at 4000 x g for 10 sec and the flow through discarded. This step was 
repeated at least twice to remove DNA, degraded proteins and non-polyadenylated 
RNA. The spin-column was placed into a new (sterile and RNase-free) tube and 100 
pi elution buffer was added to the cellulose bed. The tube was centrifuged at 4000 x g 
for 10 sec, and the flow-through containing polyA+ mRNA was retained. A second 
100 pi aliquot of elution buffer was added to the column, mixed well with the oligo 
(dT) cellulose, and centrifuged at 4000 x g for 10 sec. The column was removed from 
the tube, and the polyA+ RNA was precipitated with 10 pi of 2 mg/ml glycogen 
carrier, 30 pi of 2 M sodium acetate and 600 pi of 100% ethanol. The sample was
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frozen on dry ice until solid, thawed, and centrifuged at 12000 x g for 15 min at 4°C. 
The supernatant was discarded, and traces of ethanol removed from the RNA pellet 
after another brief centrifugation. The polyA* RNA was resuspended in 20 pi of 
elution buffer and stored at -70°C. Typical yields obtained using this procedure were 
10-20 pg polyA+ RNA per 108 cells.
2.2.6.3 Determination of RNA yield
To determine the concentration of the eluted mRNA in a Beckman DU-62 
spectrophotometer, the sample was diluted by adding 1 pi of sample to 99 pi of H2O. 
A sample of H2O was used to establish the baseline of the spectrophotometer at 260 
nm, and absorbance of the diluted RNA sample was determined. The RNA 
concentration in the undiluted RNA sample was determined from the following 
formula:
Concentration of RNA (pg/pl) = 4 x A260 
A260 is the absorbance of sample at 260 nm.
2.2.7 Northern blotting
2.2.7.1 Agarose gel electrophoresis of polyA* RNA
PolyA* RNA was separated on a formaldehyde-agarose gel. To avoid contamination 
with RNase, sterile disposable plastics were used wherever possible, and all glassware 
was autoclaved before use.
To prepare the gel, agarose (1 g) was dissolved in 85 ml dFhO by boiling and cooled 
to 55°C. Formaldehyde (5.8 ml) and 10 x MOPS (10 ml) were preheated at 55°C and 
added to the agarose, which was mixed well and poured immediately into a gel former 
with comb and allowed to set at room temperature. A standard 30 pi RNA sample was 
prepared as follows:
RNA 3 pg polyA* RNA or 3 pi RNA marker
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Formaldehyde 
Formamide 
10 x MOPS 
dH20
Samples were incubated at 55°C (65°C for the marker) for 15 min, and cooled on ice 
for 5 min. Sterile 10 x loading buffer (3 pi) was added to the samples and mixed well. 
The gel was electrophoresed at 80 V for 10 min using 1 x MOPS as electrophoresis 
buffer prior to loading the samples. The samples were electrophoresed at 80 V for 3 h 
until the bromophenol blue reached the bottom of the gel. Following electrophoresis, 
the gel was stained with 0.05 pg/ml ethidium bromide for 20 min. RNA was 
visualised with a ruler placed at one side of the gel using short wave UV light and 
photographed using the Gel Doc system.
2.2.7.2 Transfer of RNA to membrane
RNA was transferred from the gel to a membrane by capillary blotting (Southern, 
1975). The gel was incubated in distilled water twice for 5 min and then twice in 10 x 
SSC for 15 min, with shaking at room temperature. RNA was transferred overnight to 
a Nytran Supercharge membrane which was pre-soaked in water and then in 20 x 
SSC. The gel was placed on a wick of Whatman 3MM paper (soaked in 2 x SSC and 
descending from a platform into a 20 x SSC reservoir). The membrane, three sheets of 
Whatman 3MM paper presoaked in 20 x SSC and a stack of absorbent paper towels 
were added sequentially to the top of the gel. Care was taken to eliminate air bubbles 
between layers, and a plastic tray and a weight were added to the top of the stack. 
After transfer overnight, the membrane was rinsed gently in 10 x SSC for 1 min and 
air-dried. The RNA was fixed to the membrane using a Stratagene UV crosslinker set 
to ‘auto-crosslink’ (12000 Jem'2). The blots were then either prehybridised 
immediately or wrapped in clingfilm and stored at 4°C.
5.5 pi 
15 pi
1.5 pi 
to 30 pi
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2.2.7.3 Preparation of RNA probes
Since the use of RNA probes in northern blot analysis reportedly provides a 
significant increase in sensitivity compared to using randomly-primed labelled DNA 
probes, strand-specific RNA probes were used in hybridisation reactions. RNA probes 
were prepared using the Lig'n Scribe and MAXIscript T7 kit (Ambion). The 
Lig’nScribe reaction is a two step process (Fig 2.1) which adds a phage T7 RNA 
polymerase promoter in a chosen orientation to a PCR fragment. The first step was T4 
ligase-mediated ligation of the T7 promoter adapter to an appropriate 5’-RACE 
product (see section 2.2.8), or PCR product if a 5’-RACE product was not available. A 
standard 10 pi ligation reaction was as follows:
10 x ligation buffer 1 pi
T7 adapter 1 pi
5’-RACE PCR product 2 pi
T4 DNA ligase 1 pi
H20 5 pi
i
ii
The reaction was incubated at room temperature for 15 min, and was either used in the 
second step of the Lig’nScribe protocol or stored at -20°C. The second step involved 
PCR amplification using a gene specific primer (GSP) (Table 2.1) and adapter primer 
1 (API). A standard 50 pi Lig’nScribe PCR reaction was as follows:
Ligation reaction 2 pi
API 1 pi
GSP (10 pM) 1 pi
h 2o 39.8 pi
10 x PCR buffer 5 pi
dNTPs (10 mM) 1 pi
Taq polymerase 0.25 pi
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ORF Primer3 Sequences (5’ - 3’) Position
UL22A RUL22 AGCAG C GAC G C C GACAAGAC C T CA 2 7 0 8 2 -2 7 1 0 5
UL23 RUL23 TTTGTCCACCGACGCGCGACCGCG 2 8 7 4 1 -2 8 7 1 8
UL24 RUL24 CTCGCCCACTGACTCGGCGCGTCA 2 9 8 6 0 -2 9 8 3 7
UL2 6 RUL26 GTCATCGACCGACAAGGCGCGGCG 3 2 7 9 9 -3 2 7 7 6
UL2 9 RUL29 TGGAGCGGGTCGCCGAGGCTACTG 3 7 0 7 5 -3 7 0 5 2
UL36 RUL36 G C GAG C GAAG GTAGAGGAGTCCGT 4 9 8 0 1 -4 9 7 7 8
UL4 3 RUL4 3 TGGGAACGCGCGCACGGCGCGGTC 5 6 0 2 2 -5 5 9 9 9
US22 U S 2 2 - I I TCCGACTCGCTGTCGAGACGGCTC 2 1 1 6 3 1 -2 1 1 6 0 8
US23 RUS23 GGGGTGTCTAGCTGGCGGCCTCTT 2 1 3 5 2 1 -2 1 3 4 9 8
US24 RUS24 AGGAACTGTTGTTTTGCCTGGAGC 2 1 4 9 6 9 -2 1 4 9 4 6
UL128 U L128-S3 GCGTCATGAGTCCCAAAGACCTGA 1 7 5 6 2 7 -1 7 5 6 0 4
UL131A U L131-S4 TATTACCGAGTACCGCATTACTGG 1 7 6 7 3 7 -1 7 6 7 1 4
Table 2.1: Gene-specific primers for making RNA probes.
a Position of primer in the AD169 genome (5 -3 ’).
ii
i
i
i
!j
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Figure 2.1: summary of Lig’nScribe and MAXIscript reactions.
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The standard set of cycling temperature was as follows:
(94°C, 3 min) x 1
(94°C, 30 sec / 57°C, 30 sec / 72°C, 1 min 30 sec) x 30 
Hold at 4°C.
The PCR product was purified from a 1.5% (w/v) low melting point agarose gel using 
P-agarase (section 2.2.12). The size of the adapter-ligated PCR product was that of the 
5’-RACE product plus 64 bp. This fragment was then used directly as DNA template 
in an in vitro transcription reaction to produce radiolabelled RNA probe, using a 
MAXIscript kit (Ambion). A standard 20 pi MAXIscript reaction was as follows:
10 x Transcription buffer 2 pi
ATP(lOmM) l p l
CTP(lOmM) l p l
GTP(lOmM) l p l
DNA template (from Lig’nScribe PCR) 1 pg
[a32P]UTP 5 |il
T7 RNA polymerase 2 pi
The MAXIscript reaction was incubated at 37°C for 20 min, and then DNasel (1 pi) 
was added and incubated at 37°C for 15 min. T7 RNA polymerase binds to the 
double-stranded T7 promoter and uses the 3’ to 5’ strand as a template to synthesize a 
complementary 5’ to 3’ RNA transcript (Fig 2.1). Transcription stops at the end of the 
DNA template. To separate radiolabelled RNA probe from unincorporated 
nucleotides, water (30 pi), 5 M ammonium acetate (5 pi) and 100% ethanol (150 pi) 
were added and incubated at -20°C for 30 min. Radiolabelled RNA was pelleted in a 
microfuge at 12000 x g for 15 min at 4°C, washed with 70% ethanol, air dried and 
resuspended in 20 pi RNase-free water. The probe was used immediately or stored at - 
20°C.
A positive control reaction was carried out to ensure the kit was functioning properly. 
The control consisted of a plasmid containing sequence from the mouse cyclophilin 
gene and appropriate 3’ and 5’ primers, and was supplied with the kit.
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| 2.2.7.4 Preparation of DNA probe
j
Plasmid pSP64 (Promega) containing the glyceraldehyde 3’-phosphate de- 
hydrogenase (GAPDH2) coding region was labelled with 20 pCi each of [a P]dGTP
9^and [a PJdCTP using the Nonaprimer random labelling kit (Appligene). 
Approximately 500 ng of plasmid DNA was made up to a volume of 10 pi in a 1.5 ml 
microfuge tube with H2O and heated to 95°C for 10 min to denature the dsDNA. The 
tube was chilled on ice for 5 min and then centrifuged briefly in a microfuge at 12000 
x g. The denatured plasmid DNA was mixed with 4 pi of primer solution (random 
nonanucleotide mixture), 1 pi each of unlabelled dATP and dTTP, 2 pi each of 
[a32P]dGTP and [a32P]dCTP and 1 pi of enzyme solution (2.5 U/pl ‘Klenow’ 
fragment in buffer). The tube was incubated at 37°C for 30 min.
Following incubation, 2 pi of DNAprep resin (P2) and 60 pi of adsorption solution 
(PI) were added, mixed well by vortexing and incubated at room temperature for 2 
min to absorb radiolabelled DNA onto the resin. The tube was centrifuged briefly at 
12000 x g and the supernatant was discarded. The pellet was resuspended in 100 pi 
wash buffer, mixed well by vortexing, and centrifuged briefly at 12000 x g. This step 
was repeated at least three times in order to separate the radiolabelled DNA from 
unincorporated dNTPs. The pellet was resuspended in 100 pi of ‘elute’ solution (2.5 
mM EDTA in 50% deionized formamide), and incubated at 100°C for 10 min. The 
i tube was centrifuged briefly at 12000 x g and the supernatant (containing the purified
; denatured DNA probe) was recovered. The probe was used immediately or stored at -
20°C.
2.2.7.5 Nucleic acid hybridisation
| Membranes containing RNA were prehybridised in a hybridisation oven (Hybaid
I:
j minioven MK II) for 2-4 h at 68°C in 15 ml Rapid-Hyb buffer (Amersham) in glass
hybridisation tubes. Denatured probe (DNA or RNA) was added and hybridisation 
continued overnight. The membranes were washed twice with 2 x SSC, 0.1% (w/v) 
SDS at room temperature for 30 min, then with 0.5 x SSC, 0.1% (w/v) SDS at 68°C
I
for 1 h. The membrane was then air-dried.
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2.2.7.6 Phosphorimager analysis
The dried membrane was wrapped in clingfilm and exposed to a phosphorimager 
screen for 3-16 hr. The image was visualised using a Bio-Rad Personal FX 
phosphorimager running the Quantity One software package.
2.2.8 5’- and 3*- RACE
cDNAs were synthesised from polyA+ mRNAs using the Marathon SMART RACE 
cDNA amplification kit (Clontech). This kit integrates the Marathon cDNA 
Amplification kit (Chenchik et al., 1995, 1996, 1998) with the SMART (Switching 
Mechanism At 5’ end of RNA Transcript) cDNA synthesis technology. Clontech’s 
SMART technology provides a mechanism for generating full length cDNAs (5’- 
RACE-Ready cDNA or 3’-RACE-Ready cDNA) in reverse transcription reactions 
(Fig. 2.2). The cDNA for 5’-RACE is synthesized using a 5’-RACE cDNA synthesis 
primer (5’-CDS) and the SMART II oligonucleotide. The 5’-CDS has two degenerate 
nucleotide positions at the 3’-end. These nucleotides position the primer at the start of 
the poly-A tail. When certain MMLV-RT variants reach at the end of an RNA 
template, they exhibit a terminal transferase activity that adds 3-5 residues 
(predominantly dC) to the 3’-end of the first strand cDNA. This feature is exploited by 
the SMART oligonucleotide, whose terminal stretch of dG residues can anneal to the 
dC-rich cDNA tail and serve as an extended template for RT. After RT switches 
templates from the mRNA molecule to the SMART oligonucleotides, a complete 
double-stranded cDNA copy of the original RNA is synthesized with the additional 
SMART sequence at the end. Following reverse transcription, this cDNA is used 
directly in 5’-RACE PCR to amplify the 5’ ends using a universal primer (UPM in 
Fig. 2.2) and a gene-specific primer (GSP) in each reaction. This process ensures that 
the use of high quality RNA will result in products that contains the 5’-end sequences 
of the RNA.
The 3’-RACE cDNA is synthesized using a traditional reverse transcription procedure 
(Fig. 2.3), but with a special oligo (dT) primer, 3’-RACE cDNA synthesis (3’-CDS) 
primer. This 3’-CDS primer includes the lock-docking nucleotide positions as in the
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5’-CDS primer and also has a portion of the SMART sequence at its 5’-end.
Following reverse transcription, this cDNA is used directly in 3’-RACE PCR to *
amplify the 3’ ends using a universal primer (UPM in Fig. 2.3) and a gene-specific 
primer (GSP) in each reaction.
IE, E, L or MI RNA (1 pg) was combined with 3’ or 5’-CDS (1 pi), SMART II oligo 
(1 pi) and water (to 5 pi) in a sterile 1.5 ml microfuge tube and incubated at 70°C for 
2 min to make the first strand cDNA. The tube was cooled on ice for 2 min and 
centrifuged briefly. A mixture of 5 x first strand cDNA synthesis buffer (2 pi), dNTP 
(1 pi), DTT (1 pi) and Superscript II RT (1 pi) was added, mixed well and incubated 
for 90 min at 42°C. Tricine-EDTA buffer (20 pi ) was added and the tube was 
incubated for 7 min at 72°C. The first strand cDNA (also called 3’ or 5’-RACE-ready 
cDNA) was used immediately for 3’ or 5-RACE PCR or stored at -20°C.
To perform 5’- or 3’-RACE PCR, a 24 bp GSP was designed from the region 
approximately 500 bp downstream from the putative initiation ATG codon or 
upstream from the stop codon, respectively, of the target gene. A standard 50 pi 
reaction was as follows:
5 ’ - or 3 ’ -RACE-ready cDNA 2 pi
10 pM GSP (designed from the appropriate end) 1 pi
PCR grade H2O 35 pi
10 x UPM 5 pi
dNTP mix 1 pi
10 x Advan 2 PCR buffer 5 pi
50 x Advantage 2 polymerase mix 1 pi
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Figure 2.2: Mechanism of 5’-RACE reactions.
5’-RACE-ready cDNA is synthesized using the 5’-CDS primer and the SMART II 
oligonucleotide. After RT reaches the end of the mRNA template, it adds several dC 
residues. The SMART II oligonucleotide anneals to the tail of the cDNA and serve as an 
extended template for RT. Adapted from Chenchick etal. (1998).
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Poly A+ RNA
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Figure 2.3:Mechanism of 3’-RACE reactions.
3’-RACE-ready cDNA is synthesized using the 3’-CDS primer in the reverse 
transcription reaction. Adapted from Chenchick et al. (1998).
S M A R T  II o l i g o
87
Materials and methods
The standard set of cycling temperatures was as follows:
(94°C, 30 sec / 72°C, 3 min) x 5
(94°C, 30 sec / 70°C, 30 sec / 72°C, 3 min) x 5
(94°C, 30 sec / 68°C, 30 sec / 72°C, 3 min) x 20
Hold at 4°C.
A positive control reaction was carried out to ensure the kit was functioning properly. 
The control consisted of a control human placenta total RNA and appropriate 3’ and 
5’- RACE primers, and was supplied with the kit.
PCR products (5 pi) were analysed on a 1.2% agarose gel (section 2.2.11). Major 
bands were then excised and cloned into pGEM-T (Promega) for sequencing (section 
2 .2 .12).
Splicing patterns in certain genes were confirmed by RT-PCR. IE, E and L RNAs 
were used as templates with two primers (listed in Table 2.2) mapping in the exons 
flanking predicted introns. RT-PCR was carried out using the Titan™ One Tube RT- 
PCR System kit (Boehringer-Mannheim). The standard 50 pi reaction was as follows:
2.2.9 RT-PCR
RNase-free H2O 
dNTPs (10 mM each)
32.5 pi 
1 pi
Primers (10 pM) 
Template RNA 
100 mM DTT 
5 x buffer
1 pi each
1 pi 
2.5 pi 
10 pi
Enzyme mix (AMY reverse transcriptase in storage buffer) 1 pi
The standard set of cycling temperatures was as follows:
Pre-heat block to 50°C.
(50°C, 30 min) x 1
(94°C, 30 sec / 55°C, 30 sec / 68°C, 1 min) x 10
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(94°C, 30 sec / 55°C, 30 sec / 68°C, 1 min) x 25, 
increasing the 68°C step by 5 sec at each cycle 
(94°C, 30 sec / 55°C, 30 sec / 68°C, 7 min) x 1 
Hold at 4°C.
2.2.10 PCR
PCR was performed using Taq polymerase in a total volume of 50 pi containing 20- 
200 ng of template DNA (cosmid or virion DNA). Stringent measures were 
undertaken to prevent PCR contamination and sterile conditions were used for pre- 
PCR, PCR and post-PCR steps. The conditions used to amplify the products are as 
follows:
(96°C, 4 min / 55°C, 2 min / 72°C, 3 min) x 1
! (96°C, 1 min / 55°C, 2 min / 72°C, 3 min) x 25
| Hold at 4°C.
j
j
ORF Primer Sequence (5’-3’) Position*
UL22A UL22A
U L 2 2 A -3 '
TTTGGCTTGATTTTCTTTGTGTTC
GGCTTTGGCGGCACCTTCTCAGAA
2 7 4 7 8 -2 7 4 5 5
2 7 1 5 8 -2 7 1 8 1
UL36 U L36-S1
U L36-S2
ATGGGCCGCTGGTAGTCGCGCATA
GCCTACGGCTGCATCGCCATCCGA
4 9 2 4 4 -4 9 2 6 7
4 9 7 4 9 -4 9 7 2 6
UL2 9 UL29S1
UL29S2
UL29SP1
UL29SP2
UL28 ( I I )
UL29P1
GCGCACCACCCCAAAGTACTGAGT
TGCGGATTCTCTGCGGCGACACGG
GATGCCGTGCAGCGGCGGCCAGCA
GGCGCTGGTGGGGCAGGATAAGTT
CGGCGTGGAGCTGACATACGCGCA
TGGAGCGGGTCGCCGAGGCTACTG
3 5 5 3 7 -3 5 5 6 0
3 6 1 3 7 -3 6 1 1 4
3 5 5 7 3 -3 5 5 9 6
3 6 1 0 0 -3 6 0 7 7
3 5 1 7 6 -3 5 1 9 9
3 7 0 7 5 -3 7 0 5 2
UL128 U L128-S1
U L128-S3
CGCCCGTCAGCTTCGAGGTATAAC
GCGTCATGAGTCCCAAAGACCTGA
1 7 5 0 5 8 -1 7 5 0 8 1
1 7 5 6 2 7 -1 7 5 6 0 4
□L131 U L131-S3
U L131-S2
CGCTGAACTCGAGGCTCCGGGCGT
CATGCGGCTGTGTCGGGTGTGGCT
1 7 6 3 4 7 -1 7 6 3 7 0
1 7 6 8 6 2 -1 7 6 8 0 3
Table 2.2: Primers used in RT-PCR.
a Position of primer in the AD169 genome (5’-3 ’).
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2.2.11 Agarose gel electrophoresis
DNA fragments generated by PCR (RACE PCR, RT-PCR or PCR) or restriction 
endonuclease digestion were analysed on 1.0-1.5% agarose gels in 1 x TBE. Samples 
were prepared in DF dyes and electrophoresis was performed at 100 V for 3 h. DNA 
bands were visualised using short wave UV light and photographed using the Gel-Doc 
system (Bio-Rad).
2.2.12 Recovery of DNA fragments and cloning
DNA fragments were separated by gel electrophoresis using 1% (w/v) SeaPlaque 
agarose. Fragments were visualized under long wave UV light for short periods to 
minimise DNA damage. Appropriate bands were excised, and the DNA was recovered 
using p-agarase (New England Biolabs). In a sterile 1.5 ml microfuge tube, 1/10 
volume 10 x p-agarase buffer (New England Biolabs) was added to the excised 
agarose. The tube was incubated for 10 min at 65°C and then at 40°C for 10 min. P- 
agarase (2 pi ) was added, and incubation was continued for 60 min at 40°C. P- 
agarase acts by cleaving carbohydrate bonds in the agarose and releasing trapped 
DNA. 3 M sodium acetate (1/10 volume) was added, and the tube was incubated on 
ice for 15 min. Centrifugation was then carried out in a microfuge at 12000 x g for 10 
min to pellet residual agarose. The supernatant was transferred to a fresh tube and two 
volumes of 100% ethanol were added. The tube was incubated for 60 min at -20°C 
and centrifuged at 12000 x g for 15 min. The pellet was washed with 70% ethanol, 
dried at room temperature and resuspended in 20 pi TE. Recovered DNA was cloned 
into pGEM-T using pGEM-T Vector System I (Promega).
2.2.13 Miniprep plasmid DNA preparation
A culture (1.5 ml) of E. coli bearing a plasmid was grown overnight at 37°C with 
shaking, pelleted in a microfuge at 12000 x g for 15 min, resuspended in 100 pi GTE 
containing lysozyme (4 mg/ml) and incubated at room temperature for 5 min. 
NaOH/SDS (200 pi) was added and the tubes were incubated for 5 min on ice. The 
solution was neutralised by the addition of potassium acetate solution (200 pi), and
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incubated on ice for 5 min. After centrifugation at 12000 x g for 10 min, the
supernatant was transferred to a fresh tube and extracted with equal volume of 
$
phenol/chloroform. The DNA was precipitated for 30 min after the addition of two 
volumes of ethanol, pelleted by centrifugation at 12000 x g for 10 min, washed with 
70% ethanol, dried and dissolved in 100 pi TE containing 100 pg/ml RNase. 
Digestion of the plasmid DNAs using restriction enzymes (see section 2.2.14) were 
then carried out to ascertain the size of the insert.
For DNA sequencing miniprep DNA from selected clones was incubated at 37°C for 
30 min. DNA was precipitated by the addition of 120 pi PEG/NaCl and incubation on 
ice for 1 h. The DNA was pelleted by centrifugation at 12000 x g for 5 min, washed 
with 70% ethanol, air-dried, and resuspended in 20 pi TE.
2.2.14 Restriction endonuclease digests
Digestion of plasmid DNAs using restriction enzymes was carried out using 
commercial restriction enzymes and the buffers supplied, in accordance with the 
manufacturer’s instructions. A typical digest would involve 1 U of enzyme/0.5 pg 
DNA in a volume of 20 pi, incubated for 1-4 h at the recommended temperature 
(usually 37°C).
2.2.15 DNA sequencing
Sequencing was performed using the M l3 universal primer (Pharmacia Biotech) and 
gene specific primers. Some PCR products were sequenced directly using the 
appropriate PCR primers. DNA samples were provided for sequencing at 0.4 pg in 2 
pi (usually 1/10 of a miniprep) with 1.6 pmol primer. All the samples were sequenced 
by Lesley Taylor and Mairi Hope (Institute of Virology) using an ABI PRISM 377 
DNA sequencer.
2.2.16 DNA sequence analysis
Sequences were analysed for matches with the HCMV genome sequence using the 
Basic Local Alignment Search Tool (BLAST) similarity search program. BLAST uses
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a heuristic algorithm which seeks local as opposed to global alignments, and is 
therefore able to detect relationships among sequences which share only isolated 
regions of similarity with the nucleotide sequence databases (Altschul et al., 1990). 
BLAST was used online at the National Center for Biotechnology Information 
(NCBI) at www.ncbi.nlm.nih.gov.
The DNA sequence of HCMV (strains AD 169 and Toledo) and CCMV were 
conceptually translated into amino acid sequences using Ptrans (Taylor, 1986).
2.2.17 Primer extension
Primer extension experiments were carried out using the Primer Extension System- 
AMV Reverse Transcriptase kit (Promega). A 5'-end-labelled 24 bp GSP (see section 
2.2.17.1) mapping in the region approximately 100 nucleotides downstream from the 
proposed 5'-end of the mRNA was utilised as a primer for RT (section 2.2.17.3). The 
labelled cDNA was analysed on a denaturing 8% polyacrylamide gel (section 
2.2.17.4). Labelled DNA size markers were included. The 1.2 kb kanamycin positive 
control RNA (10 ng/pl) and corresponding primer (5 pmol/pl) supplied with the kit 
were used as a positive control and H2O was used as a negative control. The length of 
the cDNA is equivalent to the number of nucleotides between the 5’-end of the primer 
and the 5' end of the mRNA.
2.2.17.1 5’-labelling of primer
In order to end-label the primer (listed in Table 2.3), the following reaction was 
assembled in a sterile microfuge tube.
Control primer or GSP 
10 x T4 PNK buffer 
[y^PJATP (3,000 Ci/ml)
T4 polynucleotide kinase (10 u/pl) 
Nuclease-free water
10 pmol
1 pi 
3 pi 
1 pi
to 10 pi
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The tube was incubated for 10 min at 37°C. It was then incubated at 90°C for 2 min to 
inactivate the T4 polynucleotide kinase and centrifuged briefly at 12000 x g in a 
microfuge. The final concentration of end-labeled primer was adjusted to 100 fmol/pl 
by adding 90 pi nuclease-free water. The end-labeled primer was used immediately or 
stored at -20°C.
2.2.17.2 Labelling of DNA markers
The protocol described above (section 2.2.17.1) was followed to label 5 pi of the 
DNA marker. The marker was diluted by adding 190 pi nuclease-free water and stored 
at -20°C. One pi of the diluted labelled marker was loaded onto the gel.
ORF Primer Sequence (5’ to 3’) Position3
TRL2 PET2 GCCTTCACCCTCTTCACTCCCTGT 2 1 5 9 - 2 1 3 6
TRL5 PET5 TCTTCCGCGTCTCCCGGCCGTACC 4 3 2 6 - 4 3 0 3
TRL8 PET8 TGTGGGTGATACCCAACCGGACGC 7 4 2 6 - 7 4 0 3
TRL9 PET 9 CTCCGTTTCTCCTCAGCTGCCGTA 7 7 9 3 - 7 7 7 0
UL24 PEL24 CGCGGCCAGCGTGGCGAGGACACT 2 9 9 0 5 - 2 9 9 2 8
UL36 PEL36 TCGGATGGCGATGCAGCCGTAGGC 4 9 7 2 6 - 4 9 7 4 9
U S22 PE S22 AGCATCTTCGCAGCGCTCGTCGCG 2 1 2 5 2 4 - 2 1 1 5 4 8
U S24 PES24 ACAGCGTCCCTCGTTACGATGAAC 2 1 4 9 0 2 - 2 1 4 9 2 5
Table 2.3: Primers used in primer extension experiments.
a Position of primer in the AD169 genome (5’-3’).
2.2.17.3 Primer extension reaction
Control RNA (50 ng) or sample RNA (1 pg) was combined in a sterile microfuge tube 
with 1 pi of control or specific labelled primer, 5 pi of 2 x AMV primer extension 
buffer and nuclease-free water (to 11 pi). The control RNA sample was incubated for 
30 min at 58°C. However, as the melting temperature (Tm) of each primer is the 
optimal temperature for annealing that primer to RNA (Sambrook et al., 1989), each
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tube was incubated at its calculated Tm for 30-60 min. Following incubation, the tubes
were cooled for 10 min at room temperature. A ‘master’ RT extension mixture was 
/
prepared in a sterile microfuge tube by combining 5 pi 2 x AMV primer extension 
buffer, 1.4 pi sodium pyrophosphate (40 mM), 1.6 pi nuclease-free water and 1 pi 
AMV-RT per reaction. AMV-RT was added last and the solution was mixed well by 
pipetting and by gently inverting the tube. Immediately after mixing, 9 pi of ‘master’ 
RT mixture was added to each reaction tube containing the annealed primer and RNA. 
The tubes were incubated for 30 min at 42°C. After incubation, sodium acetate (1/10 
volume) and two volumes of 100% ethanol were added to the tube and incubated at - 
20°C for at least 3 h. Centrifugation was then carried out at 12000 x g for 15 min at 
4°C, and the supernatant was removed carefully. The pellet was washed with 70% 
ethanol and resuspended in nuclease-free H2O. Samples were used immediately or 
stored at -20°C.
2.2.17.4 Polyacrylamide gel electrophoresis
Primer extension products were analyzed by electrophoresis on an 8% polyacrylamide 
gel. Two siliconised glass plates (33 x 37 cm), polished with 95% ethanol and 
separated by 1.5 mm spacers, were sealed with 38 mm Scotch electrical tape and 
secured by two large foldback clips positioned over each spacer. TGM (80 ml) was 
mixed with 160 pi 25% (w/v) APS and 160 pi TEMED. The mixture was poured into 
the gel sandwich, and bubbles were dislodged by striking the glass plates vigorously. 
The gel sandwich was placed almost horizontal and a 20 tooth Teflon well-forming 
sharks tooth comb was inserted, 0.5 cm into the gel (teeth uppermost). Three large 
foldback clips were positioned to secure the combs, and the gel was allowed to set for 
30 min before removing the clips and the tape at the bottom of the gel. The gel 
sandwich was clamped into a BRL S2 electrophoresis kit and the reservoirs were 
filled with 0.5 x TBE. The comb was removed from the gel and the well was washed 
out three times with 0.5 x TBE using a 60 ml syringe fitted with a needle. The gel was 
pre-electrophoresed at 40 W for 15 min.
Primer extension product (5 pi) was mixed with 5 pi of loading dyes, denatured for 10 
min at 90°C and cooled on ice for 5 min. The surface of the gel was washed and the
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Teflon comb was repositioned with its teeth touching the surface of the gel. Aliquots 
(10 pi) of the samples were loaded onto the wells. One pi of labelled denatured DNA 
marker was loaded onto well alongside the samples. The samples were 
electrophoresed at 40 W for approximately 3 h until the bromophenol blue was 2 cm 
from the bottom of the gel. The gel sandwich was removed from the electrophoresis 
apparatus and the plates were separated using the point of a pair of scissors. The gel 
was soaked 5 times with 10% acetic acid for 5 min in a fume hood, transferred onto 
two sheets of 3MM paper, and covered with clingfilm. The gel was dried on a gel 
drier for 45 min at 80°C under vacuum and exposed to a phosphorimager screen at 
room temperature for 16-24 h. The image was analysed using a Personal FX 
phosphorimager (Bio-Rad).
CHAPTER 3: RESULTS 1
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Potential Errors in the HCMV DNA Sequence
Amino acid sequence comparisons carried out between translated forms of the CCMV 
and HCMV genome sequences indicated the presence of five potential frameshift errors 
in the AD169 sequence, in TRL14, UL15, UL102, UL131 and US22 (Davison et al., 
unpublished data). Errors in UL102 were recognised previously by Smith and Pari 
(1995). A sixth error was identified in UL145, which is absent from AD 169 but present 
in Toledo. To investigate these potential errors, cognate HCMV sequences were 
analysed by PCR and sequencing. AD169-infected cellular DNA was used as template 
for PCR in all cases except for UL145, where Toledo-infected cellular DNA was used. 
In the case of US22, AD 169 cosmid IB was also used. PCR primers were designed to 
amplify fragments containing the potential errors and are listed in Table 3.1. PCR 
products (208-712 bp) were separated by gel electrophoresis (Fig. 3.1), excised and 
purified, and cloned into pGEM-T. The fragments were sequenced in both orientations. 
Sequences from five clones were analysed for each region analysed.
3.1 Sequences of PCR products
3.1.1 UL15
Fig. 3.2 shows six-frame translations of the relevant regions of the AD 169 and CCMV 
genomes. UL15 as defined in AD 169 and shown in blue in panel I is not conserved in 
CCMV (panel II). However, a CCMV ORF (UL15A) located on the other strand and 
shown in red in panel II appears to be conserved in AD 169 in three different reading 
frames (bold black font with conserved residues underlined). This analysis indicates that 
the potential presence of two frameshift errors in the AD 169 sequence within the region 
marked in yellow in panel I. Sequence analysis of a PCR product derived from this 
region of the AD 169 genome using the primers shown by arrows in Fig. 3.2 (panel I) 
indicated the presence of one extra G residue after nucleotide 21955 and
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ORF Primer Sequence (5* - 3’) Position in 
genome*
Region
analysed0
PCR
product (bp)
TRL14 ETRL14
TRL14
GCCCATTGAGCGAGAACTAATATT
TTACAGGGCATGTGCCAAGAGTGG
10769-10792
11481-11458
11481-10769
(11201-11209)
714
434
UL15 UL15-I
UL15-II
ATCGTACCGGCGTCTGAACACCGA
ACACGCGTTCCTTGACATCGATTC
21757-21780
22222-22199
21800-22200 
(21956, 22005)
465
UL102 UL102-1
UL102-2
TAGAGGCCTCGGTGCCTATCGTAC
TCTCCACGCCACTAGCGTCCGTCT
146607-146630
146915-146892
146915-146607
(146744-146749)
309
UL131 UL131-S3
UL131-S2
GCTGATGAGCAACGACACCTCGGT
CATGCGGCTGTGTCGGGTGTGGCT
176547-176570
176826-176803
176347-176826
(176742-176749)
379
UL145 UL145-1
UL145-2
AATAAGTGTCGCCTACATAAGAGC
ACGGCTGTCACGGCACTGTATCGA
8715-8738b
9015-8992
8715-9015 
(8884 - 8889)
301
US22 US22
US22-II
TCCCAGTCGTAGACGTAGACGGTG
TCCGACTCGCTGTCGAGACGGCTC
211144-211167
211631-211608
211631-211171
(211536)
488
Table 3.1: PCR primers designed to investigate potential errors in the HCMV 
sequence.
a Position of primer in the AD169 genome (Chee et al, 1990). 
b Position of primer in the Toledo sequence (Cha et a/., 1996). 
c Region containing potential errors is underlined.
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M 1 2 3
1.0 kbp
0.5 kbp
0.1 kbp m
M 1 2 3 4 5 6  7
0.5 kbp
O.l kbp
Figure 3.1 : Gel electrophoresis of PCR products from regions of the HCMV 
genome containing potential errors.
Gel a: Products from US22 (488 bp). M, 100 bp ladder. 1 & 2; AD169 template. 3; cosmid 1B 
template.
Gel b: Products from other regions. M, 100 bp ladder. 1, UL145 (301 bp) with Toledo template. 2, 
UL131 (379 bp) with AD169 template. 3, UL131 (-379 bp) with GW template. 4, UL102 (309 bp) with 
AD169 template. 5, UL15 (465 bp) with AD169 template. 6, TRL14 (714 bp) with AD169 template. 7, 
TRL14 (approx. 450 bp) with Toledo template.
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another extra G residue after 22004. The electrophoregrams are shown in Fig. 3.3 (panel 
II) and the additional nucleotides are highlighted in yellow in Fig. 3.3 (panel I). These 
corrections disrupt AD 169 UL15 and introduce a novel ORF corresponding to CCMV 
UL15A. The amino acid sequences of AD 169 and CCMV UL15A are shown in red in 
Fig. 3.3 (panels I and III); each is followed by a putative polyadenylation signal 
(AATAAA or ATTAAA) underlined in green. Inability to detect the 5*-end of an 
mRNA for AD 169 UL15 (section 7.1) is consistent with the conclusion that this ORF 
does not encode a protein. Consequently, UL15 has been removed from the list of 
AD 169 genes, and a novel gene (UL15A) introduced. The proteins encoded by UL15A 
in AD 169 and CCMV possess potential transmembrane domains near their C termini, 
18 residues in AD 169 and 20 residues in CCMV (shown in boxes in Fig 3.3 panels I 
and III), and lack homologues in public protein databases.
3.1.2 UL102
HCMV UL102, together with a large upstream region (735 bp), was found to be 
absolutely necessary for origin-dependent DNA replication (Pari and Anders, 1993). 
Subsequently, this upstream region was shown to contain a small ORF (UL101X) 
comprising 208 bp immediately upstream from UL102 (Smith and Pari, 1994). Fig. 3.4 
shows the relevant regions of the AD 169 and CCMV genomes. AD 169 UL102 (Fig. 3.4 
panel I) is well conserved in CCMV (Fig. 3.4 panel II). However, the coding capacity of 
an additional region of approximately 200 bp near the 5’-terminus of CCMV UL102 
appears to be conserved in AD169 UL101X (Fig 3.4 panel I). This analysis indicates the 
potential presence of errors in the AD 169 sequence within the region marked in yellow 
in panel I. Consistent with this, Smith and Pari (1995) mapped a single mRNA species 
extending through UL102 with its 5’-end located 20 bp upstream of the first ATG codon 
in the UL101X. Sequence analysis of a PCR product derived from this region of the 
AD 169 genome indicated that the G residue in the UL101X stop codon at nucleotide 
146746, is actually a C residue, changing a TAG to a TAC codon. Moreover, the G 
residue in the subsequent codon at 146748, is actually a C residue, changing this codon 
from GGT to GCT. These two codons now encode Y and A residues, respectively, and 
replace UL101X and UL102 by a single ORF (Fig. 3.5 panels I and II). These results 
confirm the findings of Smith and Pari (1995), who detected these errors by sequencing
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T T T A A A G I E L T A L G G A I I Y G G I T G - R I R R S G C W P  
U L 1 4  N N C S R R H R V D G A R R R Y H L R R D Y W L T D P K I G L L A  
Q Q L Q P P A S S - R R - A A L S S T E G L L A D G S E D R V A G  
CAACAACTGCAGCCGCCGGCATCGAGTTGACGGCGCTAGGCGGCGCTATCATCTACGGAGGGATTACTGGCTGACGGATCCGAAGATCGGGTTGCTGGCC 2 1 7 0 0  
L L Q L R R C R T S P A L R R - - R R L S - Q S V S G F I P N S A  
V V A A A P M S N V A S  P P A I M  -  P P I V P Q R I  R L D P Q Q G  
C C S C G G A D L Q R R - A A S D D V S P N S A S P D S S R T A P R
R D R W P - P P S A T C C A T G V P N R T G V - T P R R K A R R R  
A G S V A L T S L C H L L C Y W C S E S Y R R L N T E E E S E A A  
R G I G G P D L P L P P A V L L V F R I V P A S E H R G G K R G G G  
GCGGGATCGGTGGCCCTGACCTCCCTCTGCCACCTGCTGTGCTACTGGTGTTCCGAATCGTACCGGCGTCTGAACACCGAGGAGGAAAGCGAGGCGGCGG 2 1 8 0 0  
A P D T A R V E R Q W R S H - Q H E S  ~ D  Y R R R F V S " ^ S  S L S A A S 
R S R H G Q G G E A V Q Q A V P T G F R V P T Q V G L L F A L R R  
P I P P G S R G R G G A T S S T N R I T G A D S C R P P F R P P P
R K L P R E K P L R - R R R P S L R K S S G G S K R G E P - S G -  
E E T A A G E A S A V A A A A V S E E E Q R R E - T R R A M K R M I  
G N C R G R S L C G S G G G R L - G R A A A G V N E E S H E  A~ D D 
AGGAAACTGCCGCGGGAGAAGCCTCTGCGGTAGCGGCGGCGGCCGTCTCTGAGGAAGAGCAGCGGCGGGAGTAAACGAGGAGAGCCATGAAGCGGATGAT 2 1 9 0 0  
S V A A P S A E A T A A A A T E S S S C R R S Y V L L A M F R I I  
L F S G R S F G R R Y R R R G D R L F L L P P L L R P S G H L P H N  
P F Q R P L L R Q P L P P P R R Q P L A A A P T F S S L W S A S S
F A V T A G K R N V R - R A P A S D A L R R R C A H L R Q R Y P T R
R S H G R K T E C g M T S A G E R R A P P S V R P S A A A V P D A
S ~ Q S  R Q E  N G M S  D D E  R R R~ A T R S A V G A P I C G S G T R R  
TCGCAGTCACGGCAGGAAAACGGAATGTCAGATGACGAGCGCCGGCGAGCGACGCGCTCCGCCGTCGGTGCGCCCATCTGCGGCAGCGGTACCCGACGCG 2 2 0 0 0  
R L - P L F V S H - I V L A P S R R A G G D T R G D A A A T G S A  
A T V A P F R F T L H R A G A L S A S R R R H A W R R C R Y G V R  
E C D R C S F P I D S S S R R R A V R E A T P A G M Q P L P V R R P
H G A N E R R D S D V G P I A H S S G T R R G S A N E T S A C T R
A R R Q R T P R L R R R S H R P Q - ”  R~ Y Q T R F G E - N V R L Y A  
G T A P T N A A T  P T S V  P S  P T V A V P D A V R R M K R  P P V R G  
GCACGGCGCCAACGAACGCCGCGACTCCGACGTCGGTCCCATCGCCCACAGTAGCGGTACCAGACGCGGTTCGGCGAATGAAACGTCCGCCTGTACGCGG 2 2 1 0 0  
A R R W R V G R S R R R D W R G C Y R Y W V R N P S H F T R R Y A S  
C P A L S R R S E S T P G M A W L L P V L R P E A F S V D A Q V R  
V A G V F A A V G V D T G D G V T A T G S A T R R I F R G G T R P
T D  H g K A D  I  G L W F M F L V F G L C S W L A M R Y R A Q  -  I L
D R S P E G G H W A V V H V S G F W -  T V F ~  V V G D A V S R T I N F E  
P I  T R R R T  L G C G S C  F W  F L D C V R G W R C G I A H N K F -  
ACCGATCACCAGAAGGCGGACATTGGGCTGTGGTTCATGTTTCTGGTTTTTGGACTGTGTTCGTGGTTGGCGATGCGGTATCGCGCACAATAAATTT^GA 2 2 2 0 0  
R D G S P P C Q A T T - T E P K Q V T N T T P S A T D R V I  F 
V S - W F A S M P S H N M N R T K P S H E H N A I R Y R A C Y I K F  
G I V L L R V N P Q P E H K Q N K S Q T R P Q R H P I A C L L N Q
N R C Q G T R V L Y F I G N I G G D K P V S .  D V Y P - S Y R G P R C  
S M S R N A C F V F Y W E Y W R G - T C F G C L P L I L P G T S L  
I  D V K E R V F C I  L L G I  L A G I N L F R M F T L N L T G D L V  
JircGATCTCAAGGAACGCGTGrTTTGTATTTTATTGGGAATATTGGCGGGGATAAACCTGTTTCGGATGTTTACCCTTAATCTTACCGGGGACCTCGTTG 2 2 3 0 0  
■ ^D  I D L F A H K T N - Q S Y Q R P Y V Q K P H K G K I K G P V E N  
R H - P V R T K Y K I P F I P P S L G T E S T - G - D - R P G R Q  
I S T L S R T N Q I K N P I N A P I F R N R I N V R L R V P S R T T
P L L L L P R T P G S M L T - V P T G V K S L G T Y E E R A Q R T  
S S P P S S S D T G L H A D V G T D W G Q K P G Y L - G A R T K D  
V L S S F F L G H R A P C - R R Y R L G S K A W V L M R S A H K G P  
TCCTCTCCTCCTTCTTCCTCGGACACCGGGCTCCATGCTGACGTAGGTACCGACTGGGGTCAAAAGCCTGGGTACTTATGAGGAGCGCGCACAAAGGACC 22 4  00 
D E G G E E E S V P S W A S T P V S Q P - F G P Y K H P A R V F S R  
G R R R R G R V G P E M S V Y T G V P T L L R P V - S S R A C L V  
R E E K K R P C R A G H Q R L Y R S P D F A Q T S I L L A C L P G
V R R R H G A S P R Y G T A G M G V F C S L L I C L F L V C C - P  
R - A P A W S V A E V R Y R W D G C F L F F A Y L P L P R V L L T W  
U L 1 6  L G A G M E R R R G T V P L G W V F F V L C L S A S S S C A V D L
GTTAGGCGCCGGCATGGAGCGTCGCCGAGGTACGGTACCGCTGGGATGGGTGTTTTTTGTTCTTTGCTTATCTGCCTCTTCCTCGTGTGCTGTTGACCTG 2 2 5 0 0  
- A G A H L T A S T R Y R Q S P H K K N K A - R G R G R T S N V Q  
T L R R C P A D G L Y P V A P I P T K Q E K S I Q R K R T H Q Q G P  
N P A P M S R R R P V T G S P H T N K T R Q K D A E E E H A T S R
G - Q V L Q L D L P L E C D G V G L D P S W G N V D V T R D V Y F Y  
V A S P P T R P A A - M - R S W P R S I L G K R G R Y T G C V F L  
G S K S S N S T C R L N V T E L A S I H P G E T W T L H G M C I S  
GGTAGCAAGTCCTCCAACTCGACCTGCCGCTTGAATGTGACGGAGTTGGCCTCGATCCATCCTGGGGAAACGTGGACGTTACACGGGATGTGTATTTCTA 2 2 6 0 0  
T A L G G V R G A A Q I H R L Q G R D M R P F R P R - V P H T N R  
Y C T R W S S R G S S H S P T P R S G D Q P F T S T V R S T Y K -  
P L L D E L E V Q R K F T V S N A E I W G P S V H V N C P  I  H I E  I
L L L R E C D R G R D H R R G F Y L A A - R V C G - P V V V P E R  
S A T T R M - P R T R S S A W L L L G S I T S L W L T C G C T R T  
I C Y Y E N V T E D E  I  I G V A F T W Q H N E  S V V D L W L Y Q N D  
TCTGCTACTACGAGAATGTGACCGAGGACGAGATCATCGGCGTGGCTTTTACTTGGCAGCATAACGAGTCTGTGGTTGACCTGTGGTTGTACCAGAACGA 2 2 7 0 0  
D A V V L I H G L V L D D A H S K S P L M V L R H N V Q P Q V L V V  
R S S R S H S R P R S - R R P K - K A A Y R T Q P Q G T T T G S R  
U L 1 5  Q - - S F T V S S S I M P T A K V Q C C L S D T T S R H N Y W F S
I
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UL15A R P R N L T G Q A G T R A M R R V I R R H T L K T S D Q Q L P H A  
UL14 E T E E S D R P G R D K G D E K S D P S S H L K D E - S T T T S C C  
D R G I  -  Q A R P G Q G R - E E - S V V T  P -  R R V I  N N Y  L M L  
AGACCGAGGAATCTGACAGGCCAGGCCGGGACAAGGGCGATGAGAAGAGTGATCCGTCGTCACACCTTAAAGACGAGTGATCAACAACTACCTCATGCTG 1 9 8 0 0  
V S S D S L G P R S L P S S F L S G D D C R L S S H D V V V E H Q  
L G L F R V P W A P V L A I L L T I R R - V K F V L S - C S G - A A  
S R P I Q C A L G P C P R H S S H D T T V G - L R T I L L - R M S
A Y P G S P Q D G E R R R S S G L L S S P P F S G S G G Y S I L D K  
I P R  F T T R W R A P S Q F W  P P I V S S L L R Q R R V L D S R -  
H T Q V H H K M A S A V A V L A S Y R L L P S  P A A A G T R  F -  I 
CATACCCAGGTTCACCACAAGATGGCGAGCGCCGTCGCAGTTCTGGCCTCCTATCGTCTCCTCCCTTCTCCGGCAGCGGCGGGTACTCGATTCTAGATAA 1 9 9 0 0  
M G L N V V L H R A G D C N Q G G I T E E R R R C R R T S S E L Y  
Y G P E G C S P S R R R L E P R R D D G G K E P L P P Y E I R S L  
C V W T - W L I A L A T A T R A E - R R R G E G A A A P V R N - I L
K T  X I  I T T T A C G S G W W S W T P Q Q K A E A Y L W L M L L V  
E N N H H H D N G V R E R L V V L D A A A E G G S L P V A H V T G  
R K Q S S S R Q R R A G A A G G P G R R S R R R K P T C G S C Y W F  
GAAAACAATCATCATCACGACAACGGCGTGCGGGAGCGGCTGGTGGTCCTGGACGCCGCAGCAGAAGGCGGAAGCCTACCTGTGGCTCATGTTACTGGTT 2 0 0 0 0  
S F L - - - S L P T R S R S T T R S A A A S P P L R G T A - T V P K  
F V I M M V V V A H P L P Q H D Q V G C C F A S A - R H S M N S T  
F C D D D R C R R A P A A P P G P R R L L L R F G V Q P E H - Q N
L G L C S W L A A W I H A Y - K E I Y L L K P F C V Y G V V F Y F  
F G T V F V A G G V D S R I L K R D L P A E T L L C V W C G F L F R  
W D C V R G W R R G F T H I K K R F T C - N P F V C M V W F F I S  
TTGGGACTGTGTTCGTGGCTGGCGGCGTGGATTCACGCATATTAAAAAGAGATTTACCTGCTGAAACCCTTTTGTGTGTATGGTGTGGTTTTTTATTTCG 2 0 1 0 0  
P V T N T A P P T S F . R M N F L S K G A S V R K H T H H P K K N R  
K P S H E H S A A H I - A Y - F S I - R S F G K Q T Y P T T K - K P  
Q S Q T R P Q R R P N V C I L F L N V Q Q F G K T H I T H N K I E
G G L D R V D V G R D L K E T L S T - E E T A Q R I A A Q H G E G Q  
G S R P R - R R T - S Q G D A K Y L G R D R T A H R G S A W R R T  
U L16 G V - T A L T - D V I S R R R - V L R K R P H S A S R L S M A K D
GGGGTCTAGACCGCGTTGACGTAGGACGTGATCTCAAGGAGACGCTAAGTACTTAGGAAGAGACCGCACAGCGCATCGCGGCTCAGCATGGCGAAGGACA 2 0 2 0 0  
P D L G R Q R L V H D - P S A L Y K P L S R V A C R P E A H R L V  
P R S R T S T P R S R L S V S L V - S S V A C R M A A - C P S P C  
P T - V A N V Y S T I E L L R - T S L F L G C L A D R S L M A F S L
R E R S H D G N R V D P F R R G M F R V D R P G K V L Q L H V Q R  
E G A F P - W E S R G S F S S G D V S G - - T W K S T P T A R T T  
R G S V P M M G I A W I L F V G G C F G L I D L E K Y S N C T Y N A  
GAGGGAGCGTTCCCATGATGGGAATCGCGTGGATCCTTTTCGTCGGGGGATGTTTCGGGTTGATAGACCTGGAAAAGTACTCCAACTGCACGTACAACGC 2 0 3 0 0  
S P A N G H H S D R P D K E D P S T E P Q Y V Q F L V G V A R V V G  
L S R E W S P F R T S G K R R P I N R T S L G P F T S W S C T C R  
P L T G M I P I A H I R K T P P H K P N I S R S F Y E L Q V Y L A
I I
Figure 3.2: Comparison of the region containing AD169 UL15 with the cognate 
CCMV sequence.
Panels I and II show six-frame translations of the relevant regions of the AD169 and CCMV sequences 
respectively, with nucleotide coordinates on the right. The locations of PCR primers for AD169 an 
indicated by arrows in panel I. AD169 UL15 is shown in blue in panel I, and CCMV UL15A is shown ii 
red in panel II. Regions in AD169 that appear to be conserved in CCMV UL15A are shown in bold blacl 
font in panel I, with conserved amino acid residues underlined. The region containing possible errors ii 
the AD169 sequence is highlighted in yellow. ORF UL14 and UL16 are represented in green in botl 
panels.
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Figure 3.3: Comparison of the corrected sequence of the region containing 
AD169 UL15A with the cognate CCMV sequence.
Panel I shows the corrected sequence of AD169 and panel III shows the corresponding CCM V  
sequence, with nucleotide coordinates on the right. In each panel, UL15A is shown in red with 
conserved residues underlined and putative polyadenylation signals are underlined in green. 
The hydrophobic domain is boxed in each panel. The two additional G residues are highlighted 
in yellow in panel I. Panel II shows an electropherogram of the sequence of the relevant region 
of AD169 (upper strand) with the additional residues indicated by arrows.
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UL15A M K R M I
AGGAAACTGCCGCGGGAGAAGCCTCTGCGGTAGCGGCGGCGGCCGTCTCTGAGGAAGAGCAGCGGCGGGAGTAAACGAGGAGAGCCATGAAGCGGATGAT
R S H G R K T E C Q M T  S A G E R R R S A V G A P  I  C G S G T R R  
TCGCAGTCACGGCAGGAAAACGGAATGTCAGATGACGAGCGCCGGCGAGCGACGCgGCTCCGCCGTCGGTGCGCCCATCTGCGGCAGCGGTACCCGACGC
G S G A N E R R D S D V G P I A H S S G T R R G S A N E T S A C T
GGCAgCGGCGCCAACGAACGCCGCGACTCCGACGTCGGTCCCATCGCCCACAGTAGCGGTACCAGACGCGGTTCGGCGAATGAAACGTCCGCCTGTACGC
H g  K A W M W Q
GGACCGATCACCAGAAGGCGGACATTGGGCTGTGGTTCATGTTTCTGGTTTTTGGACTGTGTTCGTGGTTGGCGATGCGGTATCGCGCACAATAAATTTT
GAATCGATGTCAAGGAACGCGTGTTTTGTATTTTATTGGGAATATTGGCGGGGATAAACCTGTTTCGGATGTTTACCCTTAATCTTACCGGGGACCTCGT
TGTCCTCTCCTCCTTCTTCCTCGGACACCGGGCTCCATGCTGACGTAGGTACCGACTGGGGTCAAAAGCCTGGGTACTTATGAGGAGCGCGCACAAAGGA
UL16 M E R R R G T V P L G W V F F V L C L S A S S S C A V D
CCGTTAGGCGCCGGCATGGAGCGTCGCCGAGGTACGGTACCGCTGGGATGGGTGTTTTTTGTTCTTTGCTTATCTGCCTCTTCCTCGTGTGCTGTTGACC
I I
UL15A M R R V I R R H T L K T S D Q Q L P H A
AGACCGAGGAATCTGACAGGCCAGGCCGGGACAAGGGCGATGAGAAGAGTGATCCGTCGTCACACCTTAAAGACGAGTGATCAACAACTACCTCATGCTG
A Y P G S P Q D G E R R R S S G L L S S P P F S G S G G Y S I L D K
CATACCCAGGTTCACCACAAGATGGCGAGCGCCGTCGCAGTTCTGGCCTCCTATCGTCTCCTCCCTTCTCCGGCAGCGGCGGGTACTCGATTCTAGATAA
Q g  K A
GAAAACAATCATCATCACGACAACGGCGTGCGGGAGCGGCTGGTGGTCCTGGACGCCGCAGCAGAAGGCGGAAGCCTACCTGTGGCTCATGTTACTGGTT
TTGGGACTGTGTTCGTGGCTGGCGGCGTGGATTCACGCATATTAAAAAGAGATTTACCTGCTGAAACCCTTTTGTGTGTATGGTGTGGTTTTTTATTTCG
UL16 M A K D
GGGGTCTAGACCGCGTTGACGTAGGACGTGATCTCAAGGAGACGCTAAGTACTTAGGAAGAGACCGCACAGCGCATCGCGGCTCAGCATGGCGAAGGACA
I I I
2 1 9 0 0
22000
22100
22200
2 2 3 0 0
2 2 4 0 0
2 2 5 0 0
1 9 8 0 0
1 9 9 0 0
20000
20100
20200
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L H V R V F T L S T C E G A M A I A A A R S L G R R W G R A D D D  
A P C P C I  H L I H V R G G H G D S G G P L A R E A M G A R R - R Q  
UL101 S M S V Y  S P Y P R A R G P W R - R R P A R S G G D G G A P M T T
CTCCATGTCCGTGTATTCACCTTATCCACGTGCGAGGGGGCCATGGCGATAGCGGCGGCCCGCTCGCTCGGGAGGCGATGGGGGCGCGCCGATGACGACA 14 64 C 0
R L A G R  -  I L R W E  P P R L T T R  F E H V R A V G E K R  P R G P S  
A R G S L N T T M G A A A A H D A V - A R P G G R - K K T P R A F  
G S R V V K Y Y D G S R R G S R R G L S T S G R S V K K D P A G L  
GGCTCGCGGGTCGTTAAATACTACGATGGGAGCCGCCGCGGCTCACGACGCGGTTTGAGCACGTCCGGGCGGTCGGTGAAAAAAGACCCCGCGGGCCTTC 146500
R L S S V R G - P L S R R C T T A T T R T P C S G P A V I S A G T  
UL101X  A T  L F C  P R  M T A Q P P L H H R H H P Y T L F G T S C H L S W Y  
R D S L L S E D D R S A A A A P P P P P V H P V R D Q L S S Q L V R
GCGACTCTCTTCTGTCCGAGGATGACCGCTCAGCCGCCGCTGCACCACCGCCACCACCCGTACACCCTGTTCGGGACCAGCTGTCATCTCAGCTGGTACG 14 6600
A F - R P R C L S Y N V C F W I W V A A V P S R G F T R S W C A V  
G L L E A S V P I V Q C L F L D L G G G R A E P R L H T F V V R G D  
P S R G L G A Y R T M S V F G S G W R P C R A A A S H V R G A R -  
GCCTTCTAGAGGCCTCGGTGCCTATCGTA(^ATGTCTGTTTTTGGATCTGGGTGGCGGCCGTGCCGAGCCGCGGCTTCACACGTTCGTGGTGCGCGGTGA 14 6 7 )0
T V Y R R L R C V L C I A P A R V R W P R P - L R T P M S V G A A -  
U L102 R L P P A E V - R A V H R A S 0 G A L A S A V T T D A D E R R R G L  
P S T A G - G A C C A S R Q L G C A G L G R D Y G R R - A S A R P  
CCGTCTACCGCCGGCTGAGGTGCGTGCTGTGCATCGCGCCAGCTAGGGTGCGCTGGCCTCGGCCGTGACTACGGACGCCGATGAGCGTCGGCGCGGCCTA 14 6 8 )0
S S V A P C W R A C C - K A A R - S A C W R A P S R R C R F R R T
I Q R S . A V L A R V L L E G S A L I R V L A R T F T P y g i Q T D
r a a - r ' r v g a r v a r r q r v n p r v g a h l h a g a d s d g r
GAGCAGCGTAGCGCCGTGTTGGCGCGCGTGTTGCTAGAAGGCAGCGCGTTAATCCGCGTGTTGGCGCGCACCTTCACGCCGGTGCAGATTCA^ACGGACG 14 6 9 )0
L V A W R F W R P H R H W A W K P Q R C R T R L V F S T - P S - W  
A § 5 Y § i I t ! : A A E A i ; G V E T A A L S N A L S L F H V A K L V V  
- W R G D F G G R T G T G R G N R S A V E R A - S F P R S Q A S G  
CTAGTGGCGTGGAGATTTTGGAGGCCGCACCGGCACTGGGCGTGGAAACCGCAGCGCTGTCGAACGCGCTTAGTCTTTTCCACGTAGCCAAGCTAGTGGT 14 7010
S S A R I  P K C T S R V W S R I  P R N A S P K S M A P T R T K N C V  
I G S Y P E V H E P R V V T H T A E R V S E E Y G T H A H K K L R  
H R L V S R S A R A A C G H A Y R G T R L R R V W H P R A Q K I A  
CATCGGCTCGTATCCCGAAGTGCACGAGCCGCGTGTGGTCACGCATACCGCGGAACGCGTCTCCGAAGAGTATGGCACCCACGCGCACAAAAAATTGCGT 14 7110
A V T T P T I W P C R F A S A L T S M C W S A T T R P S W H A S L  
5 5 X X A X 2 L A M S F R y G T H K Y y L E R D D E A y L A R L F  
S R L L R L R F G H V V S R R H S Q V C A G A R R R G R P G T P L -  
CGCGGTTACTACGCCTACGATTTGGCCATGTCGTTTCGCGTCGGCACTCACAAGTATGTGCTGGAGCGCGACGACGAGGCCGTCCTGGCACGCCTCTTTG 1472 1 0
I
Figure 3.4: Comparison of the region containing AD169 UL102 with the cognate 
CCMV sequence.
Panels I and II show three-frame translations (upper strand) of the relevant regions of the AD169 and 
CCMV sequences, respectively, with nucleotide coordinates on the right. The locations of PCR primers 
for AD169 are indicated by arrows in panel I. UL102 is shown in red in panels I and II. Regions in 
AD169 that appear to be conserved in CCMV UL102 are shown in italic green font in panel I, with 
conserved amino acid residues underlined. The region containing possible errors in AD169 sequerce 
is highlighted in yellow. UL101 and UL101X are shown in green in panel I.
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G G R C V L M T K S P R V V K Y Y Y G G P C R G C A S S R A F P E  
G W P V R A D D E K P A G R - I L L W R P M P R L R L L P R L P R  
ITL102 G V A G A C - - R K A R G S L N T T M E A H A A A A P P P A P S P R
GGGTGGCCGGTGCGTGCTGATGACGAAAAGCCCGCGGGTCGTTAAATACTACTATGGAGGCCCATGCCGCGGCTGCGCCTCCTCCCGCGCCTTCCCCGAG 14 87 00
D A V - T R R R D R P K D R A A P V G P S Q R S S R G R A A K N G  
G R G L N A S T R P A K R P R G A R R A L T A L V A R P G G E K R P  
T R F E R V D A T G Q K T A R R P S G P H S A R R A A G R R K T A  
GACGCGGTTTGAACGCGTCGACGCGACCGGCCAAAAGACCGCGCGGCGCCCGTCGGGCCCTCACAGCGCTCGTCGCGCGGCCGGGCGGCGAAAAACGGCC 14 8 8 0 0
P E L G G D G R Q P L H A R R G Q L P P Q L V R H P R G L R A H R A  
R A R R G W P P T T T R S S G P A A T S A G T A S S R P P C P S C  
P S S A G M A A N H Y T L V G A S C H L S W Y G I L E A S V P I V  
CCGAGCTCGGCGGGGATGGCCGCCAACCACTACACGCTCGTCGGGGCCAGCTGCCACCTCAGCTGGTACGGCATCCTCGAGGCCTCCGTGCCCATCGTGC 14 8 90 0
V P L H G S G C P R R S R R G A A A A D V H R A R R P P A L G R G  
S A S S W I W V P S A V A P R S R G C G R S S C A A T A C P R P R  
Q C L F M D L G A L G G R A E E P R L R T F I V R G D R L P S A E V  
AGTGCCTCTTCATGGATCTGGGTGCCCTCGGCGGTCGCGCCGAGGAGCC'GCGGCTGCGGACGTTCATCGTGCGCGGCGACCGCCTGCCCTCGGCCGAGGT 14 9 0 0 0
A C R A P R Q L R Q P G L G R G R R R G A P P R H R A P Q R R A G  
C V  P C T A P A T  P A W  P R  P W  P T  P R S A A A A S S T A A P C W R  
R A V H R A S Y A S L A S A V A D A E E R R R G I E H R S A V L A  
GCGTGCCGTGCACCGCGCCAGCTACGCCAGCCTGGCCTCGGCCGTGGCCGACGCCGAGGAGCGCCGCCGCGGCATCGAGCACCGCAGCGCCGTGCTGGCG 14 9 1 0 0
A C A A G G Q R H H P R A G A H L H A R P D P D R P Q R R G D S R G  
V C C W R A A P S S A C W R A P S R P S R S R P T P A A W R F S R  
B Y i i i l i G S A I I R V L A R T F T P V Q I Q T D P S G V E I L E  
CGTGTGCTGCTGGAGGGCAGCGCCATCATCCGCGTGCTGGCGCGCACCTTCACGCCCGTCCAGATCCAGACCGACCCCAGCGGCGTGGAGATTCTCGAGG 14 9 2 0 0
R A R A G L R R G R A L A R P Q P L P R R Q A G G H R L L P G D P  
P C P R W A S T R P R S R T P S A S T T S P S W W S S A P T R R S  
A V P A L G F D A A A L S H A L S L Y H V A K L V V I G S Y P E I H  
CCGTGCCCGCGCTGGGCTTCGACGCGGCCGCGCTCTCGCACGCCCTCAGCCTCTACCACGTCGCCAAGCTGGTGGTCATCGGCTCCTACCCGGAGATCCA 14 9 3 0 0
R R R G H L V V R L G A R R H R R P R G L R H P G P Q E A A A R L  
T T  P W  P P R R P S R R A S  P P A A T R T T  P P R P T R S C G A A T  
D A V A T S S S V S A R V A T G G H E D Y A T Q A H K K L R R G Y  
CGACGCCGTGGCCACCTCGTCGTCCGTCTCGGCGCGCGTCGCCACCGGCGGCCACGAGGACTACGCCACCCAGGCCCACAAGAAGCTGCGGCGCGGCTAC 14 94 00
L R L R R G H V V P R R R  P Q V R A G A R R R G R R G L T  P L R G A  
T P T T W P C R S A S A P T S T C W S A T T R P P W S H A S S R C  
Y A Y D V A M S F R V G A H K Y V L E R D D A A A V V S R L F E V 
TACGCCTACGACGTGGCCATGTCGTTCCGCGTCGGCGCCCACAAGTACGTGCTGGAGCGCGACGACGCGGCCGCCGTGGTCTCACGCCTCTTCGAGGTGC 14 9 5 0 0
I I
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Figure 3.5 Comparison of the corrected sequence of the region containing 
AD169 UL102 with the cognate CCMV sequence.
Panel I shows the corrected sequence of AD169 and panel III shows the corresponding CCM V  
sequence, with nucleotide coordinates on the right. In each panel, UL102 is shown in red and 
conserved residues are underlined. The two G residues replaced by C residues are highlighted 
in yellow in panel I. Panel II shows an electrophoregram of the sequence of the relevant region 
of AD169 (upper strand) with the altered residues indicated by arrows.
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U L 1 0 2  M T A Q P P L H H R H H P Y T L F G T S C H L S W Y
GCGACTCTCTTCTGTCCGAGGATGACCGCTCAGCCGCCGCTGCACCACCGCCACCACCCGTACACCCTGTTCGGGACCAGCTGTCATCTCAGCTGGTACG 14 6 6 0 0
G L L E A S V P I V Q C L F L D L G G G R A E P R L H T F V V R G D  
GCCTTCTAGAGGCCTCGGTGCCTATCGTACAATGTCTGTTTTTGGATCTGGGTGGCGGCCGTGCCGAGCCGCGGCTTCACACGTTCGTGGTGCGCGGTGA 14 6 7 0 0
5 i 5 p A E y R A V H R A S Y A A L A S A V T T D A D E R R R G L  
CCGTCTACCGCCGGCTGAGGTGCGTGCTGTGCATCGCGCCAGCTAgGgTGCGCTGGCCTCGGCCGTGACTACGGACGCCGATGAGCGTCGGCGCGGCCTA 14 6 8 0 0
E Q R S A V L A R V L L E G S A L I R V L A R T F T P V g l g T D A  
GAGCAGCGTAGCGCCGTGTTGGCGCGCGTGTTGCTAGAAGGCAGCGCGTTAATCCGCGTGTTGGCGCGCACCTTCACGCCGGTGCAGATTCAGACGGACG 14 6 9 0 0
§ 2 ^ I i t I A A P A L G V E T A A L S N A L S L F H y A K L V V  
CTAGTGGCGTGGAGATTTTGGAGGCCGCACCGGCACTGGGCGTGGAAACCGCAGCGCTGTCGAACGCGCTTAGTCTTTTCCACGTAGCCAAGCTAGTGGT 14 7 0 0 0
I G S Y P E V H E P R V V T H T A E R V S E E Y G T H A H K K L R  
CATCGGCTCGTATCCCGAAGTGCACGAGCCGCGTGTGGTCACGCATACCGCGGAACGCGTCTCCGAAGAGTATGGCACCCACGCGCACAAAAAATTGCGT 14 7 1 0 0
5 5 X X A X 2 L A H S F R V G T H K Y V L E R D D E A V L A R L F  
CGCGGTTACTACGCCTACGATTTGGCCATGTCGTTTCGCGTCGGCACTCACAAGTATGTGCTGGAGCGCGACGACGAGGCCGTCCTGGCACGCCTCTTTG 14 7 2 0 0
I
I I
U L 1 0 2  M A A N H X l i v G A S C H L S W Y G I L E A S V P I V
CCGAGCTCGGCGGGGATGGCCGCCAACCACTACACGCTCGTCGGGGCCAGCTGCCACCTCAGCTGGTACGGCATCCTCGAGGCCTCCGTGCCCATCGTGC 14 89 0 0
Q C L F M D L G A L G G R A E E P R L R T F I V R G D R L P S A E V  
AGTGCCTCTTCATGGATCTGGGTGCCCTCGGCGGTCGCGCCGAGGAGCCGCGGCTGCGGACGTTCATCGTGCGCGGCGACCGCCTGCCCTCGGCCGAGGT 14 9 0 0 0
R A V H R A S Y A S L A S A V A D A E E R R R G I E H R S A V L A  
GCGTGCCGTGCACCGCGCCAGCTACGCCAGCCTGGCCTCGGCCGTGGCCGACGCCGAGGAGCGCCGCCGCGGCATCGAGCACCGCAGCGCCGTGCTGGCG 14 9 1 0 0
B Y i f L E G S A I I R V L A R T F T P V g l g T D P S G V E I L E  
CGTGTGCTGCTGGAGGGCAGCGCCATCATCCGCGTGCTGGCGCGCACCTTCACGCCCGTCCAGATCCAGACCGACCCCAGCGGCGTGGAGATTCTCGAGG 14 9 2 0 0
A V P A t 2 F D A A A i S H A L S L Y H y A K L V V I G S Y P E I H  
CCGTGCCCGCGCTGGGCTTCGACGCGGCCGCGCTCTCGCACGCCCTCAGCCTCTACCACGTCGCCAAGCTGGTGGTCATCGGCTCCTACCCGGAGATCCA 14 9 3 0 0
D A V A T S S S V S A R V A T G G H E D Y A T Q A H K K L R R G Y  
CGACGCCGTGGCCACCTCGTCGTCCGTCTCGGCGCGCGTCGCCACCGGCGGCCACGAGGACTACGCCACCCAGGCCCACAAGAAGCTGCGGCGCGGCTAC 14 94 00
Y A Y D V A M S F R V G A H K Y V L E R D D A A A V V S R L F E V  
TACGCCTACGACGTGGCCATGTCGTTCCGCGTCGGCGCCCACAAGTACGTGCTGGAGCGCGACGACGCGGCCGCCGTGGTCTCACGCCTCTTCGAGGTGC 14 9 5 0 0
I I I
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this region of the Towne and AD 169 genomes. The predicted protein-coding region for 
the amended AD 169 UL102 contains 870 amino acids. Several other nucleotide 
substitutions were reported in this region of Towne by Smith and Pari (1995), but none 
were found in the AD 169 DNA sequence in the present study.
3.1.3 UL145
UL145 is present in Toledo but absent from AD 169. Fig. 3.6 shows three-frame 
translations of the relevant regions of the Toledo and CCMV genomes. UL145 as 
defined in Toledo (Fig. 3.6 panel I) is conserved in CCMV (Fig. 3.6 panel II), but 
appears to be disrupted in the region of nucleotide 8884-8889. This indicates the 
potential presence of a frameshift error in the Toledo sequence. Sequence analysis of a 
PCR product derived from this region of the Toledo genome demonstrated the presence 
of one extra G residue after nucleotide 8884. The electropherograms are shown in Fig. 
3.7 (panel II) and the additional nucleotide is highlighted in yellow in Fig. 3.7 (panel I). 
These correction extends Toledo UL145 at its 5’-end so that it corresponds to CCMV 
UL145. The correct ATG is located at position 8777 instead of 8866 as published. 
These two ORFs are shown in Fig. 3.7 (panels I and III).
3.1.4 US22
AD 169 US22 is well conserved in CCMV (Fig. 3.8 panels I and II). However, a region 
near the 5’-end is conserved in another frame in CCMV. This indicates a possible 
frameshift error in the sequence of AD 169 US22 as marked in yellow in Fig. 3.8 (panel 
I). Sequence analysis of a PCR product demonstrated the presence of one extra G 
residue after nucleotide 211535 (Fig. 3.9 panels I and II). This correction extends the 
protein-coding region of AD 169 US22 at its 5’-end and introduces an additional 45 
amino acid residues at the N terminus of the protein. The first ATG codon in the US22 
is now at 211601 instead of 211462 as originally described by Chee et al. (1990). The 
transcript mapping data for the US22 mRNA (section 5.1) also correlate with the 
correction made in this region.
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A D V R K N K C R L H K S P V L S C C H S F L L P S M Y G V L A H Y  
R R Q E K - V S P T - E P G A I V L S L F L V A F D -  V R R P G S L  
P T S G K I  S V A Y  I R A R C Y R A V T L S C C L R C T A S W L I  
CCGACGTCAGGAAAAATAAGTGTCGCCTACATAAGAGCCCGGTGCTATCGTGCTGTCACTCTTTCTTGTTGCCTTCGATGTACGGCGTCCTGGCTCATTA 8 8 0 0
Y S F I S S P S V M V N F K H H N A V Q L L C A R T R D @ L P D G
U L 1 4 5  L L L H Q  -  P Q R Y G  -  F -  A S  -  R R A A V M C  T D  P R R T A G W
T T P S S V A P A L W L I L S I I T P C S C Y V H G P E T H C R M G  
CTACTCCTTCATCAGTAGCCCCAGCGTTATGGTTAATTTTAAGCATCATAACGCCGTGCAGCTGTTATGTGCACGGACCCGAGACGCACTGCCGGATGGG 8 9 0 0
N V - P I M R R I T R T T G H T P C - W L H R K E S P - C Y I D T  
E R L T H H A S Y R A N Y G A Y A V L M A T S Q R K S L V L H R Y S  
T F N P S C V V S R E L R G I R R V D G Y I A K K V P S V T S I Q  
AACGTTTAACCCATCATGCGTCGTATCACGCGAACTACGGGGCATACGCCGTGTTGATGGCTACATCGCAAAGAAAGTCCCTAGTGTTACATCGATACAG 9 0 0 0
V P - Q P W P C S S C L L R S S A S - I S R T G C G V P G S C Q R L  
A V T A V A L Q L M P V E I V R K L D Q S D W V R G A W I V S E T  
C R D S R G P A A H A C  -  D R  P Q A R S V G L G A G C L D R V R D  
DSCCGTGACAGCCGTCGCCCTGCAGCTCATGCCTGTTGAGATCGTCCGCAAGCTAGATCAGTCGGACTGGGTGCGGGGTGCCTGGATCGTGTCAGAGACT 9 1 0 0
F Q L A T P K E F G A T M T P R W V E V M I D D E N L T R K T R E
f p t s d p k g v w s d d d s s m g g s d d - - - e p d k k d e r
F S N - R P Q R S L E R R - L L D G W K - - L M M R T - Q E R R E R  
TTTCCAACTAGCGACCCCAAAGGAGTTTGGAGCGACGATGACTCCTCGATGGGTGGAAGTGATGATTGATGATGAGAACCTGACAAGAAAGACGAGAGAG 9 2 0 0
I
Figure 3.6 Comparison of the region containing Toledo UL145 with the cognate 
CCMV sequence.
Panels I and II show three-frame translations of the relevant regions of the Toledo and CCMV 
sequences, respectively, with nucleotide coordinates on the right. UL145 is oriented left to right in 
Toledo (panel I) and right to left in CCMV (panel II). In each panel, UL145 is shown in red, and 
conserved residues are underlined. The locations of PCR primers for Toledo are indicated by 
arrows In panel I. Regions in Toledo that appear to be conserved in CCMV UL145 are shown in 
bold black font in panel I, with conserved amino acid residues underlined. The region containing 
possible errors in the Toledo sequence is highlighted in yellow.
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TAAAACGGGAACCACACTTTCACACCAGCTCTACCAACACGGCTCGGACCTTTCTCTTTTGCAGACCGCTCTCAAGCGTCACCTCCACCCACCGCGGATT 1 8 3 9 0 0  
F R S G C K - V L E V L V A R V K R K Q L G S  E L T V E V W R  P N  
- F P F W V K V G A R G V R S P G K E K A S R E - A D G G G V A S E  
L V P V V S E C W S - W C P E S R E R K C V A R L R - R W G G R I
CCCCCTCGCGTCCCTCGTGTCTCTTATCTCCCTCGTCGTTTTCCCCCTCGTCGCCGCTGCTACTGCTGCGACGGTCCCGAAATCCGTCCGGATCGCAGGT 184 00 0  
G R A D R T D R I E R T T K G R T A A A V A A V T G F D T R I A P  
G E R G E H R K D G E D N E G E D G S S S S R R D R F G D P D C T  
G G R T G R T E - R G R R K G G R R R Q - Q Q S P G S I R G S R L D
CGGAAATGTCTCCGACACGATCCACGCGCCTTTCACCCAGTCCGACTGGTCCAGTCTCGCCAACACGTTACTCGGCATCAGCTGCAGAGCCACGGCCGTC 1 8 4 1 0 0  
R F H R R C S G R A K - G T R S T W D R W C T V R C - S C L W P R -  
P F T E S V I W A G K V W D S Q D L R A L V N S P M L Q L A V A T  
S I  D G V R D V R R E G L G V P G T E G V R  -  E A D A A S G R G D
ACGGCGCTGTACCGGTGCAACACCAGGGACTTGGTCTGCGACGTAGCCATCAGTACGGCGTAGGCCCCGTAGTCCGCCTGATAGGCCGCGTGGTGGGTTA 184 20 0  
P A T G T C C W P S P R R R L W - Y P T P G T T R R I P R T T P -  
Y * § X 5 M t Y t § l ? T S § I A H L V A Y A G Y D A Q i f A A H H T L  
R R Q V P A V G P V Q D A V Y G D T R R L G R L G G S L G R P P N
GACGTTCCCACCCCGAGGTGCCGTCGCGAGCCCTCGCGCACAGCAGCTGGACGGCGTTCTGATGTCTGTAGTGGACCATGGCGCTCGGACCGCTGATGAA 184 30 0  
V N G G R P A T A L G R A C C S S P T R I D T T S W P A R V A S S  
R E W G S  T G D R A R A C L L Q V A N Q H R Y  H V M A S P G S I F  
S T G V G L H R R S G E R V A A P R R E S T Q L P G H R E S R Q H V
CGAGTAATAATGCGCGGCCGAGACGGCGTGTTGATCGTGCATGGGCGAGCGACGACAACACTACCTGCGGCGTCGTCCTCCATGCTTCGTCCTCTCACCT 184 4 00  
R T I I R P R S P T N I T C P R A V V V S G A A D D E M S R G R V K  
U1145 S Y Y H A A S V A H Q D H M P S R R C C - R R R R G G H K T R E G  
L L L A R G L R R T S R A H A L S S L V V Q P T T R W A E D E - R
I I
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Figure 3.7 Comparison of the corrected sequence of the region containing 
Toledo UL145 with the cognate CCMV sequence.
Panel I shows the corrected sequence of Toledo and panel III shows the corresponding CCM V  
sequence, with nucleotide coordinates on the right. UL145 is oriented left to right in Toledo 
(panel I) and right to left in CCM V (panel III). In each panel, UL145 is shown in red, and 
conserved residues are underlined. The additional G residue is highlighted in yellow in panel I. 
Panel II shows an electrophoregram of the sequence of the relevant region of Toledo (upper 
strand) with the additional residues indicated by arrows.
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U L 1 4 5  M Y  G V L A H Y
CCGACGTCAGGAAAAATAAGTGTCGCCTACATAAGAGCCCGGTGCTATCCTGCTGTCACTCTTTCTTGTTGCCTTCGATGTACGGCGTCCTGGCTCATTAC 8 8 0 0
Y S F I S S P S V M V N F K H H N A V Q L L C A R T R D A T A G W  
TACTCCTTCATCAGTAGCCCCAGCGTTATGGTTAATTTTAAGCATCATAACGCCGTGCAGCTGTTATGTGCACGGACCCGAGACGgCACTGCCGGATGGG 8 9 0 0
E R L T H H A S Y H A N Y G A Y A V L M A T S g R K S L V L H R Y S  
AACGTTTAACCCATCATGCGTCGTATCACGCGAACTACGGGGCATACGCCGTGTTGATGGCTACATCGCAAAGAAAGTCCCTAGTGTTACATCGATACAG 9 0 0 0
A V T A V A L Q L M P V E I V R K L D Q S D W V R G A W I V S E T  
TGCCGTGACAGCCGTGGCCCTGCAGCTCATGCCTGTTGAGATCGTCCGCAAGCTAGATCAGTCGGACTGGGTGCGGGGTGCCTGGATCGTGTCAGAGACT 9 1 0 0
F P T S D P K G V W S D D D S S M G G S D D -  
TTTCCAACTAGCGACCCCAAAGGAGTTTGGAGCGACGATGACTCCTCGATGGGTGGAAGTGATGATTGATGATGAGAACCTGACAAGAAAGACGAGAGAG 9 2 0 0
I
I I
TAAAACGGGAACCACACTTTCACACCAGCTCTACCAACACGGCTCGGACCTTTCTCTTTTGCAGACCGCTCTCAAGCGTCACCTCCACCCACCGCGGATT 1 8 3 9 0 0
- A D G G G V A S E
CCCCCTCGCGTCCCTCGTGTCTCTTATCTCCCTCGTCGTTTTCCCCCTCGTCGCCGCTGCTACTGCTGCGACGGTCCCGAAATCCGTCCGGATCGCAGGT 184 00 0  
G E R G E H R K D G E D N E G E D G S S S S R R D R F G D P D C T
CGGAAATGTCTCCGACACGATCCACGCGCCTTTCACCCAGTCCGACTGGTCCAGTCTCGCCAACACGTTACTCGGCATCAGCTGCAGAGCCACGGCCGTC 1 8 4 1 0 0  
P F T E S V I W A G K V W D S Q D L R A L V N S P M L Q L A V A T
ACGGCGCTGTACCGGTGCAACACCAGGGACTTGGTCTGCGACGTAGCCATCAGTACGGCGTAGGCCCCGTAGTCCGCCTGATAGGCCGCGTGGTGGGTTA 1 8 4 2 0 0  
Y * § Y R H L V L S K T g S T A M L V A Y A G Y D A Q Y A A H H T L
GACGTTCCCACCCCGAGGTGCCGTCGCGAGCCCTCGCGCACAGCAGCTGGACGGCGTTCTGATGTCTGTAGTGGACCATGGCGCTCGGACCGCTGATGAA 184 3 0 0  
R E W G S T G D R A R A C L L Q V A N Q H R Y H V M A S P G S I F
CGAGTAATAATGCGCGGCCGAGACGGCGTGTTGATCGTGCATGGGCGAGCGACGACAACACTACCTGCGGCGTCGTCCTCCATGCTTCGTCCTCTCACCT 184 4 00 
U L 1 4 5  S Y Y H A A S V A H Q D H M
I I I
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AAAGGCTTTGATATGACTGGCCACCTCGTAGAGCCCGTCGGTCrCCCAGTCGrAGACGTAGACGGrGCCGTAATGACTTAGCATGAGCACGCAGGGCAGT 2 1 1 2 0 0  
L S Q Y - Q G G R L A R R  D G L R L R L R H R L S K A H A R L A T  
F P K S I V P W R T S G T P R G T T S T S P A T I V - C S C A P C N  
F A K I D S A V E Y L G D T E W D Y V Y V T G Y H S L M L V C P L
TCCTGCGCCTGCTYGGTGTTTCGTGTTAGATCGCTGTCGGGTGGACGCACGGCTAGTACACCGACGGCTTCCAGGGTGTCATCGCAGCAGAGATAGTCGG 2 1 1 3 0 0
g a g a c h k t n s r q r t s a r s t c r r s g p h - r l l s l r
R R R S P T E H - I A T P H V C P - Y V S P K W P T M A A S I T P
E Q A Q K T N R T L D S D P P R V A L y G V A E L T D D C C L Y D A
CGGCCAGAGAACGTGCGTAAATCTGCGGGATGGCGGCCTGTTCGCGCATCACTAGGAACCAGTTGGCGGGGTTGCGCAGTGCTACGGTGGTTCCTTGGTG 2 1 1 4 0 0  
R G S F T R L D A P H R G T R A D S P V L Q R P Q A T S R H N R P P  
P W L V H T F R R S P P R N A C - - S G T P P T A C H - P P E K T  
^ ^ s r a y i q p i a a q e r m v l f w n a p n r l a v t t g q h
GCGTTGCACGTAGGTTCTCAGCGCCGGAGGATCGTACTGGCGCAGATAGAGGCCTTGCAGCATCGATAACGTCTTTTGAAAGACGGTGTTTCTAAATTGA 2 1 1 5 0 0  
T A R L N E A G S S R V P A S L P R A A D I V D K S L R H K - I S  
A N C T P E - R R L I T S A C I S A K C C R Y R R K F S P T E L N F  
R Q V Y T R L A P P D Y Q R L Y L G Q L ^ S L T K g F V T N R F Q
AAAACGCCGTAGTCGCAGCGGATAGCATCTTC|GCACGCT|CGTCGCGCTGTCGGAGATAGGTGCCCCAGGCTTCGGCGGCGGCTTTGGTGAGTAGGGACAT 2 1 1 6 0 0  
F R R L R L P Y  C R R V S T A S D S I  P A G P K P P P K P S Y  P C  
F A T T A A S L M K A R E D R g R L Y T G W A E A A A K T L L S M
f v g y d c r i a d e c a r r a t p s l h ~ g l s r r r s q h  T p v h
GCCGGCQGAGCCGrCTCGACAGCGAGTCGGATAAAGCGCGCTGCGCGAAAGCTTAATATAGGAGCAGCGTCAGACGAATCGCGGCTGGTGGCCCGGGGGG 2 1 1 7 0 0  
A P P  A T E V A L R 1 ~  F R A A R F S L I  P A A D S S D R S T A R P T  
G A S G D R C R T P Y L A S R S L K I Y S C R - V F R P Q H G P P  
US22 R R L R R S L S D S L A R Q A F A - Y L L L T L R I A A P P G P P
I
Figure 3.8: Comparison of the region containing AD169 US22 with the cognate 
CCMV sequence.
Panels I and II show three-frame translations of the relevant regions of the AD169 and CCMV 
sequences, respectively, with nucleotide coordinates on the right. The locations of PCR primers are 
indicated by arrows in panel I. Part of US22 is shown in red in each panel. In panel I, the first ATG codon 
in US22 as originally defined is shown in a box, and regions in AD169 that appear to be conserved in 
CCMV US22 are shown in bold black font, with conserved amino acid residues underlined. The region 
containing possible errors in the AD169 sequence is highlighted in yellow.
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GTTCTTGGCGAAGACCTTGAGGTCGCTGGCTACCTCGTACAGCCCGTCCGTCTCCCAGTCGTAGACGTAGACGGTGCCGTGCTTACCCATCATCAGCACG 2 2 3 2 0 0  
E Q R L G Q P R Q S G R V A R G D G L R L R L R H R A - G D D A R  
T R P S S R S T A P - R T C G T R R G T T S T S P A T S V W - - C A  
N K A F V K L D S A V E Y L G D T E W D Y V Y V T G H K G M M L V
CAGGGCACCTCCTGCGCCCACTTGGTATGGCGGTGGGGGTCGTCGTCCGCCGGTCGCACGGCCAGCACGCCGACGGCCTCCAGGTCATCGTCACAGCACA 2 2 3 3 0 0  
L A G G A G V Q Y  P P P  P R R G G T A R G A R R R G G P - R  -  L V  
P C R R R G S P I A T P T T T R R D C P W C A S P R W T M T V A C  
C P V E Q A W K T H R H P D D D A P R V A L V G V A E L D D D C C L
GATACTCGGAGGCCAGCGAACGTGCGTAGATCTGCGGGATGGCGGCCGTCTCGCGCAGCACCAGGAGCCAGTTGGCCGGGTTACGCAGGGCCACCGTGGT 2 2 3 4 0 0  
S V R L G A F T R L D A P H R G D R A A G P A L Q G P - A P G G H H  
I S P P W R V H T S R R S P P R R A C C W S G T P R T V C P W R P  
Y E S A L S R A Y I Q P I A A T E R L V L L W N A P N R L A V T T
GCCCCGGTGCTGGCGTACGTAGCTCCGCAGCGCGTCGGGGTCGTATTGACGCAGGTAGAGCCCCTGCAGCAGCGAGAGCGTGCGCTGGTAGATGGTGTTG 2 2 3 5 0 0  
G P A P T R L E A A R R P R I S A P L A G A A A L A H A P L H H Q  
A G T S A Y T A G C R T P T T N V C T S G R C C R S R A S T S P T A  
G R H Q R V Y S R L A D P D Y Q R L Y L G g L L S L T R Q Y I T N
CGAAACTGAAAGACACCATAGTCGCAGCGGATGGCGTCCTCGCAGCGCTCGTCGCGCTGCCGCAGATAGGTGCCCCAGGCCTCGGCGGCGGCCTTGGTCA 2 2 3 6 0 0  
S V S L C W L R L P H R G R L A R R A A A S L H G L G R R R G Q D  
F S F S V M T A A S P T R A A S T A S G C I P A G P R P P P R P -  
R F Q F V G Y D C R I A D E C R E D R Q R L Y T G  W A E A A A K T L
GCAGCGACATCGCGGCGCCCCGACGCGGGCCGTGTGGCGCCCCGGCGCGGCGTCAAAGCTTAATATAGGGAGCGGTCCCTCTCGAGTCTGGGCCGCCGCG 2 2 3 7 0 0  
A A V D R R G S A P R T A G R R P T L A - Y L S R D R E L R P R R A  
C R C R P A G V R A T H R G P A A D F S L I P L P G E R T Q A A A  
U S 2 2  L S M A A G R R  P G H  P A G A R R  -  L K I  Y P A T G R S D P G G R
II
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Figure 3.9 Comparison of the corrected sequence of the region containing 
AD169 US22 with the cognate CCMV sequence.
Panel I shows the corrected sequence of AD169 and panel III shows the corresponding CCM V  
sequence, with nucleotide coordinates on the right. In each panel, US22 is shown in red, and 
conserved residues are underlined. The inserted G residue is highlighted in yellow in panel I. 
Panel II shows an electrophoregram of the sequence of the relevant region of AD169 (lower 
strand) with the inserted residue indicated by an arrow.
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AAAGGCTTTGATATCACTGGCCACCTCGTAGAGCCCGTCGGTCTCCCAGTCGTAGACGTAGACGGTGCCGTAATGACTTAGCATGAGCACGCAGGGCAGT 2 1 1 2 0 0  
F A K I D S A V E Y L G D T E W D Y V Y V T G Y H S L M L V C P L
TCCTGCGCCTGCTTGGTGTTTCGTGTTAGATCGCTGTCGGGTGGACGCACGGCTAGTACACCGACGGCTTCCAGGGTGTCATCGCAGCAGAGATAGTCGG 2 1 1 3 0 0  
E Q A Q K T N R T L D S D P P R V A L V G V A E L T D D C C L Y D A
CGGCCAGAGAACGTGCGTAAATCTGCGGGATGGCGGCCTGTTCGCGCATCACTAGGAACCAGTTGGCGGGGTTGCGCAGTGCTACGGTGGTTCCTTGGTG 2 1 1 4  00  
* i § 5 £ X I 2 5 i A A Q E R M V L F W N A P N R L A V T T G Q H
GCGTTGCACGTAGGTTCTCAGCGCCGGAGGATCGTACTGGCGCAGATAGAGGCCTTGCAGCATCGATAACGTCTTTTGAAAGACGGTGTTTCTAAATTGA 2 1 1 5 0 0  
R Q V Y T R L A P P D Y g R L Y L G g L M S L T K g F V T N R F g
AAAACGCCGTAGTCGCAGCGGATAGCATCTTCGCAgCGCTCGTCGCGCTGTCGGAGATAGGTGCCCCAGGCTTCGGCGGCGGCTTTGGTGAGTAGGGACA 2 1 1 6 0 0  
U S 2 2  E Y G Y D C R I A D E C R E D R Q R L Y T G W A E A A A K T L L S M
TGCCGGCGGAGCCGTCTCGACAGCGAGTCGGATAAAGCGCGCTGCGCGAAAGCTTAATATAGGAGCAGCGTCAGACGAATCGCGGCTGGTGGCCCGGGGG 2 1 1 7 0 0
I
I I
GTTCTTGGCGAAGACCTTGAGGTCGCTGGCTACCTCGTACAGCCCGTCCGTCTCCCAGTCGTAGACGTAGACGGTGCCGTGCTTACCCATCATCAGCACG 2 2 3 2 0 0  
N K A F V K L D S A V E Y L G D T E W D Y V Y V T G H K G M M L V
CAGGGCACCTCCTGCGCCCACTTGGTATGGCGGTGGGGGTCGTCGTCCGCCGGTCGCACGGCCAGCACGCCGACGGCCTCCAGGTCATCGTCACAGCACA 2 2 3 3 0 0  
C P V E g A W K T H R H P D D D A P R V A L V G V A E L D D D C C L
GATACTCGGAGGCCAGCGAACGTGCGTAGATCTGCGGGATGGCGGCCGTCTCGCGCAGCACCAGGAGCCAGTTGGCCGGGTTACGCAGGGCCACCGTGGT 2 2 3 4 0 0  
Y E S A L S R A Y I g P I A A T E R L V L L W N A P N R L A V T T
GCCCCGGTGCTGGCGTACGTAGCTCCGCAGCGCGTCGGGGTCGTATTGACGCAGGTAGAGCCCCTGCAGCAGCGAGAGCGTGCGCTGGTAGATGGTGTTG 2 2 3 5 0 0  
G R H Q R V Y S R L A D P D Y g R L Y L G g L L S L T R g Y I T N
CGAAACTGAAAGACACCATAGTCGCAGCGGATGGCGTCCTCGCAGCGCTCGTCGCGCTGCCGCAGATAGGTGCCCCAGGCCTCGGCGGCGGCCTTGGTCA 2 2 3 6 0 0  
R F g F V G Y D C R I A D E C R E D R g R L Y T G W A E A A A K T L
GCAGCGACATCGCGGCGCCCCGACGCGGGCCGTGTGGCGCCCCGGCGCGGCGTCAAAGCTTAATATAGGGAGCGGTCCCTCTCGAGTCTGGGCCGCCGCG 2 2 3 7 0 0  
U S 2 2  L S M
I I I
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3.1.5 UL131A
Fig. 3.10 shows sequences of the relevant regions of the AD 169 and CCMV genomes. 
AD 169 UL131 (Fig. 3.10 panel I) is not conserved in CCMV (Fig. 3.10 panel IV). 
However, a predicted spliced CCMV gene (UL131A) (Fig. 3.10 panel IV) appeared to 
be conserved in AD 169, including the acceptor and donor sites, except that the first 
exon is in two different reading frames (Fig. 3.10 panel I). This analysis indicated the 
potential presence of a frameshift error in the AD 169 sequence within the region 
marked in yellow in Fig. 3.10 (panel I). However, sequence analysis of a PCR product 
derived from this region of the AD 169 genome using the primers shown in Fig. 3.10 
(panel I) failed to detect errors in this region (Fig. 3.10 panel II). The AD 169 sequence 
is therefore correct. However, the spliced structure of AD 169 UL131A was confirmed 
by transcript mapping (section 8.2.1)
To confirm whether AD 169 UL131A is naturally ffameshifted, PCR products derived 
from the corresponding regions of Toledo and a clinical sample (GW) were analysed 
using the same primers. As can be seen in the electrophoregram shown in Fig. 3.10 
(panel III), one T residue is absent from the relevant region in GW in comparison with 
AD 169. Toledo UL131A was also found to have one fewer T residue in this region 
(data not shown). These corrections disrupt UL131 and introduce a novel ORF 
corresponding to the first exon of CCMV UL131A. Consequently, it appears that 
AD 169 UL131A is naturally frameshifted, thus failing to encode a functional protein 
since it lacks an initiation codon. A version of the sequence of AD 169 UL131A in 
which the first exon is in frame, by removal of a T residue, in comparison with CCMV 
UL131A is shown in Fig. 3.11. In comparison with the AD 169 sequence, two other 
nucleotide substitutions were found in GW which are indicated by green arrows in Fig. 
3.10 panel III.
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CAGCATATTATTTCCCGTGACGCAGGCTAGTTGGCAAAGAGCCGCACGCTGAACTCGAGGCTCCGGGCGTCTGGCGCCAGCGAACCGGCGGCGTTGAACG 17  6 4 0 0  
A Y - K G H R L S T P L S G C  ~  S S S A G P r  H R W R V P P T S R  
C C  I I  E R S A P - N A F L R V S F E L S R A H P A L S G A A N F T
L M N N G T V C A L Q C L A A R Q V R P E P R T A G  ~ A F R R R Q V
TGGTCCTTTTGTTGGTGCCGCCGCGACGGTTCTGACGTCTAAAGTCGCTGATGAGCAACGACACCTCGGTCACGTTGATTctgcaagcacaggttccaaa 17 6 5 0 0  
P G K T  P A A A V T R V D L T A S S C R C R  P -  T S E A L V P E L  
T R K N T G G R R N Q R R F D S I L L S V E T V N I R C A C T G F  
H D K Q Q H  R R ~ S  P E  S ~ T  -  L R Q  H A _ V V G R D ~ R Q N Q  L C L N W V
cgtcatttcataccccatgcggttacttagccgttacccgttcgcccttaccttcccgttgtcatgcacctttagcgcgtaccctcacCTCTTGAGCACG 17 6 6 0 0  
R - K M G W A T V - G N G T R G - R G T T M C R - R T G E G R S C T  
T M E Y  G M R N S  L R  -  G N A R V K G N  D H V K L A Y  G - R K L V  
D N - V G H P - K A T V R E G K G E R Q - A G K A R V R V E Q A R
TCAAAGTTGTCCAAGCCGTGGCTCGCATCGTAGTGGTAGTTCAACGTGAGGTCCACGAGCTGTTCCACATACTTGTAACGGGTTTGGTCGGGCAGCGCGC 17 6 7 0 0  
L T T W A T A R M T T T T - R S T W S S N W M S T V P K T P C R A  
E I F N D L G H S A D Y H Y N L T L D V L Q E V Y K Y R T Q D P L A R
-  ~ L ~ Q G L R ~ P  E C R L P L E V  H P _ G ~ R - A T  G C V Q  L P N P R A A R
GAGAGCACGCGTCCCAGTAATGCGGTACTCGGTAATAATCGTTTTTTTTCCGCGGTTTCCCGCTGGCACTGACCCAGCACCACGGCGCACAGACAAACAG 17 6 8 0 0  
L A R T G T I R Y E T I I T K K G R N G A P V S G A G R R V S L C  
S C A D W Y H P V R Y Y D N K K R P K G S A S V W C W P A C V F L  
S _ L V R G L L A T S P L L R K K E A T E R Q C Q G L V V A C L C V S
/^GCCACACCCGACACAGCCGCATGTTGCAGACTGAGAAAGAAAGCTTTATTATGAGACATCATACACATAGTATAGGCGAGGTGATGGGGCGGGGAAA 17 6 9 0 0  
UL131 A V G S V A A i T  Q L S L F F A K N H S M M C M T Y A L H H P P S L
C G C G V C G C T A S Q S L F S - - S V D Y V Y Y L R P S P A P F  
L W V R C L R M N C V S  F S  L K I  I  L C - V C L I  P S T  I  P R P F
I
I I
UL
h i
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GGTGCATGACCTCCGCCGCGGTTTTACTGGGGAAAGAGCCGCACGCTGAATTCCAGCATGCGGTAGTGCGGTCCCAGAAAGCCGGAGGCGCTGAACGTGG 17 940 0  
H M V E A A T K S P F S G C A S N W C A T T R D W F A P P A S R P  
P A H  G G G R N  - Q P F L R V S F E L M R Y H P G L F G S A S F T T  
T C S R R R P K V P S L A A R Q I G A H P L A T G S L R L R Q V H
TTCTCTTGTTGGTCCCGCCGCGGGCCTTCTGGCGCCTGAACTCGCCGGCCAGCAGCGTTACCTCCGTTACGTTGATCcfcgcgaacaaaccccga t  tggtt 1 7 9 5 0 0  
E R T P G A A P R R A G S S A P W C R - R R - T S G A F L G R N T  
R K N T G G R A K Q R R F E G A L L T V E T V N I R R V F G S Q N  
N E Q Q D R R P G E P A Q V R R G A A N G G N R Q D Q S C V G I P E
cgcgcgcacgtcgttcgggtgccctcttttcgtcctcccctttc c c g a a a c cg tac g cg tc g c tcg g c tcac C T C T T G A G C G T C T T A A A G T T A T C C A A A C  17 9 6 0 0  
R A C T T R T G E K R G G R E R F R V R R E A - R K L T K F N D L G  
A R V D N P H G R K T R G K G S V T R T A R S V E Q A D - L - G F  
R A R R E P A R K E D E G K G F G Y A D S P E G R S R R L T I W V
CGTGGCTCACGTCGTAGTGGTACTCCACCAACGTGTCCACCAGCCGCTTGACGTACTCCTGACGGGTACGCTCCGGCAGCGCCGGGGAACACGTGTCCCA 17 9 7 0 0  
H S V D Y H Y E V L T D V L R K V Y E Q R T R E P L A P S C T D W  
R P E R R L P V G G V H G G A A Q R V G S P Y A G A A G P F V H G L  
T A - T T T T S W W R T W W G S S T S R V P V S R C R R P V R T G
GTAGTCCCACGGGCGCGCAAAGTCGTCCCGCTCGGCTTCCTCCCTGCGACACTGGCCCCACACCGCGACGCTCAGACACAAAACAGACAGAAACACACGG 17 9 8 0 0  
Y D W P R A F D D R E A E E R R C Q G W V A V S L C L V S L F V R  
L G V  P A C L R G A R S G G Q S V P G V G R R E  S V F C V S V C  P 
T T G R A R L T T G S P K R G A V S A G C R S A - V C F L C F C V T
TACAACCACATGTTGCACACTGAAGGTCAACTTTATTGTTACACAGGGAAGAATATGGACGTGGGTGGTGGTGGTTTCACGGGACTCGGACAGGTGACCG 17 99 0 0  
U X .131A  Y L W M N C V S P - S - Q - V P F F I S T P P P P K V P S P C T V A  
V V V H Q V S F T L K I T V C P L I H V H T T T T E R S E S L H G  
C G C T A C Q L D V K N N C L S S Y P R P H H H N - P V R V P S R
IV
Figure 3.10: Comparison of the region containing AD169 UL131A with the 
cognate CCMV sequence.
Panels I and IV show three-frame translations of the relevant regions of the AD169 and CCMV 
sequences, respectively, with nucleotide coordinates on the right. The locations of PCR primers for 
AD169 are indicated by arrows in panel I. AD169 UL131 is shown in blue in panel I and CCMV 
UL131A is shown in red in panel IV. Regions in AD169 that appear to be conserved in CCMV 
UL131A are shown in bold black font with conserved amino acid residues underlined. Predicted 
introns are shown in lower case. The region containing possible errors in the AD169 sequence is 
highlighted in yellow in panel I. Panels II and III show electrophoregrams of the sequences of the 
PCR-amplified region containing lower strand of AD169 UL131A and GW UL131A, respectively, 
with the regions containing 7 or 8 T residues, indicated by black arrows. Nucleotide substitutions in 
GW UL131A are indicated by green arrows in panel III.
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CAGCATATTATTTCCCGTGACGCAGGCTAGTTGGCAAAGAGCCGCACGCTGAACTCGAGGCTCCGGGCGTGTGGCGCCAGCGAACCGGCGGCGTTGAACG 17 64 00
N A F L R V S F E L S R A H P A L S G A A N F T
TGGTCCTTTTGTTGGTGCCGCCGCGACGGTTCTGACGTCTAAAGTCGCTGATGAGCAACGACACCTCGGTCAGGTTGATTctgcaagcacaggttccaaa 17 65 0 0  
T R K N T G G R R N Q R R F D S  I L L S V E T V N I
cgtcatttcataccccatgcggttacttagccgttacccgttcgcccttaccttcccgttgtcatgcacctttagcgcgtaccctcacCTCTTGAGCACG 17 66 0 0
R K L v
TCAAAGTTGTCCAAGCCGTGGCTCGCATCGTAGTGGTAGTTCAACGTGAGGTCCACGAGCTGTTCCACATACTTGTAACGGGTTTGGTCGGGCAGCGCGC 17 67 0 0  
d f n d l g h s a d y h y n l t l d v l q e v y k y r t q d p l a r
GAGAGCACGCGTCCCAGTAATGCGGTACTCGGTAATAATCGTTTTTTTCCGCGGTTTCCCGCTGGCACTGACCCAGCACCACGGCGCACAGACAAACAGA 1 7 6 8 0 0  
S C A D W Y H P V R Y Y D N K E A T E R Q C Q  j G L V V A C L C V g
CAGCCACACCCGACACAGCCGCATGTTGCAGACTGAGAAAGAAAGCTTTATTATGAGACATCATACACATAGTATAGGCGAGGTGATGGGGCGGGGAAAG 17 6 9 0 0  
U L 1 3 1 A  ■. W v|  R C L R M
GGTGCATGACCTCCGCCGCGGTTTTACTGGGGAAAGAGCCGCACGCTGAATTCCAGCATGCGGTAGTGCGGTCCCAGAAAGCCGGAGGCGCTGAACGTGG 17 94 00
Q P F L R V S F E L M R Y H P G L F  G 3 A S F T T
TTCTCTTGTTGGTCCCGCCGCGGGCCTTCTGGCGCCTGAACTCGCCGGCCAGCAGCGTTACCTCCGTTACGTTGATCctgcgaacaaaccccga ttggtt 17 9 5 0 0  
R K N T G G R A K Q R R F E G A L L T V E T V N I
cgcgcgcacgtcgttcgggtgccctcttttcgtcctcccctt tc c c g a aac cg tac g cg tc g c tcg g c tcac C T C T T G A G C G T C T T A A A G T T A T C C A A A C  17 9 6 0 0
R K L T K F N D L G
CGTGGCTCACGTCGTAGTGGTACTCCACCAACGTGTCCACCAGCCGCTTGACGTACTCCTGACGGGTACGCTCCGGCAGCGCCGGGGAACACGTGTCCCA 17 9 7 0 0  
H S V D Y H Y E V L T D V L R K V Y E Q R T R E P L A P S C T D W
GTAGTCCCACGGGCGCGCAAAGTCGTCCCGCTCGGCTTCCTCCCTGCGACACTGGCCCCACACCGCGACGCTCAGACACAAAACAGACAGAAACACACGG 17 9 8 0 0  
Y D W P R A F D D R E A E E R R C Q  | G W V A V S L C L V S L F V ~ |  R
TACAACCACATGTTGCACACTGAAGGTCAACTTTATTGTTACACAGGGAAGAATATGGACGTGGGTGGTGGTGGTTTCACGGGACTCGGACAGGTGACCG 17 9 9 0 0  
U L 1 3 1 A  Y L W M
II
Figure 3.11: Corrected sequence of AD169 UL131A.
Panels I shows a version of the sequence of AD169 UL131A in which the first exon is in frame by 
removal of a T residue, and panel II shows the cognate sequence of CCMV, with nucleotide 
coordinates on the right. In each panel, UL131A is shown in red and conserved residues are 
underlined. Hydrophobic domains are shown within boxes. Putative intron sequences are shown in 
lower case.
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3.1.6 TRL13/TRL14
Fig. 3.12 shows three-frame translations of the relevant regions of the AD 169 and 
CCMV genomes. TRL13 and TRL14 are two separate ORFs in AD 169 (Fig. 3.12 panel 
I) and are weakly conserved as a single ORF (TRL13) in CCMV (Fig. 3.12 panel IV). 
AD 169 TRL14 is a member of the RL11 family and contains a hydrophobic domain 
(shown within a box in Fig. 3.12 panel I). In addition an S+T-rich region is located in 
TRL13 (at nucleotides 10820-11200). Like AD169 TRL13/14, CCMV TRL13 encodes 
a hydrophobic domain near the 3’-end and a S+T-rich region near the 5’-end (Fig. 3.12 
panel II). Moreover, only one mRNA 5’-end was determined for both AD 169 TRL13 
and TRL14 by transcript mapping, located upstream from TRL13 (see section 6.1). This 
suggests the presence of a frameshift error in the AD 169 sequence within the region 
marked in yellow in Fig. 3.12 (panel I). However, sequence analysis of a PCR product 
derived from this region of the AD 169 genome using the primers shown in Fig. 3.12 
(panel I) indicated that AD 169 sequence is correct (shown in Fig. 3.12 panel II).
To confirm whether AD 169 TRL13/14 is naturally frameshifted, a PCR product derived 
from the corresponding region of Toledo was analysed using the same primers. As can 
be seen in Fig. 3.12 (panel III), in comparison with AD169 (Fig. 3.12 (panel II)), an 
additional T residue is present in the Toledo in the region indicated by arrow. This 
replaces TRL13 and TRL14 by a single ORF. Consequently, it appears that the AD 169 
TRL13/14 is naturally frameshifted. AD 169 TRL13 would encode a truncated protein 
and TRL14 probably encodes no protein.
The PCR product from Toledo was smaller than that obtained using AD169 (Fig. 3.1b). 
Sequence analysis of this region confirms the absence of 276 bp (encoding the region 
rich in S+T residues) as highlighted in gray in Fig. 3.12 (panel I). Since CCMV TRL13 
also encodes an S+T-rich region in a similar position, this is likely to reflect a deletion 
in Toledo in comparison with ADI69.
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D I L - S - T I N - N I L - G S A F K G I L M P I E R E L I L Q W  
T R L 1 3  R H L M K L N N K L K H S V R L S V Q R N I N A H - A R T N I A M D  
T S Y E A E Q - T K T F C K A Q R S K E Y - C P L S E N - Y C N G  
GACATCTTATGAAGCTGAACAATAAACTAAAACATTCTGTAAGGCTCAGCGTTCAAAGGAATATTAATGCCCATTGAGCGAGLAACrAATATTCCAATGGA 1 0 8 0 0
T G D L R L C G R Y - Y P R Y Q K A A I K P V P V N V P V V L P L T  
W R F T V M W T  I L I  S A L S E S C N Q T C S C Q C P C S T T V N  
L A I Y G Y V D D T N I R V I R K L Q S N L F L S M S L - Y Y R -  
CTGGCGATTTACGGTTATGTGGACGATACTAATATCCGCGTTATCAGAAAGCTGCAATCAAACCTGTTCCTGTCAATGTCCCTGTAGTACTACCGTTAAC ■
I P L V L R Q P H Q H T V Q Q L S A I  K A L Q N L - I A L L Q L H  
Y S T S T E T A T S T Y S T T V I S N K S T S E S I N C S T A T A  
L F H - Y - D S H I N I Q Y N S Y Q Q - K H F R I Y K L L Y C N C T  
TATTCCACTAGTACTGAGACAGCGACATCAACATACAGTACAACAGTTATCAGCAATAAAAGCACTTCAGAATCTATAAATTGCTCTACTGGAACTGCAC
Q Q P P F L Q N R R K Q P H R Y P Q R Q I Q T L R L P H V P T P P  
P A T T V S T K P S K T T T Q I S T T T N T N V E T T T C T N T T T  
S N H R F Y K T V E N N H T D I H N D K Y K R - D Y H M Y Q H H H  
CAGCAACCACCGTTTCTACAAAACCGTCGAAAACAACCACACAGATATCCACAACGACAAATACAAACGTTGAGACTACCACATGTACCAACACCACCAC 111 0 0
R P L L V M V S I I Q S I K D A T A V T R - S T - Q D T L V A T - L  
T V T C D G F N Y T V H K R C D R S Y E V I N V T G Y V G G N I T  
T  R l i l  4 D R Y  L - W  F Q L Y  S P -  K M R P Q L R G N Q R N R I R W W Q H N
GACCGTTACTTGTGATGGTTTCAATTATACAGTCCATAAAAGATGCGACCGCAGTTACGAGGTAATCAACGTAACAGGATACGTTGGTGGCAACATAACT 1 1 2 0 0
-  K M Q S D - E M A Q C R L D S L - V P H A - N V R I  R Q L S  P N  
L K N A I R L R N G T M - T G F I M S T P R I K C A N - A T I T K  
S K K C N Q T E K W H N V D W I H Y E Y P T H K M C E L G N Y H Q T
CTAAAAAATGCAATCAGACTGAGAAATGGCACAATGTAGACTGGATTCATTATGAGTACCCCACGCATAAAATGTGCGAATTAGGCAACTATCACCAAAC 1 1 3 0 0
N T T A R H M F - L Q R H L P N Y L Q L N H K K R W K I Y Q A S P
Q H H G T T Y V L T A T T P P - L S T T - P Q E T L E N I P G I T V
T P R H D X C F D C N D T S L T I Y N L T T R N A G K Y T R H H R
AACACCACGGCACGACATATGTTTTGACTGCAACGACACCTCCCTAACTATCTACAACTTAACCACAAGAAACGCTGGAAAATATACCAGGCATCACCGT 114 00
- - R S R R K L L R N G V N W R H N V I H S W H M P C K I  -  R I  -  E 
I T V K K K I T T - R C - L E T Q R Y P L L A H A L - D I K N L G  
D N G Q E E N Y Y V T V L I G D T T L S T L G T C P V R Y K E S R  
GATAACGGTCAAGAAGAAAATTACTACGTAACGGTGTTAATTGGAGACACAACGTTATCCACTCrTGGCACATGCCCrGTAAGATATAAAGAATCTAGGA 1 1 5 0 0
H - K H H W K - H H K N H - E S - H S P G N S C C M G R R S G I S  
T L K T P L E V T S - K P L R K L T F P W E F M  L Y G Q A - W Y Q  
N T E N T I G S N I  I K T I E K A N I P L G I H  [ A V W A G V V V S V
ACACTGAAAACACCATTGGAAGTAACATCATAAAAACCATTGAGAAAGCTAACATTCCCCTGGGAATTCATGCTGTATGGGCAGGCGTAGTGGTATCAGT 1 1 6 0 0
G A Y S V V H G - P S H S Q K T A L H Q T S Q I - S R - I L D - G  
W R L - R C T W V A I A F P K N R I T P N F P N M I Q M N F G L R L  
A L  I A L Y M G ~ s |  H R I  P K K P H Y T K L P K Y D P D E F W T K A
GGCGCTTATAGCGTTGTACATGGGTAGCCATCGCATTCCCAAAAAACCGCATTACACCAAACTTCCCAAATATGATCCAGATGAATTTTGGACTAAGGCT 1 1 7 0 0
I
I I
I I I
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T R L 1 3  A R T R E Y  S M V D H F A  I T W T L V F L T L A S G T V T S S C H  
C P Y T G V Q H G R S L R D Y L D V G V L N T G I R N S D F F M S  
M P V H G S T A W S I T S R L L G R W C S - H W H Q E Q - L L H V I  
TGCCCGTACACGGGAGTACAGCATGGTCGATCACTTCGCGATTACTTGGACGTTGGTGTTCTTAACACTGGCATCAGGAACAGTGACTTCTTCATGTCAT
T S H S V S S T T V A T T S S T P S V N T T N S A D T S N T S T T  
Y E S L R K Q Y Y R R Y Y - F D S L S - Y D E L C R Y E - H V H H R  
R V T  P - A V L P S L L L V R L P Q L I  R R T L  P I  R V T R P P Q  
ACGAGTCACTCCGTAAGCAGTACTACCGTCGCTACTACTAGTTCGACTCCCTCAGTTAATACGACGAACTCTGCCGATACGAGTAACACGTCCACCACAG
E S S T T S I T S T S N T T S T S L T T G T S A V S S A S T T S K P
K Q Y Y F Y N I Y I E Y N F Y E S H Y W D I C R F F R L N H I K T
K A V L L L - H L H R I Q L L R V S L L G H L P F L P P Q P H Q N
AAAGCAGTACTACTTCTATAACATCTACATCGAATACAACTTCTACGAGTCTCACTACTGGGACATCTGCCGTTTCTTCCGCCTCAACCACATCAAAACC
T T P S T T I Q S T T T T K T T T V I T S T S T V P A S P T N T T
N N A I Y H Y S E H Y H Y - D H H R H H - H L Y S T C E S H - H Y
Q Q R H L P L F R A L P L L R P P P S S L A P L Q Y L R V P L T L Q
AACAACGCCATCTACCACTATTCAGAGCACTACCACTACTAAGACCACCACCGTCATCACTAGCACCTCTACAGTACCTGCGAGTCCCACTAACACTACA
K F E C D  T A T T K T W I  N I  T A K V G D N V T F  P A C N T S G K  
K I - M - Y R N N - D V D - Y H S E S W - Q C N V S S L - Y E R Q I  
N L N V I P Q Q L R R G L I S Q R K L V T M - R F Q P V I R A A N  
AAATTTGAATGTGATACCGCAACAACTAAGACGTGGATTAATATCACAGCGAAAGTTGGTGACAATGTAACGTTTCCAGCCTGTAATACGAGCGGCAAAT
Y H T A R W T K V V N T K E T D L C L F G P D Y Y S T S P Q A G I C  
P Y R Q M D - G G K Y K R N R P M P L W A G L L L H V T T S R Y M  
T I  P P D G L R W - I Q K K Q T Y A S L G R I  I T P R H H K P V Y  
ACCATACCGCCAGATGGACTAAGGTGGTAAATACAAAAGAAACAGACCTATGCCTCTTTGGGCCGGATTATTACTCCACGTCACCACAAGCCGGTATATG
F K C H W Q S M T I Y D V T T E N A G N Y I V R V H G D G N H H Y  
F Q M S L A E Y D Y L - C D D R E C W K L Y R Q S S W - W Q S P L  
V S N V I G R V - L F M M - R P R M L E I  I S S E  F M V M A I T I M  
TTTCAAATGTCATTGGCAGAGTATGACTATTTATGATGTGACGACCGAGAATGCTGGAAATTATATCGTCAGAGTTCATGGTGATGGCAATCACCATTAT
D K G Y R L Q V T S N H T T G T N R K K C P N D F T S Y T P D H D
- - R L P F T S D V Q P H H G N E P K K M S Q - L H F V H S R S - Q
I K V T V Y K - R P T T P R E R T E K N V P M T S L R T L Q I M T
GATAAAGGTTACCGTTTACAAGTGACGTCCAACCACACCACGGGAACGAACCGAAAAAAATGTCCCAATGACTTCACTTCGTACACTCCAGATCATGACA
N K E T K T I E N E F G M N Y D Q P T F P M G M H  | A X W A A V V V  
K Q R D E N H - K - I W N E L - S T Y F S Y G Y A C H L G G S G S  
K T K R R K P L K M N L E - T M I N L L F L W V C M P S G R Q W -  
AAAACAAAGAGACGAAAACCATTGAAAATGAATTTGGAATGAACTATGATCAACCTACTTTTCCTATGGGTATGCATGCCATCTGGGCGGCAGTGGTAGT
I V A L L A L Y M G S j  R S S V T I V K G G K P R Y K K L S N K D P  
D R S I T G I V H G Q P Q Q R D H C Q G R Q T A L Q E A I - Q G S  
- S - H Y W H C T W A A A A A - P L S R A A N R A T R S Y L T R I R  
GATCGTAGCATTACTGGCATTGTACATGGGCAGCCGCAGCAGCGTGACCATTGTCAAGGGCGGCAAACCGCGCTACAAGAAGCTATCTAACAAGGATCCG
D E Y W A S P - R A S V S M Y N K D I F C P R K S L P M - F Y C P  
G R V L G L S L A R V S V Y V - - R Y  I L S Q K K S P D V I  L L S C  
T S I G P L P S A R Q C L C I I K I Y F V P E K V S R C D F I V L  
GACGAGTATTGGGCCTCTCCCTAGCGCGCGTCAGTGTCTATGTATAATAAAGATATATTTTGTCCCAGAAAAAGTCTCCCGATGTGATTTTATTGTCCTG
IV
Figure 3.12: Comparison of the region containing AD169 TRL13/14 
with the cognate CCMV sequence.
Panels I and IV show three-frame translations of the relevant regions of the AD169 and CCMV 
sequences, respectively, with nucleotide coordinates on the right. The locations of the PCR 
primers for AD169 are indicated by arrows in panel I. AD169 TRL13 and TRL14 are shown in 
green and blue respectively in panel I and CCMV TRL13 is shown in red in panel IV. The region 
containing possible errors in the AD169 sequence is highlighted in yellow and the region that is 
absent from the Toledo genome is highlighted in grey in panel I. Panels II and III show 
electrophoregrams of the sequences of the PCR-amplified region containing AD169 TRL13/14 
(lower strand) and Toledo TRL13 (upper strand), respectively, with the regions containing one 
fewer/more T residues indicated by arrows.
9 2 0 0
9 3 0 0
9 4 0 0
9 5 0 0
9 6 0 0
9 7 0 0
9 8 0 0
9 9 0 0
10000
10100
10200
123
Potential errors in the HCMV DNA sequence
3.2 Discussion
On the basis o f conservation o f putative protein-coding regions between HCMV and 
CCMV, sequence errors were detected and confirmed in four published ORFs (UL15, 
UL102, UL145 and US22). Two other ORFs in AD 169 (UL131A and TRL13/14) were 
found to be naturally frameshifted and therefore probably non-functional. The 
characteristics o f the errors and natural frameshifts are listed in Table 3.2. The analysis 
results in 5’-extension o f the protein coding regions o f three genes (UL102, UL145 and 
US22) as well as to the introduction o f two novel genes (UL15A and UL131A) to the 
AD 169 genome.
ORF Position in 
sequence3
Sequence 
change to AD169
Outcome
UL15 21956 Insert G Removes UL15 and introduces a
22005 Insert G novel gene, UL15A
S e q u e n c e UL102 146744 C->G 5’-extension of protein-coding region
errors 146749 C->G
UL145 (Toledo) 8886 Insert G 5’-extension of protein-coding region
US22 211536 Insert G 5’-extension of protein-coding region
TRL13/14 11201-11209 None No error in AD169, insert T in Toledo
Natural
frameshifts
UL131A 176742-176749 None No error in AD169, delete T in Toledo 
and GW
Table 3.2: Corrections to HCMV DNA sequences.
a AD169 DNA genome (Cheeetal . ,  1990), except for UL145 (Cha et al., 1996).
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The proteins encoded by HCMV and CCMV UL15A (Fig. 3.3) possess a potential 
transmembrane domain near the C terminus which may be a membrane spanning 
segment (Tomita and Marchesi, 1975). The UL131A protein contains a short 
hydrophobic domain near its N terminus which may act as a signal sequence for 
translation on membrane-bound ribosomes (McGeoch, 1985). The UL15A and UL131A 
proteins lack homologues in public databases. The natural frameshift in the T R l region 
of AD 169 results in splitting a single ORF (TRL 13) into two (TRL 13 and TRL 14). 
TRL 14 is thus an artifact of the frameshift.
!
The error in UL102 and an error near the 3’-end of US28 were reported previously 
(Smith and Pari, 1995; Kuhn et al., 1995). The present work did not re-examine the 
latter but confirmed the former. It also added errors in three other genes. Detection of 
these errors depended on analysis of amino acid sequence conservation between HCMV 
and CCMV. Therefore, errors in non-coding-regions are likely to have escaped
I
| detection. It must be considered probable that additional sequencing errors exist in the
| published AD 169 and Toledo sequences.
j
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This chapter describes an assessment of the methods used in this study. The areas covered 
include reliability of the method, comparisons of the results with published data, drawbacks 
of the methods and potential sources of artifacts. Greatest emphasis is placed on RACE 
techniques, as these continue to develop and are less commonly employed than the standard 
techniques of northern blotting, primer extension and RT-PCR.
4.1 SMART RACE
In order to map the 5’- and 3’-ends of HCMV genes, experiments were carried out using 
the SMART RACE cDNA amplification kit (Clontech). This kit provides a novel method 
for performing rapid amplification of cDNA 5’- and 3’-ends (see chapter 2 for a detailed 
explanation). The integrity and purity of the RNA used as starting material is an important 
element in high-quality cDNA synthesis. Therefore, RACE was performed using polyA+ 
RNA (IE, E, L and MI) isolated directly from cells using the FastTrack 2.0 mRNA isolation 
kit (Invitrogen) or from total cellular RNA prepared using Trizol reagent. Prior to 
performing RACE with the templates, a positive control experiment was successfully 
performed using RNA provided in the kit (data not shown).
The cDNA for 5’-RACE is synthesised in RT reactions using a modified lock-docking 
oligo (dT) primer (5’-CDS) and the SMART II oligonucleotide as described in section 
2.2.8. The 5’-CDS primer has two degenerate nucleotide positions at the 3’ end which 
position the primer at the start of the poly A tail, thus eliminating the 3’ heterogeneity 
inherent with conventional oligo (dT) priming (Borson et al., 1992). The 3’-RACE cDNA 
was also synthesised by RT reactions, using a special oligo (dT) primer (3’-CDS) (section 
2.2.8). This primer includes the lock-docking nucleotides as in the 5’-CDS primer, and also 
has a portion of the SMART sequence at its 5’-end. By incorporating the SMART sequence 
into both the 5’- and 3’-RACE-ready cDNA populations, both ends of the cDNA can be 
amplified using a universal primer (UPM) that recognises the SMART sequence plus a 
distinct gene-specific primer (GSP).
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ORF Primer Sequence (5’-3’) Position0 PCR product(s)d
UL22A UL22A3 TTTGGCTTGATTTTCTTTGTGTTC 2 7 4 7 8 -2 7 4 5 5 150 , 450
UL22A U L 2 2 A - 3 'b GGCTTTGGCGGCACCTTCTCAGAA 2 7 1 5 8 -2 7 1 8 1 300
UL36 U L3 6 -S 1 3 ATGGGCCGCTGGTAGTCGCGCATA 4 9 2 4 4 -4 9 2 6 7 550
UL36 U L 3 6 - 3 'b CACGCACCTGTGGCCGCAGGAGCT 4 8 5 5 8 -4 8 5 3 5 500
Table 4.1: Primers used in RACE to map 5’- and 3’-ends of transcripts from 
UL22A and UL36.
“Primer used in 5 ’-RACE. 
bPrimer used in 3 ’-RACE.
'Position o f  the primers in the positive strand o f  the AD  169 genome. 
dApproximate sizes (bp) o f  RACE products excised for cloning (See Fig. 4.1 and 4.2).
The efficiency of the RACE reaction depends on the GSP used, since different primers 
have different optimal annealing temperatures. GSPs should have a G+C content of 50-70% 
and a Tm of at least 65°C (Freier et al., 1986). Longer primers closer to the ends of the 
cDNA with annealing temperatures above 70°C give more robust amplification. Therefore, 
GSPs were designed to be 24 nucleotides in size, located approximately 500 bp 
downstream from the putative initiation codon or 500 bp upstream from the putative stop 
codon of the target gene. Care was also taken to avoid using self-complementary primers 
which can fold back and form intramolecular hydrogen bonds. Similarly, primers that 
exhibit complementarity to the UPM were also avoided.
5’- or 3’-RACE PCR products were separated by agarose gel electrophoresis (two examples 
are shown in Figs. 4.1 and 4.2). Fragments were excised and cloned into pGEM-T, and 5- 
30 separate clones were sequenced for each PCR product using M l3 universal primers and, 
in some cases, gene-specific primers. The sequence obtained from the highest proportion of 
clones was considered as the 5’- or 3’-end. Genes can have more than one 5’-end in a local 
region of a few bp, or even two promoters that give quite separate 5’-ends. The nuances of 
5’-end identification are discussed below.
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Since the cDNA contains the SMART II oligonucleotide (30 nucleotides) at its 5’ end (see 
section 2.2.8), the size of a 5’-RACE PCR product was the sum of the relevant ADI69 
sequence plus 30 bp. The 5’-RACE products contained the SMART sequence adjacent to 
the end of 5’-end of the target gene (an example is underlined in red in Fig. 4.3 panel II). 
The sequences of 3’-RACE products contained a poly A tract at the 3’-end.
The SMART sequence contains four G residues at its 3’-end designed to anneal to a short 
tract of C residues introduced at the 3’-end o f the cDNA (equivalent to the 5’-end of the 
mRNA) by RT. This feature introduces ambiguity regarding the precise 5’-ends of certain 
genes, since one or more of the G residues could have been templated by the RNA rather 
than having originated by the action of RT in adding non-templated C residues to the 3’- 
end of the cDNA. In this study, the first nucleotide of HCMV sequence that was found at 
the end of the G tract was considered as the 5’-end. However, the initiating nucleotide of 
eukaryotic and prokaryotic mRNAs is usually (>90%) a purine (Lewin, 1994b). Therefore, 
if the 5’-end identified was a pyrimidine preceded by one or more G residues in the HCMV 
sequence, the terminal G residue in the SMART sequence was considered as the 5’-end of 
the target gene. Similarly, since 3’-RACE products contained a poly A tract at the 3’-end, it 
is possible that one or more A residues are templated. In this study, the last nucleotide of 
HCMV sequence prior to the poly A tract was considered the 3’-end.
Almost all eukaryotic RNA polymerase II promoters appear to contain a TATA element, 
but there are examples where TATA boxes are absent (Hall and Brown, 1985; Melton et 
al., 1984). In this study, indicators predictive of whether an mRNA has a TATA element 
include the presence of a six residue consensus TATA (TATAAA) element (Breathnach 
and Chambon, 1981; Carbon et al., 1987; Lewin, 1994a) 20-35 bp upstream from the 5’- 
end of a target gene. In most instances the consensus TATA was not present, and the 
sequence most closely related to TATAAA (for example, TATA AG, TATATG) was 
considered the TATA element. The definition of the polyadenylation signal for a target 
gene was the presence of a consensus motif, AATAAA (Proudfoot and Brownlee, 1976), 
ATTAAA (Rawlinson and Barrell, 1993) or CATAAA (Kouzarides et al., 1988) in the 
region close upstream from the 3’-end of a target gene.
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The 5’-end and 3’-ends of the HCMV UL36 and UL22A transcripts were mapped 
previously by Kouzari<jes et al. (1988) and Rawlinson and Barrell (1993), respectively. 
Therefore, these transcripts were analysed as controls in this study.
UL36 - 5’-RACE using primer UL36 detected a band of similar size and intensity from IE, 
E and L RNA but not from MI RNA (Fig. 4.1a). Sequence analysis indicated that the 5’- 
end of UL36 is located at nucleotide 49863, 21 bp downstream from a potential TATA 
element (49884-49889). As expected, the 5’-RACE cDNA sequence of UL36 lacked the 
intron (data not shown). A band corresponding to the 3’-end of the UL36 transcript was 
obtained from IE, E and L RNA (Fig. 4.2a), again indicating that UL36 is an IE gene. 
Sequencing indicated that the 3’-end is at 48094, and is preceded 20 nucleotides upstream 
by a typical polyadenylation signal (AATAAA). The position of the 5’-end of the UL36 
mRNA determined by Kouzarides et al. (1988) using primer extension is in exactly the 
same positions as those determined in this study by RACE.
UL22A - ORF UL22 as originally described in AD 169 genome was replaced by a spliced 
gene (R27080s) mapped by Rawlinson and Barrell (1993) and confirmed (and renamed 
UL21.5) by Bresnahan and Shenk (2000). In this study this gene is named UL22A (see Fig. 
1.9). Primer UL22A generated two bands of approximately 150 and 450 bp from L RNA 
(Fig. 4.1b). The smaller band was cellular in origin, but the larger band mapped the 5’-end 
of UL22A to 27080, 25 bp downstream from a potential TATA element (Fig. 4.3). The 5’- 
RACE cDNA sequence lacked the intron (Fig. 4.3). Primer UL22A-3’ mapped the 3’-end 
to 27574, 20 bp downstream from a polyA signal. Rawlinson and Barrell (1993) analysed 
the UL22A transcript by sequencing a cDNA derived from a library prepared from L RNA, 
and mapped the 5’-end to 27082 and the 3’-end to 27574.
The results with UL36 and UL22A show that SMART RACE detects the authentic 5’- and 
3’-ends of HCMV mRNAs.
In many of the experiments described in later chapters, RACE yielded a single band 
corresponding to the 5’- or 3’-end. However, in some experiment multiple RACE products 
were generated, making the interpretation difficult. Multiple bands can have several 
sources, including alternative splicing, multiple promoters or use of different
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polyadenylation signals, amplification of cellular RNA, premature termination of first- 
strand cDNA and degradation of RNA used as starting material. Alternatively, the gene 
may be a member of a multigene family, in which case the GSP may simultaneously 
amplify several cDNAs.
In some experiments, the 5’-RACE product was smaller than expected in that it mapped the 
5’-end downstream from the first ATG codon in the ORF. This may indicate that 
translation is not initiated at the first ATG, or that the RACE product does not correspond 
to the 5’-end. There are several possible sources of incomplete RACE products generated 
from correctly primed sites. These include degradation of input RNA, and premature 
termination of first-strand cDNA due to specific sequences or structures in the RNA. 
Moreover, the presence of G tract at the 3’-end of the SMART sequence may cause non­
specific priming from C tracts within the first strand cDNA, giving a truncated RACE 
product. This may not be common, however, since no RACE product originating from the 
C tract (marked as a G tract underlined in yellow on the strand shown in Fig. 4.3) was 
detected for UL22A. Moreover, during the course of this study no 5’-end (except that for 
UL18; see chapter 7) mapping to a tract of four or more G residues was identified. 
However, the possibility that there might be rare situations in which this occurs cannot be 
ruled out.
The sensitivity of RACE depends in part on the abundance of the target mRNA. 
Consequently, the studies described here revealed some examples of ORFs that clearly 
encode proteins but whose 5’-ends could not be mapped.
4.2 Northern blot
RACE experiments give an indication of the kinetic class of a target gene but, since PCR is 
not necessarily quantitative, the results must be considered as preliminary. Northern blot 
experiments were carried out to determine the expression kinetics of HCMV genes and to 
determine mRNA sizes. Equal quantities (usually 1-3 pg) of polyA+ mRNA (determined 
spectrophotometrically) were electrophoresed in agarose-formaldehyde gels. RNA was
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M1 Ml IE E L M1 Ml IE E L
b: UL22A
Figure 4.1: 5’-RACE of control HCMV genes.
EtBr-stained 1 or 1.5% (w/v) agarose gels showing representative 5’-RACE products 
containing regions of the HCMV (a) UL36 and (b) UL22A genes that were amplified 
from 5’-cDNA with GSPs (listed in Table 4.1) and UPM. Sizes are in kbp. 5’-cDNAwas 
prepared from different kinetic classes (IE, E and L) of AD169 mRNAs and from Ml 
RNA. M1 is a 100 bp ladder.
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Figure 4.2: 3’-RACE of control HCMV genes.
EtBr-stained 1% (w/v) agarose gels showing representative 3’-RACE products 
containing regions of the HCMV (a) UL36 and (b) UL22A genes that were amplified 
from 3’-cDNA with GSPs (listed in Table 4.1) and UPM. Sizes are in kbp. 3’-cDNA was 
prepared from different kinetic classes (IE, E and L) of AD169 mRNAs and from Ml 
RNA. M1 and M2 are 100 bp and 1 kbp ladders, respectively.
132
Validation of methods
GTTGTTTTTCAGAAGCGGCCACATGACCTCGAGATGTCGTCACCCAAGGrATTTAACGGCACACAGCCAGACGCGTTCGTCAGCAGCGACGCCGACAAGA 2 7 1 0 0
M A R R L W I L S L L A V T L T V A L A A P S Q K S K R  
CCTCAGCATGGCTCGGAGGCTATGGATCTTGAGCrrACTAGCCGTGACCTTGACGGTGGCTTTGGCGGCACCTTCrCAG^ATCGAAGCGCAGgtaaacg 2 7 2 0 0
V T V E Q P S T
gaatctggggaattcaacacaggtaagaaatacaaaaaataacgtgattgtgaacgcggttatcgtgtttttgcagCGTGACGGTGGAACAACCCAGTAC 27 30 0
S A D G S N T T P S K N V T L S Q G G S T T D G D E D Y S G E Y D  
CAGCGCTGATGGTAGTAATACCACCCCCAGCAAGAACGTAACTCTCAGTCAGGGGGGGTCCACCACCGACGGAGACGAAGATTACTCCGGGGAGTATGAC 27 4 00
V L I  T D G D G S E H Q Q P Q K T D E H K E N Q A K E N E K K I Q  
GTTTTGATTACAGACGGAGATGGCAGCGAACATCAGCAACCACAAAAGACTGAT^ACACAAAGAAAArCAAC^CAAAGAAAATGAAAAGAAGATTCAGT 2 7 5 0 0
AACAGCAGACCCCAAGGGTTAACGATTATGTTGACTACCTTGTTTTTTATTAAAAAGCTGTAAGGTTTTGCTCTAAAAACACCCCGCCTCCGGTCTTTTT 27 600
I
O T  a » T  A A C A  A C  O C A  Q A Q T A C O C O O O Q A  O C A O C  O A C O C  C  G AC A A Q  A C C  T C A  Q C  » T f l  o r .  T C f l O A f l a C  T A T  O Q A T  C T T  Q  
170 180 190 200 210 220 230 24C
A Q C T  T A C T A G C C Q T  Q A C  C l  1 U » C  U  G i  O O C T T T f l a c  B 8 C A C C  T T  C T  C A  O A A A  T C O A A  A C  O C A  6 C  O ’  O A C O O l f l l  
260 260 2 /0  280 290 300 310
II
Figure 4.3: Sequences at the 5'- and 3'-ends of the UL22A mRNA.
Panel I shows AD169 UL22A and its encoded amino acid sequence. Coordinates are shown on the right. 
RACE primers are shown in italic bold font with orientations indicated by arrows. The intron is shown in 
lower case. The black and red vertical arrows indicate the positions of the 5’- and 3’-ends of the UL22A 
mRNA, respectively, as represented in the majority of 5’-cDNA clones. The putative TATA element 
(TATTTA) and polyA signal (ATTAAA) are shown in italic font and underlined in red and green, 
respectively. Panel II shows an electropherogram of the sequence of the 5'-RACE product (upper strand of 
AD169 genome) with the 5'-end and the splice sites indicated by black and blue arrows, respectively. The 
SMART sequence is underlined in red. The internal G-tract in the RNA, discussed in the text, is underlined 
in yellow.
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blotted to membranes and fixed by UV irradiation. A synthetic polyA+ RNA ladder was 
electrophoresed alongside the mRNA samples to facilitate estimations of transcript sizes. 
Blots were initially hybridised with transcribed antisense RNA probes corresponding to 
regions of the target gene. Single-strand RNA probes were preferred to double-stranded 
DNA probes because RNA-RNA hybrids are more stable than RNA-DNA hybrids and 
because they are strand specific and are not depleted by hybridisation to the complementary 
strand of the probe. 32P-RNA probes were produced using the Lig'nScribe and MAXIscript 
kit (Ambion). The Lig'nScribe reaction involves the addition of a phage T7 RNA 
polymerase promoter in a chosen orientation to a PCR fragment (explained in detail in 
section 2.2.7.3). In general, 5’-RACE products were used for making the probes. The PCR 
products generated by the Lig’nScribe reaction were examined on agarose gels in order to 
estimate their concentration and to verify that the products were unique and of the expected 
size (64 bp larger than the 5’-RACE product). The PCR product was then used as a 
template in an in vitro transcription reaction using the MAXIscript kit (see section 22.13  
for details). A successful positive control reaction was carried out initially to ensure that the 
kit was functioning properly (data not shown). Most of the blots were rehybridised with a 
control cellular DNA probe (GAPDH2) to normalise the amount of RNA loaded in each 
lane.
UL36- The UL36 probe hybridised to a single band of 1.6 kb (Fig. 4.4a) which was of 
similar intensity in IE, E and L RNA. Therefore, UL36 is considered to be an IE gene as 
indicated in the RACE experiment (Fig. 4.1a and 4.2a) and reported previously by 
Mocarski et al. (1988) using northern blotting with a single-strand probe. Chambers et al. 
(1999) detected UL36 mRNA at E and L times post infection using gene microarray 
technology. The size of the mRNA (1.6 kb) is consistent with the spliced UL36 transcript 
mapped by RACE (1666 nucleotide transcript; see section 4.1).
UL22A- Probing a northern blot with UL22A sequences yielded a single band of 0.4 kb in 
L RNA (Fig. 4.4b). Since 5’- and 3’- ends of the UL22A mRNA are located at 27080 and 
27574, respectively (495 nucleotide transcript including a 83 nucleotide intron) (see section
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Figure 4.4: Northern blot analysis of control HCMV genes.
Northern blots showing the expression profile of transcripts from HCMV genes (a: UL36 and b: 
UL22A). IE, E and L RNA prepared from HCMV-infected cells were hybridised with a single­
strand specific RNA probe (top) or GAPDH2 probe (bottom). Sizes are given in kb.
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4.1), the 0.4 kb band (Fig. 4.4b) represents the spliced UL22A mRNA. Consistent with this, 
Bresnahan and Shenk (2000) and Rawlinson and Barrell (1993) detected a 0.4 kb UL22A 
mRNA at L times post-infection by northern blotting with a DNA probe. Therefore, 
UL22A is considered to be an L transcript as indicated by the RACE experiment (Fig. 
4.1b), previous northern blotting experiments and gene array hybridisation (Chambers et 
al., 1999).
In many experiments, northern blots probed with single-strand probes yielded a single band 
corresponding to a specific gene. However, in other experiments more than one band was 
generated. Multiple bands can have several sources, including alternative splicing, 
alternative 5’-ends and presence of 3’-coterminal genes.
4.3 Primer extension
To confirm the 5’-ends of transcripts from certain HCMV genes, primer extension 
experiments were carried out using the Primer Extension System-AMV Reverse 
Transcriptase kit (Promega). A 24 bp GSP was designed from the region approximately 
100 bp downstream from the 5’-end of a target gene determined by RACE (Table 2.3). The 
primer was 5’-end-labeled with 32P (see section 2.2.17.1) and extended by RT in the 
presence of the four dNTPs and polyA+ RNA (see section 2.2.17.3). The RNA was thus 
reverse transcribed into end-labelled cDNA. The cDNA was analysed on a denaturing 8% 
polyacrylamide gel. The size of the cDNA corresponds to the number of nucleotides 
between the 5’-end of the primer and the 5’-end of the mRNA. A 5’-end for a target gene 
mapped ±5 nucleotides from that mapped by RACE was considered an accurate result. A 
positive control RNA and primer supplied with the kit were successfully tested (data not 
shown).
The 5’-end of primer PEL36 (Table 2.3) maps 137 nucleotides downstream from the 5’-end 
of UL36 determined using RACE (49863) and previously reported by Kouzarides et al. 
(1988) using a primer extension assay. This primer yielded a single band of approximately 
140 ± 5 bp (measured from gel; see Fig. 5.5), thus mapping the 5’-end for UL36 gene at 
position 49861-49866, essentially the same as that mapped by 5’-RACE (section 4.1). This
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result shows that the primer extension kit used in this study detects authentic 5’-ends. 
However, other features An successful primer extension include the quality and quantity of 
the target RNA and the annealing conditions. Moreover, primer extension, unlike RACE, 
does not involve amplification, and therefore is less sensitive.
4.4 RT-PCR
The predicted splice sites in certain HCMV genes were confirmed by RT-PCR. This 
strategy has proven useful in identifying the exact locations of splice signals and is widely 
used. RT-PCR was carried out using the Titan™ One Tube RT-PCR System kit 
(Boehringer-Mannheim). As a test of this kit, two known spliced HCMV transcripts 
(UL22A and UL36) were analysed. PolyA+ RNAs (IE, E and L) were used as templates 
with two primers (listed in Table 2.2) mapping in the exons flanking predicted introns. RT- 
PCR products were cloned into pGEM-T for sequencing.
UL36 -  Primers UL36-S1 and UL36-S2 (Table 2.2) were used to amplify the sequence 
between 49749 and 49244 (Fig. 4.5a). Two products, were generated from IE, E and L 
RNA (Fig. 4.5a). The smaller (400 bp) represents the spliced RNA and the larger (500 bp) 
the unspliced RNA. The locations of the splice sites in the DNA sequences and the 
corresponding electropherogram are shown in Fig. 4.6 (panels I and II). The sites 
correspond to those detected by Kouzarides et al. (1988) using Si nuclease and in this study 
by 5’-RACE (see section 4.1). Since 5’-RACE failed to detect the unspliced sequence, it is 
likely that the larger RT-PCR product originated from DNA contamination rather than from 
RNA.
UL22A - Primers UL22A and UL22A-3’ (Table 2.2) were used to amplify the sequence 
between 27157 and 27478 (Fig. 4.5b). Two products were generated from L RNA (Fig. 
4.5b). The smaller (250 bp) representing the spliced RNA and the larger (350 bp) the 
unspliced RNA or contaminating DNA. The locations of the splice sites in the DNA 
sequences and the corresponding electropherogram are shown in Fig. 4.3 (panels I and II).
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a: UL36
Ml IE E L
1 . 0 -
0.5
0.1
1
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b: UL22A
Figure 4.5: Gel electrophoresis of RT-PCR products from control HCMV 
genes.
EtBr-stained 1% (w/v) agarose gel showing the RT-PCR products (sizes in kbp) amplified from 
HCMV IE, E and L RNA using primers (listed in Table 2.2) mapping in the exons flanking an 
intron. (a) UL36 with primers UL36-S1 and UL36-S2. (b) UL22A with primers UL22A and 
UL22A-3'. M1 is 100 bp ladder.
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CGGTAGAGCATGACGGCGTTCCAGTAGTCGTCGTACTGCACCATGGGCCGCTGGrAGTCGCGCATAGTGTGGAAGTGGTCGCGGTGACGAAAGCCGTTCC 4 9 3 0 0
m ” ‘ 3 T~ r  h m *
GCAGAAAGTCCTTCATGGTGGGTGCCAGCTCGTAGACGCAGTCGCGCAGGTCATCGTAGCAGTAGATGCCGCCGCGCTGCCCGATGAGCACGATGAGTTG 4 94 0 0  
GTAGCGCATAAAGCCCGGACCCTCGACGAAGCCAAAGGGGTGCAGGTACTCCTGACAGCAGACGTAAGCACctggtagagaa t a g a a a a a a  t c c a  c g c a  c  4 9 5 0 0
g t t g a a a a c a c c tg g a a a g a a c g tg c c c g a g c g a a c g tc c tc t t t c c a g g t g tc t t c a a c g a c g tg g g g c t ta c C T T G C G A A C A G A C G G T G C C C A T C T T G  4 9 6 0 0
Q S C V T G M K
CCCACGAAGGGCCCCAGGGCGCTGCGCGAACGGAGCTGGATGAAGCAGCGTTCGGGCCAGGCCACGTGCAGCCGGGTGCCGCATTCCTGCTCCAGAAAGT 4 9 7 0 0
G V F F G L A S R S R L Q I F C R E F W A V H L R T G C  E Q E L F D
CGTTGAGACCGTTAAAGTCCCCGGCICGGATGGCGATGCAGCCGTAGGCCATCAGCGTGTCCCGTAGGTCGTCCATGACGGACTCCTCTACCTTCGCTCG 4 9 8 0 0
3 G T A C T  C C T  G A C A G C A G A C G T A A  G C A C  CT T G C G A A C A  G A C G G 1  GC C C A  TC  T T G C C C A  C GA AG G G C C C C A G G  G C G C T  QCG 
170 100 190 200 210 220 , 230 240
I I
Figure 4.6: Interpretation of splicing in HCMV UL36 by RT-PCR.
Panel I shows the sequences of the first exon of AD169 UL36 and part of the second exon, with 
coordinates on the right. The amino acid sequence of UL36 is shown in red. RT-PCR primers are 
shown in italic bold font and their orientations by arrows. The intron is shown in lower case. Panel II 
shows an electropherogram of the sequence of the RT-PCR product (upper strand of AD169 
genome), with the splice site indicated by a blue arrow.
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sequences and the corresponding electropherogram are shown in Fig. 4.3 (panels I and II). 
They correspond to the splice sites previously detected by Rawlinson and Barrell (1993) 
using RT-PCR and in this study by 5’-RACE (see section 4.1).
The results presented here confirm that the usefulness of RT-PCR as a strategy for 
identifying the exact locations of splice signals. The experimental design, however, 
depends on sound prediction of splicing patterns.
4.5 Discussion
Transcriptional expression patterns of certain previously mapped HCMV genes (UL22A 
and UL36) were analysed in several ways, including RACE to identify the 5’- and 3’-ends 
of mRNAs, primer extension, northern blot assay and RT-PCR. The results were in 
agreement with previously published data, and point to the general reliability of these 
methods in characterising HCMV mRNAs.
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The HCMV US22 family is defined on the basis of amino acid sequence homology and 
consists of 13 members (UL23, UL24, UL26, UL28, UL29, UL36, UL43, IRS1, US22, 
US23, US24, US26 and TRS1). US22 family members are distributed in Us, Ul and TRs, 
and contain up to four conserved motifs (Kouzarides et al., 1988; Nicholas and Martin, 
1994) (see section 1.3.10). Although certain HCMV US22 genes have been investigated 
with respect to RNA or protein products (e.g. UL36, US22, TRS1 and IRS1), others have 
not. In this study, transcriptional expression patterns of US22 gene family members were 
analysed in several ways, including RACE techniques to identify the 5’- and 3’-ends of 
mRNAs, primer extension, northern blot assay and RT-PCR.
5.1 Mapping the 5’- and 3’-ends of US22 genes by RACE
In order to map the 5’- and 3’-ends of HCMV US22 genes, experiments were carried out 
using the SMART RACE kit. The 24 bp GSPs used in 5’- and 3’-RACE were designed 
from the region approximately 500 bp downstream from the putative initiation codon or 
upstream from the putative stop codon of the target genes and are listed in Tables 5.1 and 
5.3, respectively.
5’- or 3’-RACE PCR products were separated by agarose gel electrophoresis (Fig. 5.1 and 
5.3). Fragments were excised and cloned into pGEM-T, and 5-30 separate clones were 
sequenced for each PCR product using M l3 universal primers and, in some cases, gene- 
specific primers. Sequences were compared with the AD 169 DNA sequence using BLAST, 
and 5’- or 3’-ends were defined as those obtained from the highest proportion of clones.
5.1.1 Sequences o f5 ’-ends
5’-ends were identified for seven of the US22 family genes: UL23, UL24, UL26, UL36, 
US22, US23 and US24. TRS1 and IRS1 were not examined. The ends are listed in Table 
5.2, and a summary of the overall results is listed in Appendix 1 at the back of this thesis.
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ORF Primer Sequence (5’ - 3’) Position3 PCR
product(s)b
UL23 UL23 AAG G T CAAC GAG T CAGAG TAGAT G 2 8 3 7 4 -2 8 3 9 7 550
UL24 UL24 
U L 2 4 ( I I )  
PEL24
GATCTGCGGTTGCCGACGCGACGA
TCGGCCGTGAGCGCCAGGCTAGCC
CGCGGCCAGCGTGGCGAGGACACT
2 9 7 0 1 -2 9 7 2 4
2 9 8 0 1 -2 9 8 2 4
2 9 9 0 5 -2 9 9 2 8
350 ,
350
150,
450
250
UL2 6 UL26 AAGTTCTCACGGCTGATCTCGTAG 3 2 4 7 7 -3 2 5 0 0 400
UL28 UL28
U L 2 8 ( I I )  
UL28S1
ACAGTCTCCTCCTTCACGACGCCC
CGGCGTGGAGCTGACATACGCGCA
GCGCACCACCCCAAAGTACTGAGT
3 4 7 4 1 -3 4 7 6 4
3 5 1 7 6 -3 5 1 9 9
3 5 5 3 7 -3 5 5 6 0
No p r o d u c t  
500
No p r o d u c t
UL29 UL2 9 
UL2 9 ( I I )  
UL29 ( I I I )
CCGGCAGGTGGCGTGCGAGACCGT
TGCTCCAGATCGATCTCGGTCAGC
AGCGCCGCAAGTAACGCCGCAGGC
3 6 6 2 8 -3 6 6 5 1
3 6 7 0 1 -3 6 7 2 4
3 6 8 0 1 -3 6 8 2 4
300,
400,
350,
450
500
500
UL4 3 UL4 3 
U L 4 3 ( I I )  
U L 4 3 ( I I I )
TAACCAGCTCGACAGCCAGCGCGT
AGCGTGCGTTCCTTCATCTCGTCG
ATGCTCTGACGGCGCCGCCGGATT
5 5 6 4 2 -5 5 6 6 5
5 5 6 7 1 -5 5 6 9 4
5 5 6 9 8 -5 5 7 2 1
No p r o d u c t  
No p r o d u c t  
450 , 650
US22 US22 TCCCAGTCGTAGACGTAGACGGTG 2 1 1 1 4 4 -2 1 1 1 6 7 550
US23 US23 
U S 2 3 ( I I )
AGCACCAGCTCCGTCTCTTCGTAG 
CACCAT GAT CAC GCAC T T GC C TAG
2 1 3 1 4 0 -2 1 3 1 6 3
2 1 3 1 7 2 -2 1 3 1 9 5
400,
350,
550
500
US24 US 2 4
US24 ( I I )  
PES24
TCGTAGGCGTAGACGCGAGAAAAG
AGCGTATCCCAACGGCGTCAACGG
ACAGCGTCCCTCGTTACGATGAAC
2 1 4 6 7 2 -2 1 4 6 9 5
2 1 4 7 7 3 -2 1 4 7 9 6
2 1 4 9 0 2 -2 1 4 9 2 5
350
250
150
US26 US26 
U S 2 6 ( I I )  
U S 2 6 ( I I I )
AGGACCGCGGCCCGTGTACTCTGG 
AG CGATTCTTCG CAG CAGAT GAG C 
CGTCGGTGACAGCCGCGCTGCCAA
2 1 7 2 0 9 -2 1 7 2 3 2
2 1 7 2 7 3 -2 1 7 2 9 6
2 1 7 3 1 9 -2 1 7 3 4 2
No p r o d u c t  
200 , 1100 
650, 1000
Table 5.1: Primers used in 5’-SMART RACE PCR to map the 5’-ends of US22 genes.
a Position of primers in the AD169 genome (upper strand). 
b Approximate sizes (bp) of PCR products excised for cloning.
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The 5’-end of the UL36 transcript mapped by Kouzarides et al. (1988) was confirmed by 
RACE (see section 4.1).
A RACE product representing the 5’-end (at 28855) of the UL23 transcript was detected in 
approximately equal yields from E and L RNA (Fig. 5.1a). This 5’-end is preceded by a 
potential TATA element. A higher molecular weight product was obtained from MI RNA 
and sequencing indicated, as expected, that it did not originate from HCMV. No product 
was obtained from IE RNA. This suggests that UL23 is an E gene. Chambers et a l (1999) 
were unable to detect UL23 transcripts cells using an HCMV gene microarray, presumably 
owing to low levels of expression. Inability to detect the UL23 protein in infected 
fibroblasts (R. Adair, personal communication) is also consistent with the conclusion that 
UL23 is expressed at low levels. Sequence comparisons between HCMV and CCMV 
indicate that HCMV UL23 is well conserved in CCMV, but the TATA element is not 
conserved in the same location in CCMV as it is in HCMV.
More than one product was obtained from E and L RNA when primer UL24 was used for 
RACE (Fig. 5.1b). Two bands, the major of 450 bp and the minor of 350 bp, were found to 
originate from HCMV, indicating the presence of two 5’-ends for UL24 (Table 5.2). The 
larger product represents a 5’-end located at 30086, which is 25 bp downstream from a 
potential TATA element, suggesting that the first ATG in UL24 is used as an initiation 
codon. The smaller product represents a 5’-end at 29994, which is also preceded by a 
TATA element; in this case the second ATG would be used as an initiation codon. This 
investigation was extended using two additional GSPs (Fig. 5.1c and 5.Id). Primer UL24 
(II) failed to amplify the smaller transcript to detectable levels (Fig. 5.1c), but primer 
PEL24 amplified both (Fig. 5.Id). HCMV UL24 is conserved in CCMV, including the first 
ATG codon and the TATA element (TATAAA) of the larger transcript (see Table 5.2). As 
with UL23, expression of UL24 mRNA in infected cells appeared to be low. Indeed, 
Chambers et a l (1999) failed to detect a transcript from UL24 by gene microarray 
experiments, and the UL24 protein has proved difficult to detect in infected cells using anti- 
UL24 monoclonal antibodies (R. Adair, personal communication).
The UL26 protein is a component of the virion (Baldick and Shenk, 1996), and contains a 
strong transcriptional activation domain. Primer UL26 yielded a single clear band in
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Figure 5.1: 5’-RACE of HCMV US22 genes.
EtBr-stained 1-1.5% (w/v) agarose gels, showing representative 5’-RACE PCR products 
containing regions of the HCMV US22 genes that were amplified from 5’-cDNA with gene- 
specific primers, (listed in Table 5.1) and UPM. 5’-cDNA was prepared from different kinetic 
classes (IE, E and L) of AD169 mRNAs and Ml RNA. M1 and M2 are 100 bp and 1 kbp ladders, 
respectively, (a) UL23 with primer UL23. (b) UL24 with primer UL24. (c) UL24 with primer UL24 
(II). (d) UL24 with primer PEL24. (e) UL26 with primer UL26. (f) UL28 with primer UL28 (II). (g) 
UL28 with primer UL28. (h) UL29 with primer UL29 (II). (i) UL29 with primer UL29 (III). G) UL43 
with primer UL43 (III), (k) US22 with primer US22. (I) US23 with primer US23. (m) US24 with 
primer US24. (n) US24 with primer PES24. (o) US26 with primer US26. (p) US26 with primer 
US26 (II). (q) US26 with primer US26 (III).
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M2 Ml IE E L
2.0
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a: UL23
M1 Ml IE E L
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approximately equal amounts from E and L RNA (Fig. 5.1e), indicating that UL26 is an E 
gene. Sequence analysis of 5’-cDNA clones showed that the 5’-end of UL26 is located at 
32785 and is preceded by a potential TATA element. In CCMV, UL26 is highly conserved, 
including the first ATG and the TATA element.
The HCMV US22 product is an early protein that locates in the cytoplasm and nucleus and 
is secreted from cells (Mocarski et al., 1988). A sequence error in A DI69 US22 (see 
section 3.1) resulted in 5’ extension of the protein-coding region. A 5’-RACE product of 
550 bp was obtained from E and L RNA (Fig. 5.1k), suggesting that US22 is an E 
transcript. Analysis of 5’-sequences indicated a single 5’-end for US22 (Table 5.2), with the 
first ATG used as an initiation codon. The sequence of 5’-cDNA clones showing the 
position of the 5’-end of US22 and an electrophoregram of a representative sequence are 
shown in Fig. 5.2. HCMV US22 is well conserved in CCMV, including the first ATG and 
the TATA element.
Analysis of the 5’-end of the US23 transcript revealed two major products from E and L 
RNA (Fig 5.11). These two bands correspond to initiation at 213512 and 213654 (142 bp 
apart from each other). The latter 5’-end is preceded by a TATA element, but the former is 
not. Furthermore, the first ATG would be used as the initiation codon in both mRNAs. The 
experiment was repeated using a different GSP and led to the same conclusions (data not 
shown).
Three different primers (US24, US24 (II) and PES24) were used to determine the 5’-end of 
US24. Each time, a single RACE product was obtained from E and L RNA that 
corresponds to a 5’-end at 214970, 21 bp downstream from a TATA element (Fig 5.1m and 
5.In). The mapped 5’-end is located downstream from the first ATG codon in the ORF, and 
the mRNA is likely to use an initiation codon at 214943. Sequence comparisons indicate 
that HCMV US24 is well conserved in CCMV, including the first ATG (at 215093). It is 
possible that US24 encodes two transcripts, of which the larger was not detected in this 
study.
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AAAGGCTTTGATATCACTGGCCACCTCGTAGAGCCCGTCGGTCTCCCAGrCGTAGACGTAGACGGircCGTAATGACTTAGCATGAGCACGCAGGGCAGT 2 1 1 2 0 0  
F A K I  D S A V E Y L G D T  E W D Y V Y V T *  Y H S L M L V C P L
TCCTGCGCCTGCTTGGTGTTTCGTGTTAGATCGCTGTCGGGTGGACGCACGGCTAGTACACCGACGGCTTCCAGGGTGTCATCGCAGCAGAGATAGTCGG 2 1 1 3 0 0  
E Q A Q K T N R T L D S D P P R V A L V G V A E L T D D C C L Y D A
CGGCCAGAGAACGTGCGTAAATCTGCGGGATGGCGGCCTGTTCGCGCATCACTAGGAACCAGTTGGCGGGGTTGCGCAGTGCTACGGTGGTTCCTTGGTG 2 1 1 4  00  
A L S R A Y  I  Q P I A A Q E  R M V L F W N A P N R L A V T T G Q H
GCGTTGCACGTAGGTTCTCAGCGCCGGAGGATCGTACTGGCGCAGATAGAGGCCTTGCAGCATCGATAACGTCTTTTGAAAGACGGTGTTTCTAAATTGA 2 1 1 5 0 0  
R Q V Y T R L A P P D Y Q R L Y L G Q L M S L T K Q F V T N R F Q
AAAACGCCGTAGTCGCAGCGGATAGCATCTTCGCAGCGCTCGTCGCGCTGTCGGAGATAGGTGCCCCAGGCTTCGGCGGCGGCTTTGGTGAGTAGGGACA 2 1 1 6 0 0  
F V G Y D C R I A D E C R E D R Q R L Y T G W A E A A A K T L L S M
TGCCGGCGGAGCCGTCTCGACAGCGAGTCGGATAAAGCGCGCTGCGCGAAAGCTTAATATAGGAGCAGCGTCAGACGAATCGCGGCTGGTGGCCCGGGGGG 2 1 1 7 0 0
I
A A C G C A G A G T A C  GC G G G G G C T  G T C G A G A C G G C T C C  GC C G  G C A  T G T  C  C  C  T AC T C A  C  C A A A  G C C  G C C G C C G A  A G C C T  G G  < 
16 0  V70~ 180. 1 90  2 0 0  2 1 0  2 2 0  23 0
II
Figure 5.2: Sequences at the 5'-end of the US22 mRNA.
Panel I shows the region containing the 5’-end of US22 in the AD169 genome, with 
coordinates on the right. The gene is oriented right to left. The position of the RACE-PCR 
primer is shown in bold italic and its orientation by the arrow. The vertical arrow indicates 
the position of the 5’-end of the US22 mRNA as represented in the majority of 5’-cDNA 
clones. The putative TATA element is underlined in red. Panel II shows an 
electropherogram of the sequence of the 5’-RACE product (lower strand) with the 5’-end 
indicated by an arrow and the SMART sequence underlined in red.
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ORF C on d itio n  o f P os ition  o f 5’- Puta tive  TATA 
e lem ent0
P os ition  o f TATA 
boxd
P os ition  o f 
ATG codon
D istance8
e xp re ss io n 3 endb In HCMV In CCMV
UL23 E 28855 TACTTC 28880-28875 (20) 28717 156
UL24 E 29994 TGCTTA 30025-30020 (25) 29835 182
30086 TATAAA 30117-30112 (25) 30009 102 164
UL26 E 32785 TATAAG 32814-32809(24) 32775 33 33
UL28 No RACE product
UL29 Cellular8
UL36f IE 49863 TATAAA 49890-49885 (21) 49776 108 142
UL43 Not detected Cellular8
US22 E 211626 TATTAA 211658-211653 (28) 211601 52 49
US23 E 213512 213492
213654 TGATTA 213685-213680 (25) 213492 161
US24 E 214970 TTATAC 214996-214991 (21) 214943 48
US26 Cellular8
Table 5.2: 5’-ends of HCMV US22 genes.
a Conditions of expression as determined by RACE. b Position of 5’-ends as represented in the 
majority of 5’-cDNA clones. 5’-end located downstream from the first ATG in the ORF as described 
by Chee et al. (1990) is shown in blue. c Position of the putative TATA element in the AD169 
genome. The number of nucleotides between the 5’-end and the closest TATA element is shown in 
brackets. TATA boxes conserved in CCMV are shown in red. d Position of the first ATG codon in the 
O R F .8 Number of nucleotides between the putative TATA box and the first ATG codon in the O R F.f 
RACE result shown in section 4 .1 .9 PCR products not originating from HCMV.
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The 5’-ends of the UL28, UL29, UL43 and US26 mRNAs were not detected in RACE 
experiments (Table 5.1). RACE products produced using primers UL28 (II) and UL28 are 
shown in Fig. 5.I f  and 5.1g, respectively. The single band detected (Fig. 5.lg ) was also 
generated from MI RNA, and sequence analysis showed that it did not originate from 
HCMV. Primers UL29 and UL29 (II) yielded a single band from L RNA (Fig. 5.1h) and a 
larger band from MI RNA. Primer UL29 (III) yielded bands only from E and L RNA (Fig. 
5.1i). None of these bands originated from HCMV. As can be seen in Fig. 5.1j, primer 
UL43 (III) yielded multiple bands from IE, E and L RNA, and faint bands from MI RNA. 
None of these bands originated from HCMV. Primer US26 (II) generated products from E 
and L RNA (Fig. 5.1p), and primer US26 (III) generated products from L RNA (Fig. 5.lq), 
but none originated from HCMV. It is likely that expression of UL28, UL29, UL43 and 
US26 is below detectable levels.
5.1.2 Sequences of 3’-ends
3’-ends were identified for eight of the 13 US22 genes: UL23, UL24, UL26, UL36, UL43, 
US22, US23 and US24. UL28, UL29, TRS1, IRS1 and US26 were not analysed. The 3’- 
RACE products are shown in Fig. 5.3 and positions of the 3’-ends of US22 genes are listed 
in Table 5.4.
The 3’-end of the UL36 transcript mapped by Kouzarides et al. (1988) was confirmed by 
RACE (see section 4.1).
Primers UL23-3’ and UL24-3’ each yielded a single band from E and L RNA (Fig. 5.3a 
and 5.3b). However, the UL24 product was approximately 1000 bp larger than that of 
UL23. Analyses of these products indicated that UL23 and UL24 share a common 3’-end at 
27788, preceded by a polyA signal. An identical polyA signal is also present in CCMV 
UL23 in similar position (Table 5.4).
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ORF Primer Sequence (5’- 3’) Position® PCR
product(s)b
UL23 U L 2 3 -3 ' GACTGGAGGGTCATGGTCGGCAGT 2 8 1 4 1 -2 8 1 1 8 500
UL24 U L 2 4 -3 ' CGGCCTGGGAACCGTCAGCCTCAA 2 0 2 0 0 -2 9 1 7 7 1500
UL2 6 U L 2 6 -3 ' CTACGAGAT CAG C C G T GAGAAC T T 3 2 5 0 0 -3 2 4 7 7 750
UL4 3 U L 4 3 -3 ' AAAGAAGGGGCTCTTTGCTCGAAG 5 4 8 5 1 -5 4 8 7 4 600, 1700
US22 U S 2 2 -3 ' TCTTTCCGCCGCCCATGTGCCGCG 2 1 0 2 4 1 -2 1 0 2 1 8 550
US23 U S 2 3 -3 ' GGAAGACGCGGTTGCCGCGCGTAT 2 1 2 0 1 4 -2 1 2 0 3 7 2300
US24 U S 2 4 -3 ' ACACCGTCACCTGTGCCCGCACCA 2 1 4 0 5 3 -2 1 4 0 7 6 500
Table 5.3: Primers used in 3’-RACE to map the 3’-ends of US22 genes.
a Position of primers in the AD169 genome (upper strand). 
b Approximate sizes (bp) of PCR products excised for cloning.
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Ml IE E L M1 M1 Mi IE E L
«Ma»
0.1 -*►
b:UL24a: UL23
M1 Ml IE E L
■4-0.75
c: UL26
Figure 5.3: 3’-RACE of HCMV US22 genes.
EtBr-stained 1-1.5% (w/v) agarose gels showing representative 3’-RACE PCR products 
containing regions of HCMV US22 genes that were amplified from 3’-cDNA with GSPs 
(listed in Table 5.3) and UPM. 3’-cDNA was prepared from different kinetic classes (IE, E 
and L) of AD169 mRNAs and Ml RNA. Sizes are in kbp. M1 is a 100 bp ladder, (a) UL23 
with primer UL23-3’. (b) UL24 with primer UL24-3’. (c) UL26 with primer UL26-3’. (d) UL43 
with primer UL43-3’. (e) US22 with primer US22-3’. (f) US23 with primer US23-3’. (g) US24 
with primer US24-3’.
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AACGCCGGCGGTTATCGCCGAGATTCGTCTAAATACACGAAGCGAACTAGAAAACGCACACACGTGATTTGCAAAAAGAAAGCAGCTGCCGGCTTATTAT 2 0 9 8 0 0
TTTATTAAAAATTTATCTGTGCAGAATCATAAGTTTATGATGAATAAAAACGGGGAAAGGGAATCTGCTTTTAGGGACCCGGGTCTGGTCCGTCGTCTCC 2 0 9 9 0 0
P G P D P G D D G
CATCTGGTCGGGTTCGGGGATGGGGACCTGTTTCAGCGTGTGTCCGCGGGCGTGCATGGCTTTTGCTCGCCGGCCGCGCTGTAACCAGGCCTCTTTCTCT 2 1 0 0 0 0  
M Q D P E P I P V Q K L T H G R A H M A K A R R G R Q L W A E K E
GTGGTCGGCGAGTCTTCCGACGGGTAGGGAGCCTGGGAGTCCATCGCTTCAGGCCCACCGCTCGTTCCCTCGACCGTCGTGTCGTCCTCGTTTTCGCTAT 2 1 0 1 0 0  
T T P S D E S P Y P A Q S D M A E P G G S T G E V T T D D E N E S N
TACACGGGGTTTCTGGAGTATCGCCTATACGGTTGGCGATTCTCCGGGGGCGGCCGCTCTCGTCCTCGTCGCTGCTATCGCCGCCCGGTAACTCGACGCC 2 1 0 2 0 0  
C P T E P T D G I R N A I R R P R G S E D E D S S D G G P  L i !  V G~
GCArTCGrTGTACGGAACGCGGCACATGGGCGGCGGAAAGAACTTGGGCATGCGAAAGCAGCGTTGTCCATCCACGGTCTGCGTGGTTTCATCGTTATCC 2 1 0 3 0 0  
C E N Y P V R C M P P P F F K P M R F C R Q G D V T Q T T E D N D
I
^ A G A C C C G G G 'C C C T A A A A G C A G A 'i T C C C T T 'C C C C G  T T i TAT TGAT CAT A A A C t 1 A T G A t ~ C t  G C A C A G A T A A A T T T T T A A T A A A A t A A T A A G C C Q Q 2 A Q C T  GC7 '  T P T T  TTQ 3A A A A A A A A A A A A A A A A A / 
310 330 340 360 370 380 390 400 410 420 430
I I
Figure 5.4: Sequences at the 3’-end of the US22 mRNA.
Panel I shows the region containing the 3’-end of US22 in the AD169 genome, with 
coordinates at the right. The gene is oriented right to left. The position of the RACE-PCR 
primer is shown in bold italic and its orientation by an arrow. The vertical arrow indicates the 
position of the 3’-end of the US22 mRNA as represented in the major proportion of 3’-cDNA 
clones. The polyA signal is underlined in green. Panel II shows an electropherogram of the 
sequence of the 3’-RACE product (lower strand of the AD169 genome), with the 3’-end 
indicated by an arrow and the polyA signal underlined in green.
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ORF Conditions
of
expression*
Position 
of 3’-endb
Polyadenylation
signal
Position of polyA 
signal0
Distance0
In HCMV In CCMV
UL23 E, L 27788 AATAAA 27814-27809(20) 48 71
UL24 E,L 27788 AATAAA 27814-27809 (20) 1118 1123
UL26 E, L 31878 CATAAA 31892-31887 (22) 317 410
UL36® IE, E, L 48094 AATAAA 48119-48114(20) 123 114
UL43 L 53135 AATAAA 53161-53156 (20) 1660 1566
US22 E, L 209771 AATAAA 209806-209801 (29) 65 41
US23 E, L 209771 AATAAA 209806-209801 (29) 1895 2001
US24 E, L 209771 AATAAA 209806-209801 (29) 3879 3904
213539 AATAAA 213523-213518 (20) 20 20
Table 5.4: 3’-ends mapped for HCMV US22 genes.
a Conditions of expression as determined by 3’-RACE. b Position of 3’-end in the AD169 genome as 
represented by majority of the 3’-cDNA clones. 0 Position of putative polyadenylation signal in the 
AD169 genome. The number of nucleotides between the 3’-end and polyadenylation signal is 
shown in brackets. Polyadenylation signals conserved in CCMV are shown in red. d Number of 
nucleotides between the polyadenylation signal and the stop codon in the ORF. e RACE result 
shown in section 4.1.
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Primer UL26-3’ yielded products from E and L RNA (Fig. 5.3c) that mapped the 3’-end at 
31878, 22 bp downstream from a non-canonical polyA signal (CATAAA) that is also 
conserved in CCMV. Analysis of the AD 169 DNA sequence indicated that this polyA 
signal is likely to be shared by UL27, UL28, UL29 and UL30.
UL43 3’-RACE products were obtained from L RNA (Fig. 5.3d). Only the largest product 
(1.7 kbp) originated from HCMV, corresponding to a 3’-end at 53135. Consistent with this, 
Chambers et al. (1999) reported that the UL43 transcript was detected only in L mRNA 
using gene microarray technology. Sequence analysis indicated that the 3'-end of UL43 
contains a polyadenylation site 20 bp upstream that is probably shared by UL40-UL46. A 
similar polyadenylation signal is also present in CCMV UL43, but further upstream (Table
5.4).
3’-RACE products from US22, US23 and US24 were generated from E and L RNA (Fig. 
5.3e, 5.3f, 5.3g, respectively), suggesting that they are E transcripts. The products obtained 
from US22 and US23 corresponded to the same 3’-end at 209771, and the product obtained 
from US24 corresponded to a different 3’-end at nucleotide 213539. Both 3’-ends have a 
polyA signal (AATAAA) 20-29 bp upstream.
5.2 Mapping the 5’-ends of US22 genes by primer extension 
analysis
To confirm the 5’-ends of transcripts from certain US22 genes, a primer extension 
experiment was carried out using the Primer Extension System-AMV Reverse 
Transcriptase kit. A 24 bp GSP was designed from the region approximately 100 bp 
downstream from the 5’-end of each target gene determined by RACE (Table 2.3).
Four US22 genes were analysed using primer extension assay: UL24, UL36, US22 and 
US24 (Fig 5.5). All except US24 yielded products. Those from UL36 and UL24 were very 
faint compared to that from US22. This may reflect abundance of cognate mRNAs, 
efficiency of primer labelling or efficiency of the primer in the RT reaction. The 5’-end of
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Figure 5.5: Primer extension analysis of transcripts from the US22 
gene family.
Phosphorimage showing products (marked with black stars) obtained from primer 
extension assay. Sizes are shown in nucleotides. (1) UL36 with primer PEL 36. (2) US24 
with primer PES 24. (3) US22 with primer PES 22. (4) UL24 with primer PEL 24. M is a 
(j)X174 H/nf I DNA marker.
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ORF Primer Sequence (S’ to 3’) Position* 5’-endsb Distance0
(bp)
Product*1
size
U L24 P E L 24 CGCGGCCAGCGTGGCGAGGACACT 2 9 9 0 5 -2 9 9 2 8 2 9 9 9 4 9 0
3 0 0 8 6 1 8 2 1 8 5 ,1 8 7
U L36 P E L 36 TCGGATGGCGATGCAGCCGTAGGC 4 9 7 2 6 -4 9 7 4 9 4 9 8 6 3 1 37 13 9
U S 2 2 P E S 2 2 AGCATCTTCGCAGCGCTCGTCGCG 2 1 1 5 2 4 -2 1 1 5 4 8 2 1 1 6 2 6 1 03 9 8 ,1 0 2
U S 2 4 P E S 2 4 ACAGCGTCCCTCGTTACGATGAAC 2 1 4 9 0 2 -2 1 4 9 2 5 2 1 4 9 7 0 6 9 -
Table 5.5: Primers extension analysis of transcripts from the US22 gene 
family.
a Position of primer in the AD169 genome (upperstrand). 
b Position of 5’-end in the AD169 genome determined by RACE.
c Distance between the 5’-end of the primer and the 5 ’-end of the mRNA determined by RACE. 
d Approximate size of the product (measured from the gel) determined by primer extension assay. 
The accuracy of primer extension data is estimated at ± 5 nucleotides.
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the UL36 transcript mapped by Kouzarides et ol. (1988) was confirmed by primer 
extension (see section 4.3). The overall results are shown in Table 5.5.
Two 5’-ends were determined for UL24 by primer extension assay, differing by 
approximately 2 nucleotides. These represent 5’-ends at 30089 and 30091 (each ±5). 
Consistent with this, four closely spaced 5’-ends within the region 30082-30098 were 
determined for the larger transcript from UL24 gene using RACE (see Appendix 1), but the 
5’-end at 30086 was represented by the majority of 5’-cDNA clones (see section 5.1). The 
5’-end (at 29994) of the smaller transcript from UL24 gene identified by 5’-RACE was not 
detected in this experiment, due to high background in this region of the gel. Two 5’-ends 
were detected for US22 within approximately 4 nucleotides (Table 5.5) at 211622 and 
21625 nucleotides (each ±5). A single 5’-end (211626) was detected for US22 using RACE 
(section 5.1).
In conclusion, 5’-ends for UL24, UL36 and US22 determined by primer extension were 
consistent with those mapped using RACE.
5.3 Mapping US22 genes by northern blot
Northern blot experiments were carried out to determine the expression kinetics and sizes 
of transcripts from genes in the US22 family (described in section 2 and 4.2). Primers for 
making single-stranded RNA probes using Lig’nScribe kit (2.2.7.2) are listed in Table 2.1. 
The PCR products (5’-RACE product of the cognate gene + 64 bp) generated by the 
Lig’nScribe reaction (for details see section 2.7 and 4.2) were examined on an agarose gel 
and are shown in Fig. 5.6. The PCR product was then used as a template in an in vitro 
transcription reaction using the MAXIscript kit to produce labeled single-stranded RNA 
probes (section 2.2.7.3). All blots, except those assaying the UL23 and UL24 mRNAs, 
were rehybridised with a control DNA probe (GAPDH2) to normalise the amount of RNA 
loaded in each lane.
In the present study, the kinetic classes of nine US22 genes (UL23, UL24, UL26, UL28, 
UL29, UL36, US22, US23 and US24) were determined by northern blotting (Fig. 5.7a to
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<  1.0 kb
r<- 0.5 kb
0.1 kb
Figure 5.6: Gel electrophoresis of Lig’nScribe PCR products used to 
generate RNA probes.
EtBr-stained 1% (w/v) agarose gel showing representative Lig’nScribe PCR products 
amplified from adapter-ligated 5’-RACE products using GSPs (listed in Table 2.1) and 
adapter primer 1. Fragments of expected sizes (64 bp bigger than the PCR product) are 
indicated by white stars. (1) UL24. (2) US22. (3) UL29. (4) UL26. (5) US23. (6) UL43. M1 
is a 100 bp ladder.
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5.7h). TRS1, IRS1 and US26 were not analysed. The results are summarised in Table 5.6 in 
comparison with published data.
The kinetics of expression and size of the UL36 transcript were consistent with previously 
published data (Mocarski, 1988) (see section 4.2).
The UL23 probe hybridised to three major bands of 2.3, 2.2 and 1.1 kb (Fig. 5.7a). These 
bands were of similar intensity in E and L RNA and therefore represent E transcripts. 
Consistent with this, UL23 RACE products (both 5’- and 3’-) were generated from E and L 
RNA (see section 5.1.1 and 5.1.2). Since the RACE experiments mapped the 5’-end of 
UL23 to 28855 and the 3’-end to 27788 (1068 nucleotide transcript), the 1.1 kb band is the 
UL23 transcript. The 3’-end of UL24 is also at 27788, with two 5’-ends at 30086 and 
29994 (2299 and 2207 nucleotide transcripts), indicating that the 2.3 and 2.2 kb bands are 
from UL24. A blot hybridised with the UL24 probe also identified the 2.3 and 2.2 kb bands 
(Fig. 5.7b). Only the larger transcript of UL24 was detected in the primer extension 
experiment (see section 5.2). Chambers et al. (1999) failed to detect UL23 and UL24 
mRNAs using gene micrarray technology.
The UL26 probe hybridised to several bands putatively corresponding to a set of 3’- 
coterminal transcripts from UL26 to UL30 (Fig. 5.7c). Since the RACE experiments 
indicated that the 5’-end of UL26 is at 32785 (section 5.1.1) and the 3’-end at 31878 
(section 5.1.2; 908 nucleotide transcript), the 0.9 kb band is the UL26 transcript. The 5’-end 
of UL30 (see section 7.1) is at 37525 (5648 nucleotide transcript), indicating that the 5.6 kb 
band is from UL30. The 5.0, 3.5, and 2.5 bands may represent the UL29, UL28 and UL27 
mRNAs, respectively. Normalisation with a control probe (GAPDH2) indicated that each 
transcript was approximately equally abundant in E and L RNA. The UL29 probe 
hybridised to a barely discernible 5.0 kb band (corresponding to the UL29 transcript) and a 
5.6 kb band (corresponding to the UL30 transcript) from E and L RNA (Fig. 5.7d). Thus, 
UL26, UL29 and UL30, and probably UL27 and UL28, are E genes.
The US22 probe hybridised to five bands of 1.9, 2.5, 3.8, 3.9 and 5.4 kb (Fig. 5.7e). The 
3.8, 3.9 and 5.4 kb transcripts were also detected with the US23 probe (Fig. 5.7f). These 
bands were of similar intensity in E and L RNA and therefore represents E transcripts,
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Figure 5.7: Northern blot analysis of transcripts from members 
of the US22 gene family.
IE, E and L RNA prepared from HCMV-infected cells, and Ml RNA, were 
hybridised with gene-specific probes (top) and rehybridised (except (a) and 
(b)), with GAPDH2 probe (bottom). Single-stranded RNA probes were 
designed from specific genes as indicated below each panel. Sizes are 
given in kb.
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Gene Transcript 
size (kb)
Kinetic class
Northern blot3 DNA microarrayb Northern blotc
UL23 1.1 E
UL24 2.2, 2.3 E
UL26 0.9 E E
UL28 3.5 E E
UL29 5.0 E L
UL36d 1.6 IE E IE
UL43 ND
TRS1 NA
IRS1 NA
US22 1.9 E E E
US23 3.8, 3.9 E E
US24 1.4, 5.4 E E
Table 5.6: Kinetics of expression of HCMV US22 genes.
a Northern blot analysis conducted in this study. 
b DNA microarray analysis by Chambers etal. (1999). 
c Northern blot analysis by Mocarski (1996). 
d Northern blot result shown in section 4.2.
NA: Not analysed.
ND: Not detected.
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which is consistent with the previous reports of Chambers et al. (1999) and Mocarski 
(1996). Since the RACE experiments indicated that the 5’-end of US22 is at 211626 and 
the 3’-end at 209771 (1856 nucleotide transcript), the 1.9 kb band is the US22 transcript. 
The 3’-end of US23 is also at 209771, with two 5’-ends at 213654 and 213544 (3884 and 
3774 nucleotide transcripts), indicating that the 3.9 and 3.8 kb bands are US23 transcripts. 
The 5.4 kb band probably represents the US24 transcript. The US22, US23 and US24 genes 
are thus 3’-coterminal, sharing the polyA signal at 209771. The 2.5 kb RNA does not 
correspond to any known gene.
The US24 probe hybridised to two bands of 1.4 and 5.4 kb (Fig. 5.7g), each, after 
normalisation, of approximately equal abundance in E and L RNA. US24 is thus an E gene. 
Consistent with this, Chambers et al. (1999) reported that US24 falls into the E expression 
class. The larger transcript (5.4 kb) was also detected using the US22 and US23 probes 
(Fig. 5.7e and 5.7f). However, the RACE experiments (see section 5.1,1 and 5.1.2) showed 
a 3’-end for US24 at 213539 and a 5’-end at 214970 (1441 nucleotide transcript), indicating 
that the 1.4 kb band is a US24 transcript. The larger US24 transcript is thus 3’-coterminal 
with US23 and US22, and the smaller US24 transcript terminates between US23 and US24.
The UL43 transcript was not detected by northern blotting using two different RNA probes. 
This result, and the inability to determine the 5’-end of UL43 by RACE (see section 5.1.1), 
is consistent with the conclusion that UL43 is expressed at low levels in infected 
fibroblasts.
5.4 Spliced genes in the US22 gene family
Two members of the US22 gene family were predicted to be spliced (UL36 and UL28). 
Splice sites in UL36 mapped by Kouzarides et al. (1988) were confirmed by RT-PCR (see 
section 4.4).
UL28 -  Splicing in UL28 was predicted by Davison et al. (unpublished data) on the basis 
of amino acid sequence comparisons between HCMV and CCMV. Comparisons between 
the HCMV UL28/UL29 and the cognate sequence of CCMV UL28/UL29 indicated that
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CAGATTGGCGCGGTCGTGCAGTATCTGGGAGAGTTCGTACATGCCCGCAAAGGTGTGCTTAAACCACGCGCCCTCTACGATCTCATCCACGTAGTCGCGC 3 5 3 0 0  
C I P A T T C Y R P S N T C A R L P T S L G R A R - S R M W T T A S
U L28
S Q R P R A T D P L T R V H G C L H A - V V R G R R D - G R L R A
TCAAAGAAGCTGTACACGGCAAAGAGGCCGTTCTCAAAAAACTCGCCGAACGAGAGCCCCAGCACGTACACCTTGTCCTCGCCGGGCAGGTACGCAAAGG 354 00 
L S A T C P L S A T R L F S A S R S G W C T C R T R A P C T R L P
E F F S Y V A F L G N E F F ' E S F S .  L G L V Y V K D E G P L Y A F A  
L L Q V R C L P R E  -  F V R R V L A G A R V G Q G R R A P V C L
CGTGCCCGTGCCCGGAGACCCAGATCTCGGGCGCCGTGTTTGCGTCCGGCACGCATTCGTACACACTGACGAGGCCGATAAAGTACAAGCGGCCAGCCTG 3 5 5 0 0  
T G T G P S G S R P R R T Q T R C A N T C V S S A S L T C A A L R
R A R A R L G L D R A G H K R G A R M R V C Q R P R Y L V L P W G P
GCGCAGGCACGAGAAGCGCCGGTAGGTCTTGTGATCGCGCACCACCCCAAAGTACTGAGTGTCGCCCAGCATGATGCCGTGCAGCGGCGGCCAGCACAGC 3 5 6 0 0  
A C A R S A G T P R T I A C W G L T S L T A W C S A T C R R G A C R
0
A P V L L A P L D Q S R A G G W L V S H R G A H H R A A A A L V A
GGGAGCCAACGACCCGCCGTGGCGCGCACGTAGCGCTGCAGGTGAACCCCGCTCGCACGCTCGCGCGGCTTCGGGCGCTTGTGGGTCCAGGCATCACGCA 3 5 7 0 0  
S G V V R R P A C T A S C T  F G A R V S A R S R A S T  P G  P M V C
P A L S G G H R A R L A A P S G R E C A R A A E P A Q P D L C -  A
GACCGCGCCAGATGCTGCTGAACTTGGGCTGCCCGCGCAGATAGAGCGACGAGAGCGAGTCAAAGTAGCCCACGACGAGCc tgtcgggagacacaagagc 3 5 8 0 0  
V A G S A A S S  P S G A C I  S R R S R T L T A W S S G T  P L C L L
S R A  L H Q Q V Q A A R A S L A V L A L - L L G R R A Q R S V C S R
gcgaaaatcaaacctagagcgacgacggtgaaaaaaccgaccagaagcgcgtgtctcaaacacgctactttcggttataaaaacaccgtcgccctatttc 3 5 9 0 0  
A F I L G L A V V T F F G V L L A H R L C A V K P - L F V T A R N R
' G S E T I F V G D G -  K
S F - V - L S S P S F V S W F R T D - V R - K R N Y F C R R G I E
tgggcgcgtgtacactgatgactcacCTACGCTTTTTGAACGGCAGTCTCAGCTCGGGATTGGCCTCGTACAGCGAGCTGCGGTCCACGGGGCCGATGCT 3 6 0 0 0  
U L29 P A H V S I V -
Q A R T C Q H S V - A K Q V A T E A R S Q G R V A L Q P G R P R H E
P R T Y V S S E G V S K S R C D - S P I P R T C R A A T W P A S A
I
Figure 5.8: Comparison of the region containing AD169 UL28/UL29 with the 
cognate CCMV sequence.
Panels I and II show three-frame translations of the relevant regions of the AD169 and CCMV 
sequences, respectively, with nucleotide coordinates on the right. Genes are oriented right to left. 
ORF UL28 and UL29 are shown in red, and conserved amino acid residues are underlined. The 
first ATG codon in the UL28 is shown within a box for each genome. Possible introns are shown in 
lower case.
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UL28
UL29
AGGCCGGCGCGATCGTGCAGCAGCTGCGAGAGCTCGTACATGCCGGCGAAGGTGTGCTTGAACCAGGTGCTCTCCACCACCTCGTCCACGTAGTCGCGCT 334 00 
P R R S R A A A A L A R V H R R L H A Q V L H E G G G R G R L R A  
A P A I T C C S R S S T C A P S P T S S G P A R W W R T W T T A S
i A R D H L l .  Q S L  E y H g A F T H  K F W T S E V V E D V Y D R  E
CGAAGAAGCTGTAGACGGCGAAGAGGCCGTTCTCGTAAAACTCGCTGAACGAGAGGCCCAGCACGTAGACCTTGTCCTCGCCCGGCAGGTAGGCGAAGGC 3 3 5 0 0  
R L L Q L R R L P R E R L V R Q V L P G A R L G Q G R G A P L R L R  
S S A T S P S S A T R T F S A S R S A W C T S R T R A R C T P S P
F F S Y V A F L G N E Y F E 8 F S L G L V Y V K D E G P L Y A F A
GTGGCCCTGACTGGAGACCCAGATCTCGGGCGCCACGCGAGCGTCCGGCACGCACTCATAGACACTGATGAGGCCGATGAAGTAAAGGCGGCCGGCCTGA 3 3 6 0 0  
P G S Q L G L D R A G R S R G A R V  -  L C Q H  P R H  L L P P R G S
T A R V P S G S R P R W A L T R C A S M S V S S A S S T F A A P R V
H G Q S S V W I E P A V R A  D p y C E Y V S I L G l F Y L R G A Q
CGCAGGCACGAGAAGCGCCGGTAGATCTTCTGGTCGCGCACCACCCCGAAATAGTTGCTGTCGCCCAGCAACAGGCCGTGGAGGGGCGGCCAGCAGAGCG 3 3 7 0 0  
A P V  L L A P L D E  P R A G G R  F L Q Q R G A V P R  P P A A L L A  
C A R S A G T S R R T A C W G S  I  T A T A W C C A T  S P R G A S R
R L C S F R R Y I K Q D R V V G F Y N S p G L L L G H L P P W C L P
GGATCCAGCGACCGGCCGTGGCCCGCACGTAACGCTGCAGCTGGACTCCGCCCAAGCGCTCCCGCAACTTCTGACGCTTGTGGATCCAGGCGTCGCGTAG 3 3 8 0 0  
P D L S R G H G A R L A A A P S R G L A G A V E  S A Q  P D L R R T T  
S G A V P R P G C T V S C S S E A W A S G C S R V S T S G P T A Y
1 w R G A T A R V Y R Q I. U V G G L R E R L K Q R K H I W A D R L
TCCCCGCCAGAGGCTGCTGAACTTGGGCTGCCCGCGCAGGTAGAGTGACGAGAGCGGCTCGAAGTAACCGACGATCAGCctgcggtcgacga tagaggga 3 3 9 0 0  
G A L P Q Q V Q A A R A P L T V L A A R L L R R D A Q P R R Y L S  
D G G S A A S S P S G A C T S H R S R S S T V S S - G A T S S L P L
gatagagagggaaggcgccaagttcaaaccgcgacagaggacggtgaaatcacaaaggaaagcagcgtgacttggcacgcaattttcggttgtgaaaact 34 0 0 0  
I  S L S  P A L N L G R C L V T  F D C L F A A H  S P V C N E T T  F V  
Y L P F A G L E F R S L P R H F - L P F C R S K A R L K R N H F S  
- V A V S S P S I V F S L L T V Q C A I K P Q S F E
ccgtagaccccaggggatgccgggaagtaaaaataaaatcgcgcgcgatttttcaaaata a taaagacgggtactacC T G C G T T T C T T G A A G G G C A G C T T  3 4 1 0 0  
G Y V G P S A P F Y F Y  F R A R N K L I  I F V P V V Q T E Q L A A Q  
R L G W P I G P L L F L I A R S K E F Y Y L R T S G A N R S P C S  
T S G L P H R S T F I F D R A  I K - F L L S P Y - R
GAGCTCGGGGTTGACCTCGTGCAGGGAGGTGTGGTCGATGGGCCCGATGTTCTCGTAACGAAAGTCGTCGATGAGCAGGGCCAGGCCCACGCGCACGAAG 34 20 0  
A R P Q G R A P L H P R H A R H E R L S L R R H A P G P G R A R L  
S S P T S R T C P P T T S P G S T R T V F T T S S C P W A W A C S P
L E  P N V E H L S T H H I P G I  N E Y R  F D D I  L L A L G V R V F
I I
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Figure 5.9: Gel electrophoresis of RT-PCR products potentially from a 
spliced UL28 transcript.
EtBr-stained 1% (w/v) agarose gel showing representative RT-PCR products (sizes 
in kbp) amplified from AD169 IE, E and L mRNAs using two primers UL29S1 and 
UL29S2 (Table 2.2). M1 is 1 kbp ladder.
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these ORFs are conserved (Fig. 5.8), but that the first ATG codons in UL28 are not located 
equivalently. Moreover, amino acid sequence homology extends far upstream from both 
ATG codons, with homology falling off at a splice acceptor site that is conserved in both 
genomes (Fig. 5.8). Therefore, UL28 is probably spliced, but the location of the upstream 
exon is not clear. UL29 is a possibility, since there is a potential splice donor site at the 3’- 
end of CCMV UL29 that is weakly conserved in HCMV.
To investigate whether HCMV UL28 spliced to UL29, RT-PCR was carried out using 
primers UL29S1 and UL29S2. Two bands were generated in apparently identical sizes and 
intensities from E and L RNA (Fig. 5.9). Sequencing indicated that the larger product 
represents an unspliced transcript or contaminating DNA. The smaller product was cellular 
in origin. The experiment was repeated using two additional sets of primers (listed in Table 
2.2), but evidence of splicing of UL29 to UL28 was not detected. Since RACE failed to 
determine the 5’-ends of UL28 and UL29 (see section 5.1.1), the inability to detect splice 
sites in the cognate mRNAs may reflect their low abundance. However, the possibility that 
the exon is spliced to U L28^further upstream remains a strong possibility.
5.5 Discussion
All sequenced p-herpesviruses possess members of the US22 gene family (Weston and 
Barrell, 1986; Chee et al, 1990; Messerle et al, 1991; Efstathiou et al, 1992; Thomson 
and Honess, 1992; Gompels et al, 1995; Nicholas, 1996; Rawlinson et al, 1996; Vink et 
al., 2000). The US22 gene family was initially characterized in HCMV as consisting of 12 
distantly related genes of unknown function (UL23, UL24, UL28, UL29, UL36, UL43, 
IRS1, US22, US23, US24, US26 and TRS1). A thirteenth member (UL26) was recently 
been added (see Fig. 1.10) (A. Davison, unpublished data). In the present study, transcripts 
specified by 11 of these genes were investigated: UL23, UL24, UL26, UL28, UL29, UL36, 
UL43, US22, US23, US24 and US26. Only the UL36 transcript was previously mapped. 
The results are summarised in Fig. 5.10.
Transcripts of nine US22 genes were detected by northern blotting (Table 5.7); US26, 
TRS1 and IRS1 were not examined, and the kinetics of expression of UL43 could not be
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Figure 5.10: Positions of the 5’- and 3’-ends of US22 gene family members.
Expanded version of parts of the AD169 genome (Fig. 1.9) showing the positions of 5’ and 
3’-ends of US22 family genes. US22 family genes are shown in three sections, with the 
genome coordinates in kbp and transcriptional features above the relevant ORFs.
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determined. Chambers et al. (1999) failed to detect UL23 and UL24 mRNAs using gene 
microarray technology. All of these genes are expressed with either IE (UL36) or E kinetics 
(UL23, UL24, UL26, UL28, UL29, US22, US23 and US24). Most o f the US22 family 
genes in other p-herpesviruses (MCMV, HHV-6 and HHV-7) are also transcribed with IE 
or E kinetics (Iskederian et al., 1996; Cardin et al., 1995; Nicholas and Martin, 1994; 
Stasiak and Mocarski, 1992).
Using RACE, 5’-ends were identified for the mRNAs o f seven genes in the US22 family: 
UL23, UL24, UL26, UL36, US22, US23 and US24. In most cases RACE revealed 5’-ends 
mapping in a short region (less than 10 bp), rather than at a specific nucleotide residue (see 
Appendix 1). The 5’-ends obtained from the highest proportion of clones are listed in Table 
5.2. 5’-ends for certain US22 genes (UL24, UL36 and US22) were confirmed by primer 
extension. Most of the 5’-ends mapped for US22 genes are located 25-35 bp downstream 
from potential TATA elements (Table 5.2) and upstream from the first ATG in the ORF, 
with one exception (US24). Two 5’-ends were determined for each o f UL24 and US23, 
which were further confirmed by northern blotting. Failure to map 5’-ends for four 
members (UL28, UL29, UL43 and US26) may indicate that these genes are transcribed at 
low levels.
3’-ends were mapped for eight US22 genes, all o f which are located 20-29 bp downstream 
from a polyA signal that is conserved in the same or a similar position in CCMV (Table
5.4). 3’-RACE revealed three sets o f 3’-coteiminal genes (UL40-UL47, UL23-UL24 and 
US22-US23). The latter two were confirmed by northern blotting. Northern blotting also 
confirmed the presence of an additional set of 3’-coterminal genes (UL26-UL30), and the 
existence of two 5’-coterminal transcripts from US24, the larger 3’-coterminal with US23 
and US22.
Previously published splicing patterns for UL36 was confirmed by RT-PCR. There is also 
good evidence from sequence analysis that UL28 is spliced at its 5’-end (see Fig. 5.8). 
However, RACE failed to determine the 5’-ends of UL28 and UL29 (see section 5.1.1), and 
RT-PCR failed to detect splicing between the two ORFs. However, such splicing would be 
unusual, since it would result in a protein with two contiguous US22 domains. A similar 
splicing pattern was predicted in HHV-7 U7 (homologue o f UL28) by Megaw et a l  (1998),
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who concluded that U7 might be spliced at its 5’-end, possibly to U8 (resulting in a protein 
with two contiguous US22 domains), or to an unidentified upstream exon.
Functions have been ascribed to three members of the US22 family (TRS1, IRS1 and 
UL36) (Stasiak and Mocarski, 1992; Zhang et al., 1996; Colberg-Poley et al., 2000; 
Goldmacher et al., 2001), and the gene products o f three members (US22, UL36 and UL26) 
have been identified in infected cells (Mocarski et al., 1988; Baldick and Shenk, 1996; 
Patterson and Shenk, 1999). The expression profiles and transcript mapping data presented 
in this section will facilitate studies aimed at defining the functions of proteins specified by 
US22 family genes.
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The HCMV genome consists o f an arrangement o f unique regions and inverted repeats 
(Greenaway et al., 1982; Spector et al., 1982; Hayward et al., 1984). The inverted repeats 
( T R l  and I R l;  IR s and TRs) flank the unique sequences ( U l  and Us) in the L and S 
components (see section 1). T R l as originally described is 11247 bp in size and contains 14 
ORFs: TRL1-TRL14 (Chee et al., 1990). Six ORFs are predicted to encode glycoproteins 
owing to the presence o f a potential signal sequence for membrane insertion at the 5’-end, a 
transmembrane sequence near the 3’-end and possible N-linked glycosylation sites. Three 
of these (TRL11, TRL 12 and TRL 13) are the members o f the RL11 family (Chee et al., 
1990). Most ORFs in TRl (TRL2-TRL9) are not conserved in CCMV and therefore appear 
unlikely to encode proteins (Davison et al., unpublished data). The literature indicates that 
the most abundantly transcribed E gene o f HCMV (the p2.7 RNA) is located in T R l/ I R l  
and does not encode any protein (Greenway and Wilkinson, 1987; Staprans et a l, 1988). 
The purpose o f this study was to evaluate transcription of the ORFs in AD 169 T R l as 
described by Chee et al. (1990), using RACE and primer extension techniques.
6.1 Sequences of 5’-ends in TRL
5’-RACE was carried out using the SMART RACE kit (section 5.1). GSPs were designed 
from the region approximately 500 bp downstream from the putative initiation codons of 
target genes and are listed in Table 6.1. 5’-RACE products were cloned into pGEM-T and 
at least 5 clones were sequenced for each product. Comparisons o f the results with data 
from Chambers et al. (1999) are shown in Table 6.2, and the detailed results are given in 
Appendix 1 at the back of this thesis.
6.1.1 5’-ends of ORFs that are conserved in CCMV
Five HCMV ORFs are conserved in CCMV (TRL1, TRL10-TRL14). Except for TRL1, a 
single primer was used to determine the 5’-ends o f transcripts. Two primers (TRL1 and 
TRL1 (II)) were used to determine the 5’-end of TRL 1.
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Primer Sequence (5’- 3’) Position® PCR product(s)b
T R L l T R L l 
T R L l ( I I )
AAGGTGACGACAGGTTGGCGCCCC
TGCGCGAAAGCCTGTGCCGCGGCA
1 4 2 7 -1 4 0 4
1 5 0 0 -1 4 7 7
No p r o d u c t  
No p r o d u c t
TRL2 TRL2 GCACAAGCTCGGTCGCACGGATTA 2 2 2 6 -2 2 0 3 150
TRL3 TRL3 
T R L 3 ( I I )
TGTATATGCTCCTAGATAAGATTT
GACTACTAGTACTCCAATCTTAGA
3 4 4 0 -3 4 1 7
3 4 6 4 -3 4 4 1
No p r o d u c t  
No p r o d u c t
TRL4 T R L 4 ( I I )  
TRL4
GGCAGGAACACCCTTGCGGATTGA
CTCTTGTTGGGAATCGTCGACTTT
3 8 3 5 -3 8 5 8
3 9 4 3 -3 9 6 6
300 , 400 , 700 
2 00 , 300 , 600
TRL5 TRL5 
T R L 5 ( I I )
TCTTCCGCGTCTCCCGGCCGTACC
ACGCAGGGGTTTAGCAGCTTCCCC
4 3 2 4 -4 3 0 3
4 5 9 7 -4 5 7 4
No p r o d u c t  
400
TRL6 TRL6 GCCACACATCACCACTGTATTCAT 5 6 2 9 -5 6 5 2 2 00 , 400 , 500
TRL7 TRL7 
T R L 7 ( I I )
GGTAACGATGCTACTTTTTTTAAT
ACTTGCTGGTTCCTAAAAGTTCGC
6 6 0 1 -6 6 2 4
6 6 5 9 -6 6 8 2
No p r o d u c t  
No p r o d u c t
TRL8 TRL8 GTCGAGGCCGATCGACTGCCGCAT 7 6 2 4 -7 6 0 1 350 , 450 , 750
TRL9 TRL9 GGC C T GCAT GAT CAT C G T CAT CAT 7 9 0 0 -7 8 7 7 100 , 2 00 ,  350, 
600
TRL10 TRL10 CGTGTCAGGCTCCGATAGGCCAGA 8 5 5 5 -8 5 3 2 500 , 600, 800
TRL11 TRL11 CTCGGCAGAAGCTACGTGGGTGGA 9 1 5 5 -9 1 3 2 550 , 600 , 650, 
750 , 800 , 1050, 
1150
TRL12 TRL12 CATCTGACGTGATAGTTACGGTGA 9 8 7 5 -9 8 5 2 650, 1350 , 1800
TRL13 T R L l 3 
T R L 1 3 ( I I )
GTGGTGGTGTTGGTACATGTGGTA
GGTTTTGTAGAAACGGTGGTTGCT
1 1 1 0 0 -1 1 0 7 7
1 1 0 2 5 -1 1 0 0 2
400 , 450 , 700, 
750 , 1400
TRL14 TRL14 TTACAGGGCATGTGCCAAGAGTGG 1 1 4 8 1 -1 1 4 5 8 4 0 0 ,7 5 0 ,  800, 
1050 , 1100
Table 6.1: Primers used in 5’-RACE to map 5’-ends of transcripts from ORFs in TR|_.
a Position of primers in the positive strand of the AD169 genome. 
b Approximate sizes (bp) of PCR products excised for cloning (see Fig. 6.1).
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ORF C o n d itio n s  o f express ion
RACE Gene 
te ch n iqu e 3 m ic roa rrayb
P osition  o f 5’- 
end®
P utative  TATA 
e lem ent (5 ’-3’ )
P os itio n  o f 
TATA boxd
P osition  o f 
ATG codon®
TRL1 E No RACE product
TRL2 L E 2083 2094
TRL3 L No RACE product
TRL4 E Cellular
TRL5 L Not detected 4252 4266
TRL6 E L 5800 5656
5990 TATAAC 6015-6010 (20) 5947
6080 TGATTG 6106-6101 (20) 5947 (1)
TRL7 E No RACE product
TRL8 E L 7350 7365 (1)
7259 TAACTG 7224-7229 (29) 7284 (2)
6911 TACTTT 6886-6891 (20) 7284 (4)
TRL9 E-L L 7704 7717
7350 7365 (1)
TRL10 E E-L 7704 7717
8140 8182
8071 TATAAT 8036-8041 (21) 8182 (1)
TRL11 L L 8140 8182
8071 TATAAT 8036-8041 (21) 8182 (1)
8452 8726 (1)
8509 TAATTT 8469-8474 (26) 8726 (1)
8560 TCAATG 8526-8531 (28) 8726
8605 8726
8662 TAACTC 8634-8639 (22) 8726
TRL12 E E-L 8140 8182
8509 TAATTT 8469-8474 (26) 8726 (1)
9342 TGTTGG 9307-9312 (29) 9434
TRL13 E E-L 10406 TAGTAA 10377-10382 (23) 10796 (8)
10443 TATTAA 10405-10410 (32) 10796 (7)
10677 TCATTG 10650-10655 (21) 10796 (2)
10738 TATGAA 10708-10713 (24) 10796 (1)
TRL14 E L 10406 TAGTAA 10377-10382 (23) 10796 (8)
10443 TATTAA 10405-10410 (32) 10796 (7)
10677 TCATTG 10650-10655 (21) 10796 (2)
10738 TATGAA 10708-10713 (24) 10796 (1)
Table 6.2: 5’-ends of HCMV ORFs TRL1-TRL14.
a Conditions of expression as determined by RACE. b Kinetics of expression as previously 
determined by Chambers et al. (1999). c Position of 5’-ends as represented in the majority of 5’- 
cDNA clones. 5’-ends located far upstream and downstream from the first ATG (as described by 
Chee et al., 1990) are shown in pink and blue, respectively.d Position of the putative TATA element 
in the AD169 genome. The number of nucleotides between the 5’-end and closest TATA element is 
shown in brackets. e Position of the first ATG codon in AD169 (upper strand). Coordinates in 
brackets indicate the number of ATG codons present in the region between the first ATG codon and 
the 5'-end. ORFs that are not conserved in CCMV are shown in red.
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Neither yielded a product (Fig. 6.1a). This suggests that TRLl is expressed at low levels in 
infected fibroblasts.
TRL10 codes for a putative structural glycoprotein (Spadema et al., 2002). Primer TRL10 
(Table 6.1) yielded three major bands of approximately 500, 600 and 800 bp in a RACE 
experiment (Fig. 6.1j). They were produced in similar amounts from E and L RNA, 
indicating that TRL10 specifies an E transcript. Consistent with this, previous northern blot 
experiments detected TRL10 transcripts from E and L RNA (Spadema et al., 2002). 
Sequencing indicated that all three bands originated from HCMV. The two smaller 
products represent 5’-ends at 8071 and 8140 (Fig. 6.2) and the larger product represents a 
5’-end at 7704, as detected using primer TRL9 (see section 6.1.2). Both 5’-ends of TRL10 
are located upstream from the first ATG, but only the former is preceded by a potential 
TATA element.
TRLl 1 is a member o f the RL11 family and encodes a glycoprotein that possesses IgG Fc- 
binding capabilities (Lilley et al., 2001). As can be seen in Fig. 6.1k, primer TRLl 1 yielded 
seven major bands from L RNA (Fig. 6.1k). Consistent with this, Chambers et a l (1999) 
reported from the gene microarray experiments that TRL11 specifies an L transcript. Five 
bands (550, 600, 650, 750 and 800 bp) represent 5’-ends o f TRLl 1 at 8662, 8605, 8560, 
8509 and 8452, respectively (indicated by black arrows in Fig. 6.2). Two other bands of 
approximately 1.05 and 1.15 kb were also generated by primer TRL11, and represent the 
5’-ends o f TRL10 (indicated with red arrows in Fig. 6.2) as determined using primer 
TRL10. This indicates that TRLl 1 is 3’-coterminal with TRL10.
Primer TRLl2 yielded several bands from E and L RNA (Fig. 6.11). The three major bands 
(650 bp, 1.35 and 1.8 kb) were analysed and mapped the 5’-end o f TRLl2 to 9342, and 
those o f TRLl 1 and TRL10 at 8509 and 8140, respectively. This suggests these three genes 
are 3’-coterminal.
Primer TRLl3 yielded several bands from E and L RNA (Fig. 6.1m), indicating that 
TRLl3 is an E transcript. Five major bands (400, 450, 700, 750 and 1400 bp) were 
analysed. The largest band, originating from L RNA, was cellular in origin. The other four 
represent the 5’-ends at 10738, 10677, 10443 and 10406,
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Ml IE E L M1 M1 Ml IE E L
< - 0.1
a: TRL1
0.5 -►
< -0 .1 5
b: TRL2
M1 Ml IE E L M1 Ml IE E L
0 . 1  - >  m
c: TRL3
1 . 0 -
0.5
0 . 1-
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0.70
0.40
0.30
d: TRL4
M1 Ml IE E L M1 Ml IE E  L
1.0
0.5-
0.1
0.40
1.0
0.5-
0.1
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0.40
0.20
e: TRL5 f: TRL6
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M1 Ml IE E L
0.1 - >  0
g: TRL7
M1 Ml IE E L
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0.1 f
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0.45
0.35
h: TRL8
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0.20
0.10
i: TRL9 j: TRL10
M1 Ml IE E L M1 Ml IE E L
0.1
1 . 0 -
0.5-
0.1
k: TRL11
1.8
1.35
0.65
I: TRL12
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Figure 6.1: 5’-RACE of ORFs in the TRL region.
EtBr-stained 1% (w/v) agarose gels showing representative 5’-RACE PCR products containing 
regions of AD169 ORFs TRL1-TRL14 that were amplified from 5’-cDNA with GSPs (listed in 
Table 6.1) and UPM. 5’-cDNA was prepared from AD169 IE, E or L mRNA or Ml RNA. M1 is a 
100 bp ladder, (a) TRL1 with primer TRL1. (b) TRL2 with primer TRL2. (c) TRL3 with primer 
TRL3 (II). (d) TRL4) with primer TRL4. (e) TRL5 with primer TRL5 (II). (f) TRL6 with primer 
TRL6. (g) TRL7 with primer TRL7 (II). (h) TRL8 with primer TRL8. (i) TRL9 with primer TRL9. 
(j) TRL10 with primer TRL10. (k) TRL11 with primer TRL11. (I) TRL12 with primer TRL12. (m) 
TRL13 with primer TRL13. (n) TRL14 with primer TRL14.
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respectively. 5’-ends represented by the larger two bands (700 and 750 bp) are located 
upstream from the first ATG codon in TRLl3 and the intervening regions contain an 
additional eight ATG codons in other reading frames. All the 5’-ends are preceded by a 
potential TATA element. The experiment was repeated using a different primer TRLl3 (II) 
and yielded a similar result.
Primer TRL14 yielded major five bands (400, 750, 800, 1050 and 1100 bp) from E and L 
RNA (Fig. 6 .In). The smallest band, originating from L RNA, was cellular in origin. The 
latter four bands correspond to 5’-ends at 10738, 10677, 10443 and 10406, respectively, the 
same as those determined for TRLl3 using primers TRLl3 and TRLl3 (II). This is 
consistent with the view that TRLl3 and TRLl4 represent the products o f a frameshift 
mutation within an initially larger ORF in AD 169 (see section 3.6).
6.1.2 5’-ends of ORFs that are not conserved in CCMV
Eight ORFs (TRL2-TRL9) in AD 169 TRl are not conserved in CCMV in location or 
sequence. Nevertheless, 5’-ends were mapped for five o f these ORFs. Primer TRL2 yielded 
a single band of 150 bp from L RNA (Fig. 6.1b). Sequence analysis indicated that the 5’- 
end is located at 2083, but a potential TATA element is not present upstream.
Two primers were used to determine the 5’-end o f TRL5. Primer TRL5 yielded no product 
but primer TRL5 (II) yielded a single band of 400 bp from L RNA (Fig. 6.1e), indicating 
that this is a L transcript. However, a previous northern blot analysis revealed an E 
transcript from TRL5 (Hutchinson et al., 1986). Sequence analysis indicated that the 400 bp 
band represents a 5’-end located at 4252. There is no TATA element upstream.
Primer TRL6 yielded major three bands of 200, 400 and 500 bp (Fig. 6 .If). The abundance 
of these products was greater in L RNA than in E RNA, suggesting that they are expressed 
with E-L kinetics. Consistent with this, the temporal class o f TRL6 expression was 
previously classified as E-L by northern blot analysis (Hutchinson et a l, 1986). All three of 
the bands mentioned above originated from HCMV and correspond to 5’-ends at 5800,
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AAGACAGGGAGATGGACAGTGTCACGGTGTTTTGTTATAATTAGGACATGGGGACCGGAAGCCGAGACAGAGTACTACAGGGTGTTGAAGGGTAACGTGA 8 1 0 0
TRL10 V
GGGAGATCATGTCATGGGCGGGCTGAAGACCGTGCGGGGAGGATTGACGTGTGCGGTGCTTGTGGAACACGGTGTTTTAATATGTATCCGCGTGTAATGC 8 2 0 0
H A  V G F L A L  S L V  S Y V A V G A E T K V A T N C L V K S E D T H  
ACGCGGTGTGCTTTCTGGCACTCAGCTTGGTAAGCTATGTGGCCGTCTGCGCCGAAACCAAAGTCGCCACCAACTGTCTCGTGAAATCAGAAGATACCCA 8 3 0 0
I. T C K C S P N N T S S N T G N G S K C H A M C K C R I T E P I T  
TTTGACGTGCAAGTGCAGTCCGAATAACACATCATCTAATACCGGCAATGGCAGCAAGTGCCACGCGATGTGCAAATGCCGGATCACAGAACCCATTACC 84 00
ATGCTAGGCGCATACTCGGCCTGGGGCGCGGGCTCGTTCGTGGCTACGCTGATAGTCCTGCTGGTGGTCTTCTTTGTAATTTACGCGCGCGAGGAGGAGA 8 5 0 0
I  i
AAAACAACACGGGCACCGAGGTAGATCAATGTCTGGCCTATCGGAGCCTGACACGCAAAAAGCTGGAACAACACGCGGCTAAAAAGCAGAACATCTACGA 8 6 0 0
i  I
ACGGATTCCATACCGACCCTCCAGACAGAAAGATAACTCCCCGTTGATCGAACCGACGGGCACAGACGACGAAGAGGACGAGGACGACAACGTCTGATAA 8 700
TRL11 M Q T Y S T P L T L V I V T S . L F L F T T Q G - . S S
GGAAGGCGAGAACGTGTTTTGCACCATGCAGACCTACAGCACCCCCCTCACGCTTGTCATAGTCACGTCGCTGTTTTTGTTCACAACTCAGGGAAGTTCA 8 8 0 0
S N A V E P T K K P L K L A N Y B A T C F ,  D R T R T L V T R L N T  
TCGAACGCCGTCGAACCAACCAAAAAACCCCTAAAGCTCGCCAACTACCGTGCCACCTGCGAGGACCGTACACGCACGCTGGTTACCAGGCTTAACACTA 8 900
S H  H S V V W Q R Y D I  Y S R Y M R R M P P L C I  I T D A Y K E T T  
GCCATCACAGCGTAGTCT GGCAGCGTTATGATATCTACAGCAGATACATGCGTCGTAT GCCGCCACTT TGTATCAT TACAGACGCCTATAAAGAAACCAC 9 0 0 0
R Q G G  A A F A C  T R Q N L T L Y N L T V K D T G V Y L L Q D Q Y  
GCGTCAGGGCGGTGCGGCGTTCGCGTGCACGCGCCAAAATCTGACGCTGTACAATCTCACGGTTAAAGATACGGGAGTCTACCTCCTGCAGGATCAGTAT 9 1 0 0
T G D V E A F Y L I  I H P R S F C R A L E T R R C F Y  P G P G R V  
ACCGGCGATGTCGAGGCTTTCTACCTCATCATCCACCCACGrAGCTTCTGCCGAGCCTTGGAAACGCGTCGATGCTTTTATCCGGGACCAGGGAGAGTTG 9 2 0 0
Figure 6.2: Position of 5’-ends as represented in 5’-cDNA clones of TRL11.
Fig. 6.2 shows the region containing the TRL10 and the 5'-ends of TRL11, with coordinates on 
the right. The predicted amino acid sequences of TRL10 and TRL11 are shown in red and blue, 
respectively. The position of RACE primer TRL11 is shown in bold italics and its orientation is 
indicated by an arrow. The red vertical arrows indicate the positions of 5’-ends of TRL10 mRNAs 
and the black vertical arrows indicate the 5’-ends of TRL11 mRNAs. Potential TATA elements are 
underlined in red.
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5990 and 6080. The 5’-end at 5800 is approximately 150 bp downstream from the first 
ATG and is not preceded by a TATA box. The only ATG that could be used as initiation 
codon is located 40 bp upstream from the TRL6 stop codon. The 5’-ends located at 5990 
and 6080 are 150 bp and 50 bp upstream, respectively, from the first ATG, and each is 
preceded by a potential TATA element.
Primer TRL8 yielded two bands of 350 and 750 bp from E and L RNA (Fig. 6.1h). The 
abundance of smaller product was similar in E and L RNA but that of the larger product 
was greater in E RNA. An additional minor band o f 450 bp was also obtained from L RNA 
(Fig. 6.1h). Sequence analysis indicated that all three bands (350, 450 and 750 bp) 
originated from HCMV and represent 5’-ends at 7350, 7259 and 6911, respectively. The 
former is located downstream from the first ATG. The 5’-end at 7259 is located upstream 
from the first ATG and has a TATA element 29 bp upstream. The 5’-end at 6911 is located 
approximately 350 bp upstream from the first ATG and the intervening region contains four 
ATG codons in other reading frames.
A PCR product of approximately 600 bp was obtained from E and L RNA when primer 
TRL9 was used (Fig. 6.1i). Sequence analysis indicated that this represents the same 5’-end 
detected for TRL8 at 7350. This suggests that the TRL8 and TRL9 transcripts are 3’- 
coterminal. In addition, primer TRL9 yielded two bands (100 and 350 bp) from L RNA and 
a band o f 200 bp from E and L RNA (Fig. 6.1 i). Only the 200 bp band originated from 
HCMV and indicated a 5’-end at 7704 that is 12 bp upstream from the first ATG codon in 
the ORF and is not preceded by a TATA element. The greater abundance o f the 200 bp 
band from L RNA indicates that this transcript is in the E-L kinetic class.
Primer TRL4 was used to determine the 5’-end of TRL4. Three major bands were 
generated in similar proportions from E and L RNA (Fig. 6 .Id). Sequencing indicated that 
none originated from HCMV. Use of a second primer (TRL4 (II)) failed to detect a 5’-end.
In order to determine the 5’-ends o f TRL3 and TRL7, two different primers were used for 
each (Table 6.1). None yielded a product (Fig. 6.1c and 6.1g).
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6.2 Mapping the 5’-ends of ORFs in TRL by primer extension
To confirm the 5’-ends determined by RACE, four ORFs from T R l were analysed by 
primer extension: TRL2, TRL5, TRL8 and TRL9. GSPs (listed in Table 2.3) were designed 
from the region approximately 100 bp downstream from the 5’-end o f the RNAs 
determined by RACE. In two experiments, none yielded a detectable primer extension 
product. It is therefore possible that these mRNAs are present in low abundance in infected 
fibroblasts.
6.3 Discussion
Transcripts o f the 14 ORFs from AD 169 T R l (TRLl-TRL 14) were analysed by 5’-RACE. 
The data are summarised in Fig. 6.3.
RNAs were identified for five (TRL 10, TRL11, TRL 12, TRL 13 and TRL 14) out o f six 
ORFs that are conserved in CCMV. The inability to detect the TRLl transcript may 
indicate its poor expression in infected fibroblasts. Expression of all the transcripts detected 
except that specified by TRLl 1, fall into the E kinetic class. TRL 11 was considered an L 
transcript. Chambers et al. (1999) reported similar findings using gene microarray 
technology. Transcript mapping data revealed the same 5’-end for TRL 13 and TRL 14, 
consistent with TRL 13 and TRL 14 representing the products o f a frameshift mutation 
within a larger ORF in AD 169 as discussed in section 3.6. Transcripts for certain genes 
(TRL10, TRL11 and TRL13/14) possess multiple 5’-ends. The majority o f these 5’-ends 
are preceded by a potential TATA element 25-35 bp upstream.
Five ORFs (TRL2, TRL5, TRL6, TRL8 and TRL9) were analysed that are not conserved in 
CCMV and are unlikely to encode proteins. However, Chambers et al. (1999) detected 
transcripts for each ORF using gene microarray technology. Transcript mapping data 
revealed single 5’-ends for TRL2, TRL5 and TRL9, each located upstream from the first 
ATG codon in the ORF, but none preceded by a potential TATA element. Some ORFs 
possess multiple 5’-ends that are located downstream or far upstream (TRL6, TRL8) from
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Figure 6.3: Positions of the 5’-ends of HCMV ORFs TRL1-TRL14.
Expanded version of parts of the AD169 genome (Fig. 1.9) showing the positions of 5 ’-ends of
TRL1-TRL14, with the genome coordinates in kbp.
-| 5'-end of ORFs that are oriented right to left
f- 5-end of ORFs that are oriented left to right
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the first ATG codon in the ORF. The latter arrangement results in several ATG codons in 
other reading frames preceding the first ATG codon in the ORF.
RACE failed to detect transcripts for three ORFs (TRJL3, TRL4 and TRL7) that are not 
conserved in CCMV. Greenway and Wilkinson (1987) mapped 5’-end o f the major E 
transcript (TRL4 or 02.7) at 4435 using Si nuclease analysis (as described by Akrigg et al. 
(1985) and Wilkinson et al. (1984)) and primer extension (as described by Farrell et al. 
(1983)). Rawlinson and Barrell (1993) also detected the TRL4 transcript from E and L 
RNA using northern blotting with seven probes located along TRL4. Two different primers 
were used in the present study to determine the 5’-end of TRL4. Each yielded products, but 
these were cellular in origin. It is not known why the attempts to map 5’-end of the TRL4 
transcript was unsuccessful.
The 5’-RACE revealed the existence of a set of 3’-coterminal transcripts in TRl: TRL8- 
TRL12. However, it will be necessary to map the 3’-end of these transcripts to confirm this.
Transcript mapping data shown in this study indicates that AD 169 TRl is transcriptionally 
active, but in a complex manner. TRL 10, TRL11, TRL 12 and TRL 13 appear likely to 
encode proteins since these are conserved in CCMV. TRL 14 is naturally frameshifted in 
AD 169 and encodes a truncated protein. 5’-ends were mapped for the majority of ORFs in 
the TRL2-TRL9 region, but their expression as functional proteins appear unlikely, since 
these ORFs are not conserved in CCMV. One transcript in this region (the 02.7 RNA, 
mapping to TRL4) does not encode protein and is thought to be a non-translated (Greenway 
and Wilkinson, 1987). Thus it is possible that other RNAs in the TRL2-TRL9 region may 
serve similar functions. One possibility, in light of the function of TRL2-TRL9 mRNAs, is 
that they serve a structural role in assembling and organising proteins in the tegument.
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The purpose o f this study was to map the 5’-ends of transcripts associated with UL1-UL30. 
Primers used in RACE experiments are listed in Table 7.1.
7.1 Mapping 5’- ends of genes in the UL region
A detailed summary of the results is given in Appendix 1, and a comparison of the results 
with data from Chambers et al. (1999) is shown in Table 7.2. The data are summarised 
diagrammatically in Fig. 7.1.
5’-RACE products were not produced from three ORFs (UL1, UL5 and UL9 in Fig. 7.2a, 
7.2e and 7.2i, respectively). This experiment was repeated using several GSPs (listed in 
Table 7.1) for each gene. The inability to map the 5’-ends of these genes suggests that they 
are transcribed at low levels in infected fibroblasts.
Primers UL2 and UL3 yielded similar patterns o f bands from L RNA. (Fig. 7.2b and Fig. 
7.2c, respectively). Sequence analysis indicated that the major bands (650 bp in Fig. 7.2b 
and 500 bp in Fig. 7.2c) correspond to a 5’-end at 13471. The minor bands (500 bp in Fig. 
7.2b and 350 bp in Fig. 7.2c) correspond to a 5’-end at 13296. The 5’-end at 13471 is 
located 20 nucleotides downstream from a potential TATA element and 170 bp upstream 
from the UL3 ATG codon. The 5’-end at 13296 is located downstream from the first ATG. 
The 350 bp band (Fig. 7.2b) indicated that the 5’-end o f UL2 is at 13186. This 5’-end is 28 
bp downstream from a potential TATA box. The abundance o f 5’-RACE products in Fig. 
7.2b and Fig. 7.2c indicates that the UL2 transcript is rare in comparison with that of UL3, 
and that these are 3’-coterminal genes. A candidate polyadenylation signal is located near 
the 3’-end o f UL2 (12618-12613).
Three 5’-RACE bands o f 550, 650 and 800 bp (Fig. 7.2d) from UL4 were analysed, and 
indicated a major 5’-ends at 13290 and minor 5’-ends at 13182 and 13046. Each is located 
upstream (250 to 400 bp) from the first ATG codon in UL4, and several other ATG codons 
are located between the 5’-ends and first ATG codon. Only the 5’-end at 13046 has TATA
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O R F P r im e r S e q u e n c e  (5 ’- 3 ’) P o s i t io n 8 P C R  p r o d u c t ( s ) b
ULl ULl
ULl(II)
TGGTGCTATTTATGGTGTAGTTAC
GTTCAGTATAAGCACCTGAATCGT
12299-12276
12200-12177
No product
UL2 UL2 AGAGCGTCTCGAAGCAGCTTGAGC 12872-12895 350, 500, 650
UL3 UL3 CGCGACCGAGTCTTCGGCCATGGT 13027-13050 350, 500,
UL4 UL4 AGCAACGTCAAGCGGTTATAGGTG 13825-13802 550, 650, 800
UL5 UL5
UL5(II)
AGT GAT GAT GAGAC GAC T C CAC GG 
ACGAGACGTTGATAGCGGTATTTC
14324-14301
14500-14477
No product 
No product
UL6 UL6 GCTACACGGTGTCCTAATGAGACT 15015-14992 450, 750
UL7 UL7 CACCGTTGGTGTCGTCGTGACGAT 16000-15977 1000 , 1700
UL8 UL8 TTTTGAGGTGCTCGCAGACAGATG 16535-16512 400, 500, 1.5
UL9 UL9
UL9(II)
ACAATGTATGATTCAAAAAACATC
TGACATTGTAACATAGAGGTGTCC
16900-16877
16999-16976
No product 
No product
UL10 UL10 GCCGTTGCTAATGCCGACGCATGA 17609-17632 750
ULl 1 ULl 1 GGTGGTAGTGGGAAGTGTTCCGTT 18738-18715 500, 1350, 1800
UL12 ULl 2 CCTCAAACCGATCTGTGAGCAAGT 19105-19128 300, 600
UL13 UL13 ACTGCAGCTCTTGGTACTGCCAAC 19728-19705 450, 600
UL14 UL14 AGGTCGTGCACGTCGGCCACCAGC 21377-21354 450, 750
UL15 UL15 ATCTTACCGGGGACCTCGTTGTCC 22280-22303 No product
ULl 6 ULl 6 AGCGAGCCCAATCGGACGTAGAGG 22895-22872 600, 700, 800
ULl 7 UL17 TCTTCGGGAGACCGTGCCGGATCC 23518-23495 400, 650, 1200
ULl 8 PEL18 (II)
PEL18
UL18
ATCCCCGTGTACCCGTAACGCAAC
ATAGGTAAAAAAGTGTTGCCCGTC
TAGTGTCAGGTTATCCTTGAGCTC
23725-23702
23795-23772
24095-24072
150
100,
450
200
ULl 9 UL19 CGCGACTCACATCTAGCTCGTCTT 25002-25025 800, 1350
UL20 UL20 GTATTGTTGTCAGCGCAGTTCAGA 25624-25601 400, 500, 600
UL21 UL21
UL21R
GTCGGTCGATGACGATGTCGATCT
AAAGCCAAGCGGCGCAAGGGCCGG
26602-26625
26736-26759
300
200
UL22A PEL22A TTCTGAGAAGGTGCCGCCAAAGCC 27181-27158 150, 400
UL25 UL25 CGTCGCCACCGCCGCCGGCGCCGT 30474-30451 450, 400
UL27 UL27 TCAGACCGCGGATGTCGTACTTGC 34276-34299 550, 1100
UL30 UL30 GTCAACACGCGACTCGCGCGGCAA 37319-37342 250
Table 7.1: Primers used in 5’-RACE to map 5’-ends of transcripts from UL1-UL30.
aPosition of primers in the positive strand of the AD169 genome.
Approxim ate sizes (bp) of PCR products excised for cloning (See Fig. 7.2).
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ORF C o n d itio n s  o f express ion P os ition  o f 
5 ’-end*
P uta tive  TATA 
e lem en t (5 ’-3’)
P os ition  o f TATA 
boxd
P os ition  o f 
ATG codon*
RACE
te ch n iqu e 3
Gene
m icro a rra yb
UL1 No RACE product E-L Not detected
UL2 L L 13471
13296
13186
TAATAA
TATTTG
TATACA
13496-13491 (20) 
13321-13316 (20) 
13220-13215 (28)
13324
None
13048
UL3 L L 13471
13296
TAATAA
TATTTG
13496-13491 (20) 
13321-13316 (20)
13324
None
UL4 E E 13290
13182
13046 TATAAG 13018-13023 (22)
13464 (1)
13464 (7) 
13464 (10)
UL5 No RACE product E Not detected
UL6 L Not detected 14271
14585 TATTTG 14558-14563 (21)
14612 (1) 
14612
UL7 L L 14271
15068 TATTTA 15043-15048 (20)
14612 (1) 
15526 (6)
UL8 L Not detected 15068
16027
16180
TATTTA
TATTAT
15043-15048 (20) 
16149-16154 (26)
15526 (6) 
16234 (4) 
16234 (1)
UL9 No RACE product L Not detected
UL10 E-L Not detected 16933 TATTAA 16905-16910 (22) 17426 (9)
UL11 E Not detected 16933
18270
TATTAA
TGAATA
16905-16910 (22) 
18237-18242 (27)
17426 (9) 
18295 (2)
UL12 L Not detected 19699
19353
19321 (8) 
19321 (1)
UL13 E E 19308 TCATAA 19281-19286 (20) 19320
UL14 L L 20713
20952
TATGCT 20686-20691 (22) 20843 (1) 
None
UL15 No RACE product E Not detected
UL16 E Not detected 22325 22378 (1)
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UL17 E E 22325
22896
23171
TAATCG 22862-22868 (27) 
TATAAG 23145-23150 (20)
22378 
23214 (1) 
23214
UL18 L L 23724 23645 (1)
UL19 L Not detected 23724h
24269 TTATAG 24236-24241 (28)
23645 (1) 
24740 (5)
UL20 L Not detected 25253
25161
24979
TCAATA 25214-25219(33) 
TATGAT 25136-25141 (20) 
TTAATG 24950-24955 (23)
25299 (1) 
25299 (3) 
25299 (6)
UL21A' L Not detected 26858 TATTTA 26894-26889 (25) 26839 (1)
UL25 L Not detected 30016
30065
TATAAC 29982-29987 (28) 30057
UL27 L E 35295 34657 (9)
UL30 L Not detected 37525 37500
Table 7.2: 5’-ends of HCMV ORFs UL1-UL30.
a Conditions of expression as determined by RACE. b Kinetics of expression as determined by 
Chambers et al. (1999). c Position of 5'-ends as represented in the majority of 5’-cDNA clones. 5’- 
ends located far upstream or downstream from the first ATG in the ORF (as described by Chee et 
al., 1990) are shown in pink and blue, respectively d Position of the putative TATA element in the 
AD169 genome. The number of nucleotides between the 5’-end and the closest TATA element is 
shown in brackets. e Position of the first ATG codon in the ORF. Coordinates in brackets indicate 
the number of ATG codons present in the region between the first ATG codon and the 5’-end. 
ORFs that are not conserved in CCMV are shown in red.
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element upstream. Since UL4 is 3’-coterminal with UL5 and shares a poly A signal at 
14747 to 14752 with the polyadenylation signal tail added at 14766 (Chang et al., 1989), 
the major UL4 transcript should be 1.7 kb in size. Consistent with this, a northern blot 
probed with a labeled oligonucleotide from the 5’-end o f UL4 hybridised to an mRNA of 
this size (Rawlinson and Barrell, 1993; Alderete et al., 1999).
Primer UL6 yielded several bands at late times (Fig. 7.2f). The major two bands o f 450 and 
750 bp indicated 5’-ends for UL6 at 14585 and 14271. A potential TATA element is 
present 21 bp upstream from the former. The latter 5’-end is located within UL5, 350 bp 
upstream from the first ATG codon in UL6.
As shown in Fig. 7.2g, primer UL7 yielded several bands from L RNA. Two major bands 
(1.0 and 1.7 kbp) were analysed, indicating 5’-ends at 15068 and 14271, respectively. The 
former has a potential TATA element within 20 bp and represents the 5’-end o f UL7, and 
the latter represents the 5’-end o f UL6 as determined using primer UL6 (Fig. 7.2f). The 5’- 
end of UL7 is located far upstream from the first ATG codon in UL7, and the intervening 
region contains six other ATG codons in different frames. Detection o f the 5’-end o f UL6 
by primer UL7 indicates that UL6 and UL7 are 3’-coterminal.
i
, Primer UL8 detected transcripts from L RNA (Fig. 7.2h). The larger products originated
from UL6 and UL7, and the lower two bands of 400 and 500 bp correspond to 5’-ends of 
UL8 at 16180 and 16027. A potential TATA element is present within 26 nucleotides o f the 
former. The data indicate that UL6, UL7 and UL8 are 3’-coterminal, sharing a potential 
polyadenylation signal at 16558-16563. UL8 contains a splice acceptor sequence 
(TGATGTGCTTTTATCAGG) at 16212 to 16195, but splicing was not detected by
i northern blotting and RT-PCR (Chee et al., 1990; Rawlinson and Barrell, 1993). The
I
! RACE results also produced no evidence for splicing.
Primer UL10 yielded one major band of approximately 750 bp from E and L RNA (Fig. 
7.2j). The intensity of the product was greater in L RNA, indicating that the UL10
transcript may fall into the E-L kinetic class. Sequence analysis indicated the 5’-end of
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Figure 7.2: 5’-RACE of HCMV genes UL1-UL30.
EtBr-stained 1-1.5% (w/v) agarose gels showing representative 5’-RACE products from UL1- 
UL30 (except UL22A, UL23, UL24, UL26, UL28 and UL29) produced using GSPs (listed in 
Table 7.1) and UPM. 5’-cDNA was prepared from IE, E or L AD169 mRNA and from Ml RNA. 
M1 and M2 are 100 bp and 1 kbp ladders, respectively, (a) Primer UL1. (b) Primer UL2. (c) 
Primer UL3. (d) Primer UL4. (e) Primer UL5. (f) Primer UL6. (g) Primer UL7. (h) Primer UL8. 
(i) Primer UL9. (j) Primer UL10. (k) Primer UL11. (I) Primer UL12. (m) Primer UL13. (n) 
Primer UL14. (o) Primer UL15. (p) Primer UL16. (q) Primer UL17. (r) Primer UL18. (s) Primer 
UL19. (t) Primer UL20. (u) Primer UL21. (v) Primer UL25. (w) Primer UL27. (x) Primer UL30.
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UL10 is located at 16933, far upstream from the first ATG codon in this ORF. The region 
between the 5’-end and the ATG codon contains nine other ATG codons in different 
frames. A potential TATA element is present within 22 bp from this 5’-end.
Multiple RACE products were detected using primer UL11 (Fig. 7.2k). The largest band 
corresponded to the 5’-end of UL10 as determined using primer UL10 (Fig. 7.2j). The 
smaller product of 500 bp represented the 5’-end of UL11 at 18270 and is located 27 bp 
downstream from a potential TATA box. An additional band of 1.35 kbp from L RNA was 
found to be cellular in origin.
Primer UL12 yielded two bands of approximately 300 bp and 600 bp from L RNA (Fig. 
7.21) that correspond to 5’-ends at 19353 and 19699. The latter is located far upstream, with 
the intervening region containing eight other ATG codons in different frames. Both 5’-ends 
lack TATA elements 25-35 bp upstream. UL12 is not conserved in CCMV and is at present 
considered not to encode a protein.
Primer UL13 produced two major bands of 450 and 600 bp (Fig. 7.2m). The former was 
detected early and late times and mapped the 5’-end of UL13 to 19308. The other band was 
cellular in origin. The 5’-end of UL13 has a potential TATA box at 19281 to 19286.
Primer UL14 yielded four principal bands from L RNA (Fig. 7.2n). The 750 bp band 
indicated a 5’-end at 20713. A potential TATA element is present 22 bp upstream. The 450 
bp band corresponds to a 5’-end at 20952, 110 bp downstream from the first ATG codon in 
UL14. The two other bands generated by primer UL14 were not analysed.
Two primers were used to determine the 5’-end of UL15. Neither yielded products (one 
example is shown in Fig. 7.2o). Subsequent to this experiment, two errors were identified 
in this region that resulted in replacement of UL15 by a new gene, UL15A, on the opposite 
strand (see section 3.1.1). Nevertheless, Chambers et a l (1999) detected a UL15 transcript 
using gene microarray technology and northern blotting (using a cDNA probe designed 
from the 3’-end of UL15). The 5’-end of UL15A was not mapped.
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The UL16 protein exhibits eight potential N-linked glycosylation sites and is predicted to 
be a membrane glycoprotein (Chee et al., 1990; Kaye et al, 1992a). It is not detectable in 
purified enveloped virions and is non-essential for virus growth in cell culture (Kaye et al, 
1992a). Primer UL16 yielded a major band of approximately 600 bp from E and L RNA 
(Fig. 7.2p). Published northern blot data previously showed that UL16 is an E transcript 
(Kaye et al., 1992a). The 600 bp band corresponds to a 5’-end for UL16 at 22325. 
Translational initiation would occur at 22378-22380 rather than at 22414-22416 concluded 
by Chee et al. (1990). Two other bands (700 and 800 bp) that were generated from L RNA 
were cellular in origin.
Primer UL17 yielded three principal bands of 1.2 kbp, 650 bp and 400 bp (Fig. 7.2q). The
1.2 kb band corresponds to the 5’-end of UL16 as mapped using primer UL16 (Fig. 7.2p). 
This suggests that UL16 and UL17 are 3’-coterminal. Analysis of the 650 and 400 bp bands 
indicated two 5’-ends for UL17 at 22896 and 23171, respectively. The former 5’-end is 
located far upstream from the first ATG in UL17, with the intervening sequence containing 
another ATG codon in a different frame. The 5’-end at 23171 is 20 bp downstream from a 
potential TATA box.
ORF UL18 exhibits significant sequence homology with the class 1 a-chain genes of HLA. 
Primer UL18 yielded a major band of 450 bp from L RNA (Fig. 7.2r) that mapped the 5’- 
end of UL18 to 23724. This places the initiation codon for UL18 at 23745-23747, the sixth 
ATG codon in the ORF (Fig. 7.4). This experiment was repeated several times using four 
different primers (listed in Table 7.1) designed from the region 150 bp to 1.4 kbp 
downstream from the first ATG codon in UL18. As can be seen in the Fig. 7.3, all primers 
yielded a major band that mapped the 5’-end at same position (23724). Primer PEL18 (Fig.
7.3 lane 1) generated an additional band of 200 bp in apparently similar intensity to the 
smaller product but was cellular in origin. Additional low abundance bands were also 
generated (Fig. 7.3) but were not analysed. Therefore, it is formally possible that a major 
downstream 5’-end for UL18 mRNA has been mapped but a minor upstream 5’-end has 
been missed. The likely initiation codon for the mapped UL18 is at 23745 to 23747, 21 bp 
dpwnstream from the mRNA start site. There is no potential TATA box immediately 
upstream of the initiation site.
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Figure 7.3: 5’-RACE of the HCMV UL18 mRNA.
EtBr-stained 1% (w/v) agarose gels showing representative 5’-RACE products amplified from 5’- 
cDNA with four different GSPs (listed in Table 7.1). 5’-cDNA was prepared from IE, E or L AD169 
mRNA or Ml RNA. M1 and M2 are 100 bp and 1 kbp ladders respectively. 1; primer PEL18. 2; 
primer PEL18 (II). 3; primer UL18. 4; primer UL19.
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GGCACGGTCTCCCGAAGAGGAGGAGTAAACAACACACGGCTAAGAGGATACATCATCAAAGAAGATAGGAGGGGTCAAAACGCGGACTGAAAGTATATAA 2 3 6 0 0
0 M T M W C L T L F V L W M L R V V G M H  
CGCCGATCATGTCCGAGGAACTGTTAATAAAACGCCATGATGACAATGTGGTGTCTGACGTTGTTTGTGCTGTGGATGTTGAGAGTGGTGGGAATGCACG 2 3 7 0 0
V L R Y G Y T g T [  F D D T S H 0 T L T V V G I F D G Q H F F T Y H V  
TGTTGCGTTACGGGTACACGGGGATTTTCGATGATACATCGCATATGACGTTGACCGTTGTGGGGATTTTT^CGGGCAACACTTTTrTACCTATCACGT 2 3 8 0 0
n s s d k a s s r a n g t i s w m a n v s a a y p t y l d g e r a
TA ^ ’TCCAGCGATAAAGCGrCAAGTCGGGCCAACGGTACCATTTCTTGGATGGCTAACGTCTCGGCGGCCTACCCCACCTACCTGGACGGGGAAAGAGCC 2 3 9 0 0
k g d l i f n q t e q n l l e l e i a l g y r s q s v l t w t h e
AAAGGTGACCTTATTTTTAACCAAACCGAGCAAAACCTGTTAGAGCTGGAAATTGCGTTGGGTTACCGGTCACAGAGCGTGCTGACGTGGACGCACGAGT 24 000
I
G C M G C A ' G G T M C A A C G C A G 4 G ' A C g : Q G G G A ~ T T T C G A T G A ' A C A ' C G C > '  A T G t C G ' ^ G ^ C G T ' G T Q S G G A T ’ T T i G / C G G G C A A C A C T T T T ' ^ C C T A T C A C g T A A T T C O G C G A ' A A A G C G ' C A A G ' C G G G C O
I I
Figure 7.4: Sequence at a 5'-end of the UL18 mRNA.
Panel I shows a portion of AD169 UL18 and its encoded amino acids, with the coordinates on the right. 
Amino acid residues conserved in CCMV are underlined. RACE primers are shown in italic bold font with 
orientations indicated by arrows. The black vertical arrow indicates the position of 5'-end of the UL18 as 
represented in the majority of 5'-cDNA clones. The first ATG codon in UL18 (as originally described by 
Chee et a l., 1990) and the ATG likely to be used as initiation codon by the mapped 5'-end are shown in 
red and blue boxes, respectively. A potential TATA element is underlined in red. Panel II shows an 
electropherogram of the 5'-RACE product (upper strand of AD169 genome) with the 5’-end indicated by 
an arrow and the SMART sequence underlined in red.
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Primer UL19 yielded two major bands of 800 and 1.35 kbp (Fig. 7.2s). The former mapped 
the 5’-end of UL19 to 24269, which is 28 bp downstream from a potential TATA element. 
The other band corresponds to the 5’-end of UL18 as described above (Fig. 7.3). This 
indicates that ORF UL18 and UL19 are 3’-coterminal. A candidate poly A signal 
(AATAAA) is located at 25216-25221, downstream from UL19.
The product of ORF UL20 is homologous to the T-cell y-chain receptor (Beck and Barrell, 
1991) and is dispensable for replication in cell culture (Mocarski, 1996). Primer UL20 
yielded multiple bands from L RNA (Fig. 7.2t). Three bands (approximately 400, 500 and 
600 bp) were analysed, placing 5’-ends at 25253, 25161 and 24979, respectively. Each is 
located upstream from the first ATG codon in UL20 and has a potential TATA box within 
24-33 nucleotides. The 5’-end at 24979 represents the major UL20 transcript. It is located 
300 bp upstream from the first ATG codon in UL20, with the intervening sequence 
containing six other ATG codons in different frames.
Primer UL21 generated a single band of 300 bp from L RNA (Fig. 7.2u) that mapped a 5’- 
end to 26858, downstream from the first ATG codon in UL21. The experiment was 
repeated using a second primer UL21R, and yielded the same end (data not shown). The 5’- 
end is preceded by a potential TATA element and the first ATG codon in the mRNA is in 
an alternative reading frame from UL21. This is consistent with the implication from 
sequence comparisons that UL21 does not encode a protein (Davison et al., unpublished 
data). Comparison of three-frame translations of the relevant regions of the AD 169 and 
CCMV genomes indicates that AD 169 UL21 (shown in blue in Fig. 7.5 (panel I)) is not 
well conserved in CCMV (Fig. 7.5 (panel II)). However, a CCMV ORF (UL21A) (shown 
in red in Fig. 7.5 (panel II) is conserved in AD169 (bold black font with conserved residues 
underlined). As a consequence, UL21 is replaced by a novel gene, UL21A, in AD 169. The 
proteins encoded by UL21A in AD 169 and CCMV lack homologues in protein databases.
UL25 encodes a virion structural protein (Baldick and Shenk, 1996). Primer UL25 yielded 
two major bands of approximately 400 and 450 bp from L RNA (Fig. 7.2v). Consistent 
with this, the UL25 transcript was detected by northern blotting only at L times post 
infection (Battista et al., 1999). The larger product places the 5’-end of UL25 at 30016, 29
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CTGACAATGGACTGAATATACAGACTTTTATATGATCCTTGTACAGATGTAAATAAAATGTTTTTATTTAAAACTGGTCCCAATGTTCTTCGGGAATCAT 2 6 5 0 0  
Q C H V S Y V S K - I I R T C I Y I F H K - K F S T G I N K P F  
L 21A  S L P S F I C V K I  H D K Y L H L Y F T K I  -  F Q D W H E E P I M  
S V I S Q I Y L S K Y S G Q V S T F L I N K N L V P G L T R R S D H
GGGGTGGGGACGGGGGACGCGGTAAGGAGCAAAACCGGGTACATGGGGGGGAACATCGTCCAGCAGTAGCACCAGCGGATTGGGTAGGGGTTGCTGCGGA 2 6 6 0 0  
21
P H P R P V R Y P A F G P V H P P V D D L L L V L P N P L P Q Q P
P P S P P R P L S C F R T C P P S C R G A T A G A  ~ S  Q ~ T P T A A S
GGTCGGTCGATGLACGATGTCGAT^GCATCGGCAGATCCGGCAACATCTCTTCGTCTCCCTCACCGACCAGCACTCGGCGCTGTTCTGGATGTATATGAT 2 6 7 0 0
P R D I V I D I E M P L D P L M E E D G E G V L V R R Q E P H I H N
T P R H R H R D G D A S G A V D R R R G - R G A S P A T R S T Y S
TTTGGAAAAGCCTCCGACGAGCTCGCGGCGCGTAGAAAGCCAAGCGGCGCAAGGGCCGGCGAGCCCGAAAGTCCATGCGCACAGATGGCA'TGAGTCCTTG 2 6 8 0 0^C
T
Q F L R R R A R P A Y F A L R R L P R R A R F D M R V S P M L G Q
K P F A E S S S A A R L F G L P A L A P S G S L G H A C I A H T R S
2 6 9 0 0
T V T T L Q P V P S G G 0 A V T V T S G H S L R R V S C P - I G H
H R H H A P S C P - R G D R R H C H I W S L P A A R Q M A L Y R S
ATCCCCTGACGTCGTCTTTCGTCCCGAACGCGTCATGTTGGGGGCGAGGCGTAAACCGTCGAGGTTGAAAAACCGCGTATCTGCGACCCGTCCGGACTAC 2 7 0 0 0
I G Q R R R E D R V R - T P P S A Y V T S T S F G R I Q S G D P S R
D G S T T K R G S R T M N P A L R L G D L N F F R T D A V R G S -
GTTGTTTTTCAGAAGCGGCCACATGACCTCGAGATGTCGTCACCCAAGGTATTTAACGGCACACAGCCAGACGCGTTCGTCAGCAGCGACGCCGACAAGA 2 7 1 0 0  
f j V E L H R - G L Y K V A C L W V R E D A A V G V L  
Q K E S A A V H G R S T T V W P I - R C V A L R T R - C R R R C S  
T T K - F R G C S R S I D D G L T N L P V C G S A N T L L S A S L V
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TGGTGTGCGTCACCATCTGATGGACATAGACTCTCATTCAGAGACATAACACTACGGCTTTCCATGAAAGCACAGAGACTGTACAAAATTCCACTTTTTT 2 4 1 0 0  
P T R - W R I S M S E - E S V Y C - P K G H F C L S Q V F N W K K  
T H T V M Q H V Y V R M - L C L V V A K W S L V S V T C F E V K K  
H H A D G D S P C L S E N L S M V S R S E M F A C L S Y L I G S K K
TATTGATGTATACATCATGTAATAAAATACAAGCTTGTATTTTCTTATTTAAAAATGTTCCCAGTTCTCTTCGCGTATCACGGGGTACTCGCGGGGCACT 2 4 2 0 0  
-  Q H I C - T I F Y L S T N E - K F I N G T R K A Y - P T S A P C E  
U L21A  I S T Y M M Y Y F V L K Y K R I -
N I Y V D H L L I C A Q I K K N L F T G L E R R T D R P V R P A S
CGGAAAGGAGCGAAGCCGGGCGGCATGGGCGGAACGTCGTCCAACAGCAGCACCAGCGGGTTGGGCAGCGGGCGGTCGGGCGGTATATCGGCGGCGACCT 24 30 0  
S L L S A P R C P R F T T W C C C W R T P C R A T P R Y I P P S R
R F P A F §  F P M P F V D g  L L L V L P N P E j? R D P P X D A A V Q 
P F S  R L R A A H A S R R G V A A G A P Q A A P P R A T Y R R R G
GGATCTCCCTCGGCAGGTCCATCGGTATCGCTTCCTCGTCCCCTCCGGGCACAGCGACGATCCGATGAATCGGCGGCGGGACCTGAAGGTGCTGGTGATG 24 4 00  
S R G R C T W R Y R K R T G E P C L S S G I F R R R S R F T S T I
I E R P  L D M P I A E E D G G F V A V I R H 1 P P P V Q L H Q H H 
P D G E A P G D T D S G R G R R A C R R D S S D A A P G S P A P S A
CTGATGGTAGTTCTCAAAAAGCCGGCGCCGGGCCCGCGGAGCATAGAAAGCCAGACGGCGCAGGGGCCGGCGGGCTCGGAACAGGTCCGCGCGGACCACG 24 500  
S I T T R L F G A G P G R L M S L W V A C P G A P E S C T R A S W P
S P L E - F A P A P G A S C L F G S P A P A P P S P V P G R P G R
GGCCTCACACCCTCGGTGGCCACCGAGAGATCGGGGTCGGGACTGCCTCCCATATTGCGCACTCATGATGATTCCAGGCACGGTACATTACTAAATACCG 24 600  
G - V R P P W R S I P T P V A E W I A C E H H N W A R Y M V L Y R
N R V - S S E L C P V N S F V T
A E C G R H G G L S R P R S Q R G Y Q A S M I I G P V T C - - I G
I I
Figure 7.5: Comparison of the region containing AD169 UL21 with the cognate 
CCMV sequence.
Panels I and II shows three-frame translations of the relevant regions of the AD169 and CCMV 
sequences, respectively, with nucleotide coordinates on the right. UL21A is oriented right to left. The 
locations of RACE primers are indicated by arrows in panel I. AD169 UL21 is shown in red in panel I and 
CCMV UL21A is shown in red in panel II. An ORF in AD169 that appear to be conserved in CCMV 
UL21A are shown in bold blue font in panel I, with conserved amino acid residues underlined. The 
vertical arrow indicates the position of the 5’-end of the UL21A mRNA as represented in the majority of 
5’-cDNA clones. The first ATG codon in UL21 (as described by Chee et al., 1990) and the first ATG 
codon in UL21A are shown in red and blue boxes, respectively. The putative TATA element and 
polyadenylation signals are underlined in red and green, respectively.
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bp downstream from a potential TATA element. The smaller product represents a 5’-end at 
30065, 7 bp downstream from the first ATG codon in the UL25. This 5’-end has no 
potential TATA element upstream.
Primer UL27 yielded a major band of 1 kbp (Fig. 7.2w) from L RNA. The corresponding 
5’-end is located 650 bp upstream from the first ATG in the ORF, with the intervening 
sequence containing nine ATG codons in different frames. A potential TATA box is not 
present immediately upstream from this 5’-end. The less intense band of 550 bp detected in 
this experiment (Fig. 7.2w) was cellular in origin.
A major band of 250 bp was produced in L RNA using primer UL30 (Fig. 7.2x), mapping 
the 5’-end of UL30 to 37525. This end is located upstream from the first ATG codon in 
UL30 but is not preceded by a potential TATA element.
7.2 Discussion
The aim of this chapter was to map the 5’-ends of UL1-UL30, excluding six genes 
(UL22A, UL23, UL24, UL26, UL28 and UL29) whose transcription is described in 
chapters 4 and 5. The ORFs within the region of Ul immediately adjacent to TRl belong to 
the RL11 family (Chee et al., 1990). This family consists of 12 ORFs, three in TRl and 
nine (UL1, UL4, UL5, UL6, UL7, UL8, UL9, UL10 and UL11) in UL that are predicted to 
encode glycoproteins.
Of the 25 ORFs analysed, potential 5’-ends were obtained for 22, including six members of 
the RL11 family (UL4, UL6, UL7, UL8, UL10 and UL11). Most of these 5’-ends have a 
potential TATA element within 20-35 bp and are positioned such that the first ATG in the 
ORF is also the first in the mRNA. Kinetic classes indicated by RACE correspond well to 
those obtained by Chambers et al. (1999) using gene microarray technology. However, 
RACE-PCR is not a quantitative method, and expression kinetics should be confirmed by 
northern blotting. Transcription from certain genes (e.g. UL4, UL16, UL25) showed perfect 
concordance with results obtained earlier by Rawlinson and Barrell (1993), Alderete et al. 
(2001), Kaye et a l (1992a) and Battista et a l (1999) by northern blotting.
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5’-ends mapped for certain genes (UL4, UL7, UL10, UL20 and UL27) are located far 
upstream from the first ATG codon in each ORF, with intervening sequences containing 
several ATG codons in other reading frames. This is generally considered to be inconsistent 
with efficient translation. However, all these ORFs are conserved in CCMV, and are 
presumably expressed. One example is UL20, which has three 5’-ends located 45-319 bp 
upstream from the first ATG codon with the furthest upstream being the most abundant. 
Consequently, presence of low level expression of shorter transcripts with more 
appropriately located 5’-ends cannot be ruled out. UL4 has been shown previously to use a 
distal promoter to encode a structural glycoprotein. The manner in which translation of this 
mRNA is controlled is unusual. A 22-codon ORF (uORF2) in the 5’-leader sequence of the 
UL4 mRNA is conserved in HCMV strains, and the peptide product represses translation of 
UL4. The nascent uORF2 peptide remains covalently attached to the tRNA that decodes the 
final uORF2 codon (Cao and Geballe, 1996), and prevents the peptidyl-tRNA hydrolysis 
reaction during translational termination, resulting in ribosomal stalling and inhibition of 
downstream translation (Cao and Geballe, 1995; Alderete et al, 1999). It is notable 
however, that uORF2 is not conserved in CCMV. Nevertheless, a potential exists for 
similarly complex regulation of the expression of other HCMV genes.
Transcripts of certain genes among those analysed (UL4, UL6, UL8, UL11, UL17 and 
UL20) appear to be initiated from multiple sites, the majority located downstream from a 
potential TATA boxes. One small ORF (73 codon) is not conserved in CCMV. As a 
consequence, it may represent mRNA that does not encode protein. Chambers et al. (1999) 
failed to detect UL12 transcript using gene microarray technology. Further studies are 
required to elucidate transcription of this ORF and to determine whether it encodes a 
functional protein unique to HCMV.
A single 5’-end was mapped for one gene (UL18) in this region that is located downstream 
from the first ATG codon in the ORF and does not have a potential TATA box. The first 
ATG codon in UL18 as described by Chee et al. (1990) is, however, preceded by a TATA 
box. Since abundance RACE products were not analysed in this study, it is possible that a 
major downstream 5’-end for UL18 mRNA has been mapped and a minor upstream 5’-end 
has been missed.
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The 5’-RACE technique revealed the existence of five sets of 3’-coterminal genes in the 
region analysed: UL2-UL3, UL6-UL8, UL10-UL11, UL16-UL17 and UL18-UL19. 
However, it is necessary to map the 3’-ends of these co-terminal families to confirm these 
findings. Another set of 3’-coterminal genes: UL26-UL30, was detected by northern 
blotting and is described in chapter 5. Sets of 3’-coterminal transcripts, with a different 
promoter for each gene, are well documented in HCMV (Stenberg et al, 1989; Welch et 
al, 1991; Adam et al, 1995; Wing and Huang, 1995). Rawlinson and Barrell (1993) 
reported another set of 3’-coterminal genes (UL4-UL5) but this was not confirmed in this 
study owing to poor expression of UL5.
Except for UL22A and UL36 (see section 4), no evidence of splicing was found in the 
region analysed. UL28 is predicted to be spliced, but this was not confirmed using RACE 
and RT-PCR (see chapter 5). In this study, RACE also failed to confirm predicted splicing 
in UL8 or in the UL4 and UL5 region as predicted by Rawlinson and Barrell (1993).
This study confirmed the existence of novel gene (UL21A) predicted by Davison et al 
(unpublished data). This replaced an existing ORF (UL21) as originally described in the 
AD 169 sequence. The transcriptional expression pattern of another novel gene (UL15A; 
Davison et a l, unpublished data) remains to be determined.
This study mapped the 5’-ends of 20 genes (Table 7.1) in the left region of Ul- The 
majority possess potential TATA box 25-35 bp upstream. The 5’-ends of three genes (UL1, 
UL5 and UL9) were not determined, suggesting that they are probably expressed at low 
levels in fibroblasts. Further studies using different techniques (e.g. northern blotting) are 
therefore needed to elucidate transcription of these ORFs.
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On the basis of the conservation of protein coding regions and other sequence features, 
Davison et al. (unpublished data) proposed five novel genes (UL15A, UL21A, UL128, 
UL131A and US34A) in AD 169, two of which (UL128, UL131A) are predicted to be 
spliced. In this section, these two novel spliced genes were characterised by northern 
blotting, RACE and RT-PCR. The GSPs used in Lig’nScribe PCR are listed in Table 2.1. 
Primers used in RT-PCR and in RACE are listed in Tables 2.2 and 8.1, respectively.
8.1 UL128
8.1.1 Characterisation of spliced transcripts from UL128
ORF UL128, as originally described by Chee et al. (1990) (shown in red in Fig. 8.1 panel I) 
is partially conserved in CCMV at its 3’-end (Fig. 8.1 (panel II)). A HCMV ORF 
overlapping the 5’-end of UL128, and another overlapping UL129 (bold black font with 
conserved residues underlined in Fig. 8.1 (panel I)) are conserved in CCMV. Splice donor 
and acceptor sites are conserved in the appropriate register in CCMV and HCMV. UL128 
is thus predicted to be spliced, with exon 3 containing part of ORF UL128 as originally 
defined. Exon 1 appears to be naturally frameshifted in CCMV.
RT-PCR from this region of the AD 169 genome using the primers shown by black arrows 
in Fig. 8.1 (panel I) generated multiple bands (Fig. 8.2) from E and L RNA. Three bands 
(0.55, 0.45 and 0.3 kbp) were analysed. The 0.55 kbp band corresponds to the unspliced 
DNA sequence and could have originated either from unspliced RNA or from 
contaminating DNA. The 0.45 kbp band represents partially spliced RNA that contains the 
second intron. The 0.3 kbp band represents the fully spliced form. This result confirms the 
prediction made by Davison et al. (unpublished data). The sequences of the RT-PCR 
products with the relevant electropherograms are shown in Fig. 8.3 (panels I, II and III). 
The novel UL128 gene is thus a 5’-extended, spliced form of the original UL128 ORF 
described by Chee et al. (1990), and hence is also named UL128. The coding region is 
shown in red in Fig. 8.3 (panel I).
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ORF Primer Sequence (5’-3’) Position0 PCR product(s)d
UL128 UL128R3 TTGTAGTTGCAGCTCGTCAGTTTG 1 7 5 2 0 4 -1 7 5 2 2 7 300 , 450
UL128 U L1 28 -S 2 b GCTGCTATTGGGTCACAGCCGCGT 1 7 5 5 8 1 -1 7 5 5 5 8 500 , 650
UL131A UL131Ra AACGGGTTTGGTCGGGCAGCGCGC 1 7 6 6 7 7 -1 7 6 7 0 0 No p ro d u c t
UL131A U L 1 3 1 -1 3 CGTTGTCATGCACCTTTAGCGCGT 1 7 6 5 5 7 -1 7 6 5 8 0 400 , 500
UL131A U L1 31 -S 2 b CATGCGGCTGTGTCGGGTGTGGCT 1 7 6 8 2 6 -1 7 6 8 0 3 2000 bp
Table 8.1: Primers used in RACE to map 5’- and 3’-ends of transcript from 
UL128 and UL131A.
“Primer used in 5’-RACE. 
bPrimer used in 3’-RACE.
cPosition of the primers in the positive strand of the AD169 genome. 
dApproximate sizes (bp) of RACE products excised for cloning (See Fig. 8.4 and 8.10).
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CATGAATTTAGTCGGCGACAGAAATCTCAAAACGCGTATTTCGGACAAACACACATTTTATTATTCACTGCAGCATATAGCCCATTTTAGCGCGGCACAC 17 4 900  
U L 128  H I  -  D A V S I E F R T N R V F V C K I  I -
C S N L R R C F D  -  F A Y K P C V C M K N N V A A V  L G N  -  R P V C  
M F K T  P S L F R L V R  I E S L C V N  -  -  E S C C  I A W K L A A C
ATCCAGCCGTTTGTGTTTTTTAACGCTCTCCAGGTACTGATCCAGGCCCACGATCCGGGTTATCTTGTCGTATTCCAGGTTGATCCATCGATAGGGAACG 1 7 5 0 0 0
G A T Q T K - R E G P V S G P G R D P N D Q R I G P Q D M S L S R
M W G N T N K L A R W T S I W A W S G P - R T T N W T S G D I P F A
CTGCCAGCGGCGCCCAGCAGGTACTGCGCCTTGTCGTTCACTTTGCCGCAGCGTATTCGCCCGTCAGCTTCGAGGTATAACc t a c a a c a c g g a q q q q a a q  1 7 5 1 0 0
Q W R R G A P V A G Q R E S Q R L T N A R - S R P I V - L V S P F  
A L P A W C T S R R T T - K A A A Y E G T L K S T Y  G V V R L  P L
ggggggtacaaaacgtgaaattagactttttttttaatgatgttttgtccctctgtcttactttcccataggctgtaaggccctcgaggaagagacttac 1 7 5 2 0 0
P P Y L V H F - V K K K I I N Q G E T K S E W L S Y P G R P L S K R
P P V F R S I L S K K - H H K T G R D - K G M P Q L A R S S S V -
GGATTGTAGTTGCAGCTCGTCAGTTTGTTGTGTACGACCTGGCGTGTCAATGAATGGGTCATGGTGGTGACGATCCCGCGAATCTCAGCCGTTTTCTCGG 17 5 3 0 0
Q L 0  1. E D T 0  Q T F< G p T !• I F P P H H II R P R G ! -  G N E R
I T T A A R - N T T Y S R A H - H I P - P P S S G A F R L R K R P  
P N Y N C S T L K N H V V Q R T L S H T M T T V I G R I E A T K E P
GACTGTAGCAGACTTCGCCGTCCGGACACCGCAGCctgtggattcatgaaaatctactctggcattcccgaggatcgtcgatggaacatggctatcagaa 17 5 4  00  
U L 129S  Q L L S R R G S V A A Q P N M F I  -
V T A S K A T R V G C G T S E H F D V R A N G L I T S P V H S D S
S Y C V E G D P C R L R H I - S F R S Q C E R P D D I S C P - - F
acgtcgagagacaaatccagacgcaccacagaacgcagacaatcataaaaatacgtacGCGACGGTGAAGCGATTGCACATTTTGAAATCGTAACAGCGT 1 7 5 5 0 0
V D L S L D L R V V S R L C D Y F Y T R S P S A I A C K S I T V A N  
R R S V  F G S A G C  F A S  L -  L F V Y  A V T F R N C M K F D Y C R
TCCGGCGGGTGGTTGACGTTTATGAATTCGCAACATTCTTCTGCGCGCACCCGCGGCACGCGGCTGTGACCCAATAGCAGCCACAACGTCGTCAAGAACG 175  60 0
R R T T S T - S N A V N K Q A C G R C A A T V W Y C G C R R - S R
E P P H N V N I F E C C E E A R V R P V R S H G L L L W L T T L F P
GCGjjjpAGGTCTTTGGGACrCATGACGOICGGTTTTCAAAATTCCCTGCGCGCGCGACGGGCTCAAACGATGAGATTGGGATGGGTACAGAAGGTGTAAGT 17 57 00
R - T K P V - S A R N E F N G A R A V P E F S S I  P I  P V S P T L  
T L D K P S M V R P K - F E R R A R R A - V I L N P H T C F T Y T
CTGGTTATTGGCCTCGGTGAACGTCAATCGCACCTGAAAAGACACGCTGTAGTCCCGGAAGACGTGGGCCCAGCTCTCCAGCTTCATCACACACATCTGA 1 7 5 8 0 0  
- Q G R H V D I A G S F V R Q L G P L R P G L E G A E D C V D S  
R T I P R P S R - D C R F L C A T T G S S T P G A R W S - - V C R I  
Q N N A E T F T L R V Q F S V S Y D R F V H A W S E L K M V C M Q
I
Figure 8.1: Comparison of the region containing AD169 UL128 with the 
cognate CCMV sequence.
Panel I shows the three-frame translation of the relevant region of the AD169 sequence, with 
nucleotide coordinates on the right. AD169 UL128 and UL129 as defined by Chee et al. (1990) are 
shown in red, oriented right to left. The predicted introns are shown in lower case. Regions in AD169 
that appear to be conserved in CCMV UL128 are shown in bold black font, with conserved amino 
acid residues underlined. The primers used in RT-PCR and their orientations are indicated by 
arrows. Panel II shows the three-frame translation of the cognate CCMV sequences with nucleotide 
coordinates on the right. The CCMV UL128 protein-coding region is shown in red with conserved 
amino acid residues underlined. The region containing a putative natural frameshift in CCMV UL128 
is highlighted in yellow.
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TTGGTTTTCTATTGCAGCATGTAGCCCAGCTCTGCGTTGCACACGTCCAGTCTCCGGCGGGCCATCACGCTCTTCAGGTAGCTGTTCAGGTCGGTGATCC 17 7  9 0 0  
P K R N C C T A W S Q T A C T W D G A P W - A R - T A T - T P S G  
N T K -  p  L M
Q N E  I A A H  L G A R R Q V R G T E P P G D R E E  P L Q E  P R H D
GCCCGGGTTTCTCGTATTCCAGGCTGATCCAGCGGTACGGTACGCTGCCCGTGGCGCCCAAGATGTACTGGGGCTGTTCTTCCTTGACCTTAGCGCAGCG 1 7 8 0 0 0  
G P N R T N W A S G A T R Y A A R P A W S T S P S N K R S R L A A
G P K E Y E L S I W R Y P V 3 G T A G L  I Y Q P Q E E K V K A C R  
A R T E R I G P Q D L P V T R Q G H R G L H V P A T R G Q G - R L A
C A G C T T A C C G T C T G A T T C C A A G T A C A G C ctgcggg tacaaaaaaaggaca tgcatatccataactttctctgtcccgcgccccgtaaactgttaagttat 1 7 8 1 0 0  
C S V T Q N W T C G A P V F F P C A Y G Y S E R D R A G Y V T L N D
R T C F F S M C I W L K R Q G A G R L S N L -
A - R R I G L V A Q P Y L F L V H M D M V K E T G R G T F Q - T I
cctccttcccgaaagcgaggcacttacGGGTTGTGGTTGCACGCCGTCAGCTTATCGTGTACCACCTGCCGGGTCAGAGAGCGGGCCATGCCCATGATGA 1 7 8 2 0 0  
E K G F A L C K R T T T A R R - S I T Y W R G P - L A P W A W S S  
G G E R F R P V -  
R R G S L S A S V P Q P Q V G D A - R T G G A P D S L P G H G H H
TACCGCGGATCTCCGCCGTCTTTTGGGGGGTGTAGCACACCTCGCCCTCAGGGCATCGTAGCctggaga tatcatcacagcgatttgtgtatgtgttcca 17 8 3 0 0  
V A S R R R R K P P T A C R A R L A D Y G P S I M V A I Q T H T G
S I  D D C R N T Y T N W  
Y R P D G G D K P P H L V G R G - P M T A Q L Y - - L S K H I H E M
tcaggatagagaagacgcagacgaggatc c g cac a ta caag c accg c ag g acg a acac g cag a tacc taC G A G A C G G T G T A A G G G G T G C A C A T C T T G A A G  17 84 00  
D P Y L L R L R P D A C V L V A P R V R L Y R R S P T L P A C R S T  
-  S L S S A S S S G C M C A G C S S C A S V -  
L I S F V C V L I R V Y L C R L V F V C I G V L R H L P H V D Q L
TTGTAGCAjGTTCCCGGGGGGGGTAGGCGAT|GTTCACCATCTCGCAGCATGATTCCGCGCGCGCGAACGAGCGGGACGGGTTCGGCCACATCATATACAGC 1 7 8 5 0 0  
T A T G P P P L R H E G D R L M I G R A R V L P V P E A V D Y V A  
G P P T P S T - W R A A H N R A R S R A P R T R G C - I C C
Q L L E
AACGTCAAGGACAGCAGCGGGCCCGGAGACATGACGACGACGGCGGTTTCCAAAAATCCCCGTGCGCGCGCGGCGGGCTCAGACGAGGAGATTGGGGTGC 17 8  60 0  
V D L V A A P G S V H R R R R N G F I G T R A R R A - V L L N P H  
R - P C C R A R L C S S S P P K W F D G H A R P P S L R P S Q P A
' V V V A T E L F G R A R A A P E S S S  I  P T R
I I
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Figure 8.2: Gel electrophoresis of RT-PCR products from HCMV UL128.
EtBr-stained 1% (w/v) agarose gel showing RT-PCR products (sizes in kbp) amplified from 
HCMV IE, E and L RNA using primers UL128-S1 and UL128-S3. M1 and M2 are 100 bp and 1 
kbp ladders, respectively.
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CATGAATTTAGTCGGCGACAGAAATCTCAAAACGCGTATTTCGGACAAACACACATTTTATTATTCACTGCAGCATATAGCCCATTTTAGCGCGGCACAC i  7 4 9 0 0  
1 2 8  _ S L M X 9 m k A R C V
ATCCAGCCGTTTGTGTTTTTTAACGCTCTCCAGGTACTGATCCAGGCCCACGATCCGGGTTATCTTGTCGTATTCCAGGTTGATCCATCGATAGGGAA^'' 1 7 5 0 0 0  
D L R K H K K V S E L Y Q D L G V I R T I K D Y E L N I W R  |Y P V
CTGCCAGCGGCGCCCAGCAGGTACTGCGCCTTGTCGTTCACTTTGCCGCAGeGTATTCGCCCGTCAGCTTCGAGGTATAACctacaacacggaggggaag 1 7 5 1 0 0  
| s g a a g l l y q a |  k d n v k g c r i r g d a e l y l
ggggggtacaaaacgtgaaattagactttttttttaatgatgttttgtccctctgtcttactttcccataggctgtaaggccctcgaggaagagacttac 1 7 5 2 0 0
GGATTGTAGTTGCAGCTCGTCAGTTTGTTGTGTACGACCTGGCGTGTCAATGAATGGGTCATGGTGGTGACGATCCCGCGAATCTCAGCCGTTTTCTCGG 1 7 5 3 0 0  
P N Y N C S T L K N H V V Q R T L S H T M T T V I G R I E A T K E P
G A C T G T A G C A G A C T T C G C C G T C C G G A C A C C G C A G C c tg tg g a t tc a tg a a a a tc ta c tc tg g c a t tc c c g a g g a tc g tc g a tg g a a c a tg g c ta tc a g a a  17 54 00  
S Y C V E G D P C R L
a c g t c g a g a g a c a a a tccagacgcaccacagaacgcagacaatcataaaaatacgtacGCGACGGTGAAGCGATTGCACATTTTGAAATCGTAACAGCGT 17 5 5 0 0
A V T F R N C M K F D Y C R
TCCGGCGGGTGGTTGACGTTTATGAATTCGCAACATTCTTCTGCGCGCACCCGCGGCACGCGGCTGTGACCCAATAGCAGCCACAACGTCGTCAAGAACG 1 7 5 6 0 0  
E P P H N V N I F E C C E E A R V R P V R S H G L L L i W L T T L F P
T
GCGTCAGGTCTTTGGGACTCATGACGCGCGGTTTTCAAAATTCCCTGCGCGCGCGACGGGCTCAAACGATGAGATTGGGATGGGTACAGAAGGTGTAAGT 1 7 5 7  00 
T L D K P S M
CTGGTTATTGGCCTCGGTGAACGTCAATCGCACCTGAAAAGACACGCTGTAGTCCCGGAAGACGTGGGCCCAGCTCTCCAGCTTCATCACACACATCTGA 17 5 8 0 0
I
Q C A  Q C G C G A C G G t G A A G C G A T T G C A C A T  T A A T C C C G C G G C C A T G G C G G C C  g g g a  g c a  t  g c  g a c  g t  c  g g g c  c c a a t  t c g
I I
G G  A T I G T  A G T  T g c  A g c  T C  g t  C A  G T  T T GT T G T  GT A C  G A  C  C  T G  G C  G T  G T  C A  A T G AG C C C G T C A G C T  T C  G A  G  GT  A T A A C
I I I
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GATCTCTCATACACAGAAGCGCCGCGACGAGTTTTTTATTATTATATCTTTATTCACAGCGACAAGACACGGCAACAGTGTTAATGGTAGCGGTCGGTTA 1 7 7 8 0 0
TTGGTTTTCTATTGCAGCATGTAGCCCAGCTCTGCGTTGCACACGTCCAGTCTCCGGCGGGCCATCACGCTCTTCAGGTAGCTGTTCAGGTCGGTGATCC 17 7 9 00
-  Q L M Y G L E A N C V D L R R R A M V ' S K L Y S N L D T I R
GCCCGGGTTTCTCGTATTCCAGGCTGATCCAGCGGTACGGTACGCTGCCCGTGGCGCCCAAGATGTACTGGGGCTGTTCTTCCTTGACCTTAGCGCAGCG 1 7 8 0 0 0
G P K E  Y E L S I ^ W R Y P V S G  T A G L I Y Q P Q E E K V K A C R
C A G C T T A C C G T C T G A T T C C A A G T A C A G C c tg c g g g ta c a a a a a a a g g a c a tg c a ta tc c ataactttctctgtcccgcgccccgtaaactgttaagttat 1 7 8 1 0 0
L K G D S E L Y L
cctccttcccgaaagcgaggcacttacGGGTTGTGGTTGCACGCCGTCAGCTTATCGTGTACCACCTGCCGGGTCAGAGAGCGGGCCATGCCCATGATGA 1 7 8 2 0 0
P N H N C A T L K D H V V  Q R T L S R A M  G M I I
TACCGCGGATCTCCGCCGTCTTTTGGGGGGTGTAGCACACCTCGCCCTCAGGGCATCGTAGCctggaga t a  t e a  t c a c a g c g a  t t t g t g t a  tgtgttcca 1 7 8 3 0 0
5 B I E A T K Q P T Y C V E G E P C R L
tc a g g a ta g a g a a g a c g c a g a c g a g g a tc c g c a c a ta c a a g c a c c g c a g g a c g a a c a c g c a g a ta c c ta c G A G A C G G T G T A A G G G G T G C A C A T C T T G A A G  1 7 8 4  00
S V T Y  P T C M K F
TTGTAGCA|GTTCCCGGGGGGGGTAGGCGAT|GTTCACCATCTCGCAGCATGATTCCGCGCGCGCGAACGAGCGGGACGGGTTCGGCCACATCATATACAGC 1 7 8 5 0 0
N Y C N
R P P Y A I  N V M E C C S E A R A F 3 R S  P N  P W M M Y L  
AACGTCAAGGACAGCAGCGGGCCCGGAGACATGACGACGACGGCGGTTTCCAAAAATCCCCGTGCGCGCGCGGCGGGCTCAGACGAGGAGATTGGGGTGC 1 7 8 6 0 0
I V
Figure 8.3: Interpretation of splicing in HCMV UL128 by RT-PCR.
Panel I shows the sequence of AD169 UL128, with nucleotide coordinates on the right. ORF UL128 is 
shown in red with conserved residues underlined. The gene is oriented right to left. Introns are shown in 
lower case. The red and green vertical arrows accordingly indicate the position of the 5’- and 3’-ends of 
UL128 mRNA as represented by the majority of 5’- or 3’-cDNA clones. A potential TATA box and 
polyadenylation signal are underlined in red and green respectively. Panel IV shows the corresponding 
CCMV sequence, with coordinates on the right and introns in lower case. The region containing a 
possible natural frameshift in CCMV UL128 is highlighted in yellow. Panels II and III show 
electropherograms of the RT-PCR product (upper strand of AD169 genome), with the splice sites 
indicated by blue arrows.
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8.1.2 Mapping the 5’- and 3’-ends of the UL128 mRNA
Primer UL128R, which maps in exon 2, yielded two major bands (450 and 300 bp) from E 
and L RNA in 5’-RACE (Fig.- 8.4a). The 450 bp band corresponds to the sequence lacking 
the first intron, and mapped a 5’-end of UL128 to 175681. A potential TATA element is 
present 24 bp upstream from this 5’-end. The 300 bp band that originated from L RNA was 
cellular in origin.
Primer UL128-S2, which maps in exon 1, yielded two major products (500 and 650 bp) 
from E and L RNA in 3’-RACE (Fig. 8.4b). Each band corresponds to a polyadenylation 
site at 174842, 15 bp downstream from a putative polyadenylation signal (AATAAA). The 
3’-RACE cDNA sequence obtained from the smaller product (500 bp) lacked both introns, 
but the 650 bp band corresponded to the sequence containing second intron and lacking the 
first intron.
8.1.3 Northern blot analysis of the UL128 mRNA
Northern blotting with a UL128 probe identified multiple bands from E and L RNA (Fig. 
8.5). The RACE experiments indicated that the 5’-end of the UL128 transcript is at 175681 
and the 3’-end is at 174842 (880 nucleotide unspliced transcript), and RT-PCR indicated 
that size of the first and second introns are 123 and 119 bp, respectively (638 nucleotide 
fully spliced transcript). Therefore the 0.8 and 0.6 kb bands in L RNA probably correspond 
to the unspliced or partially spliced and fully spliced UL128 transcripts, respectively. The 
bands of 1.2, 2.0 and 3.0 kb in Fig. 8.5 probably correspond to 3’-coterminal UL130, 
UL131A and UL132 transcripts, respectively, spliced in the UL128 region (see section 8.2). 
The origins of the 4.0, 6.5 and 7.5 kb bands are unknown.
I
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M2 Ml IE E L Ml IE E L M1
1.5 -► 
1 . 0 + -
a: 5’-RACE product
0.65-
0.50
s
• 1.0
0.5
0.1
b: 3’-RACE product
Figure 8.4: 5*- and 3'-RACE of HCMV UL128 mRNA.
EtBr-stained 1% (w/v) agarose gels showing RACE products of HCMV UL128 that 
were amplified from 5' or 3’-cDNA with GSPs (listed in Table 8.1) and UPM. Sizes are 
in kbp. (a) 5-RACE products with primer UL128R. (b) 3-RACE products with primer 
UL128-S2. 5' or 3’-cDNA was prepared from different kinetic classes (IE, E and L) of 
AD169 mRNAs and from Ml RNA. M1 and M2 are 100 bp and 1 kbp ladders, 
respectively.
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Figure 8.5: Northern blot analysis of HCMV UL128 mRNA.
Northern blot showing the expression profile of transcripts from HCMV UL128. Ml, IE, E and L 
RNA were hybridised with a single-stranded RNA probe (top) or a GAPDH2 probe (bottom). 
Transcript sizes are given in kb.
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8.2 UL131A
8.2.1 Characterisation of spliced transcripts from UL131A
The novel gene UL131A is naturally frameshifted in AD 169 (see section 3.1.5). Amino 
acid sequence comparisons indicated the presence of a spliced gene in CCMV 
corresponding to HCMV UL131A (see Fig. 3.11; section 3.1.5), with the predicted splice 
donor and acceptor sites in the same register in both genomes. Therefore, HCMV UL131A 
is predicted to be spliced.
RT-PCR amplification of the relevant region in AD 169 revealed two bands (Fig. 8.6) from 
L RNA. The 0.4 kbp band corresponded to the unspliced sequence and could have 
originated either from unspliced mRNA or from contaminating DNA. The 0.3 kbp band 
corresponded to the spliced mRNA. The splicing patterns in AD 169 UL131A in 
comparison with CCMV UL131A are shown in Fig. 8.7 (panels I and III).
8.2.2 Mapping the 5’- and 3’-ends of the UL131A mRNA
Two primers (Table 8.1) were used in 5’-RACE to determine the 5’-end of AD 169 
UL131A. Primer UL131R yielded no product (data not shown). Primer UL131-2 yielded a 
band of 500 bp (Fig. 8.8a) from L RNA and a band of 400 bp from MI, IE and E RNA. 
Both were cellular in origin. The 5’-end of UL131A was therefore not detected.
Primer UL131-S2, which maps in the first exon, yielded a single band of 2 kbp (Fig. 8.8b) 
from L RNA in 3’-RACE which corresponds to a 3’-end at 174842, identical to that 
determined for UL128 using primer UL128-S2 (see section 8.1.2). Therefore, the 
polyadenylation signal (AATAAA) at 174857-174862 is shared by UL131A and UL128. 
Northern blotting with a UL128 probe also suggested that UL128, UL130, UL131A and 
UL132 are 3’-coterminal genes (see section 8.1.3).
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Figure 8.6: Gel electrophoresis of RT-PCR products from HCMV UL131A.
EtBr-stained 1% (w/v) agarose gel showing RT-PCR products (sizes in kbp) amplified from 
HCMV IE, E and L RNA using primers UL131-S3 and UL131-S2. M1 and M2 are 100 bp and 1 
kbp ladders, respectively.
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CAGCATATTATTTCCCGTGACGCAGGCTAGTTGGCAAAGAGCCGCACGCTGAACTCGAGGCTCCGGGCGTGTGGCGCCAGCGAACCGGCGGCGTTGAACG 17 64 00
“ N A F L R V S F E L S R A H P A L S G A A N F T
TGGTCCTTTTGTTGGTGCCGCCGCGACGGTTCTGACGTCTAAAGTCGCTGATGAGCAACGACACCTCGGTCACGTTGATTctgcaagcacaggt tccaaa 17 6 5 0 0  
T R K N T G G R R N Q R R F D S I L L S V E T V N I
cgtcattteataccccatgcggttacttagccgttacccgttcgcccttaccttcccgttgtcatgcacctttagcgcgtacccteacCTCTTGAGCACG 17 6 6 0 0
R K L V
TCAAAGTTGTCCAAGCCGTGGCTCGCATCGTAGTGGTAGTTCAACGTGAGGTCCACGAGCTGTTCCACATACTTGTAACGGGTTTGGTCGGGCAGCGCGC 17 6 7 0 0  
D F N D L G H S A D Y H Y N L T L D V L Q E V Y K Y R T Q D P L A R
GAGAGCACGCGTCCCAGTAATGCGGTACTCGGTAATAATCG|TTTTTTT|CCGCGGTTTCCCGCTGGCACTGACCCAGCACCACGGCGCACAGACAAACAGA 17 68 0 0  
S C A D W Y H P v R Y Y D N K E A T E R Q C g  | G L V V A C L C V S
GAGCCACACCCGACACAGCCGCATGTTGCAGACTGAGAAAGAAAGCTTTATTATGAGACATCATACACATAGTATAGGCGAGGTGATGGGGCGGGGAAAG 17 69 0 0  
|L W V|  R C L R M
I
G A C C T  C A C G T  T G A A C T A C C A C T  A C G A T  G C  GA G C C A C G G C T T  G G A C A  A C T  T T G A C G T  GC T C A A G A G A A  TC A A C G T G A C C G
I I
GGTGCATGACCTCCGCCGCGGTTTTACTGGGGAAAGAGCCGCACGCTGAATTCCAGCATGCGGTAGTGCGGTCCCAGAAAGCCGGAGGCGCTGAACGTGG 17 9 4 0 0  
- Q P F L R V S F E L M R Y H P G L F G S A S F T T
TTCTCTTGTTGGTCCCGCCGCGGGCCTTCTGGCGCCTGAACTCGCCGGCCAGCAGCGTTACCTCCGTTACGTTGATCctgcgaacaaaccccgattggtt 1 7 9 5 0 0  
R K N T G G R A K Q R R F E G A L L T V E T V N I R
cgcgcgcacgtcgttcgggtgccctcttttc g tc c tc c c c t t tc c c g a a a c c g ta c g c g tc g c tc g g c tc a c C T C T T G A G C G T C T T A A A G T T A T C C A A A C  17 96 0 0
K L T K F N D L G
CGTGGCTCACGTCGTAGTGGTACTCCACCAACGTGTCCACCAGCCGCTTGACGTACTCCTGACGGGTACGCTCCGGCAGCGCCGGGGAACACGTGTCCCA 17 97 0 0  
H § V D Y H Y E V L T D V L R K V Y E Q R T R E P L A P S C T D W
GTAGTCCCACGGGCGCGCAAAGTCGTCCCGCTCGGCTTCCTCCCTGCGACACTGGCCCCACACCGCGACGCTCAGACACAAAACAGACAGAAACACACGG 17 98 0 0  
Y D W P R A F D D R E A E E R R C Q  | G W V A V S L C L V S L F y R |
TACAACCACATGTTGCACACTGAAGGTCAACTTTATTGTTACACAGGGAAGAATATGGACGTGGGTGGTGGTGGTTTCACGGGACTCGGACAGGTGACCG 17 9 9 0 0  
Y L W M
I I I
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Figure 8.7: Interpretation of splicing in HCMV UL131A by RT-PCR.
Panel I shows a version of the sequence of AD169 UL131A with the natural frameshift corrected by 
removal of a T  residue from the region highlighted in yellow, with nucleotide coordinates on the right. 
The gene is oriented right to left. The amino acid sequence of UL131A is shown in red with conserved 
residues underlined and the hydrophobic domain boxed. The intron is shown in lower case. Panel III 
shows the corresponding CCMV sequence, with coordinates on the right and the intron in lower case. 
Panel II shows an electropherogram of the sequence of the relevant region of AD169 with the splice 
sites indicated by a vertical arrow.
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Figure 8.8: 5'- and 3'-RACE of HCMV UL131A mRNA.
EtBr-stained 1% (w/v) agarose gels showing RACE products of HCMV UL131A that 
were amplified from 5' or 3’-cDNA with GSPs (listed in Table 8.1) and UPM. Sizes are 
in kbp. (a) 5'-RACE products with primer UL131-1. (b) 3'-RACE products with primer 
UL131-S2. 5' or 3’-cDNA was prepared from different kinetic classes (IE, E and L) of 
AD169 mRNAs and from Ml RNA. M2 is a 1 kbp ladder.
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Figure 8.9: Northern blot analysis of HCMV UL131A mRNA.
Northern blot showing the expression profile of transcripts from the HCMV UL131A. Ml, IE, E 
and L RNA were hybridised with a single-stranded specific RNA probe (top) or a GAPDH2 probe 
(bottom). Transcript sizes are given in kb.
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8.2.3 Northern blot analysis of UL131A transcript
A major band of 2.0 kb was detected on probing a northern blot with a UL131A probe (Fig. 
8.9). Consistent with this, the 3’-RACE product and the RT-PCR product of ORF UL131A 
were generated from L RNA (see section 8.2.1 and 8.2.2). The 5’-end of UL131A was not 
detected. However, since the initiation codon of UL131A is probably at 176825 and the 3’- 
end is at 174842 (see section 8.2.2), the unspliced transcript is anticipated to be at least 
2023 nucleotides in size and the spliced transcript 1672 nucleotides, including the splicing 
in UL128. Therefore, the 2.0 kb band probably corresponds to the UL131A transcript. 
Another faint band (3.0 kb) was also detected in this blot (Fig. 8.9) and may correspond to 
the UL132 transcript.
8.3 Discussion
Two novel spliced HCMV genes (UL128 and UL131A) predicted by Davison et al. 
(unpublished data) were analysed by RACE, northern blotting and RT-PCR. The transcript 
mapping data (summarised in Fig. 8.10) confirm and extend the predictions made by 
Davison et al. (unpublished data).
RT-PCR experiments confirmed the presence of three exons in UL128 and two exons in 
UL131A, and mapped the exact locations of the splice sites. The sizes of the exons and 
their amino acid sequences are conserved in CCMV. RACE identified a single 5’-end for 
UL128 and a shared 3’-end for UL128 and UL131A at 175622 and 174842, respectively. 
The conclusion that these genes are 3’-coterminal was confirmed by northern blotting. 
Moreover, the northern blot analysis also indicated that UL128, UL130, UL131A and 
UL132 are 3’-coterminal.
RACE, RT-PCR and northern blotting demonstrated that UL131A is an L gene. The UL128 
transcript was detected in E and L RNA using RACE and RT-PCR, but predominantly in L 
RNA by northern blotting. Chambers et al. (1999) detected UL128 from E RNA using gene 
microarray technology. As PCR methods may not be quantitative, and the gene microarray
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Figure 8.10: Transcription from HCMV novel genes , UL128 and UL131A.
Expanded version of parts of the AD169 genome (Fig 1.9) showing the positions of 5’ and 3’-ends 
of two HCMV novel genes (UL128 and UL131A), with the genome coordinates in kbp and 
transcriptional features above the relevant ORFs.
-| 5'-end 
M 3’-end
RNA (and orientation)
—  exon
—  intron
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system only detects transcription through the region containing the probe, UL128 is 
currently considered an L (or E-L) gene.
The RT, 3’-RACE and northern blotting experiments indicated that UL131A is transcribed 
at a moderate level. The inability to detect 5’-end of the UL131A mRNA was unexpected, 
and may reflect the efficiency of the primers used.
AD 169 UL131A is naturally frameshifted near its 5’-end and, is unlikely to be translated 
into a functional protein. CCMV UL128 contains a potential frameshift error near its 5’-end 
and may encode a truncated protein initiated at the second ATG codon. It is interesting to 
note that UL128 is also non-functional in Toledo due to a local inversion.
The predicted proteins encoded by CCMV and AD 169 UL131A contain a short 
hydrophobic domain near the N terminus (Fig. 8.9) which may act as a signal sequence for 
translation on membrane-bound ribosomes (McGeoch, 1985). Homologues of UL128 and 
UL131A are not present in protein databases. At present, the functions of UL128 and 
UL131A are not known.
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Discussion
9.1 Overall discussion
9.1.1 Purpose of the study
The sequence of the highly passaged AD 169 strain was described in 1990 as containing 208 
ORFs that may encode proteins. These were predicted on the basis of size, extent of overlap 
and codon usage. However, the Toledo strain and other low passage isolates were later 
found to possess 19 ORFs that are absent from high passaged strains such as AD 169 and 
Towne (Cha et al, 1996; Lurain et al., 1999). None of these extra ORFs have detectable 
counterparts in other p-herpesviruses. An additional 929 bp sequence, unrelated to the extra 
15 kbp found in Toledo, was also discovered in most stocks of AD 169 (Dargan et al., 1997; 
Mocarski et al., 1997). These studies provide insights into the gene content of the wild-type 
HCMV genome. The extra sequence found in Toledo and other low passage isolates is 
likely to be present in wild-type since they have undergone less laboratory passaging than 
AD 169. Thus, wild-type HCMV has been surmised to contain over 220 genes. However, 
even Toledo differs from clinical isolates in that a sequence near the right end of Ul is in 
inverse orientation.
Recently, the gene content of HCMV has been re-evaluated by comparison to the CCMV 
sequence and the estimated number of unique protein-coding genes in AD 169 is now 145 
(Davison et a l, unpublished data; see Fig. 1.9). The best estimate for the complement of 
wild type HCMV is now 164-167 genes, ten (UL15A, UL21A, UL128, UL131A, UL147A, 
UL148A, UL148B, UL148C, UL148D and US34A) of which are novel. It anticipated that 
this picture of HCMV gene content will be improved further.
Although the AD 169 genome was sequenced over ten years ago, transcriptional and 
functional data are not available for the majority of the genes, and the assignment of gene 
function to many genes is based only on sequence similarity to homologous genes in HSV- 
1. Recently, Chambers et al (1999) determined the kinetic class of the majority of 
predicted HCMV transcripts using gene microarray technology. However, this technique is 
limited in the extent of information it can supply, and much work is still required to 
characterise transcripts fully. The purpose of this study was to evaluate transcription of a 
selection of HCMV genes, including several that are conserved in CCMV, some that appear
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Discussion
unlikely to encode functional proteins because they are not conserved in CCMV, and two 
novel genes. Transcript mapping data are summarised in Fig 9.1. Additional work was 
undertaken to detect sequencing errors in published HCMV sequences.
9.1.2 Sequencing errors
i
On the basis of conservation of putative protein-coding regions, Davison et a l 
(unpublished data) proposed sequence errors in six ORFs (TRL13/14, UL15, UL102, 
UL131 A, UL145 and US22). The error in UL102 and an additional error near the 3’-end of 
US28 were reported previously (Smith and Pari, 1995; Kuhn et al., 1995). The present 
work did not re-examine the latter but confirmed the former. It also added errors in three 
other ORFs (UL15, UL145 and US22) and confirmed that two other ORFs in AD 169 
(UL131A and TRL13/14) are naturally frameshifted and therefore probably non-functional. 
As a result of this study, two novel genes (UL15A and UL131A) were introduced into the 
AD 169 genome, and the protein-coding regions of three genes (UL102, UL145 and US22) 
were extended at their 5’-ends.
As originally described by Chee et al. (1990), the size of the US22 ORF from its first ATG 
codon was 530 codons, corresponding to a protein product of approximately 60 kDa. 
However, the error identified in the US22 sequence indicates that translation commences at 
an upstream ATG codon. The size of the revised US22 ORF is 576 codons, with a
I
predicted protein product of 65 kDa. This is closer to the size of the US22 protein (76 kDa) 
detected in infected cells and expressed in recombinant bacteria (Mocarski et al., 1988; Dal 
Monte etal., 1998).
I
Since detection of these errors that were investigated depended on analysis of amino acid 
sequence conservation between HCMV and CCMV, it is anticipated that additional 
| sequencing errors, especially in non-coding-regions, are likely to exist in the published
AD 169 and Toledo sequences.
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9.1.3 Novel genes in HCMV
Drawing largely on the correspondence between the HCMV and CCMV gene 
arrangements, Davison et al. (unpublished data) proposed five novel genes in AD 169: 
UL15A, UL21A, UL128, UL131A and US34A, of which two (UL128 and UL131A) were 
predicted to be spliced. The present work did not examine expression of US34A, but 
experimentally investigated the other four genes. The presence of UL15A was confirmed 
from identification of sequencing errors, but transcription of this gene was not analysed. 
The amino acid sequence of the predicted protein encoded by UL15A possesses a 
hydrophobic domain near the C terminus and is therefore likely to be membrane-bound 
protein. Expression of UL21A was confirmed by 5’-RACE. The UL15A and UL22A 
proteins lack homologues in public databases.
UL128 was predicted to consist of three exons, and UL131A of two. The splice sites were 
mapped by RT-PCR. HCMV UL89 is the only gene that is spliced in all of the sequenced 
herpesviruses. In addition, several HCMV non-core genes, including UL22A, UL33, UL36, 
UL37, UL111A, UL112, UL119, UL122 and UL123 are spliced, and certain of these (e.g. 
UL36, UL37) make use of alternative, temporally regulated splicing (Mocarski, 1996). 
Alternative splicing, such as that in the MIE locus (UL122 and UL123) presents an 
additional means of diversifying functions.
Identification of novel genes from comparisons between the HCMV and CCMV geneome 
was dependent on substantial amino acid sequence homology. Additional spliced genes in 
poorly conserved regions or splice genes unique to one or other virus (such as is the case 
for UL111A in HCMV) may remain to be discovered. Consequently, further experimental 
investigation is necessary. Transcript mapping by the northern blotting, primer extension 
and cDNA cloning are the obvious routes.
Mapping the transcripts from UL128 and UL131A showed that they are 3’-coterminal. The 
5’-end of UL128 was mapped, but the 5’-end of UL131A was not detected. The predicted 
protein encoded by UL131A contains a short hydrophobic domain near the N terminus
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which may act as a signal sequence for secretion. However, homologues of the UL128 and 
UL131A predicted proteins were not found in protein databases.
The functions of the novel genes are not known. However UL131A is naturally 
ffameshifted in AD 169 and UL128 is disrupted in Toledo and CCMV. Thus, HCMV 
UL131A and UL128 appear to be non-essential for growth in cell culture.
9.1.4 US22 family genes
The HCMV US22 gene family includes genes UL23, UL24, UL26, UL28, UL29, UL36, 
UL43, IRS1, US22, US23, US24, US26 and TRS1 (Weston and Barrell, 1986; Davison et 
al., unpublished data). In this study, transcripts were detected by northern blot for nine of 
these 13 genes. UL28, TRS1, IRS1 and US26 were not analysed. Of the HCMV US22 
genes analysed, one is expressed with IE (UL36) and eight with E (UL23, UL24, UL26, 
UL28, UL29, US22, US23 and US24) kinetics. 5’- and 3’-ends were identified for eight of 
these genes (UL23, UL24, UL26, UL36, UL43, US22, US23 and US24). The 5’-ends of 
three (UL36, UL24 and US22) were further confirmed by primer extension assay. Most of 
the 5’-ends mapped for US22 gene family mRNAs are located 20-35 bp downstream from 
TATA elements, and the 3’-ends of all the ORFs analysed are located 20-24 bp upstream 
from AATAAA elements. The majority of TATA elements and all polyadenylation signals 
are conserved in CCMV.
3’-RACE implied the existence of three sets of 3’-coterminal genes containing members of 
the US22 family: UL23-UL24, US23-US24 and UL40-UL47. The former two sets were 
confirmed by northern blotting. In addition, northern blotting also indicated that UL26 is 
3’-coterminal with four other genes (UL27-UL30). However, further transcript mapping of 
UL40-UL47 and UL26-UL30 are required to confirm these initial findings. Sets of 3’- 
coterminal transcripts with alternative promoters are well documented in other regions of 
HCMV (Adam et al., 1995; Wing and Huang, 1995; Stenberg et a l,  1989; Welch et al., 
1991). Moreover, the current study identified several other sets of 3’-coterminal genes, 
including TRL8-TRL12, UL128-UL132, UL2-UL3, UL6-UL8, UL10-UL11, UL16-UL17 
and UL18-UL19 (see section 9.1.5).
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Two members of the US22 gene family were predicted to be spliced (UL36 and UL28). 
The splicing in UL36 shown by Kouzarides et al. (1988) was confirmed using RT-PCR. 
There is also good evidence from sequence analysis that UL28 is spliced at its 5’-end 
(Davison et al., unpublished data). In the current study however, RACE failed to determine 
the 5’-ends of UL28 and UL29, and RT-PCR failed to detect splicing sites between the two 
ORFs or of UL28 to an ORF further upstream.
The HCMV US22 gene family has been relatively little studied and the functions it 
provides are for the most part unknown. pTRSl, pIRSl and pUL36 are known to be 
components of the virus tegument, and pIRSl, pUL36 and pUL43 are dispensable 
(Romanowski et al., 1997; Jones and Muzithras, 1992; Patterson and Shenk, 1999; Dargan 
et a l,  1997). There are homologues for most of the HCMV US22 genes in the p- 
herpesviruses HHV-6 (Gompels et al., 1995), HHV-7 (Megaw et al., 1998; Nicholas, 
1996), MCMV (Rawlinson et al, 1996), rat CMV (Vink et al., 2000) and tupaiid 
herpesvirus (Bahr and Darai, 2001). Each of these P-herpesviruses encodes a similar 
number of US22 genes, suggesting that the family provides important functions during 
virus replication. In support of this view, Hanson et al. (2001) reported that the E proteins 
encoded by two US22 family genes in MCMV, M l40 and M141 (US23 and US24 
homologues, respectively) appear to act co-operatively and independently to regulate 
MCMV replication in a cell-type specific manner and are predicted to influence viral 
pathogenesis. Continued studies with HCMV mutants lacking specific US22 family genes 
will provide an opportunity to define the function of the gene products.
9.1.5 ORFs in TRL and at left end of UL
RNAs were identified for the majority of ORFs in T R l and the adjacent region in U l. Most 
5’-ends are located 20-35 bp downstream from TATA elements. The single (i.e. not 
multiple) 5’-ends mapped for transcripts in T R l and in U l, except for UL18, are located 
upstream from the first ATG in the cognate ORF. The 5’-end of UL18 is located 
downstream from the first ATG codon in the ORF and does not have a potential TATA box 
upstream, whereas the first ATG codon in the UL18 ORF is preceded by a potential TATA 
box. Since UL18 is well conserved in CCMV, including the first ATG codon and the
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TATA element upstream, it is anticipated that UL18 may specify two transcripts, and that 
only the abundant, shorter one was detected in this study. Consequently, further 
transcriptional studies of UL18 are required.
The 5’-ends mapped for certain genes (UL4, UL7, UL10 and UL27) are far upstream of the 
first ATG codon in each ORF, and intervening sequences contain ATG codons in other 
reading frames. Consequently, these ORFs are unlikely to be translated efficiently. 
However, since they are conserved in CCMV, they are likely to be expressed, either from 
the ,5’-ends detected or from weakly expressed smaller transcripts that were not detected. 
For example, UL20 mRNA has three 5’-ends located 45-319 bp upstream from the first 
ATG codon, with the furthest upstream being the most abundant.
5’-RACE revealed the existence of six sets of 3’-coterminal transcripts (from TRL8- 
TRL12, UL2-UL3, UL6-UL8, UL10-UL11, UL16-UL17 and UL18-UL19) in the region 
analysed. However, the 3’-ends of these transcripts must be mapped to confirm these 
findings.
Except for UL36, only one gene (UL22A) in the region analysed was found to be spliced. 
Splice sites in UL22A mapped by Rawlinson and Barrell (1993) and Bresnahan and Shenk
(2000) were confirmed using RT-PCR. The overall transcript mapping data indicate that the 
majority of transcripts in TRl possess multiple start sites. It is therefore anticipated that TRl 
is transcribed in a complex manner.
9.1.6 HCMV ORFs that are transcribed but may not encode 
functional proteins
Transcripts were detected for six (TRL2, TRL5, TRL6, TRL8, TRL9 and TRL9) of the 
eight ORFs (TRL2-TRL9) identified by Chee et a l (1990) in T R l and one ORF (UL12) in 
Ul that are considered by Davison et al. (unpublished data) unlikely to encode functional 
proteins, as they are not conserved in CCMV. Davison et al. (unpublished data) discounted 
ORFs in one genome that lack positional and sequence counterparts in the other, unless 
they are located in the sequences that represent insertations in relation to flanking genes or
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unless bioinformatic or functional data indicated otherwise. Although the HCMV and 
CCMV genomes exhibit limited regions of nucleotide homology in the TRL2-TRL9 
(around 2-8 kbp in AD 169), these regions do not align in a way that indicates a common 
protein-coding capacity (e.g. initiation and termination codon are not conserved, and 
conserved blocks of sequence are frameshifted with respect to each other.
Two other regions (UL58-UL68 at 90865-98100 and UL106-UL111 at 154950-159799) in 
the HCMV genome are also unlikely to encode proteins. Neither was analysed in this study. 
Chambers et al. (1999) detected the kinetics of expression of the ORFs identified in these 
regions (TRL2-TRL9, UL58-UL68 and UL106-UL111) except for UL58 and UL63. 
However, there is no evidence thus far these transcripts encode functional proteins.
It is notable that TRL2-TRL9, UL58-UL68 and UL106-UL111 regions have a higher AT 
content than the rest of the genome. One (UL58-UL68) contains oriLyt (Huang et al., 
1996). A high AT content has also been reported for other viral ori sequences, such as 
simian virus 40 (SV40) (Bergsma et a/., 1982), polyoma virus (Soeda et al., 1979), EBV 
(Yates et al., 1984) and HSV-1 (Stow and McMonagle, 1983; Weller et al., 1985). An ori 
function, however, has not been mapped in either of the other two regions.
Non-protein coding RNAs are not unusual in herpesviruses. The EBER RNAs of EBV and 
tRNAs in MHV-68 are transcribed by RNA polymerase III (Akusjarvi et al., 1980; Rosa et 
al., 1981; Bowden et al., 1997). These are smaller than 200 nucleotides in size and are 
neither polyadenylated nor capped. For HCMV, no such small RNAs have been reported, 
but a large (5 kb) partially polyadenylated RNA lacking a major ORF has been mapped in 
the UL106-UL111 region by Plachter et al. (1988).
Recently, the HCMV tegument was reported to contain a specific subset of viral transcripts, 
termed ‘virion RNAs’, originating from UL22A, UL109, TRL4 (p2.7) and TRL7 (p i.2) 
(Bresnahan and Shenk, 2000; Greijer et al., 2000). It is assumed that delivery of virion 
RNAs to the host cell allows for their expression immediately after virus entry in the 
absence of new transcription. UL22A is known to encode a protein that localizes to the 
Golgi network, and P2.7 is a major E transcript that probably does not encode functional
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protein. It is possible that some of the virion mRNAs serve non-protein-coding functions 
immediately after infection. Alternatively, they could serve a structural role in organising 
tegument proteins.
The best parallel to non-protein-coding RNAs in HCMV may be the latency-associated 
transcript (LATs) of HSV-1. During latent infection in neurons, HSV-1 gene expression is 
restricted to a family of RNAs known as the LATs (Deatly et al., 1988; Stevens et al,
1987). The LATs are transcribed from a region located within T R l and IR l . The full-length 
8.3 kb transcript (minor LAT) accumulates in infected neurons, and abundant 2.0 and 1.5 
kb introns (major LATs) are processed from the full-length transcript (reviewed in Wagner 
and Bloom, 1997). The 2.0 kb LAT is circular. Further RNA processing occurs by which 
500 bp is removed from the 2.0 kb LAT sequence, resulting in production of the 1.5 kb 
LAT (Alvira et al., 1999). The 2.0 kb LAT is detected in productive and latent infections, 
whereas the 1.5 kb LAT is detectable only in latently infected neurons (Wagner et a l ,
1988). It appears unlikely that functional proteins are encoded by the LATs.
The existence of LATs has been known for over a decade and it has been speculated that 
they might play a central role in viral latency. Investigation using mouse latency models 
has shown that the LATs are not required for the establishment or maintenance of a latent 
infection or for reactivation (Block et a l , 1990; Steiner et a l , 1989). However, it has been 
suggested that LAT mutants reactivate less efficiently from latent infection in cultured 
trigeminal ganglionic neurons (TG) (Block et al, 1993), and that a region downstream from 
the LAT promoter plays a significant role in enhancing reactivation in a rabbit model 
(Bloom et a l , 1996). Recently, results supporting the view that LATs may facilitate the 
establishment of latent infections and also increase neuronal survival in the mouse model 
have been published (Thompson and Sawtell, 2001). However, the mechanism by which 
the LATs might facilitate establishment of latency is not known, and the role of LATs in 
reactivation still needs to be proven. LATs have been shown to play a potential role in 
apoptosis of infected TG in a rabbit model (Pemg et a l , 2000). This conclusion, however, 
is difficult to reconcile with the observations from other researchers (Thompson and 
Sawtell, 2001), who have reported that there is no significance evidence demonstrating that 
LAT null virus induces more extensive apoptosis in infected neurons.
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CMV LATs originate from both DNA strands in the IE1/IE2 region, and are the only viral 
gene products that have been associated with latent infection. Sense CLTs are oriented in 
the same direction as productive MIE transcripts, initiating at two unique transcription start 
sites in the MIE enhancer region (UL125-UL127, another region that is unlikely to encode 
proteins (Fig. 1.9), and are present in a subset of naturally or experimentally infected 
CD33+ myeloid progenitors (Slobedman and Mocarski, 1999; Hahn et al., 1998; Kondo et 
al., 1996). Antibodies to the ORFs in CLTs are recognised by sera from healthy CMV 
seropositive individuals, suggesting that they are expressed during natural infection. 
However, only one protein (94 amino acid residues) encoded from sense CLTs exhibits a 
nuclear localization pattern when expressed in mammalian cells. Genetic analysis of ORF 
has not revealed a role for this gene product in either productive or latent infection (White 
et al., 2000).
Since little is known about the potential function of HCMV RNAs in the regions that are 
unlikely to encode proteins, it will be interesting to experimentally investigate whether 
these RNAs play an important role in HCMV replicative cycle or pathogenesis.
9.2 Conclusion
Determination of the complete sequence of CCMV by Davison et al. (unpublished data) 
facilitated detailed genetic comparisons between HCMV and CCMV and led to a re- 
evaluation of the genetic content of HCMV. Transcript mapping data shown in this study 
confirms several of the predictions and extend our knowledge of HCMV gene organisation. 
Thus the study has achieved several goals. It has improved our understanding the genetic 
content of HCMV, corrected certain sequencing errors in published sequences, yielded data 
on the kinetics of expression of US22 gene family members, generated data on the 5’- and 
3’-ends of many AD 169 genes, mapped the splicing sites in UL128 and UL131A, and 
experimentally confirmed UL21A, UL128 and UL131A as novel genes in HCMV. The 
strategy used in this study for transcript mapping could be extended to complete mapping 
of a wild-type laboratory strain of HCMV when it becomes available. This analysis thus 
lays the foundation for further experimental studies of gene expression in HCMV.
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Appendix 1
5’-ends detected by RACE.
a Position of 5’-ends in the AD169 genome. b Total number of 5’-cDNA clones 
corresponding to the 5’-end .c Number of G residues immediately upstream to the 5’-end. 
d PCR products not originating from HCMV. 5’-ends located far upstream and 
downstream from the first ATG (as described by Chee et al., 1990) are shown in pink and 
blue, respectively.
ORF 5’-endsa No. of clones*5 SMART RACE 
ambiguity0 of 5’-end
TRL1 No RACE product
TRL2 2083
2086
4
1 1
TRL3 No RACE product
TRL4 Cellulard
TRL5 4252 5
TRL6 5800
5796
4
1 1
5990
5996
5999
5
1
1 1
6080 5
TRL7 No RACE product
TRL8 7350 4 1
7259
7257
7252
3
1
2
1
6911 5 3
TRL9 7704
7701
6
2 2
TRL10 8140
8143
8144
7
2
1
4
2
8071
8074
3
1
1
TRL11 8452 4
Appendix 1
8509 5
8501 1
8499 1 1
8560 4
8567 2 2
8605 5 2
8600 1 1
8662 3
8661 1 2
TRL12 9342 6 1
9339 1
TRL13 10406 4
10404 1 1
10401 2 1
10443 5
10677 3 1
10680 1 1
10736 2
10738 4 2
10745 1
TRL14 4
10404 1 1
10401 2 1
10443 5
10677 3 1
10680 1 1
10736 2
10738 4 2
10745 1
UL1 No RACE product
UL2 13186 4
13175 2 4
UL3 13471 4
13469 2
13468 1
13465 2
13296 3
13299 2 1
Appendix 1
UL4 13290 
13288
13182
13185
13188
13046
13050
3
1
5 
1 
2
6 
1
1
1
1
1
UL5 No RACE product
UL6 4 1
14275 1
14277 1 1
14585 7
14595 2 3
UL7 15068 3
15073 2
UL8
16027 4 4
16023 2
16019 1 1
16180 5
UL9 No RACE product
UL10 16933 6 3
16937 2
UL11 18270 5
18272 1
18269 2 1
18267 1 1
UL12 4
19353 5
19354 1 1
UL13 19308 4
19311 1 1
19317 1 1
UL14 20713 5
20719 1 2
20709 2 1
20704 1 3
20952 3 4
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UL15A Not analysed
UL16 22325
22324
22312
22311
5
1
2
1
2
UL17 22896 3
22894 2 1
22890 2 3
3 2
23171 1 3
23176 1 1
23168
UL18 23724 25 4
23716 4
UL19 24269 4
24271 1 1
24275 2
24281 1 3
UL20 25253 4
25252 1 2
25249 2
25248 1 1
25161 3
25168 2 3
25158 1 4
24979 4
24977 1 2
24971 2 2
UL21A 26858 10
UL22A 27080 5
UL23 28855 22
28858 4 1
UL24 29994 12 2
29990 1 3
29997 1
30086 15
30098 3 1
30088 1 3
30084 2
30082 4 1
1
UL25 30016 5
30020 1
30024 2
Appendix 1
30025
30029
2
1 1
30065 3 1
UL26 32785
32787
32791
5
2
1
1
1
UL27 35295
35292
35286
4
1
2
1
2
UL28 No RACE product
UL29 Cellulard
UL30 37525
37526 
37521 
37518
6
1
2
1
1
UL36 49863
49866
49856
49855
49849
21
3
2
5
3
1
1
1
1
2
UL43 Cellulard
US22 211626 25
US23 213544
213545 
213547
213549
213550
12
3
1
2
1
1
1
213654
213650
213646
15
1
5
1
US24 214970 
214975
214971 
214966 
214965
14
5
2
4
3
3
2
US26 Cellulard
UL128 175681
175685
175677
175676
5
1
2
1
UL131A Cellulard
